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The	   treatment	   and	  management	  of	   pain	   continues	   to	   reflect	   the	   complex	  nature	  of	   pain	   itself.	   At	  
present,	  pain	  cannot	  be	  definitively	  tested	  for,	  only	  inferred	  through	  a	  combination	  of	  sensory	  and	  
self-­‐report	  measures,	  such	  as	  quantitative	  sensory	  testing	  procedures	  and	  validated	  questionnaires,	  
which	  survey	  various	  aspects	  of	  the	  pain	  experience	  in	  more	  detail,	  as	  well	  as	  the	  impact	  of	  pain	  on	  
daily	  life	  at	  home	  and	  in	  the	  workplace.	  Whilst	  clinical	  sensory	  testing	  outcomes	  are	  analogous	  to	  in	  
vivo	  evoked	  sensory	  data,	  modelling	  the	  impact	  of	  pain	  on	  quality	  of	  life	  is	  more	  challenging.	  	  
One	  approach	  is	  to	  use	  an	  ethological	  paradigm,	  i.e.	  one	  that	  measures	  a	  behaviour	  that	  reflects	  an	  
innate	   environmental	   response.	   Tests	   such	   as	   the	   open	   field	   and	   burrowing	   measure	   how	   pain	  
affects	   threat	   avoidance	   (thigmotaxis	   in	   the	   open	   field)	   and	   tunnel	   maintenance	   (burrowing)	   in	  
laboratory	   rats.	   Studies	   have	   shown	   their	   efficacy	   in	   detecting	   subtle	   behavioural	   deficits	   in	  
experimental	  models	  of	  pain,	  including	  response	  to	  analgesics.	  Using	  ethological	  outcome	  measures	  
also	   avoids	   applying	   clinical	   terminology	   to	   animal	   behaviour,	   and	   should	   be	   used	   in	   conjunction	  
with	  classical	  sensory	  reflex-­‐driven	  assays,	  such	  as	  hotplate	  and	  von	  Frey	  filaments,	  to	  yield	  a	  global	  
picture	  of	  how	  experimental	  pain	  states	  affect	  wellbeing	  and	  quality	  of	  life.	  	  
This	   study	   examines	   how	   acute	   visceral	   inflammation,	   persistent	   visceral	   inflammation,	   and	   drug-­‐
induced	  neuropathy	  (d4T	  -­‐	  antiretroviral	  nucleoside)	  alter	  the	  behaviour	  of	  adult	  female	  Wistar	  rats	  
in	  the	  open	  field	  paradigm.	  It	  also	  investigates	  how	  the	  behavioural	  phenotype	  of	  naïve	  male	  Wistar	  
rats	  responds	  to	  repeated	  open	  field	  exposure.	  	  
Significant	   increases	   in	   thigmotaxis	   were	   observed	   following	   acute	   bladder	   inflammation,	   and	  
repeated	  exposure	  to	  open	  field	  in	  naïve	  rats.	  There	  was	  no	  effect	  on	  either	  open	  field	  behaviour	  or	  
evoked	  sensory	  measures	  in	  female	  rats	  treated	  with	  d4T,	  and	  acute	  bladder	  inflammation	  failed	  to	  
alter	  burrowing	  behaviours.	  As	  d4T	  has	  been	  previously	  shown	  to	  alter	  thigmotactic	  behaviour,	  this	  
data	  suggests	  that	  females	  show	  different	  sensitivity	  compared	  to	  males.	  	  
To	   determine	   whether	   visceral	   inflammation	   influences	   behaviour	   in	   a	   dose-­‐dependent	   manner,	  
bladder	   tissue	   from	   the	   visceral	   inflammation	   groups	  was	   assayed	   for	   levels	   of	   cytokines	  using	   an	  
RNA	  microarray	  featuring	  92	  inflammatory	  cytokines	  and	  4	  housekeeping	  genes.	  The	  greatest	  effect	  
was	   detected	   following	   acute	   inflammation,	  with	   both	  models	   showing	   increased	   levels	   of	   CCL12,	  
CCL7,	  and	  IL-­‐1β	  when	  compared	  to	  naive	  tissue.	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To	   correlate	   the	   changes	   in	   behaviour	   with	   a	   neural	   substrate,	   c-­‐Fos	   immunoreactivity	   in	   the	  
amygdala	  was	  measured	  in	  both	  visceral	  inflammation	  groups.	  No	  significant	  activational	  differences	  
were	   seen	   following	   acute	   bladder	   inflammation,	   whereas	   persistent	   visceral	   inflammation	  
significantly	   increased	   c-­‐Fos	   immunoreactivity	   in	   the	   caudal	   regions	   of	   the	   capsular	   central	  
amygdala.	  	  
Visceral	   inflammation	   is	   associated	   with	   peripheral	   increases	   in	   inflammatory	   cytokines,	   and	  
thigmotactic	  behaviour	  in	  the	  open	  field.	  Differences	  in	  activation	  in	  the	  amygdala	  were	  lower	  than	  
expected	   due	   to	   high	   levels	   of	   variation	   associated	   with	   inflammatory	   stimuli	   at	   the	   time-­‐point	  
tested.	   Significant	   variation	  was	   particularly	   seen	   in	   repeated	   visceral	   inflammation,	   suggestive	   of	  
the	  biphasic	  behavioural	  response	  to	  stress	  e.g.	  attack	  or	  defend	  phenotypes.	  Further	  examination	  
of	  these	  differences	  at	  the	  individual	  level	  could	  shed	  light	  on	  the	  process	  of	  pain	  chronification,	  and	  
ultimately	  help	  understand	  why	  only	  some	  individuals	  develop	  chronic	  pain.	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  Following	  	  
Repeated	  Open	  Field	  Exposure	  	  
Figure	  4-­‐2:	  Latency	  To	  Enter	  In	  The	  Inner	  Zone	  And	  Rearing	  Behaviour	  Following	  Repeated	  Open	  	  
Field	  Exposure	  	  
Figure	  4-­‐3:	  Distance	  Travelled	  And	  Velocity	  In	  The	  Open	  Field	  Following	  Repeated	  Exposure	  	  
Figure	  4-­‐4:	  Frequency	  In	  Inner	  Zone	  And	  Total	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  Travelled	  In	  The	  Open	  Field	  By	  Thigmotactic	  	  
Phenotype	  	  
Figure	  4-­‐5:	  Frequency	  Of	  Wall-­‐Supported	  And	  Free-­‐Standing	  Rearing	  Behaviour	  In	  The	  Repeated	  	  
Open	  Field	  By	  Thigmotactic	  Phenotype	  	  
Figure	  5-­‐1:	  Fold	  Change	  Of	  Inflammatory	  Mediators	  Following	  Turpentine	  Bladder	  Inflammation	  	  
Figure	  5-­‐2:	  Inner	  Zone	  Activity	  (Frequency	  And	  Duration)	  Following	  Acute	  Bladder	  Inflammation	  	  
Figure	  5-­‐3:	  Total	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  Travelled	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  And	  Rearing	  Activity	  In	  The	  Open	  Field	  Following	  Acute	  	  
Bladder	  Inflammation	  	  
Figure	  5-­‐4:	  Inner	  Zone	  Activity	  Following	  Repeated	  Bladder	  Inflammation	  	  
Figure	  5-­‐5:	  Distance	  Travelled	  (Cm)	  And	  Rearing	  Activity	  In	  The	  Open	  Field	  Following	  Repeated	  	  
Bladder	  Inflammation	  	  
Figure	  5-­‐6:	  Comparison	  Of	  Thigmotactic	  Outcomes	  (Frequency	  And	  Duration	  In	  The	  Open	  Field)	  	  
Following	  Acute	  And	  Repeated	  Bladder	  Inflammation	  	  
Figure	  5-­‐7:	  Comparison	  Of	  Distance	  Travelled	  And	  Rearing	  Activity	  Following	  Acute	  And	  Repeated	  	  
Bladder	  Inflammation	  
Figure	  5-­‐8:	  Weight	  Displaced	  During	  1hr	  Burrowing	  Sessions	  Following	  Acute	  Bladder	  Inflammation	  
Figure	  5-­‐9:	  C-­‐Fos	  Immunoreactivity	  In	  The	  Central	  Amygdala	  Globally	  And	  In	  Left/Right	  Hemispheres	  	  
Following	  Open	  Field	  Exposure	  (Acute	  Bladder	  inflammation)	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Figure	  5-­‐10:	  C-­‐Fos	  Immunoreactivity	  In	  The	  Three	  Subdivisions	  Of	  The	  Central	  Amygdala	  (Medial,	  	  
Cem;	  Lateral,	  Cel;	  Capsular,	  Cec),	  And	  Along	  The	  Rostro-­‐Caudal	  Axis	  (Acute	  Bladder	  
inflammation)	  	  
Figure	  5-­‐11:	  Examples	  Of	  C-­‐Fos	  Immunoreactivity	  In	  The	  Central	  Amygdala	  Following	  Acute	  (Left)	  	  
And	  Repeated	  (Right)	  Bladder	  Inflammation	  	  
Figure	  5-­‐12:	  C-­‐Fos	  Immunoreactivity	  In	  The	  Central	  Amygdala	  And	  Left/Right	  Hemispheres	  Following	  	  
Repeated	  Bladder	  Inflammation	  	  
Figure	  5-­‐13:	  C-­‐Fos	  Immunoreactivity	  In	  The	  Central	  Amygdala	  Within	  The	  Three	  Subdivisions	  Of	  The	  	  
Amygdala	  (Medial,	  Cem;	  Lateral,	  Cel;	  Capsular,	  Cec),	  And	  Along	  The	  Rostro-­‐Caudal	  Axis	  	  
Following	  Repeated	  Bladder	  Inflammation	  	  
Figure	  6-­‐1:	  Mechanical	  And	  Thermal	  Hypersensitivity	  Following	  d4t	  Treatment	  	  
Figure	  6-­‐2:	  Inner	  Zone	  Activity	  (Frequency	  And	  Duration)	  In	  The	  Open	  Field	  Following	  d4t	  Treatment	  
Figure	  6-­‐3:	  Total	  Distance	  Travelled	  And	  Rearing	  Activity	  In	  The	  Open	  Field	  Following	  d4t	  Treatment	  
Figure	  7-­‐1:	  Inflammation	  in	  the	  bladder,	  comparing	  inflamed	  (red/left)	  and	  normal	  (right).	  1)	  
Integrity	  of	  tight	  junctions	  and	  basal	  lamina	  is	  lost;	  2)	  NGF	  is	  produced	  by	  mast	  cells	  and	  
neutrophils,	  which	  activates	  sensory	  nerve	  endings	  and	  3)	  macrophages	  to	  produce	  IL-­‐1β	  and	  
CCL-­‐12;	  4)	  CCL-­‐12	  and	  CCL-­‐7	  attract	  monocytes,	  eosinophils,	  and	  lymphocytes	  (CCL-­‐12	  only)	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  Acetic	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  Area	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  Cingulate	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AChE:	  Acetylcholinesterase	  	  
ACo:	  Anterior	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  Amygdaloid	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ACTB:	  Beta	  Actin	  
ACTH:	  Adrenocorticotropic	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  Analysis	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  Only	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ARRIVE:	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Experiments	  
ART:	  Anti-­‐Retroviral	  Therapy	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  Tri-­‐Phosphate	  
AVP:	  Vasopressin	  
B	  	  
BAOT:	  Bed	  Nucleus	  of	  the	  Accessory	  Olfactory	  	  
Tract	  
BAS:	  Bed	  Nucleus	  of	  the	  Anterior	  Commissure	  
BCG:	  bacillus	  Calmette-­‐Guérin	  
BDNF:	  Brain-­‐Derived	  Neurotrophic	  Factor	  
BL:	  Basolateral	  Nucleus	  of	  the	  Amygdala	  
BM:	  Basomedial	  Nucleus	  of	  the	  Amygdala	  
BPS:	  Bladder	  Pain	  Syndrome	  
C	  	  
CCI:	  Chronic	  Constriction	  Injury	  
CCK:	  Cholecystokinin	  
CCL:	  CC	  Chemokine	  Ligand	  
Ce:	  Central	  Amygdala	  
CeC:	  Capsular	  Nucleus	  of	  the	  Central	  Amygdala	  
CeL:	  Lateral	  Nucleus	  of	  the	  Central	  Amygdala	  
CeM:	  Medial	  Central	  Amygdala	  
CFA:	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  Freund's	  Adjuvant	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  Calcitonin	  Gene	  Regulated	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CI:	  Confidence	  Interval	  
CNFD:	  Corneal	  Nerve	  Fibre	  Density	  
COCP:	  Combined	  Oral	  Contraceptive	  Pill	  
CONSORT:	  Consolidated	  Standards	  of	  Reporting	  	  
Trials	  
COX:	  Cyclooxygenase	  
CPP:	  Conditioned	  Place	  Preference	  
CPSP:	  Central	  Post-­‐stroke	  Pain	  
CRF:	  Corticotrophin	  Releasing	  Factor	  	  
CRPS:	  Complex	  Regional	  Pain	  Syndrome	  
CSF:	  Colony	  Stimulating	  Factor	  
CTLA:	  Cytotoxic	  T-­‐Lymphocyte-­‐Associated	  Protein	  	  
(AKA	  RANTES)	  
CxA:	  cortex-­‐Amygdala	  Transition	  Zone	  
CXCL:	  Chemokine	  (C-­‐X-­‐C	  motif)	  Ligand	  
CYP:	  Cyclophosphamide	  
D	  	  
d4T:	  2ʹ′,3ʹ′-­‐didehydro-­‐2ʹ′,3ʹ′-­‐dideoxythymidine	  AKA	  
Stavudine	  
DAB:	  3,3ʹ′-­‐Diaminobenzidine	  
DFNS:	  German	  Research	  Network	  on	  Neuropathic	  	  
Pain	  
DMV4:	  Diagnostic	  Manual	  v4	  
DPN:	  Diabetic	  Peripheral	  Neuropathy	  
DRG:	  Dorsal	  Root	  Ganglia	  
E	  	  
EA:	  Extended	  Amygdala	  
EQ-­‐5D:	  EuroQoL	  Test	  5	  D	  
ERK:	  Extra-­‐cellular	  Signal-­‐Regulated	  Kinase	  
ESSIC:	  International	  Society	  for	  the	  Study	  of	  BPS	  
F	  	  
FAAH:	  Fatty	  Acid	  Amide	  Hydrolase	  
FC:	  Fold	  Change	  
FDR:	  False	  Discovery	  Rate	  
FIC:	  Feline	  Interstitial	  Cystitis	  
fMRI:	  Functional	  Magnetic	  Resonance	  Imaging	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FS:	  Free-­‐standing	  Rearing	  Activity	  
FSH:	  Follicle	  Stimulating	  Hormone	  
G	  	  
GAPDH:	  Glyceraldehyde	  3-­‐Phosphate	  	  
Dehydrogenase	  
H	  	  





IASP:	  International	  Association	  for	  the	  Study	  of	  	  
Pain	  
IBS:	  Irritable	  Bowel	  Syndrome	  
IC:	  Interstitial	  Cystitis	  
IC/BPS:	  Interstitial	  Cystitis/Bladder	  Pain	  Syndrome	  
ICI:	  Inter-­‐Contraction	  Interval	  
ICN:	  Intercalated	  Nuclei	  
IENFD:	  Intra-­‐Epidermal	  Nerve	  Fibre	  Density	  
IHC:	  Immunohistochemistry	  
IL:	  Interleukin	  
iNOS:	  Inducible	  Nitric	  Oxide	  Synthase	  
IQR:	  Interquartile	  Range	  
L	  	  
La:	  Lateral	  Nucleus	  of	  the	  Amygdala	  
LH:	  Luteinizing	  Hormone	  
LORETA:	  Low	  Resolution	  Electromagnetic	  	  
Tomography	  
LOT:	  Lateral	  Olfactory	  Bulb	  
LPS:	  Lipolysaccharide	  
M	  	  
MAGL:	  Monoacylglycerol	  Lipase	  
MCP:	  Monocyte	  Chemotactic	  Protein	  
MIF:	  Migration	  Inhibitory	  Factor	  
N	  	  
N:	  Naive	  
NAc:	  Nucleus	  Accumbens	  
NC3Rs:	  National	  Centre	  for	  the	  Replacement,	  	  
Refinement,	  and	  Reduction	  of	  Animals	  in	  	  
Research	  
NCF:	  Nucleus	  Cuniformis	  
NGF:	  Nerve	  Growth	  Factor	  
NIH:	  National	  Institutes	  for	  Health	  
NK:	  Natural	  Killer	  Immune	  Cells	  
NK1:	  Neurokinin-­‐1	  
NMDA:	  N-­‐Methyl-­‐D-­‐aspartate	  
NNTRI:	  Non-­‐nucleotide	  Reverse	  Transcriptase	  	  
Inhibitors	  
NOS:	  Nitric	  Oxide	  Synthase	  
NPSI:	  Neuropathic	  Pain	  Symptom	  Inventory	  
NRS:	  Numeric	  Rating	  Scale	  
NRTI:	  Nucleoside/Nucleotide	  Reverse	  	  
Transcriptase	  Inhibitor	  
NSAID:	  Non-­‐Steroidal	  Anti-­‐Inflammatory	  
O	  	  
OAB:	  Overactive	  Bladder	  
P	  	  
PAG:	  Periaqueductal	  Grey	  
PB:	  Parabrachial	  Nucleus	  
PET:	  Positron	  Emission	  Tomography	  
PFC:	  Pre-­‐Frontal	  Cortex	  
PHN:	  Post-­‐Herpetic	  Neuralgia	  
PLCo:	  Posteriolateral	  Cortical	  Amygdaloid	  Nucleus	  
PMCo:	  Posteriomedial	  Cortical	  Amygdaloid	  	  
Nucleus	  
PPBP:	  Pro-­‐Platelet	  Basic	  Protein	  (isoform	  of	  CXCL-­‐	  
7)	  
PROK:	  Prokinectin	  
PTGES:	  Prostaglandin-­‐Endoperoxidase	  Synthase	  
PVN:	  Paraventricular	  Nucleus	  
Q	  	  
QST:	  Quantitative	  Sensory	  Testing	  
R	  	  
RCT:	  Randomised	  Controlled	  Trial	  
RM	  ANOVA:	  Repeated	  Measure	  Analysis	  of	  	  
Variance	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ROS:	  Reactive	  Oxygen	  Species	  
rTMS:	  Repetitive	  Transcranial	  Magnetic	  
Stimulation	  
RVM:	  Rostroventral	  Medulla,	  
S	  	  
SAM:	  Significance	  Analysis	  of	  Microarrays	  
SIV:	  Simian	  Immunodeficiency	  Virus	  
SLEA:	  Sublenticular	  Extended	  Amygdala	  
SNI:	  Spared	  Nerve	  Injury	  
SNRI:	  Serotonin-­‐Noradrenaline	  Re-­‐Uptake	  	  
Inhibitor	  
SNT:	  Spinal	  Nerve	  Transection	  
ST:	  Bed	  Nucleus	  of	  the	  Stria	  Terminalis	  
T	  	  
T:	  Turpentine	  
tDCS:	  Transient	  Direct	  Contact	  Stimulation	  
TENS:	  Transcutaneous	  Electrical	  Nerve	  Stimulation	  
TGF:	  Transforming	  Growth	  Factor	  
TMS:	  Transcranial	  Magnetic	  Stimulation	  
TMT:	  Trimethylthiazoline	  
TNBS:	  Trinitrobenzenesulfonic	  acid	  
TNF:	  Tumour	  Necrosis	  Factor	  
TRPM:	  Transient	  Receptor	  Potential	  
Melastatin	  
TRPV:	  Transient	  Receptor	  Potential	  Vanilloid	  
V	  	  
V:	  Vehicle	  
VAS:	  Visual	  Analogue	  Scale	  
VTA:	  Ventral	  Tegmental	  Area	  
VZV:	  Varicella	  Zoster	  Virus	  
W	  	  
WHO:	  World	  Health	  Organisation,	  
WKY:	  Wistar	  Kyoto	  
WS:	  Wall-­‐Supported	  Rearing	  Activity,
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1 Introduction	  	  
“I	  think	  about	  the	  meaning	  of	  pain.	  Pain	  is	  personal.	  It	  really	  belongs	  to	  the	  one	  feeling	  it.	  	  	  
Probably	  the	  only	  thing	  that	  is	  your	  own.”	  	  
Henry	  Rollins	  	  
1.1 Pain	  	  
Pain	   is	   a	   complex	   experience,	   dependent	   on	   the	   interplay	   between	   sensory	   aspects	   and	   centrally	  
mediated	   affective,	  motivational,	   cognitive,	   and	   behavioural	   elements.	  With	   the	   exception	   of	   rare	  
individuals,	   such	   as	   those	   with	   congenital	   insensitivity	   to	   pain,	   for	   instance	   Riley-­‐Day	   syndrome	  
(Norcliffe-­‐Kaufmann	   &	   Kaufmann,	   2012),	   everyone	   has,	   or	   will	   experience	   pain	   throughout	   their	  
lives,	  and	  yet	  it	  presents	  one	  of	  the	  most	  challenging	  problems	  in	  biomedical	  research,	  due	  mainly	  to	  
its	  subjective	  nature.	  	  	  
Fundamentally,	   pain	   is	   a	   protective	   mechanism	   –	   it	   acts	   as	   a	   warning	   system,	   facilitating	   an	  
organism’s	  avoidance	  of	  interactions	  and	  behaviours	  that	  lead	  to	  pain,	  as	  evidenced	  by	  reduced	  life	  
expectancy	  in	  those	  with	  abnormal	  pain	  processing	  (Verheyen	  &	  Castelein,	  2007).	  
Fifty	  years	  ago,	   in	  1965,	  Ronald	  Melzack	  and	  Patrick	  Wall	  published	  their	  ground-­‐breaking	  work	  on	  
Gate	  Theory	  (Melzack	  &	  Wall,	  1965).	  Until	  that	  point,	  it	  was	  generally	  accepted	  that	  pain	  was	  a	  linear	  
process,	  as	  described	  by	  Descartes,	  over	  300	  years	  previous	  in	  1644	  (DeLeo,	  2006).	  Descartes’	  theory	  
proposed	  "pain"	  was	  a	  direct	  signal	  from	  the	  site	  of	  injury	  to	  the	  brain,	  like	  electricity	  along	  a	  wire.	  	  
This	   idea	  was	   appealing	   for	   its	   simplicity	   and,	   by	   the	   19th	   century,	   had	   developed	   into	   Specificity	  
Theory	   (Moayedi	   &	   Davis,	   2013).	   However,	   specificity	   theory	   was	   based	   on	   the	   assumption	   that	  
neurones	  could	  be	  divided	  into	  different	  types,	  each	  responding	  to	  a	  specific	  stimulus	  modality,	  and	  
passing	  information	  to	  an	  equally	  discrete	  part	  of	  the	  brain,	  specialised	  to	  respond	  to	  that	  stimulus	  
alone,	  whereas	  it	  is	  now	  clear	  that	  although	  some	  nerves	  may	  show	  comparative	  modality	  specialism	  
(e.g.	  small	  fibres	  sensitive	  to	  heat),	  there	  is	  a	  high	  degree	  of	  complexity	  and	  overlap	  between	  nerve	  
function,	  in	  both	  the	  central	  and	  peripheral	  nervous	  system.	  	  
Lay	   definitions	   of	   pain	   tend	   to	   be	   circular	   -­‐	   "Pain	   is	   that	   which	   hurts"	   -­‐	   or	   use	   words	   such	   as	  
"unpleasant"	  that	  inadequately	  convey	  the	  pain	  experience,	  as	  many	  things	  that	  are	  not	  painful	  can	  
be	  unpleasant,	   and	  pain	   can	  be	   associated	  with	   sensory	   abnormalities	   out-­‐with	   the	  description	  of	  
“unpleasant”	  such	  as	  subtle	  alterations	   in	  detection	  thresholds	  for	  mechanical	  and	  thermal	  stimuli.	  
The	  currently	  accepted	  definition	  of	  pain	  was	  proposed	  by	  Merskey	  in	  1979,	  describing	  pain	  as	  "an	  
unpleasant	  sensory	  and	  emotional	  experience	  associated	  with	  actual	  or	  potential	  tissue	  damage	  or	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described	  in	  terms	  of	  such	  damage”	  (Merskey	  et	  al.,	  1979).	  This	  was	  adopted	  as	  a	  formal	  definition	  
by	  the	  International	  Association	  for	  the	  Study	  of	  Pain	  in	  1986	  .	  	  
Characteristics	  of	  Pain	  	  
As	   hinted	   at	   above,	   pain	   is	   not	   a	   purely	   sensory	   condition	   -­‐	   it	   has	   both	   affective	   and	   cognitive	  
components.	   Involvement	   of	   the	   amygdala	   and	   other	   limbic	   regions	   in	   the	   affective	   component	  
emphasise	   the	   highly	   conserved	   nature	   of	   the	   responses	   to	   pain,	   and	   are	   suggestive	   of	   an	  
evolutionary	  basis	   in	  survival	  by	  associating	  threat	  with	   fear,	   facilitating	  the	  appropriate	  protective	  
response	  (e.g.	  avoidance,	  freezing,	  flight).	  Whereas	  the	  cognitive	  aspects	  help	  maintain	  context,	  with	  
increased	   pre-­‐frontal	   activity	   acting	   to	   supress	   medial	   amygdala	   activity,	   correlating	   with	   fewer	  
feelings	  of	  distress	  (Lorenz	  et	  al.,	  2003).	  	  
Pain	   has	   a	   primarily	   protective	   role,	   signalling	   that	   something	   is	   damaged	   and	   modulating	  
behavioural	  responses	  until	  healing	  has	  occurred.	  How	  behaviour	  is	  affected	  depends	  on	  a	  number	  
of	  factors	  including	  the	  type	  and	  intensity	  of	  pain	  (e.g.	  acute	  pain	  of	  a	  scald	  compared	  to	  a	  long-­‐term	  
constant	   dull	   ache),	   the	   disposition	   of	   the	   individual	   (e.g.	   catastrophizing	   compared	   to	   resilient	  
psychological	   phenotypes)	   and	   their	  medical	   history,	   in	   addition	   to	   environmental	   factors	   such	   as	  
immediate	  surroundings,	  and	  perceived	  security.	  	  	  
Clinically,	   diagnoses	   of	   pain	   involve	   description	   of	   the	   spatial	   location	   (e.g.	   leg,	   foot,	   upper	   arm),	  
duration	   (e.g.	   acute,	   persistent,	   or	   chronic),	   intensity	   (often	   rated	   using	   a	   scale	   such	   as	   the	   visual	  
analogue	  scale	   (VAS)	  or	  numeric	  rating	  scale	   (NRS)),	  and	  descriptors	  that	  convey	  the	  quality	  of	   the	  
pain	   (e.g.	   burning,	   shooting,	   dull).	   Other	   factors	   such	   as	   previous	   surgery	   or	   injury	   are	   generally	  
included,	  although	  assessments	  of	  mental	  health	  and	  consideration	  of	  other	  co-­‐morbidities	  are	  rare	  
in	   initial	  consultations.	  By	  definition,	  a	  diagnosis	  of	  neuropathic	  pain	  requires	  the	  presence	  of	  pain	  
associated	  with	  nerve	  injury	  or	  dysfunction	  –	  this	  is	  usually	  done	  by	  a	  two-­‐stage	  triage:	  	  	  
A.	  Documentation	  of	  a	  lesion	  or	  disease	  of	  the	  somatosensory	  system.	  	  	  
Followed	  by	  	  
B.	  Use	  of	  symptom	  descriptors	  and	  pain	  location	  to	  determine	  whether	  any	  pain	  is	  likely	  to	  be	  
of	  neuropathic	  origin.	  	  	  
Diagnosis	  of	  visceral	  pain,	  on	  the	  other	  hand,	  involves	  the	  presence	  of	  pain	  originating	  from	  internal	  
organs,	  indicated	  by	  diffuse	  pain	  in	  relevant	  direct	  dermatomal	  and	  referred	  segmental	  dermatome	  
regions,	  compared	  to	  somatic	  pain,	  which	  is	  indicated	  by	  pain	  confined	  to	  a	  specific	  region	  without	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referred	   pain.	   Additionally,	   conditions	   such	   as	   arthritis	   show	   a	   mixed	   presentation,	   with	   somatic	  
elements	  acting	  in	  combination	  with	  persistent	  local	  inflammation	  at	  joints	  to	  cause	  long	  term	  pain	  
and	  progressive	  damage	  of	  affected	  joints.	  	  
The	  Study	  of	  Pain	  	  
In	   pain,	   the	   relationship	   between	   intensity	   of	   experience	   and	   severity	   of	   damage	   is	   not	   linear	   –	  
factors	  such	  as	  duration,	  intensity,	  and	  effect	  on	  daily	  activities	  contribute	  to	  the	  overall	  experience,	  
meaning	  a	  single	  measure	  of	  pain	  intensity	  gives	  little	  information	  on	  prognosis	  and	  impact	  on	  daily	  
life.	  This,	  in	  combination	  with	  a	  medical	  focus	  on	  curative	  rather	  than	  palliative	  treatment,	  has	  led	  to	  
pain	  being	  neglected,	  part	   in	  due	   to	   its	  heterogeneity,	  and	  part	  because	   it	   is	   seen	  as	  an	   inevitable	  
part	  of	   life.	  Pain	   is	  often	  assumed	  to	  have	  a	  discrete	  cause,	  which	  when	  removed	  will	  also	  remove	  
the	   pain,	   and	   any	   other	   outcome	   is	   dismissed	   as	   pain	   being	   'merely	   symptomatic'.	   However,	   pain	  
often	  lingers	  long	  after	  the	  presumed	  cause	  has	  been	  resolved.	  	  
Compared	  to	  genetic	  tests	  capable	  of	  predicting	  the	  likelihood	  of	  developing	  Alzheimer’s	  disease	  and	  
imaging	  techniques	  ranging	   from	  X-­‐ray	   to	   fMRI,	  developed	  to	  diagnose	  and	  assess	  conditions	   from	  
cancer	  to	  broken	  bones,	  pain	  remains	  unquantified	  in	  comparison.	  The	  primary	  means	  of	  'detecting'	  
pain	   is	   to	   ask:	   verbal	   report,	   or	   validated	   questionnaires	   such	   as	   the	   McGill	   Pain	   Questionnaire	  
(Melzack,	   1975),	   and	   PainDETECT	   (Freynhagen	   et	   al.,	   2006)	   can	   only	   relay	   pseudoquantitative	  
information	   about	   the	   pain.	   Sensory	   testing,	   involving	   quantitative	   measurement	   of	   evoked	  
responses	  to	  a	  variety	  of	  stimuli,	  is	  gaining	  traction	  as	  a	  method	  of	  assessing	  pain	  in	  more	  detail,	  but	  
is	  currently	  used	  more	  as	  a	  clinical	  tool	  than	  a	  diagnostic	  aid	  (Pfau	  et	  al.,	  2014).	  	  
Subjective	  Assessment	  of	  Pain	  	  
Quantification	  of	  the	  pain	  experience	  is	  difficult,	  primarily	  because	  diagnosis	  relies	  heavily	  on	  patient	  
reported	   outcomes,	   with	   no	   definitive	   and	   clinically	   useful	   biomarkers,	   lacking	   a	   means	   of	   direct	  
quantification	   in	   both	   humans	   and	   other	   organisms.	   Additional	   factors	   such	   as	   heterogeneous	  
presentation	   and	   involvement	   of	   numerous	   un-­‐related	   and	   inter-­‐dependent	   factors	   further	  
complicate	   diagnosis.	   The	   most	   widely	   used	   methods	   are	   based	   on	   communication	   between	   the	  
patient	   and	   practitioner	   (patient	   reported	   outcome).	   Visual	   (VAS)	   and	   numeric	   (NRS)	   rating	   scales	  
ask	  the	  patient	  to	  rate	  their	  pain	  on	  a	  finite	  scale,	  with	  the	  minimum	  or	  ‘zero’	  being	  no	  pain	  and	  the	  
maximum	  (e.g.	  10,	  100)	  being	   the	  worst	  pain	  you	  can	   imagine.	  These	  are	  useful	  as	  an	   indicator	  of	  
pain	   intensity	   as	   there	   is	   some	   evidence	   they	   show	   intra-­‐individual	   stability,	   although	   without	  
standardisation	   there	   is	   high	   inter-­‐individual	   variation.	   This	   is	   to	   be	   expected	   when	   reducing	   a	  
personal	   subjective	  experience	   to	  a	  number,	  and	  scores	  can	  also	  be	  heavily	   influenced	  by	  external	  
factors	   such	   as	   mood	   and	   clinical	   environment	   (Carlsson,	   1983;	   Price	   et	   al.,	   1983).	   Therefore,	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questionnaires	   have	   been	   developed	   to	   quantify	   the	   subjective	   experience	   of	   pain,	   and	   are	   often	  
combined	   with	   rating	   scales,	   questionnaires	   covering	   other	   aspects	   of	   the	   experience	   such	   as	  
catastrophizing,	   and	   elements	   from	   the	   Diagnostic	   Manual	   v4	   (DMV4)	   allowing	   comprehensive	  
psychological	  phenotyping.	  	  
The	  McGill	  Pain	  Questionnaire	   (Melzack,	  1975)	   is	  a	  widely	  validated	   specialised	  pain	  questionnaire	  
(Holroyd	  et	  al.,	  1992),	  with	  translations	  used	  worldwide	  (Vanderiet	  et	  al.,	  1987;	  Boureau	  et	  al.,	  1992;	  
Masedo	   &	   Esteve,	   2000;	  Mystakidou	   et	   al.,	   2002;	   Yakut	   et	   al.,	   2007),	   but	   there	   are	  many	   others	  
frequently	   used,	   including	   PainDETECT	   	   (Freynhagen	   et	   al.,	   2006),	   the	   neuropathic	   pain	   symptom	  
inventory	   (NPSI,	   Bouhassira	  et	   al.,	   2004)	   and	   the	   EQ-­‐5D	   (EuroQoL	   Test	   5	  D,	   Torrance	  et	   al.,	   2014)	  
which	  gives	  a	  standardised	  measure	  of	  general	  health.	  These	  are	  often	  added	  to	  give	  depth	  to	  VAS	  
scores,	   but	   as	   they	   rely	   on	   the	   patient	   being	   able	   to	   reliably	   describe	   how	   they	   feel,	   they	   are	   of	  
limited	  use	  with	  infants,	  and	  individuals	  otherwise	  unable	  to	  communicate	  their	  answers.	  	  	  
Quantitative	  Assessment	  of	  Pain:	  Biomarkers	  	  
Ideally,	   a	   clinical	   diagnosis	   is	   based	   on	   reliable	   biological	   phenomena.	   The	   search	   for	   a	   pain	  
biomarker	  has	  covered	  targets	   including	  autonomic	  measures	  such	  as	  blood	  pressure	   (Saccò	  et	  al.,	  
2013),	   heart	   rate	   (Mazurak	   et	   al.,	   2012),	   	   and	   skin	   conductance	   (Storm,	   2008),	   in	   addition	   to	  
circulating	  blood	  corticosterone	   level	   and	  even	   finger	   length	   (de	  Kruijf	  et	  al.,	   2014).	  Currently,	   the	  
most	   robust	  markers	   are	   associated	  with	   quantitative	   sensory	   testing	   (Backonja	  et	   al.,	   2013),	   and	  
functional	  imaging	  studies	  (Tracey,	  2008).	  However,	  these	  currently	  have	  more	  use	  as	  research	  tools	  
than	  diagnostic	  criteria,	  as	  there	  is	  a	  difference	  between	  measurement	  and	  quantification	  of	  the	  pain	  
experience	   and	   the	   sensory	   profiling	   and	   blood	   flow	   correlates	   provided	   by	   quantitative	   sensory	  
testing	  (QST)	  and	  fMRI	  respectively.	  	  
Sensory	  testing	  concentrates	  on	  the	  underlying	  mechanisms	  and	  takes	  a	  more	  phenotypic	  approach	  
to	  pain,	  focusing	  on	  characterising	  the	  sensory	  profile	  specific	  to	  a	  patient	  rather	  than	  determining	  a	  
profile	  to	  fit	  all	  patients	  with	  a	  specific	  diagnosis.	  It	  involves	  a	  battery	  of	  tests	  designed	  to	  assess	  the	  
limits	   and	   thresholds	   of	  mechanical,	   thermal,	   and	   vibration	   detection,	   alongside	  measurement	   of	  
hypersensitivity,	   “wind-­‐up”,	  and	  paradoxical	  heat	  sensations	   (i.e.	  mis-­‐matched	   thermal	  perception,	  
with	   cooling	   stimuli	   perceived	   as	   warm).	   The	   results	   are	   then	   compared	   with	   data	   from	   healthy	  
subjects,	   and	   the	   deviation	   from	   normal	   values	   calculated	   for	   each	   outcome	   to	   produce	   a	   visual	  
representation	  (Z-­‐score),	  which	  enables	  rapid	  assessment	  of	  abnormal	  sensory	  responses.	  One	  of	  the	  
most	  widely	  used	  and	  validated	  protocols	  was	  developed	  by	  the	  German	  Neuropathic	  Pain	  Research	  
Network	  (DFNS,	  Pfau	  et	  al.,	  2014).	  	  	  




They	  defined	  three	  types	  of	  threshold:	  	  
• Sensation	  -­‐	  the	  first	  point	  at	  which	  something	  is	  detected,	  such	  as	  warmth	  	  
o Uniform	  across	  populations	  	  
• Pain	  Perception	  -­‐	  the	  point	  at	  which	  a	  heat	  stimuli	  changes	  from	  warm	  to	  a	  
sharp	  pain	  	  
o Some	  cultural	  influence	  	  
• Pain	  Tolerance	  -­‐	  the	  limit	  of	  pain	  endurance	  	  
o Dependent	  on	  individual	  characteristics	  and	  testing	  environment	  	  
Responses	   to	   a	   range	  of	   stimuli	   are	   assessed,	   and	   compiled	   to	   produce	   a	   Z-­‐score,	  which	   indicates	  
deviation	  from	  the	  expected	  normal	  population	  values.	  Current	  guidelines	  suggest	  that	  although	  QST	  
is	   a	   reliable	   and	   robust	  method	   for	   screening	   small	   fibre	   neuropathy	   in	   clinical	   trials,	   it	   is	   not	   yet	  
suitable	  as	  a	  diagnostic	  test	  for	  neuropathic	  pain	  (Backonja	  et	  al.,	  2013).	  Additionally,	  the	  presence	  
of	  co-­‐morbidities,	  particularly	  other	  pain	  conditions,	  complicates	  the	  use	  of	  QST	  as	  a	  diagnostic	  tool,	  
as	  illustrated	  by	  studies	  looking	  for	  evidence	  of	  widespread	  sensitisation	  in	  patients	  with	  interstitial	  
cystitis/Bladder	   Pain	   Syndrome	   (IC/BPS),	   where	   inclusion	   of	   patients	   with	   both	   IC/BPS	   and	  
fibromyalgia	   showed	  more	  widespread	   hypersensitivity	   (Clemens	   et	   al.,	   2008;	   Nickel	   et	   al.,	   2010)	  
than	  those	  with	  IC/BPS	  alone	  (Lai	  et	  al.,	  2014).	  	  
Functional	  imaging	  techniques	  such	  as	  fMRI	  can	  be	  used	  to	  monitor	  alterations	  in	  blood	  flow	  during	  
the	  pain	  experience	   and	  highlight	   functional	   associations	  between	  physical	   symptoms/experiences	  
and	   cerebral	   activation.	   Such	   studies	  have	   largely	   confirmed	  anatomical	   and	   functional	  pre-­‐clinical	  
research	   indicating	   areas	   such	   as	   the	   insula	   (Wiech	   et	   al.,	   2014),	   anterior	   cingulate	   cortex	   (ACC;	  
Shackman	   et	   al.,	   2011),	   thalamus	   (Baliki	   et	   al.,	   2008),	   amygdala	   (Bornhovd	   et	   al.,	   2002),	   and	  
prefrontal	   cortex	   (PFC;	   Lorenz	  et	  al.,	   2003)	  are	  activated	  during	  pain.	   Loss	  of	   grey	  matter	  has	  also	  
been	   detected	   in	   these	   areas	   in	   patients	   with	   chronic	   back	   pain	   (Apkarian	   et	   al.,	   2004;	   Schmidt-­‐
Wilcke	   et	   al.,	   2006),	   fibromyalgia	   (Kuchinad	   et	   al.,	   2007),	   and	   osteoarthritis,	   where	   it	   was	  
demonstrated	   that	   this	   decrease	   is	   a	   consequence	   not	   cause	   of	   pain,	   as	   increases	   in	   grey	  matter	  
volume	  were	  seen	  following	  total	  hip	  replacement	  in	  these	  patients	  (Rodriguez-­‐Raecke	  et	  al.,	  2009).	  
However,	   there	   are	   a	   number	   of	   limitations	   to	   interpretation	  of	   such	  data.	   Firstly,	   fMRI	  measures	  
changes	  in	  blood	  oxygenation	  indicative	  of	   increased	  brain	  activity	  with	  a	  6-­‐10	  second	  lag	  between	  
action	  potential	  and	  altered	  perfusion.	  This	  lag	  has	  been	  shown	  to	  change	  with	  age,	  emphasising	  the	  
importance	   of	   accurately	   stating	   the	   age	   range	   of	   subjects	   (Taoka	   et	   al.,	   1998).	   Secondly,	   the	  
precision	   of	   data	   is	   dependent	   on	   the	   power	   of	  MRI	   scanner	   used,	  with	   precision	   increasing	  with	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tesla	   rating	   (Skouras	   et	   al.,	   2014),	   highlighting	   the	   need	   for	   accurate	   reporting	   of	   methods	   and	  
caution	   when	   interpreting	   results	   where	   the	   resolution	   of	   the	   equipment	   is	   unknown.	   It	   is	   also	  
important	   to	   be	   aware	   that	   studies	   discussing	   activation	   of	   small,	   complex	   nuclei	   such	   as	   the	  
amygdala	   may	  miss	   the	   subtle	   yet	   important	   differences	   in	   activation	   arising	   through	   differential	  
activation	  of	  sub-­‐nuclei	  with	  opposing	  or	  synergistic	  actions.	  	  
Pain	   has	   been	   associated	   with	   sympathetic	   abnormalities,	   particularly	   in	   conditions	   such	   as	   CRPS	  
(Complex	  Regional	  Pain	  Syndrome)	  and	  fibromyalgia	  (Maletic	  &	  Raison,	  2009;	  Borchers	  &	  Gershwin,	  
2014;	  Rockett,	  2014).	  These	  manifest	  as	  alterations	  in	  autonomically	  controlled	  phenomenon	  such	  as	  
sweating	  and	  skin	   temperature	   in	  patients	  with	  CRPS	   (Rockett,	  2014),	  however,	   these	  changes	  are	  
not	  robust	  enough	  to	  provide	  a	  definitive	  diagnosis,	  largely	  due	  to	  high	  heterogeneity.	  	  
Thermographic	  studies	  have	  been	  conducted	  to	  investigate	  whether	  differences	  in	  regulation	  of	  skin	  
temperature	   can	   be	   indicative	   of	   pain	   conditions	   (Karpman	   et	   al.,	   1970),	   with	   decreases	   in	   pedal	  
thermoregulation	   noted	   in	   IC/BPS	   patients	   (Irwin	   et	   al.,	   1993),	   although	   as	  with	   other	   autonomic	  
outcomes,	  this	  is	  not	  robust	  enough	  for	  use	  as	  diagnosis.	  	  
Loss	  of	   small	   fibres	   is	   implicated	   in	  neuropathy	   (Lauria	  et	  al.,	   2012).	   This	  was	   initially	  documented	  
clinically	   for	   the	  purpose	  of	  diagnosing	  small	   fibre	  neuropathies	  using	  skin	  biopsies,	  measuring	   the	  
intra-­‐epidermal	  nerve	  fibre	  density	  (IENFD),	  with	  decreases	  seen	  in	  HIV	  (Shikuma	  et	  al.,	  2012;	  Phillips	  
et	  al.,	  2014),	  and	  diabetes	   (Malik	  et	  al.,	  2011).	  However,	  skin	  biopsy	   is	  an	   invasive	  technique,	  with	  
values	  obtained	  dependent	  not	  only	  on	  the	  presence	  of	  neuropathy,	  but	  also	  sampling	  location.	  The	  
cornea	   is	   an	   attractive	   alternative,	   as	   it	   is	   highly	   innervated,	   and	   can	   be	   visualised	   non-­‐invasively	  
using	   confocal	   corneal	   microscopy	   (Herrmann,	   2008).	   Decreases	   in	   corneal	   nerve	   fibre	   density	  
(CNFD)	   have	   been	   found	   associated	   with	   neuropathy	   in	   sarcoidosis	   (Dahan	   et	   al.,	   2013),	   Charcot	  
Marie-­‐Tooth	   disease	   type	   1A	   (Tavakoli	   et	   al.,	   2012),	   Fabry’s	   disease	   (Tavakoli	   et	   al.,	   2009),	   and	  
diabetes	  (Quattrini	  et	  al.,	  2007;	  Tavakoli	  et	  al.,	  2010),	  with	  many	  studies	  comparing	  IEFND	  to	  CNFD	  
and	  finding	  good	  correspondence	  between	  the	  measures	  (Quattrini	  et	  al.,	  2007;	  Tavakoli	  et	  al.,	  2010;	  
Ferrari	   et	   al.,	   2013a;	   Asghar	   et	   al.,	   2014).	   Further	   characterisation	   of	   CNFD	   in	   other	   peripheral	  
neuropathies	   is	   required,	   but	   it	   offers	   an	   attractive	   means	   to	   non-­‐invasively	   survey	   nerve	   fibre	  
density,	  a	  potential	  quantitative	  biomarker	  that	  correlates	  with	  pain	  intensity.	  	  
The	   biomarkers	   documented	   to	   date	   represent	   a	   useful	   battery	   of	   research	   tools	   to	   study	   clinical	  
pain	   patient	   cohorts,	  with	   the	   aim	   of	   understanding	   individual	   differences	   in	   sensory	   dysfunction,	  
but	   until	   high	   heterogeneity	   associated	   with	   diagnostic	   imprecision	   is	   resolved,	   accurate	  
identification	  of	  patient	  populations	  using	  biomarkers	  is	  unfeasible.	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Chronic	  Vs.	  Acute	  	  
A	  useful	  method	  of	  characterising	  pain	  is	  by	  duration.	  Acute	  pain	  is	  a	  relatively	  short-­‐lived	  response	  
to	  tissue	  damage.	  It	  can	  vary	  in	  intensity	  (e.g.	  a	  cut	  finger	  versus	  appendicitis)	  but	  the	  pain	  subsides	  
rapidly	  once	  the	  harmful	  stimulus	  is	  withdrawn.	  Persistent	  pain	  is	  a	  term	  sometimes	  used	  to	  describe	  
pain	  which	  is	  of	  longer	  duration	  than	  acute,	  yet	  below	  the	  3-­‐6	  month	  classification	  of	  chronic,	  and	  is	  
often	  seen	  in	  in	  post-­‐operative	  pain,	  and	  pain	  conditions	  with	  an	  inflammatory	  component	  (Cregg	  et	  
al.,	   2013;	   Zhang	   et	   al.,	   2014b).	   Chronic	   pain,	   as	   suggested	   by	   the	   name,	   is	   of	   longer	   duration.	  
Definitions	  vary	  but	  range	  from	  3	  to	  6	  months	  as	  a	  minimum	  duration	  threshold,	  or	  alternatively,	  it	  
can	  be	  defined	  as	  "pain	  that	  extends	  beyond	  the	  expected	  period	  of	  healing",	  although	  this	  excludes	  
conditions	   such	   as	   arthritis	   where	   the	   pain	   can	   be	   present	   for	   many	   months,	   if	   not	   years,	   in	  
association	   with	   unhealed	   tissue	   damage	   due	   to	   pathological	   inflammation.	   Furthermore,	   many	  
chronic	  pain	  conditions	  involve	  neuropathic	  elements,	  complicating	  treatment.	  When	  pain	  is	  present	  
continuously	  for	  three	  or	  more	  months,	  the	  affective	  and	  cognitive	  dysfunctions	  increase	  leading	  to	  
further	   difficulties	   during	   treatment	   (Sternbach,	   1974).	   Physiologically,	   chronic	   pain	   is	   associated	  
with	  neurological	  changes	  -­‐	  neurons	  can	  become	  sensitized,	  firing	  spontaneously	  in	  the	  presence	  of	  
continued	  afferent	  barrage.	  	  
Neuropathic	  pain	  refers	  to	  pain	  due	  to	  damage	  or	  disruption	  to	  central	  or	  peripheral	  nerves	  involved	  in	  
the	  generation	  and	  control	  of	  pain,	  and	  is	  formally	  defined	  by	  IASP	  as:	  	  
Pain	  caused	  by	  a	  lesion	  or	  disease	  of	  the	  somatosensory	  nervous	  system	  	  
(Jensen	  et	  al.,	  2011)	  
It	   can	   have	   a	   variety	   of	   causes,	   including	   trauma/surgery	   (e.g.	   CRPS,	   post-­‐operative	   neuropathic	  
pain),	   infection	   (e.g.	   varicella	   zoster	   virus/VZV,	   leprosy),	   viral	   (e.g.	   HIV),	   and	   chemical	   (e.g.	  
chemotherapeutic	   or	   anti-­‐retroviral	   agents),	   and	   is	   also	   associated	   with	   other	   medical	   conditions	  
such	  as	  diabetes	  (Bridges	  et	  al.,	  2001;	  Attal	  et	  al.,	  2008;	  Jensen	  et	  al.,	  2011).	  	  	  
Other	   chronic	   conditions,	   such	   as	   chronic	   cough	   share	   many	   similarities	   with	   chronic	   pain,	   such	  
central	   and	   peripheral	   nerve	   sensitisation	   (O’Neill	   et	   al.,	   2013),	   and	   over-­‐expression	   of	   sodium	  
channels	  implicated	  in	  pain,	  such	  as	  Nav1.7-­‐1.9	  (Muroi	  &	  Undem,	  2014).	  	  
Affective	  Aspects	  	  
The	   majority	   of	   therapeutic	   approaches	   and	   research	   strategies	   concentrate	   on	   ameliorating	   the	  
sensory	   elements	   of	   pain;	   however,	   it	   is	   clear	   that	   when	   most	   people	   talk	   about	   pain,	   they	   are	  
talking	  about	  a	  category	  of	  experiences	  with	  a	  common	  theme.	  We	  are	  able	  to	  distinguish	  the	  pain	  of	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toothache	  from	  the	  pain	  of	  sunburn	  -­‐	  these	  different	  pain	  experiences	  are	  characterised	  more	  by	  the	  
emotional	  component	  than	  any	  identifiable	  common	  element.	  This	  emotional	  association	  is	  specific	  
to	   an	   individual,	   but	   is	   broadly	   based	   on	   anxiety	   concerning	   the	   current	   situation	   and	   future	  
projections	   of	   outcome.	   The	   behavioural	   response	   is	   not	   specific	   to	   the	   sensory	   experience	   that	  
triggered	   it,	   with	   cognitive	   elements	   such	   as	   anticipation	   of	   a	   painful	   stimulus	   also	   shown	   to	  
influence	  perception	  (Ploner	  et	  al.,	  2010).	  	  	  
All	  types	  of	  pain	  are	  associated	  with	  affective	  symptoms,	  but	  due	  to	  its	  prolonged	  duration,	  chronic	  
pain	  in	  particular	  is	  associated	  with	  a	  high	  burden	  of	  psychological	  symptoms.	  This	  can	  be	  explained	  
by	  the	  duration	  of	  pain	  extending	  beyond	  that	  expected,	  increasing	  anxiety,	  decreasing	  the	  patient's	  
sense	  of	  control	  over	  the	  situation,	  and	  permeating	  all	   thoughts	  about	  the	  future.	  Evidence	  of	   this	  
can	  be	  seen	  by	  the	  correlation	  between	  catastrophizing	  thought	  patterns	  and	  both	  duration	  of	  pain	  
(Gilliam	  et	  al.,	  2010),	  and	  association	  with	  prolonged	  post-­‐operative	  recovery	   (Lautenbacher	  et	  al.,	  
2010).	  	  
Surveys	   have	   shown	   numerous	   co-­‐morbidities	   within	   and	   between	   pain	   syndromes,	   with	  
anxiodepressive	   signs,	   lethargy,	   catastrophizing,	   sleep	   disturbances,	   and	   reduced	   quality	   of	   life	  
commonly	  encountered	  (Twillman,	  2007;	  Radat	  et	  al.,	  2013;	  Chung	  et	  al.,	  2014).	  There	  is	  additionally	  
considerable	  overlap	  between	  chronic	  pain	  syndromes,	  especially	  between	  somatic	  and	  visceral	  pain	  
conditions	  such	  as	  fibromyalgia,	  irritable	  bowel	  syndrome	  (IBS),	  and	  interstitial	  cystitis	  (IC)	  (Pezzone	  
et	  al.,	  2005).	  	  
The	  current	  translational	  difficulties	   in	  developing	  effective	  pain	  relief	  are	  associated	   in	  part	  with	  a	  
pre-­‐clinical	  focus	  on	  positive	  sensory	  signs,	  whereas	  the	  clinical	  burden	  of	  chronic	  pain	  comes	  largely	  
from	  negative	  behavioural	   responses,	   such	  as	  avoiding	   situations	  perceived	  as	  exacerbating,	  and	  a	  
general	  decrease	  in	  quality	  of	  life	  as	  a	  result	  of	  unpredictable	  spontaneous	  pain.	  	  
Experimental	  Pain	  in	  Human	  Subjects	  	  
The	  study	  of	  pain	  in	  humans	  relies	  on	  the	  ability	  to	  induce	  transient,	  standardised	  episodes	  of	  pain	  
without	   causing	   underlying	   damage.	   Researchers	   have	   utilised	   heat,	   cold,	   chemical	   irritants,	   and	  
ischaemia	  to	  induce	  pain	  in	  healthy	  volunteers	  (Staahl	  &	  Drewes,	  2004;	  Oertel	  &	  Lötsch,	  2013).	  One	  
problem	   quickly	   recognised	   was	   insensitivity	   to	   opioids	   in	   methods	   of	   inducing	   pain	   involving	  
thermal	  and	  chemical	  stimuli.	  Beecher’s	  constriction	  model	   is	  an	  exception	  to	   this,	  perhaps	  due	  to	  
the	  indirect	  method	  of	  activating	  nociceptors,	  suggesting	  inherent	  differences	  in	  processing	  between	  
pain	  of	  external	  or	  internal	  origin	  (Smith	  et	  al.,	  1966).	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These	  models	  are	  of	  limited	  clinical	  relevance	  to	  chronic	  pain	  due	  to	  their	  typically	  short	  duration	  of	  
nociceptor	  activation,	  compared	  to	  the	  sustained	  activation	  seen	  in	  chronic	  pain	  conditions,	  and	  the	  
fact	   they	   tend	   to	  model	   only	   one	   aspect	   of	   the	   pain	   experience	   and	   focus	   on	   evoked	   rather	   than	  
spontaneous	  pain	  (Reddy	  et	  al.,	  2012).	  	  
1.2 Visceral	  Pain	  	  
Visceral	  pain	  is	  defined	  as	  pain	  affecting	  the	  internal	  organs	  (viscera)	  and	  is	  thought	  to	  be	  the	  most	  
widely	   experienced	   type	   of	   pain,	   with	   16-­‐25%	   of	   the	   general	   population	   affected	   by	   pelvic,	  
abdominal,	  or	  thoracic	  pain	  (Collett,	  2013).	  Pain	  originating	  from	  an	   internal	  organ	   is	  characterised	  
by	   diffuse	   presentation	   due	   to	   sparse	   innervation,	   with	   less	   than	   10%	   of	   afferent	   inflow	   to	   the	  
thoracolumbar	  spinal	   cord	  coming	   from	  the	  viscera	   (Cervero	  et	  al.,	  1984).	  Viscera	   receive	  a	  higher	  
level	   of	   sympathetic	   innervation	   compared	   to	   somatic	   tissue,	   and	   both	   sympathetic	   and	  
parasympathetic	  fibres	  converge	  from	  many	  proximal	  organs	  at	  the	  spinal	  cord,	   leading	  to	  referred	  
pain	  in	  distal	  dermatome-­‐relevant	  sites	  e.g.	  arm	  pain	  during	  a	  myocardial	  infarction,	  and	  lower	  back	  
pain	  during	  urinary	  tract	  and	  kidney	  infections	  (Giamberardino,	  1999).	  The	  low	  density	  and	  increased	  
spacing	  of	   sensory	   fibres	   results	   in	   difficulty	   pinpointing	   the	  exact	   source	  of	   the	  pain,	   unlike	  most	  
other	  pain	  complaints	  involving	  highly	  innervated	  skin	  and	  muscle,	  and	  it	  is	  this	  inability	  to	  locate	  the	  
pain	  that	  underlines	  increased	  levels	  of	  anxiety	  and	  affective	  disorders	  associated	  with	  visceral	  pain	  
conditions	  (McMahon	  et	  al.,	  1995;	  Jänig,	  2010).	  This	  relationship	  is	  reciprocal,	  and	  symptoms	  often	  
flare	  up	  under	  stress	  due	  to	  activation	  of	  sympathetic	  nerves	   (Gareau	  et	  al.,	  2008;	  Larauche	  et	  al.,	  
2011).	  However,	   it	   is	   important	   to	   remember	   that	   the	   lower	  density	  of	   fibres	   is	  not	   indicative	  of	  a	  
lesser	  pain	  experience,	  as	  evidenced	  by	  not	  only	  childbirth,	  but	  also	  conditions	  such	  as	  appendicitis	  
and	  kidney	  stones.	  	  	  
Despite	  being	  so	  common,	  visceral	  pain	   is	   inherently	  difficult	  to	  study	   in	  animal	  models,	  and	  this	   is	  
reflected	   in	  the	   literature.	  A	  PubMed	  search	  conducted	  on	  the	  19th	  November	  2014	  (search	  terms:	  
(pain)	   AND	   (neuropathic)	   vs.	   (pain)	   AND	   (visceral)	   –	   no	   limitation	   on	   date	   or	   language	   range)	  
revealed	   13,562	   results	   for	   pain	   with	   a	   neuropathic	   element,	   compared	   to	   5186	   for	   pain	   with	   a	  
visceral	   component.	   Of	   these,	   6006	   neuropathic	   studies	   were	   conducted	   in	   non-­‐humans	   (filter:	  
other),	  compared	  to	  1724	  for	  visceral	  (filter:	  other).	  The	  earliest	  studies	  were	  published	  in	  1966	  and	  
1906	   for	   neuropathic	   and	   visceral	   pain	   respectively,	   and	   although	   this	   is	   a	   crude	   method	   of	  
measuring	   interest,	   it	  highlights	  the	  disparity	  present	   in	  the	  study	  of	  different	  pain	  conditions,	  and	  
reflects	  the	  difficulties	  present	  in	  the	  study	  of	  visceral	  pain.	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The	  Urinary	  Bladder	  	  
As	  the	  majority	  of	  this	  study	  focuses	  on	  bladder	  inflammation,	  I	  will	  now	  discuss	  the	  anatomy	  of	  the	  
bladder	  to	  further	  understand	  how	  it	  responds	  to	  nociceptive	  stimuli.	  The	  human	  urinary	  bladder	  is	  a	  
hollow,	  distensible	  organ	  located	  on	  the	  pelvic	  floor	  with	  an	  average	  volume	  of	  300-­‐400ml	  (Hinman	  
&	  Cox,	  1967).	  Micturition,	  or	  the	  process	  of	  expelling	  urine	  stored	   in	  the	  bladder,	  occurs	  when	  the	  
muscle	  layers	  at	  the	  bladder	  neck	  and	  sphincter	  are	  relaxed.	  The	  timing	  of	  this	  is	  dictated	  primarily	  
by	  bladder	   volume,	  with	   volumes	  of	   150ml	   sufficient	   to	   activate	   stretch	   receptors,	  which	   respond	  
proportionally	  to	  the	  rising	  volume	  of	  urine	  within	  the	  bladder	  by	  increasing	  the	  sense	  of	  ‘urgency’,	  
however	   other	   factors	   including	   stress/anxiety	   and	   environmental	   conditions	   can	   also	   influence	  
micturition	  frequency.	  	  
	  
Figure	  1-­‐1:	  Cellular	  structure	  of	  the	  bladder	  wall	  
Illustrating	   urothelial,	   suburothelial,	   and	   detrusor	  muscle	   zones,	   in	   addition	   to	  main	   cell	   types	   and	   points	   of	   innervation.	   Adapted	   from	  
Rahnama’i	  et	  al.,	  2013;	  Birder,	  2014)	  
The	  cellular	   structure	  of	   the	  urinary	  bladder	   shown	   in	  Figure	  1-­‐1	   illustrating	   the	  complexity	  of	   this	  
organ.	  Sensory	  afferents	  detect	  alterations	  in	  the	  extracellular	  environment	  between	  the	  urothelium	  
and	   muscle	   layers	   (where	   autonomic	   afferents	   controlling	   bladder	   function	   terminate),	   and	   the	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presence	   of	   mast	   cells	   and	   vascular	   structures	   enables	   rapid	   inflammatory	   responses.	  
Glycosaminoglycans	   act	   as	   a	   first	   line	   of	   defence,	   coating	   the	   inner	   lumen	   of	   the	   bladder	   in	   a	  
protective	  layer,	  minimising	  potential	  irritation	  due	  to	  contact	  with	  bladder	  contents,	  in	  addition	  to	  
the	  barrier	  provided	  by	  tight	  junctions	  between	  urothelial	  cells	  (Keay	  et	  al.,	  2014;	  Birder,	  2014).	  
Figure	  1-­‐2	  illustrates	  the	  innervation	  of	  the	  urinary	  bladder,	  with	  motor	  innervation	  provided	  by	  both	  
the	   sympathetic	   (hypogastric	   plexus	   and	   associated	   nerves;	   T12-­‐L2	   in	   man,	   L1-­‐L2	   in	   rats),	   and	  
parasympathetic	  (pelvic	  splanchnic	  nerves	  and	  inferior	  hypogastric	  plexus;	  S2-­‐4	  in	  man,	  L6-­‐S2	  in	  rats)	  
nervous	   systems,	   and	   sensory	   information	   from	   the	   superior	   and	   inferior	   aspects	   of	   the	   bladder	  
transmitted	  along	  general	  visceral	  afferent	  fibres	  which	  follow	  the	  sympathetic	  and	  parasympathetic	  
fibres	  respectively	  (Lukacz	  et	  al.,	  2011).	  The	  high	  levels	  of	  convergent	  innervation	  in	  the	  pelvic	  region	  
prompts	   some	   to	   suggest	   an	   umbrella	   term	   of	   Urologic	   Chronic	   Pelvic	   Pain	   Syndrome	   (UCPPS)	   to	  
describe	  conditions	  such	  as	  cystitis	  and	  prostatitis	  which	  share	  many	  common	  features	  (Tirlapur	  et	  
al.,	   2013;	  Clemens	  et	  al.,	   2014).	  There	  are	  also	   strong	  associations	  between	  pelvic	  pain	   conditions	  
and	  both	  chronic	  pain	  disorders	  (Suskind	  et	  al.,	  2013),	  and	  a	  wide	  range	  of	  other	  non-­‐pain	  conditions	  
(Keller	  et	  al.,	   2012).	   	   Furthermore,	   increased	   firing	   is	   also	  noted	   in	   the	  bladder	   in	  association	  with	  
colorectal	   irritation	   (Ustinova	  et	  al.,	   2006),	   and	   there	   is	   a	  high	  degree	  of	  overlap	  between	  chronic	  
visceral	   conditions	   in	   general,	   such	   as	   that	   between	   IC/BPS	   and	   IBS	   (Clemens	   et	   al.,	   2012)	  
emphasising	  the	  links	  between	  pelvic	  innervation.	  	  
	  
Figure	  1-­‐2:	  Innervation	  of	  the	  bladder	  	  
Sympathetic,	  parasympathetic,	  and	  sensory	  innervation	  in	  both	  man	  and	  the	  laboratory	  Rat,	  illustrating	  the	  differences	  and	  similarities	  
between	  species,	  with	  thoracic	  innervation	  involved	  in	  humans	  but	  not	  rats	  	  




The	   term	   ‘cystitis’	   comes	   from	   the	   Latin/Greek	   for	   ‘bladder’	   and	   ‘disease	   characterised	   by	  
inflammation’,	   and	   is	   widely	   used	   to	   describe	   inflammatory	   diseases	   of	   the	   bladder.	   Interstitial	  
cystitis	  (IC)	  is	  a	  sub-­‐type	  defined	  by	  a	  diagnosis	  of	  exclusion	  which	  shows	  considerable	  overlap	  with	  
other	  bladder	  conditions	  such	  as	  overactive	  (OAB)	  and	  bladder	  pain	  syndrome	  (BPS)	  (Diaz,	  2014).	  The	  
term	  IC/BPS	  is	  frequently	  used	  as	  an	  umbrella	  term,	  covering	  bladder	  syndromes	  featuring	  persistent	  
suprapubic	   pain	   with	   or	   without	   increased	   urinary	   frequency	   and	   urgency,	   and	   may	   include	   the	  
presence	  of	  Hunner’s	  ulcers	  (Hanno	  et	  al.,	  2011;	  Killinger	  et	  al.,	  2013),	  although	  these	  are	  only	  seen	  
in	  5-­‐10%	  of	  IC/BPS	  cases	  (Logadottir	  et	  al.,	  2012).	  	  
Clinical	  biomarkers	  such	  as	  anti-­‐proliferative	  factor	  (Kim	  &	  Freeman,	  2011),	  GP51	  (Byrne	  et	  al.,	  1999),	  
and	  increased	  nerve	  fibre	  density	  (Christmas	  et	  al.,	  1990)	  have	  also	  been	  associated	  with	  a	  diagnosis	  
of	   IC/BPS.	  These	  new	  fibres	  show	  up-­‐regulation	  of	  a	  number	  of	  factors	   implicated	  in	  pain	   including	  
substance	   P	   and	   CGRP	   (Pang	   et	   al.,	   1995;	   Schnegelsberg	   et	   al.,	   2010),	   TRPV1	   and	  NGF	   (Liu	   et	   al.,	  
2014),	   cyclooxygenase-­‐2	   (COX-­‐2)	   (Klinger	   et	   al.,	   2007)	   and	   CB1	   (Mukerji	   et	   al.,	   2010),	   with	   levels	  
correlating	  with	  pain	  scores.	  	  
Putative	  causes	  of	  IC/BPS	  include	  autoimmune,	  allergic,	  and	  genetic,	  with	  stress	  and	  anxiety	  playing	  a	  
role	  in	  common	  with	  other	  visceral	  pain	  disorders	  (Chung	  et	  al.,	  2014).	  	  	  
Referred	  hyperalgesia	  in	  IC/BPS	  and	  other	  bladder	  pain	  conditions	  has	  been	  documented.	  	  
	  




Figure	  1-­‐3:	  Segmented	  referral	  dermatomes	  for	  the	  bladder	  in	  man	  and	  the	  laboratory	  rat	  
A)	  IC/BPS:	  Suprapubic	  Area	  (T11),	  Sacral	  (S2),	  Perineum	  (S3),	  (based	  on	  an	  original	  image	  from	  Maitland,	  1968b)	  	  
B)	  Rat	  Bladder	  somatic	  referral	  regions	  (adapted	  from	  Takahashi	  &	  Nakajima,	  1996)	  
Figure	  1-­‐3	  shows	  the	  segmental	  referral	  dermatomes	  associated	  with	  bladder	  pain:	  The	  suprapubic	  
area	   (T11),	  sacrum	  (S2),	  and	  perineum	  (S3).	  A	  recent	  study	  demonstrated	   increased	  VAS	  ratings	   to	  
T11	  pressure	  pain	  stimuli	  in	  patients	  with	  IC/BPS	  and	  no	  co-­‐morbidities	  (Lai	  et	  al.,	  2014),	  in	  contrast	  
with	   previous	   studies	   which	   found	   evidence	   of	   wider	   general	   sensitisation	   to	   pressure	   stimuli	   	   in	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IC/BPS,	   although	   these	   patients	   also	   had	   a	   number	   of	   co-­‐morbidities,	   and	   exhibited	   increased	  
variation	  in	  heat	  thresholds,	  suggestive	  of	  the	  presence	  of	  different	  sensory	  phenotypes	  within	  the	  
group	  (Ness	  et	  al.,	  2005).	  	  
1.3 Current	  Therapeutic	  Approaches	  	  
Pain	   represents	   a	   serious	   economic	   concern	   in	   terms	   of	   both	   working	   days	   lost	   and	   productivity	  
(Harman	  &	   Ruyak,	   2005;	   Beckett	   et	   al.,	   2014),	   emphasising	   the	   need	   for	  more	   effective	   analgesic	  
treatments.	  	  
NSAIDs	  and	  Paracetamol	  	  
For	  mild	  to	  moderate	  acute	  pain,	  non-­‐steroidal	  anti-­‐inflammatory	  (NSAID)	  drugs,	  such	  as	  aspirin	  and	  
ibuprofen	  are	  widely	  used	  and	  generally	  available	  over	  the	  counter.	  These	  drugs	  act	  primarily	  in	  the	  
periphery,	   by	   counteracting	   inflammatory	   processes	   and	   reducing	   activation	   of	   peripheral	   sensory	  
nerve	  endings	  through	  inhibition	  of	  pro-­‐inflammatory	  enzymes	  such	  as	  COX	  (Björkman,	  1995).	  COX-­‐2	  
is	   expressed	   on	   endothelial	   tissue,	   whereas	   COX-­‐1	   predominates	   in	   the	   gastrointestinal	   tract	   –	  
NSAIDs	  which	  can	  specifically	  target	  COX-­‐2	  have	  fewer	  side-­‐effects	  such	  as	  ulceration	  (Patrignani	  &	  
Patrono,	   2014).	   Cardiovascular	   complications	   (hypertension	   and	   atherothrombosis)	   are	   associated	  
with	  increasing	  dosage	  (Bruno	  et	  al.,	  2014)	  meaning	  such	  drugs	  are	  not	  suitable	  for	  treating	  patients	  
with	  existing	  heart	  conditions.	  Additionally,	  non-­‐specific	  COX-­‐inhibitor	  NSAIDS	  are	  contraindicated	  in	  
individuals	  with	   asthma	   and	   cardiovascular	   complaints,	  which	   is	  why	   COX-­‐2	   specific	   drugs	   are	   the	  
preferred	  choice.	  Acetaminophen	  (paracetamol)	  is	  another	  commonly	  used	  analgesic,	  classified	  as	  an	  
aniline	  analgesic	  and	  recommended	  as	  a	  first	  line	  treatment	  for	  osteoarthritis,	  with	  contraindications	  
compared	  with	  classic	  NSAIDs	  (Jóźwiak-­‐Bebenista	  &	  Nowak,	  2014).	   It	   is	  comparable	  with	  NSAIDs	   in	  
terms	  of	  efficacy,	  but	  has	  low	  anti-­‐inflammatory	  activity,	  and	  has	  central	  activity	  via	  TRPV1	  receptors	  
(Mallet	  et	  al.,	  2010)	  in	  a	  fatty	  acid	  amide	  hydrolase	  (FAAH-­‐dependent	  manner,	  Barrière	  et	  al.,	  2013),	  
emphasising	   the	   role	   of	   the	   endocannabinoid	   system	   in	   nociception	   (Rice	   et	   al.,	   2002;	   Rea	   et	   al.,	  
2007).	  	  
Opioids	  	  
Morphine	   and	  other	   opioids	   are	   the	   first	   line	   therapeutic	   approach	   for	   severe	   acute	  pain,	   such	   as	  
emergencies	   characterised	   by	   sudden	   onset	   of	   severe	   pain,	   post-­‐operative	   analgesia	   and	   during	  
labour	   to	  make	   prolonged	   but	   finite	   pain	  more	   bearable,	   and	   in	   the	   final	   stages	   of	   treatment	   for	  
many	  terminal	  diseases	   (Finnerup	  et	  al.,	  2015).	  Opioids	  act	  on	  the	  descending	  control	  pathways	  of	  
the	  spinal	  cord,	  activating	  rich	  seams	  of	  endogenous	  opioid	  receptors,	  and	  causing	  the	  suppression	  
of	   signals	   returning	   from	   the	  periphery	   (Sandkühler,	   1996).	   In	   addition	   to	   the	  matter	   of	   tolerance	  
and	   addiction,	   and	   side	   effects	   such	   as	   cognitive	   impairment,	   concerns	   regarding	   the	   social	   and	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ethical	   issues	   associated	  with	  morphine	   and	   other	   opioids	   have	   negatively	   influenced	   prescription	  
and	  use	  (Flemming,	  2010).	  	  
Anti-­‐Epileptics	  and	  Anti-­‐Depressants	  	  
Since	  the	  early	  60s,	  drugs	  originally	  developed	  to	  treat	  other	  neurological	  disorders,	  such	  as	  epilepsy	  
and	   major	   depression,	   have	   been	   adopted	   as	   first-­‐line	   treatments	   for	   pain	   conditions	   with	   a	  
neuropathic	  element	  (Finnerup	  et	  al.,	  2015).	  
Drugs	   such	   as	   Gabapentin	   and	   pregabalin	   are	   examples	   of	   gabaergic	   drugs	   with	   origins	   as	   anti-­‐
convulsants	   that	   act	   by	   decreasing	   neural	   activity,	   whereas	   duloxetine	   and	   amitriptyline	   are	   anti-­‐
depressants,	  which	  act	  via	  actions	  on	  serotonin	  and	  noradrenaline	  re-­‐uptake	  inhibition.	  As	  detailed	  
below,	  both	  categories	  of	  drugs	  are	  now	  recognised	  as	  having	  analgesic	  properties.	  
Gabapentin	  (“Neurontin”)	  was	  originally	  developed	  by	  Pfizer	  and	  was	  approved	  as	  an	  anticonvulsant	  
for	   the	   treatment	   of	   epilepsy	   in	   1993	   (Graves	  &	   Leppik,	   1993;	   Goa	  &	   Sorkin,	   1993;	  Moore	   et	   al.,	  
2011).	   It	   targets	  the	  α2δ-­‐1	  accessory	  subunit	  of	  voltage-­‐gated	  calcium	  channels,	  and	   inhibits	  nerve	  
injury-­‐induced	   trafficking	   of	   α1	   pore-­‐forming	   units,	   in	   addition	   to	   reducing	   movement	   of	   α2δ-­‐1	  
subunits	  from	  dorsal	  root	  ganglia	  (DRG)	  to	  the	  dorsal	  horn	  (Kukkar	  et	  al.,	  2013).	  It	  was	  subsequently	  
found	  effective	   in	   the	   treatment	  of	   various	   chronic	  and	  neuropathic	  pain	   conditions,	  and	   is	  now	  a	  
recommended	  treatment	  for	  diabetic	  peripheral	  neuropathy	  	  (DPN;	  Attal	  et	  al.,	  2010),	  post-­‐herpetic	  
neuralgia	   (PHN;	  Segal	  &	  Rordorf,	  1996;	  Wiffen	  et	  al.,	  2013),	  and	  neuropathic	  pain	  originating	   from	  
damage	   to	   the	   central	   nervous	   system	   (Finnerup,	   2008).	   Gabapentin	   shows	   some	   efficacy	   in	  
phantom	  limb	  pain	  (Abbass,	  2012),	  and	  has	  been	  suggested	  as	  a	  surgical	  pre-­‐treatment	  to	  reduce	  the	  
incidence	   of	   post-­‐surgical	   chronic	   pain	   (Clarke	   et	   al.,	   2012).	   It	   was	   shown	   more	   effective	   than	  
amitriptyline	  in	  the	  treatment	  of	  chronic	  pelvic	  pain	  (Cheong	  et	  al.,	  2014),	  and	  has	  some	  efficacy	  in	  
chemotherapy-­‐induced	  neuropathy	  (Bar	  Ad,	  2010),	  and	  fibromyalgia	  (Moore	  et	  al.,	  2014),	  although	  
other	  studies	  have	  suggested	  pregabalin	  is	  superior	  for	  the	  treatment	  of	  fibromyalgia	  (Wiffen	  et	  al.,	  
2013).	   It	   is	   not	   effective	   for	   all	   pain	   conditions,	   and	   has	   low	   efficacy	   in	   post-­‐surgical	   pain,	   HIV-­‐
associated	   peripheral	   neuropathy,	   CRPS,	   and	   migraine	   (Moore	   et	   al.,	   2014).	   Other	   similar	   drugs	  
include	   pregabalin	   (“Lyrica”)	   and	   gabapentin	   enacarbil,	   which	   was	   approved	   for	   PHN	   in	   2012	  
(Thomas	  &	  Farquhar-­‐Smith,	  2013).	  	  	  
Duloxetine	  (“Cymbalta”)	  is	  a	  balanced	  serotonin-­‐noradrenaline	  re-­‐uptake	  inhibitor	  (SNRI,	  developed	  
by	  Eli	  Lilly	   (Bellingham	  &	  Peng,	  2010),	  and	   licensed	  for	  DPN	  and	  major	  depressive	  disorder	   in	  2004	  
(Lunn	  et	  al.,	  2014).	  In	  2008	  it	  was	  also	  licensed	  for	  the	  treatment	  of	  fibromyalgia	  (Lunn	  et	  al.,	  2009),	  
and	  in	  2010,	  osteoarthritis	  and	  musculoskeletal	  pain	  were	  added	  as	  approved	  indications	  (Citrome	  &	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Weiss-­‐Citrome,	  2012;	  Myers	  et	  al.,	  2014b).	  Its	  efficacy	  in	  fibromyalgia	  is	  thought	  to	  be	  due	  largely	  to	  
amelioration	  of	  affective	  symptoms	  (Lunn	  et	  al.,	  2009).	  	  
Amitriptyline	   (“Elavil”)	  was	  developed	  by	  Merck,	  and	   is	  one	  of	   the	  most	  widely	  prescribed	   tricyclic	  
anti-­‐depressants	  (Bryson	  &	  Wilde,	  1996;	  Mika	  et	  al.,	  2013).	  It	  was	  licensed	  in	  1961	  and	  is	  featured	  on	  
the	  WHO	  list	  of	  essential	  medicines	  (WHO,	  2013).	  In	  common	  with	  duloxetine,	  amitriptyline	  also	  acts	  
as	  an	  SNRI,	  although	  is	  associated	  with	  high	  inter-­‐patient	  variation	  in	  metabolism,	  making	  it	  difficult	  
to	   accurately	   determine	   an	   effective	   dose	   applicable	   to	   all	   patients	   (Bryson	   &	   Wilde,	   1996).	  
Amitriptyline	  is	  now	  indicated	  for	  major	  depressive	  disorder,	  generalised	  anxiety	  disorder,	  attention	  
deficit	   hyperactivity	   disorder,	   bipolar	   disorder,	   migraine,	   PHN,	   insomnia,	   fibromyalgia,	   and	   IBS	  
(Bryson	  &	  Wilde,	  1996).	  As	  it	  has	  been	  prescribed	  for	  many	  years,	  numerous	  systematic	  reviews	  have	  
been	  conducted	  to	  further	   investigate	  the	  efficacy	  of	  amitriptyline	   in	  neuropathic	  and	  chronic	  pain	  
disorders	  –	  second	  tier	  efficacy	  for	  DPN	  was	  noted	  (Bryson	  &	  Wilde,	  1996;	  Moore	  et	  al.,	  2012),	  with	  
fibromyalgia	   presenting	   both	   as	   treatable	   (Häuser	   et	   al.,	   2011)and	   unaffected	   by	   amitriptyline	  
treatment	  (Nishishinya	  et	  al.,	  2008).	  It	  is	  a	  third	  tier	  treatment	  for	  phantom	  limb	  pain	  (McCormick	  et	  
al.,	   2014),	   and	   recommended	   for	   IC/BPS	   (Offiah	  et	   al.,	   2013).	   Interestingly,	   there	   is	   evidence	   that	  
amitriptyline	  has	  topical	  efficacy	  (Kopsky	  &	  Hesselink,	  2012),	  although	  the	  quality	  of	  this	  evidence	  is	  
poor,	  as	  noted	  in	  a	  later	  systematic	  review	  of	  topical	  analgesics	  (Argoff,	  2013).	  	  
Topical	  Analgesics	  	  
The	  use	  of	  topical	  treatments	  for	  pain	  is	  well	  established	  –	  historical	  accounts	  of	  applying	  poultices	  
to	   painful	   areas	   have	   been	   documented	   for	   centuries	   (Arnstein,	   2013).	   Topical	   application	   of	  
analgesics	   is	   attractive	   as	   it	   minimises	   side	   effects	   associated	   with	   systemic	   dosing,	   and	   allows	  
targeted	   treatment	   of	   superficial	   painful	   areas	   (Stanos	   &	   Galluzzi,	   2013).	   Compounds	   applied	  
topically	  can	  be	  divided	  into	  NSAIDs	  (e.g.	  ibuprofen,	  diclofenac,	  and	  keptoprofen),	  local	  anaesthetics	  
(primarily	   lidocaine),	   and	   counter-­‐irritants	   (salicylates,	   menthol,	   camphor,	   and	   capsaicin)	   that	  
activate	   and	   then	   desensitise	   peripheral	   afferents	   (Barkin,	   2013).	   Topical	   NSAIDs	   are	   routinely	  
recommended	  as	  treatment	  for	  arthritis	  (Altman	  &	  Barthel,	  2011),	  whereas	  capsaicin	  and	  lidocaine	  
are	  more	  effective	  in	  neuropathic	  pain	  (Gilron	  et	  al.,	  2006),	  including	  conditions	  such	  as	  PHN	  (Wolff	  
et	  al.,	  2011)and	  CRPS	  (Hsu,	  2009).	  	  	  
Topical	   capsaicin	   exerts	   its	   effects	   by	   desensitising	   C-­‐fibres	   via	   defunctionalisation	   of	   TRPV1	  
receptors	   (Sharma	   et	   al.,	   2013),	   and	   induces	   die-­‐back	   of	   affected	   nociceptive	   fibres,	   resulting	   in	  
decreased	  epidermal	  nerve	  fibre	  densities	  (Gibbons	  et	  al.,	  2010),	  and	  it	  has	  been	  shown	  that	  higher	  
concentrations	   of	   capsaicin,	  whilst	   associated	  with	   increased	  management	   for	   clinicians,	   are	  most	  
effective	  in	  treatment	  of	  chronic	  neuropathic	  pain	  (Derry	  et	  al.,	  2013).	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Lidocaine,	  on	  the	  other	  hand,	  acts	  primarily	  via	  blockade	  of	  sodium	  channels	  (Barkin,	  2013),	  and	  also	  
activates	   TRPV1	   and	   TRPA1	   receptors,	   and	   studies	   into	   the	   use	   of	   5%	   transdermal	   patches	   have	  
shown	   results	   in	   a	   similar	   reduction	   in	   epidermal	   nerve	   fibre	   density	   after	   42	   days	   of	   treatment,	  
which	  is	  associated	  with	  decreased	  mechanical	  sensitivity,	  whilst	  leaving	  pressure,	  thermal,	  and	  cold	  
responses	   relatively	   unaffected	   (Wehrfritz	   et	   al.,	   2011).	   It	   has	   been	   shown	   efficacious	   for	   various	  
neuropathic	   conditions	   including	   PHN	   (Attal	   et	   al.,	   2010;	   Mick	   &	   Correa-­‐Illanes,	   2012),	   although	  
studies	  into	  other	  conditions	  such	  as	  post-­‐herniorrhaphy	  pain	  have	  so	  far	  been	  inconclusive	  (Bischoff	  
et	  al.,	  2013),	  emphasizing	  the	  need	  for	  high	  quality,	  large-­‐scale	  clinical	  trials.	  	  	  
Non-­‐Pharmaceutical	  Approaches	  	  
Non-­‐pharmaceutical	   treatments	   such	   as	   transcranial	   magnetic	   stimulation,	   acupuncture	   (and	  
associated	  acupressure	  based	  treatments)	  are	  also	  widely	  used	  to	  treat	  pain,	  with	  varying	  degrees	  of	  
efficacy	  and	  specificity	  (Dworkin	  et	  al.,	  2013).	  	  
Transcranial	   magnetic	   stimulation	   (TMS)	   is	   a	   non-­‐invasive	   technique	   that	   uses	   electromagnetic	  
induction	  of	  weak	  electric	  currents	  to	  depolarize	  or	  hyperpolarize	  neurons.	  The	  magnetic	  field	  has	  a	  
similar	   strength	   to	   that	  used	   in	  MRI.	   It	  has	  a	  penetration	  of	  approximately	  5cm,	  meaning	   targeted	  
stimulation	   by	   positioning	   the	   stimulator	   over	   relevant	   brain	   areas,	   such	   as	   the	   primary	   motor	  
cortex.	  It	  can	  take	  the	  form	  of	  direct,	  constant	  stimulation	  (tDCS),	  or	  short	  repetitive	  bursts	  (rTMS),	  
and	  both	  are	  associated	  with	  analgesic	  effect	   in	   fibromyalgia	   (Marlow	  et	  al.,	  2013),	  and	  other	  pain	  
conditions	  with	  a	  rheumatic	  element	  (Pérocheau	  et	  al.,	  2014),	  as	  well	  as	  neuropathic	  pain	  associated	  
with	  spinal	  cord	  injury	  (Nardone	  et	  al.,	  2014).	  In	  a	  recent	  set	  of	  guidelines,	  rTMS	  was	  recommended	  
as	   an	   analgesic	   when	   applied	   to	   the	   primary	   motor	   cortex	   contralateral	   to	   the	   site	   of	   pain	  
(Lefaucheur	  et	  al.,	  2014),	  and	  a	  systematic	  review	  of	  the	  animal	  literature	  on	  non-­‐invasive	  analgesic	  
therapy	  conducted	  in	  2012	  found	  analgesic	  efficacy	  in	  studies	  investigating	  both	  tDCS	  and	  rTMS	  (Volz	  
et	  al.,	  2012).	  	  
Transcutaneous	   electrical	   nerve	   stimulation	   (TENS),	   as	   the	   name	   suggests,	   involves	   application	   of	  
electrical	  stimulation	  via	  electrodes	  attached	  to	  the	  skin.	  The	  pulse	  width,	  frequency,	  and	  intensity	  of	  
electrical	  stimulation	  can	  be	  varied	  dependent	  on	  requirements	  –	   low	  frequency	   is	  associated	  with	  
muscle	  contraction,	  whereas	  higher	  frequencies	  activate	  sensory	  nerves.	  It	  has	  been	  suggested	  as	  an	  
effective	   adjunct	   therapy	   in	   the	   treatment	   of	   chronic	   pain,	   although	   the	   majority	   of	   systematic	  
reviews	   have	   been	   inconclusive	   (Nnoaham	  &	  Kumbang,	   2008;	   Khadilkar	  et	   al.,	   2008;	   Rutjes	  et	   al.,	  
2009;	   Robb	  et	   al.,	   2009).	   Efficacy	   has	   been	   suggested	   in	   treatment	   of	   DPN	   (Dubinsky	  &	  Miyasaki,	  
2010),	   and	   pre-­‐clinical	   studies	   have	   demonstrated	   TENS	   decreases	   microglial	   activation	   clinically	  
when	  applied	   immediately	   following	   surgery	   (Matsuo	  et	  al.,	  2014),	  and	  ameliorates	  Randall-­‐Selitto	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sensitivity	  in	  carrageenan-­‐induced	  pain	  in	  vivo	  in	  an	  opioid-­‐dependent	  manner	  system	  (Sabino	  et	  al.,	  
2008).	  However,	  to	  enable	  valid	  assessment	  of	  TENS-­‐induced	  analgesia,	  it	  is	  acknowledged	  that	  the	  
quality	  of	  clinical	  research	  needs	  improvement,	  particularly	  regarding	  standardisation	  of	  dosing	  and	  
outcomes	  (Bennett	  et	  al.,	  2011).	  	  
Acupuncture	   has	   been	   used	  medicinally	   in	   China	   for	   over	   3000	   years	   (Zhuang	  et	   al.,	   2013).	   It	   is	   a	  
therapeutic	  technique	  involving	  insertion	  of	  fine	  needles	  at	  specified	  points	  along	  meridian	  lines	  on	  
the	  body,	  with	  point	  corresponding	  to	  almost	  every	  ailment	  imaginable	  (Yang	  et	  al.,	  2011),	  including	  
pain	   (Wang	   et	   al.,	   2008).	   Numerous	   studies	   have	   been	   conducted	   to	   understand	   how	   and	   when	  
acupuncture	  is	  effective	  as	  an	  analgesic	  –	  in	  the	  last	  5	  years,	  1896	  articles	  looking	  at	  “(Acupuncture)	  
AND	   Pain”,	   were	   published,	   and	   while	   the	  majority	   were	   in	   English	   (1464),	   or	   Chinese	   (374),	   the	  
remainder	  were	  in	  15	  different	   languages,	  highlighting	  the	  worldwide	  interest	   in	  the	  topic,	  and	  the	  
potential	   for	   ‘lost	   data’	  when	   reviewing	   the	   literature	   related	   to	   acupuncture.	   Systematic	   reviews	  
have	   been	   cautiously	   positive	   (Lam	   et	   al.,	   2013b;	   Manyanga	   et	   al.,	   2014;	   Yang	   et	   al.,	   2014),	   but	  
acknowledge	   the	  high	  bias	  present	  due	   to	  difficulties	  using	  double	  blind	  protocols	  with	   traditional	  
acupuncture	   techniques.	   Electro-­‐acupuncture,	   a	   technique	   involving	   the	   application	   of	   electrical	  
stimuli	   to	   traditional	   acupuncture	   pressure	   points,	   is	   used	   as	   an	   alternative	   to	   traditional	   needle	  
acupuncture	   and	   involves	   activation	   of	   neurotransmitter	   systems	   including	   serotoninergic,	  
opioidergic,	   and	   GABA-­‐ergic	   (Kim	   et	   al.,	   2013).	   Pre-­‐clinical	   studies	   have	   demonstrated	   electro-­‐
acupuncture	  is	  as	  effective	  as	  celecoxib	  in	  providing	  analgesia	  following	  spinal	  nerve	  ligation	  (Lau	  et	  
al.,	  2010),	  and	  is	  also	  effective	  in	  inflammatory	  models	  of	  pain	  such	  as	  CFA	  (Lee	  et	  al.,	  2012;	  Du	  et	  al.,	  
2014),	  and	  carrageenan	  (Yoo	  et	  al.,	  2011).	  It	  is	  also	  worth	  noting	  that	  the	  increasing	  use	  of	  electro-­‐
acupuncture	  has	  to	  potential	  to	  increase	  study	  quality	  as	  it	  would	  theoretically	  be	  easier	  to	  conduct	  
high	  quality	  trials	   into	  as	   it	  permits	  double	  blinding	  through	  use	  of	  automated	  electro-­‐acupuncture	  
techniques	  (Lam	  et	  al.,	  2013b).	  	  
Surgery	  	  
All	   the	   treatments	   discussed	   so	   far	   are	   largely	  modulatory	   in	  mechanisms,	   associated	  with	  minor	  
anatomical	   alteration	   (with	   the	   exception	   of	   capsaicin-­‐induced	   denervation).	   In	   the	   early	   19th	  
century,	   neurosurgery	   was	   commonly	   used	   to	   treat	   intractable	   pain.	   Many	   neurosurgical	  
interventions,	   such	   as	   lesions	   of	   the	   spinothalamic	   tract,	   showed	   initial	   promise,	   only	   for	   the	  
analgesia	  to	  subside	  and	  be	  replaced	  with	  pathological	  sensations	  ranging	  from	  numbness	  and	  slight	  
tingling	   to	   constant	   lancinating	   pain	   worse	   than	   the	   original	   complaint.	   Furthermore,	   surgery	  
performed	  on	  individuals	  who	  were	  misdiagnosed	  would	  result	  in	  permanent	  nerve	  damage	  without	  
the	  potential	  for	  benefit	  (Giller,	  2003).	  The	  apparent	  initial	  success	  of	  these	  approaches	  may	  be	  due	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to	   a	   placebo	   effect	   associated	   with	   surgery	   itself,	   however	   modern	   treatment	   advises	   against	  
surgical	   intervention	   in	   all	   but	   the	   most	   intractable	   and	   distressing	   pain	   conditions.	   However,	  
modern	   techniques	  of	  neuroablation	   show	  promise	   for	   conditions	   including	  CRPS	  and	   failed	   lower	  
back	  surgery	  syndrome	   (Raslan	  et	  al.,	  2007).	  Neuroablation	   involves	   the	   temporary	   insertion	  of	  an	  
electrode	  into	  neural	  tissue	  and	  generation	  of	  a	  high	  frequency	  alternating	  current	  which	  heats	  and	  
de-­‐activates	   surrounding	   tissue.	   Techniques	   involving	   extremely	   low	   temperatures,	   cryogenic	  
neuroablation	   (or	   cryosurgery)	   to	   similarly	   ‘burn’	   target	   tissue	   have	   also	   shown	   some	   benefit	   in	  
lower	  back	  pain	   (Stelzer	  et	  al.,	  2013),	  although	  the	  quality	  of	   this	  evidence	   is	   low,	  as	  evidenced	  by	  
the	   single	   Cochrane	   review	   into	   the	   efficacy	   of	   neuroablation,	   which	   found	   only	   one	   high	   quality	  
study,	  showing	  no	  significant	  benefits	  associated	  with	  sympathectomy	  (Straube	  et	  al.,	  2013).	  	  
Development	  of	  Future	  Analgesic	  Therapies	  	  
One	   of	   the	   major	   obstacles	   to	   development	   of	   effective	   analgesics	   is	   high	   heterogeneity	   within	  
patient	  populations.	  Resistance	  to	  opioids	  is	  common,	  with	  fentanyl	  effective	  in	  only	  50-­‐60%	  of	  the	  
population	  (Landau	  et	  al.,	  2008).	  Therefore,	  strategies	  such	  as	  stratified	  and	  personal	  medication	  are	  
becoming	  more	  widely	  used	  (Baron	  et	  al.,	  2012;	  Demant	  et	  al.,	  2014).	  These	  aim	  to	  use	  predictors	  
that	  identify	  individuals	  who	  will	  benefit	  from	  a	  particular	  treatment	  (e.g.	  high	  efficacy,	  low	  toxicity),	  
and	  those	  for	  whom	  other	  options	  should	  be	  pursued	  (e.g.	  low	  efficacy,	  high	  toxicity).	  	  
1.4 Detecting	  Nocifensive	  Responses	  in	  Animals	  	  
The	  problems	  associated	  with	  assessing	  and	  studying	  pain	   in	  non-­‐human	  organisms	  are	  due	  to	  the	  
fact	  that	  primary	  clinical	  assessments	  of	  pain	  are	  verbal	  (e.g.	  VAS	  rating	  scales).	  Not	  all	  patients	  are	  
able	   to	  adequately	   communicate	   (e.g.	   coma	  patients,	   young	   children	  and	  babies,	   and	   the	  elderly),	  
thus	  it	  is	  essential	  we	  are	  able	  to	  detect	  and	  characterise	  pain	  when	  we	  are	  unable	  to	  ask	  the	  patient	  
to	  describe	  how	  they	  feel.	  	  
Pain	  is	  not	  unique	  in	  this	  respect	  -­‐	  any	  condition	  with	  a	  strong	  neurological	  component	  is	  subject	  to	  
problems	  when	  translating	  from	  the	  clinical	  situation	  to	  in	  vivo	  modelling.	  Further	  understanding	  of	  
how	   behaviour	   changes,	   and	   identification	   of	   related	   biomarkers	   benefits	   both	   basic	   researchers,	  
striving	   to	   improve	   existing	  models	   and	   accurately	   interpret	   what	   they	   observe,	   and	   clinicians	   by	  
providing	  an	  objective	  means	  of	  diagnosis.	  	  
The	  first	  hurdle	  is	  to	  define	  pain	  in	  non-­‐human	  species.	  To	  do	  this,	  one	  must	  identify	  what	  signs	  an	  
animal	   displays	   when	   injured,	   such	   as	   changes	   in	   posture,	   attending	   to	   the	   injured	   area,	   or	  
vocalising.	  Many	   of	   these	   are	   also	   recognisable	   as	   human	   responses	   to	   pain,	   and	   are	   emotionally	  
driven	   behaviours	   that	   can	   be	   classified	   as	   protective	   or	   defensive.	   Due	   to	   the	   involvement	   of	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emotional	   and	   cognitive	   elements,	   it	   is	   important	   to	   think	   ethologically	   when	   translating	   such	  
behaviours	   into	   animal	  models.	   Identification	   of	   innate	   behaviours	   observed	   in	   the	  model	   animal,	  
awareness	   of	   their	  wild	   behaviours	   and	   of	   how	   they	   react	   to	   naturalistic	   stimuli	   under	   laboratory	  
conditions	   is	  key	   to	  development	  of	   robust	  behavioural	  measures	  capable	  of	  detecting	  nociceptive	  
changes.	   Paradigms	   designed	   to	   detect	   these	   behavioural	   patterns	   are	   largely	   observational,	   and	  
measure	  interaction	  with	  a	  test	  environment	  using	  outcomes	  such	  as	  burrowing	  activity,	  exploration,	  
and	  thigmotaxis.	  	  	  
Compared	  to	  behavioural	  changes,	  sensory	  nociceptive	  alterations	  perhaps	  associated	  with	  pain	  are	  
much	   easier	   to	   investigate	   in	   animal	   models,	   and	   form	   the	   basis	   of	   pre-­‐clinical	   research	   into	  
understanding	  and	  treatment	  of	  pain.	  Sensitivity	  to	  mechanical,	  thermal,	  and	  cold	  stimuli	  is	  still	  the	  
most	  common	  outcome	  measures,	  used	  both	  in	  basic	  research	  to	  determine	  nocifensive	  phenotype,	  
and	  in	  pre-­‐clinical	  drug	  trials	  to	  detect	  analgesic	  effect.	  	  
Terminology	   is	   important	   to	   avoid	   misinterpretation	   of	   findings	   –	   use	   of	   words	   such	   as	   “pain”,	  
“allodynia”,	  and	  “anxiety/depression”	   implies	  knowledge	  of	   internal	  conscious	  experience.	   Instead,	  
words	   such	  as	  nociceptive/neuropathic,	  hypersensitivity,	   and	  affective	   changes	  are	  more	  objective	  
when	  applied	  to	  what	  is	  seen	  in	  animal	  models,	  and	  avoids	  the	  assumption	  that	  what	  is	  seen	  in	  the	  
animal	  is	  directly	  equivalent	  to	  that	  seen	  in	  man.	  	  
Evoked	  Sensory	  Reflexes	  	  	  
Detecting	   sensory	   abnormalities,	   and	   responses	   to	   temperature	   (heat/cold),	   pressure,	   and	   touch,	  
rely	   on	  measuring	   the	   latency	   to	   respond,	   or	   response	   threshold,	   defined	   as	   point	   of	   withdrawal	  
from	  the	  stimulus.	  	  
These	  evoked	  measures	  of	  experimental	  nociception	  approximate	   the	   sensory	   testing	  of	  QST	  used	  
clinically	  (Pfau	  et	  al.,	  2014).	  Von	  Frey	  filaments	  are	  used	  to	  assess	  mechanical	  withdrawal	  thresholds	  
-­‐	   these	   consist	   of	   a	   set	   of	   calibrated	   hairs	   or	   glass	   fibres,	   which	   produce	   a	   defined	   pressure	   on	  
contact.	  They	  are	  sequentially	  applied	  to	  the	  affected	  area	  (most	  commonly	  hind-­‐paw)	  following	  an	  
"up-­‐down"	  protocol	  (Chaplan	  et	  al.,	  1994).	  Electronic	  devices,	  such	  as	  that	   illustrated	  in	  Figure	  1-­‐4,	  
can	   be	   used	   in	   place	   of	   von	   Frey	   hairs,	   and	   apply	   ramped	   pressure	   to	   a	   point	   on	   the	   hindpaw,	  
measuring	  the	  point	  of	  withdrawal.	  Measurements	  are	  typically	   repeated	  3-­‐5	  times,	   for	  both	  hind-­‐
paws,	   and	   the	   average	  withdrawal	   threshold	   for	   each	   calculated.	   However,	   in	  models	   involving	   a	  
unilateral	   neuropathy,	   effects	   have	   been	   documented	   contralateral	   to	   the	   site	   of	   nerve	   injury	  
(Seltzer	  et	  al.,	   1990),	   although	  not	  always	   in	   the	  early	  post-­‐operative	   stages	   (Kim	  &	  Chung,	  1992),	  
mimicking	   the	   situation	   seen	   clinically	   (Konopka	   et	   al.,	   2012);	   therefore	   it	   is	   important	   to	   always	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compare	   observations	   with	   those	   seen	   in	   naïve	   and	   sham	   surgery	   animals,	   rather	   than	   using	   the	  
‘uninjured’	  side	  in	  animals	  with	  neuropathy.	  	  	  
	  
Figure	  1-­‐4:	  Measurement	  of	  evoked	  nociceptive	  outcomes	  
From	  left	  to	  right:	  electronic	  mechanical	  stimulator	  for	  measurement	  of	  mechanical	  thresholds;	  Hargreaves	  Apparatus	  for	  measurement	  of	  
thermal	  thresholds;	  Acetone	  drops	  used	  to	  test	  cold	  thresholds	  
However,	   mechanical	   sensitivity	   exhibits	   location-­‐associated	   variation	   due	   to	   differences	   in	  
innervation	   density,	   skin	   thickness	   and	   hairiness,	   and	   also	   circadian	   variations,	   with	   significantly	  
higher	  thresholds	  noted	  between	  3pm	  and	  7pm	  (Minett	  et	  al.,	  2014).	  Additionally,	  there	  are	  multiple	  
nerves	  innervating	  the	  surface	  of	  the	  hind-­‐paw;	  the	  peroneal	  nerve	  innervates	  the	  dorsal	  hind-­‐paw,	  
with	  the	  ventral	  paw	  receiving	  innervation	  from	  the	  saphenous,	  tibial,	  and	  sural	  nerves	  as	  shown	  in	  
Figure	  1-­‐5	  (Kambiz	  et	  al.,	  2014).	  Therefore,	   it	   is	   important	  to	  match	  test	  location	  with	  the	  target	  of	  
the	  nerve(s)	  affected.	  
Thermal	  sensitivity	  can	  be	  assessed	  using	  radiant	  heat	  (e.g.	  Hargreaves)	  or	  contact	  (e.g.	  Tail-­‐flick	  and	  
hot-­‐plate)	  and	  is	  typically	  recorded	  as	  latency	  to	  withdrawal.	  Thermal	  thresholds	  are	  thought	  to	  be	  
highly	  conserved	  –	  nociceptive	  fibres	  respond	  to	  a	  range	  of	  temperature	  stimuli	  through	  activation	  of	  
Transient	  Receptor	  Potential	  Vanilloid	  (TRPV)	  family	  receptors	  as	  summarised	  in	  table	  1-­‐1.	  	  	  
Table	  1-­‐1:	  Activation	  thresholds	  for	  selected	  TRP	  receptors	  involved	  in	  temperature	  sensation	  
(Benham	  et	  al.,	  2003;	  Bevan	  &	  Andersson,	  2009;	  Babes	  et	  al.,	  2011)	  
	   TRPV1	   TRPV2	   TRPV3	   TRPV4	   TRPM8	   TRPA1	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  Figure	  1:.5:	  Innervation	  of	  the	  Rat	  Hindpaw	  
Illustrating	  the	  major	  points	  of	  surgery	  involved	  in	  models	  of	  peripheral	  neuropathy	  	  and	  the	  different	  regions	  of	  the	  hindpaw	  
affected	  
	  	  	  
	  	  
40	  
Sensitivity	  to	  cold	  can	  be	  detected	  through	  use	  of	  cold	  plate	  (Yoon	  et	  al.,	  1994),	  or	  through	  topical	  application	  of	  
compounds	  such	  as	  acetone	  (Walczak	  &	  Beaulieu,	  2006),	  which	  cools	  skin	  via	  evaporation,	  methanol	  (Zhao	  et	  al.,	  
2012)	  which	  activates	  TRPA1	  receptors	  in	  the	  skin,	  or	  icilin,	  a	  specific	  TRPM8	  super	  agonist	  (Dhaka	  et	  al.,	  2007).	  	  	  
Deep	   mechanical	   and	   pressure-­‐associated	   pain	   can	   be	   measured	   using	   the	   Randall-­‐Selitto	   test	  
(Randall	  &	  Selitto,	  1957;	  Falk	  et	  al.,	  2014),	  which	  involves	  graded	  application	  of	  pressure	  to	  a	  limb	  or	  
the	   tail,	  with	   latency	   to	  struggle	   taken	  as	  an	  endpoint.	  However,	   this	   test	   requires	   restraint	  of	   the	  
animal,	  which	  can	  be	  associated	  with	  stress-­‐induced	  analgesia	  (Imbe	  et	  al.,	  2006).	  	  
One	   of	   the	   primary	   concerns	   with	   basing	   pharmaceutical	   investigations	   of	   pain	   on	   the	   ability	   to	  
reverse	   mechanical	   or	   thermal	   hypersensitivity	   is	   that	   chronic	   pain	   patients	   show	   both	  
hyposensitivity	  (lack	  of	  sensation	  and	  other	  negative	  signs)	  and	  hypersensitivity	  (Maier	  et	  al.,	  2010).	  
Therefore	  developing	  methods	  to	  detect	  the	  other	  aspects	  of	  the	  pain	  experience	  have	  the	  potential	  
to	  increase	  translation	  between	  basic	  research	  and	  drug	  development.	  
Behavioural	  Alterations	  Associated	  with	  Pain	  	  
Behavioural	  assessment	  of	  pain	   is	  one	  of	   the	  earliest	  methods	  used	   in	   the	  study	  of	  pain	  due	  to	   its	  
simplicity.	   Observation	   of	   behaviour	   following	   application	   of	   an	   irritant	   compound,	   such	   as	   CFA	  
(Fehrenbacher	  et	  al.,	  2012)	  or	  i.p.	  acetic	  acid	  (AA;	  Depoortère	  et	  al.,	  2011),	  can	  reveal	  characteristic	  
behavioural	  signs	  which	  follow	  a	  predictable	  time-­‐course.	  Behavioural	  observation	   in	  these	  models	  
involves	  counting	  the	  frequency	  of	  behaviours	  such	  as	  licking	  (CFA)	  and	  writhing	  (AA)	  at	  defined	  time	  
points.	  	  
More	  complex	  behavioural	  assays	  can	  be	  used	  to	  reveal	  subtle	  changes	  in	  behaviour	  associated	  with	  
the	   affective	   and	   cognitive	   elements	   of	   a	   nociceptive	   experience.	   Much	   has	   been	   learnt	   from	  
research	  on	  psychiatric	  disorders,	   such	  as	  anxiety	  and	  depression	  (Walsh	  &	  Cummins,	  1976;	  Lister,	  
1990;	   Cryan	  &	  Holmes,	   2005),	   and	   it	   is	   now	   routine	   to	   use	  models	   originally	   developed	   to	   detect	  
behavioural	  alterations	  associated	  with	  these	  conditions	  in	  pain	  research.	  	  
Rats	   and	   mice,	   the	   most	   commonly	   studied	   experimental	   animals,	   are	   also	   prey	   animals.	   This	   is	  
associated	  with	   an	   inherent	   tendency	   to	  minimise	  behaviours	   that	   alert	   predators	   to	   a	   vulnerable	  
state	   (Barnett,	   2001).	   Although	   humans	   are	   not	   prey	   animals,	   they	   still	   display	   an	   analogous	  
modulation	  of	  pain	  signs	  dependent	  on	  situation,	  and	  often	  showing	  a	  social	  component	  (Craig	  et	  al.,	  
1991).	   To	   detect	   these	   subtle	   changes	   in	   behaviour,	   we	   must	   first	   understand	   how	   the	   animal	  
interacts	   with	   their	   environment,	   and	   how	   they	   exist	   in	   the	   wild.	   For	   example,	   rats	   are	   social	  
creatures,	  which	  live	  in	  colonies	  numbering	  into	  the	  hundreds	  (Barnett,	  2001)	  and	  would	  find	  being	  
housed	  individually	  a	  stressful	  experience	  (Gambardella	  et	  al.,	  1994;	  Brown	  &	  Grunberg,	  1995;	  Okura	  
et	  al.,	  2009),	  whereas	  mice	  are	  comparatively	  solitary,	  and	  are	   frequently	  housed	   individually	  with	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comparatively	   little	   effect	   (Jirkof	   et	   al.,	   2012),	   although	   sex-­‐related	   differences	   in	   this	   have	   been	  
noted,	   with	   solitary	   housing	   decreasing	   exploration	   in	   female	  mice,	   with	   the	   reverse	   observed	   in	  
males	  (Palanza,	  2001).	  	  
The	  Open	  Field	  Paradigm	  	  
The	   open	   field	   paradigm	   was	   developed	   in	   1934	   (Hall,	   1934)	   to	   detect	   emotionality	   in	   rats.	   The	  
original	  paradigm	   involved	  a	   large	   circular	   arena	   (1.2m	  diameter)	   and	   featured	   food	  placed	  within	  
the	  arena	  to	  test	  how	  hunger	  status	  influenced	  exploration.	  It	  was	  noted	  that	  animals	  that	  had	  eaten	  
showed	  increased	  ambulation,	  but	  not	  all	  animals	  ate,	  and	  those	  that	  didn’t	  eat	  showed	  decreased	  
inner	  zone	  activity	  and	  increased	  defecation.	  This	   increased	  defecation,	  and	  associated	  decrease	   in	  
digestive	   transit	   time	   was	   seen	   as	   an	   indication	   of	   increased	   emotionality,	   and	   for	   a	   long	   time,	  
defecation	   rates	   in	   the	  open	   field,	   in	   combination	  with	  general	  measures	  of	  ambulation,	  were	   the	  
primary	   outcomes	   measures,	   with	   high	   defecation	   and	   low	   ambulation	   taken	   as	   indicative	   of	  
increased	  emotionality	  (Walsh	  &	  Cummins,	  1976).	  Thigmotaxis,	  as	  defined	  by	  movement	  in	  parallel	  
with	  the	  walls,	  was	  evident	  in	  this	  early	  study,	  but	  not	  suggested	  as	  a	  valid	  outcome	  measure	  until	  
much	   later.	   Other	   outcomes	   measures	   highlighted	   as	   being	   robust	   and	   useful	   included	   rearing	  
activity	   (Ivinskis,	  1968),	  although	  the	  measurement	  of	   rearing	   fell	  out	  of	   favour	  with	  the	  advent	  of	  
automated	  scoring	  systems,	  which	  are	  adept	  at	  quantifying	  horizontal	  movement,	  but	  less	  accurate	  
on	  ‘vertical	  activity’	  such	  as	  rearing.	  These	  early	  studies	  often	  involved	  a	  multi-­‐factorial	  factor	  design,	  
and	   although	   the	   sample	   sizes	   are	   small	   and	   not	   justified	   by	   sample	   size	   calculations,	   significant	  
differences	  attributable	  to	  environmental	  enrichment	  (McCall	  et	  al.,	  1969),	  illumination	  levels	  (Valle,	  
1970),	   and	   early	   life	   experiences	   (Whimbey	   &	   Denenberg,	   1967a;	   Whimbey	   &	   Denenberg,	  
1967b)were	   detected.	   Repeated	   exposure	   was	   also	   investigated,	   with	   decreases	   in	   ambulation	  
observed	  over	   time	   (Hall,	   1934),	   and	  during	   the	   course	   of	   each	   trial	   (Lát	  &	  Gollová-­‐Hémon,	   1969;	  
Oldham	  &	  Morlock,	  2013).	  	  	  
An	  alternative	  method	  of	  interpreting	  open	  field	  activity	  was	  proposed	  by	  Lát	  and	  Gollová-­‐Hémon	  in	  
1969,	   who	   suggested	   a	   continuum	   of	   arousal,	   with	   rearing	   representing	   the	   peak	   of	   arousal,	   and	  
sleeping/immobility	   at	   the	   lower	   end	   as	   indicated	   in	   Table	   1-­‐2,	   corresponding	   with	   characteristic	  
hippocampal	  slow	  wave	  activity	  (Lát	  &	  Gollová-­‐Hémon,	  1969).	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Table	  1-­‐2:	  Arousal	  continuum	  for	  rat	  behaviour	  in	  the	  open	  field	  
(Lát	  &	  Gollová-­‐Hémon,	  1969)	  	  
High	  Arousal	   	   	   	   	   Low	  Arousal	  
Rearing	   Locomotor	  Activity	   Sniffing	   Cleaning	   Sitting	   Sleeping	  
Automated	  scoring	  of	  open	   field	  behaviour	  was	   introduced	   in	   the	  1970s,	  with	   the	  aim	  of	   reducing	  
observer	   bias	   (Delbarre	  et	   al.,	   1970),	   and	   is	   now	  widespread.	  As	   alluded	   to	   earlier,	   this	  may	  have	  
skewed	  the	  selection	  of	  relevant	  behaviours	  by	  biasing	  towards	  those	  most	  simple	  to	  detect	  such	  as	  
spatial	   and	   temporal	  patterns	  of	   ambulation,	   at	   the	  expense	  of	  more	   complex	  behaviours	   such	  as	  
sniffing	   and	   grooming.	   This	   initial	   study	   of	   automation	   utilised	   a	   beam-­‐breaking	  method,	   allowing	  
quantification	  of	  vertical	  activity	  (i.e.	  rearing),	  although	  the	  majority	  of	  systems	  used	  currently	  focus	  
on	  2D	  video	  capture	  of	  horizontal	  movement,	  with	  rearing	  activity	  often	   ignored	  due	  to	  difficulties	  
defining	   rearing	   activity	   associated	   with	   overhead	   image	   capture	   techniques	   such	   as	   Ethovision	  
(Noldus	  et	  al.,	  2001).	  The	  main	  advantage	  of	  such	  video	  tracking	  software	  is	  that	  minimal	  specialist	  
equipment	  is	  required,	  compared	  to	  more	  sophisticated,	  and	  therefore	  most	  costly	  options	  such	  as	  
bespoke	   open	   field	   systems	   which	   utilise	   infra-­‐red	   beam-­‐break	   detection	   of	   vertical	   movement	  
(Tatem	  et	  al.,	  2014).	  The	  combination	  of	  automated	  video	  software	  with	  manual	  observer	  scoring	  of	  
behaviours	   such	   as	   rearing	   offers	   a	   cost-­‐effective	   way	   of	   maximising	   data	   collected,	   as	   well	   as	  
providing	   experimenters	   with	   a	   permanent	   record	   of	   the	   raw	   data,	   which	   offers	   the	   benefit	   of	  
allowing	  independent	  analysis,	  and	  re-­‐analysis	  using	  different	  techniques.	  	  
Thigmotaxis	  overtook	  defecation	  as	  a	  measure	  of	  emotionality	  during	   the	  1980s,	  due	   to	   increased	  
use	   of	   automated	   detection,	   evidence	   of	   poor	   predictive	   value	   of	   emotionality	   (Wilcock	   &	  
Broadhurst,	   1967;	   Whimbey	   &	   Denenberg,	   1967a;	   Blizard,	   1971),	   and	   the	   suggestion	   that	  
‘emotionality’	  is	  not	  necessarily	  a	  characteristic	  which	  is	  dramatically	  influenced	  by	  a	  single	  exposure	  
(Candland	   &	   Nagy,	   1969).	   Thigmotactic	   behaviour	   is	   characterised	   by	   movement	   in	   relation	   to	   a	  
surface,	  and	  can	  take	  both	  positive	  (preference	  for	  proximity	  to	  a	  surface,	  e.g.	  “the	  tendency	  to	  run	  
in	   contact	   with	   objects”)	   and	   negative	   (avoidance)	   forms.	   It	   was	   first	   noted	   in	   protozoa	   such	   as	  
paramecium	   (Kline,	   1899),	   and	   positive	   thigmotactic	   behaviour	   (henceforth	   simply	  
‘thigmotactic/thigmotaxis’)	   was	   subsequently	   described	   during	   aversive	   social	   situations	   in	   rats	  
during	  the	  1920s	  (Stone,	  1926;	  Sturman-­‐Hulbe	  &	  Stone,	  1929).	  In	  the	  1970s	  thigmotactic	  behaviour	  
was	  observed	  in	  rats	  following	  electric	  shocks	  (Grossen	  &	  Kelley,	  1972),	  and	  subsequently	  suggested	  
as	  representative	  of	  anxiety	  in	  the	  open	  field	  paradigm	  (Walsh	  &	  Cummins,	  1976).	  In	  initial	  open	  field	  
studies,	   low	   inner	   zone	   activity	   (high	   thigmotaxis)	   was	   noted	   in	   high	   emotionality	   subjects	   (Hall,	  
1934),	   and	   included	   as	   a	   measure	   of	   ‘timidity’	   (Morrison	   &	   Thatcher,	   1969;	   King,	   1970)	   which	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showed	  no	  significant	   sex	  differences	   (Valle,	  1970).	  However,	   it	  was	  also	  described	  as	  having	  poor	  
reliability,	   despite	   showing	   a	   negative	   correlation	   with	   ambulation	   (Ivinskis,	   1968),	   which	  may	   be	  
related	  to	  imprecision	  in	  the	  methods	  then	  used	  to	  quantify	  behaviour.	  Later	  studies	  emphasised	  the	  
link	   between	   thigmotaxis	   and	   anxiety	   via	   the	   effects	   of	   social	   isolation	   in	   combination	   with	  
‘agoraphobia’	  suggested	  by	  the	  aversive	  nature	  of	  unfamiliar	  spaces	  (Prut	  &	  Belzung,	  2003),	  although	  
this	   contradicts	   earlier	   studies	   indicating	   ambulation	   increases	   proportional	   to	   open	   field	   size	  
(Blizard,	  1971).	  It	  has	  also	  been	  shown	  that	  thigmotactic	  behaviour,	  at	  least	  in	  mice,	  is	  dependent	  on	  
environmental	  awareness,	  as	  evidenced	  by	  mice	  without	  vibrissae	  showing	  very	  low	  thigmotaxis	  and	  
high	  inner	  zone	  activity	  (Prut	  &	  Belzung,	  2003).	  Furthermore,	  thigmotaxis	  has	  been	  recently	  noted	  as	  
corresponding	  with	  general	  phobic	  avoidance	  and	  decreased	  working	  memory	   function	   in	  humans	  
(Kallai	  et	  al.,	   2007).	   In	   rats,	   it	   shows	  an	   inverse	   relationship	  with	  exploration	  of	  novel	  areas	  and	   is	  
hypothesised	   as	   related	   to	   risk	   assessment	   and	   predator	   avoidance,	   with	   the	   presence	   of	  
spontaneous	  or	  on-­‐going	  pain	  decreasing	  potentially	  risky	  behaviours,	  such	  as	  exploration.	  The	  open	  
field	   paradigm	   is	   capable	   of	   detecting	   these	   thigmotactic	   differences	   in	   experimental	   models	   of	  
neuropathic	   pain	   with	   varying	   aetiologies	   including	   antiretroviral	   therapy-­‐induced	   neuropathy	  
(Wallace	  et	  al.,	  2007b;	  Wallace	  et	  al.,	  2008;	  Huang	  et	  al.,	  2013),	  chemotherapy-­‐induced	  neuropathy	  
(Barzegar-­‐Fallah	  et	  al.,	  2014),	   spinal	  nerve	   transection	   (SNT;	   	  Blackbeard	  et	  al.,	  2012),	   spinal	  nerve	  
ligation	  (Kontinen	  et	  al.,	  1999;	  Suzuki	  et	  al.,	  2007;	  Ewan	  &	  Martin,	  2014),	  chronic	  constriction	  injury	  
(CCI;	  Grégoire	  et	  al.,	  2012),	  and	  post-­‐traumatic	  peripheral	  nerve	  trauma	  (Medico	  et	  al.,	  2004).	  	  	  
Studies	   have	   shown	   decreases	   in	   open	   field	   activity	   in	   rats	   associated	   with	   pre-­‐clinical	  models	   of	  
myocardial	  infarction	  (Banozic	  et	  al.,	  2014),	  following	  indole-­‐3-­‐acetic–induced	  gastritis	  in	  female	  but	  
not	  male	  rats	  (Luo	  et	  al.,	  2013),	  with	  a	  mixed	  picture	  regarding	  IBS,	  with	  both	  decreases	   in	  activity	  
(Zhang	   et	   al.,	   2014a),	   and	   no	   effect	   noted	   (Traub	   et	   al.,	   2008).	   In	   mice,	   similar	   decreases	   in	  
locomotor	   activity	   have	   been	   seen	   following	   administration	   of	  mustard	   oil	   (Maia	  et	   al.,	   2006),	   AA	  
((Hu	  et	  al.,	  2009b),	  and	  TNBS	  (Cattaruzza	  et	  al.,	  2013).	  None	  of	  these	  studies	  explicitly	   investigated	  
thigmotaxis,	  with	   inner	   zone	  activity	  only	  noted	   in	   a	   few	   studies	   (Zhong	  et	  al.,	   2012;	   Zhang	  et	  al.,	  
2014a),	  most	  using	  immobility	  or	  ambulation/distance	  travelled	  as	  primary	  outcome	  measures.	  	  
	   	  




Many	  fossorial	  mammals,	  birds,	  reptiles,	  and	  insects	  engage	  in	  burrowing	  behaviour	  (Kinlaw,	  1999).	  	  
They	  can	  be	  categorised	  as	  follows:	  	  
1) Primary	  excavators	  	  
a) dig	  their	  own	  tunnels	  from	  scratch	  	  
2) Secondary	  modifiers	  	  
a) inhabit	  and	  modify	  burrow	  systems	  created	  by	  another	  	  
3) Tertiary	  occupants	  	  
a) inhabit	  without	  contributing	  to	  or	  modifying	  the	  existing	  burrow	  structure	  	  
Rats	   are	   an	   example	   of	   primary	   excavators,	   and	   in	   the	   wild,	   live	   underground	   in	   large	   colonies	  
(Barnett,	  2001).	  In	  the	  wild,	  burrowing	  is	  a	  necessary	  survival	  skill	  –	  a	  rat	  with	  poor	  burrowing	  skills	  
will	   rapidly	   be	   exposed	   to	   increased	   risk	   of	   predation.	   Laboratory	   rats,	   despite	   their	   divergent	  
appearance	   from	  their	  originator	   strain,	   readily	  burrow	  when	  given	   the	  opportunity	   (Stryjek	  et	  al.,	  
2012).	  Since	  the	   late	  70s,	   researchers	  have	  studied	  the	  burrowing	  habits	  of	   rats	  and	  other	  rodents	  
(Boice,	   1977;	   Deacon,	   2009;	   Stryjek	   et	   al.,	   2012).	   Early	   studies	   tended	   to	   focus	   on	   qualitative	  
observation	  of	  burrowing	  activities,	  highlighting	  associations	  with	  morphine	  withdrawal	   (Livingston	  
et	  al.,	  1988;	   Jones	  &	  Barr,	  1995),	  orexin	  treatment	  (Ida	  et	  al.,	  1999)	  and	  maternal	  behaviour	   (Jirik-­‐
Babb	  et	  al.,	  1984;	  Kosten	  &	  Kehoe,	  2010).	  Following	  on	  from	  this,	   the	  burrowing	  detour	  study	  was	  
developed,	   featuring	   obstruction	   of	   a	   familiar	   route	   that	   could	   only	   be	   bypassed	   by	   burrowing	  
(Holson,	   1986;	   Ferguson	   et	   al.,	   1998;	   Tran	   et	   al.,	   2002).	   During	   the	   early	   2000s’,	   a	   quantitative	  
burrowing	   assay	   was	   developed,	   based	   on	   displacement	   of	   the	   burrowing	   substrate,	   and	   found	  
sensitive	   to	   behavioural	   changes	   associated	   with	   prion	   diseases	   (Guenther	   et	   al.,	   2001;	   Deacon,	  
2009),	   hippocampal	   lesions	   (Deacon	  et	   al.,	   2002),	   and	  numerous	   aetiologies	  of	   experimental	   pain,	  
including	  traumatic	   (Andrews	  et	  al.,	  2012;	  Lau	  et	  al.,	  2013),	  drug-­‐induced	  (Huang	  et	  al.,	  2013),	  and	  
inflammatory	   models	   (Rutten	   et	   al.,	   2014b).	   Pharmacological	   validation	   has	   shown	   that	   the	  
burrowing	  deficits	  observed	  in	  experimental	  models	  of	  pain	  are	  associated	  with	  nociception	  and	  the	  
associated	  affective	  and	  cognitive	  alteration,	  as	  stimulants	  such	  as	  amphetamine,	  anxiogenics,	  and	  
anxiolytics	   have	   no	   effect	   (Rutten	   et	   al.,	   2014a),	   whilst	   drugs	   such	   as	   pregabalin,	   carbamazepine,	  
naproxen,	  and	  morphine	  effectively	  reverse	  observed	  deficits	  (Andrews	  et	  al.,	  2012;	  Lau	  et	  al.,	  2013).	  	  	  
Other	  Behavioural	  Paradigms	  	  
Other	   non-­‐conditioned,	   exploration-­‐based	   paradigms	   are	   frequently	   used	   to	   detect	   pain-­‐related	  
behavioural	   alterations,	   such	   as	   the	   elevated	   plus	   maze	   (Parent	   et	   al.,	   2012),	   the	   light-­‐dark	   box	  
(Zhang	   et	   al.,	   2014a),	   and	   social	   interaction	   (Li	   et	   al.,	   2014b),	   although	   most	   emphasise	   these	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outcomes	   as	   related	   to	   anxiety	   rather	   than	   general	   behavioural	   changes	   related	   to	   nociceptive	  
stimulation.	  	  
As	  brain	  areas	  such	  as	  the	  amygdala	  are	  implicated	  in	  both	  nociceptive	  responses	  and	  generation	  of	  
conditioned	  responses,	  studies	   investigating	  differences	   in	  conditioned	  responses	  are	   instructive	   in	  
elucidating	  how	  pain	  and	  nociceptive	  stimuli	  change	  behaviour.	  Conditioned	  place	  preference	  (CPP),	  
traditionally	  used	  to	  investigate	  addictive	  properties	  of	  drugs	  of	  abuse	  (Jian	  et	  al.,	  2014),	  can	  be	  used	  
to	  detect	  analgesic	  efficiency	  by	  pairing	  a	  context	  with	  analgesic	  treatment	  and	  observing	  whether	  
animals	  subjected	  to	  neuropathy	  display	  a	  preference	  for	  that	  environment	  (as	  would	  be	  expected	  if	  
pain	   is	  being	  relieved).	  CPP	  for	  clonidine	  has	  been	  demonstrated	   in	  models	  of	  spinal	  nerve	   ligation	  
(King	   et	   al.,	   2009),	   sciatic	   axotomy	   (Qu	   et	   al.,	   2011),	   spinal	   cord	   lesion	   models	   of	   central	   pain	  
(Davoody	  et	  al.,	  2011),	  spared	  nerve	  injury	  (SNI;	  Wei	  et	  al.	  2013),	  and	  for	  gabapentin	  in	  a	  model	  of	  
cisplatin-­‐induced	  peripheral	  neuropathy	   (Park	  et	  al.,	  2013).	  Morphine	   is	  also	  used	  to	  test	  analgesia	  
place	  preference,	  but	  shows	  hedonic	  effects	  in	  naïve	  animals	  reducing	  the	  ability	  to	  properly	  assess	  
analgesic	   effect,	   although	   the	   shape	   of	   the	   dose-­‐response	   curve	   in	   CCI	   differs	   from	   that	   seen	   in	  
naïve,	  emphasising	  the	  neural	  plasticity	  seen	  in	  neuropathic	  pain	  (Cahill	  et	  al.,	  2013).	  	  
Place	  preference/avoidance	  paradigms	  have	  also	  been	  designed	  to	  detect	  avoidance	  of	  nociceptive	  
stimuli	  indicative	  of	  hypersensitivity,	  with	  thermal	  (Yezierski	  et	  al.,	  2010)	  and	  mechanical	  (LaBuda	  &	  
Fuchs,	  2000)	   stimuli	   studied	   thus	   far,	  although	  operant	  paradigm	  such	  as	   these	   require	   training	  of	  
the	   animals,	   which	   could	   bias	   results	   though	   subtle	   differences	   in	   handling	   between	   groups,	   in	  
addition	  to	  entailing	  increased	  labour	  and	  equipment	  costs	  which	  may	  not	  be	  feasible	  for	  all	  research	  
groups.	  	  
A	   recent	   study	   suggests	   the	   use	   of	   facial	   grimace	   analysis	   as	   a	   means	   to	   detect	   responses	   to	  
nociceptive	  and	  neuropathic	  stimuli	  in	  both	  mice	  (Langford	  et	  al.,	  2010a;	  Matsumiya	  et	  al.,	  2012)	  and	  
rats	  (Sotocinal	  et	  al.,	  2011).	  However,	  this	  measure	  only	  detects	  responses	  within	  the	  first	  48	  hours	  
of	  an	  insult,	  and	  has	  yet	  to	  be	  cross-­‐validated.	  	  
However,	  analysis	  of	  complex	  behaviour	  has	  become	  over-­‐reliant	  on	  automated	  systems.	  Whilst	  this	  
saves	  time	  and	  reduces	  the	  sources	  of	  human	  error	  inherent	  in	  manual	  scoring,	  it	  is	  at	  the	  expense	  of	  
giving	  the	  experimenter	  a	  qualitative	   'feel'	   for	  what	   the	  data	  mean	  -­‐	  only	  by	  observing	  can	  you	  be	  
aware	   of	   the	   different	   types	   of	   movement	   exhibited,	   for	   example	   the	   various	   different	   types	   of	  
approach	   to	   the	   central	   zone	   (e.g.	   cautious,	   exhibiting	   stretch-­‐attend	  postures	   versus	  walking	   in	   a	  
straight	  line	  at	  a	  constant	  speed).	  By	  being	  aware	  of	  the	  variation	  present,	  the	  experimenter	  is	  then	  
better	   equipped	   to	   interpret	   behavioural	   data	   collected,	   although	   it	   is	   important	   to	  minimise	   the	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potential	   observer	   effects	   by	   maximising	   distance	   between	   the	   experimenter	   and	   the	   testing	  
apparatus,	  and	  using	  remote	  observation	  or	  other	  means	  of	  hiding	  the	  experimenter	  from	  the	  test	  
animal.	  	  
1.5 Modelling	  ‘Pain’	  in	  Animals	  	  
When	  working	  with	  nociceptive	  models,	   it	   is	  vital	  to	  be	  familiar	  with	  legal	  requirements	  concerning	  
the	   treatment	   of	   animals	   (Zimmermann,	   1983).	   In	   the	   UK,	   the	   Home	   Office	   guidelines	   on	   animal	  
welfare	   state	   that	   "pain,	   suffering,	   distress	  or	   lasting	  harm"	  must	  be	  minimized	  as	   far	   as	  possible,	  
and	  that	  any	  procedure	  causing	  such	  effects	  must	  be	  regulated	  and	  only	  performed	  by	  a	  trained	  and	  
licenced	   individual,	   working	   under	   both	   project	   and	   institutional	   licences	   which	   specify	   which	  
procedures	   can	   be	   performed	   and	   what	   the	   ethical	   endpoints	   of	   each	   procedure	   are.	   Recent	  
amendments	  now	  require	  the	  reporting	  of	  actual	  harm	  incurred	  during	  an	  experiment,	  in	  addition	  to	  
pre-­‐specification	   of	   expected	   severity.	   This	   will	   enable	   regulators	   greater	   awareness	   of	   actual	  
experimental	   conditions,	   allowing	   identification	   of	   refinements	   that	   could	   improve	   experimental	  
validity.	  Piloerection	  and	  weight	  loss	  are	  frequently	  mentioned	  as	  signs	  of	  distress,	  but	  as	  previously	  
noted,	   the	   prey-­‐animal	   status	   of	   most	   rodents	   means	   the	   presence	   of	   such	   signs	   is	   indicative	   of	  
severe	   pain,	   and	   it	   is	   unethical	   to	   permit	   such	   suffering,	   therefore	   are	   not	   recommended	   as	  
experimental	  endpoints.	  Autotomy	  (chewing	  of	  digits)	  is	  another	  outcome	  measure,	  initially	  noted	  in	  
models	  of	  axotomy	  (Blumenkopf	  &	  Lipman,	  1991;	  Kachramanoglou	  et	  al.,	  2011),	  although	  it	   is	  now	  
generally	   recognised	   that	   autotomy	   is	   associated	   with	   denervation	   and	   not	   necessarily	  
representative	  of	  a	  pain	  state.	  Due	  to	  the	  obvious	  distress	  associated	  with	  autotomy,	   its	  use	  as	  an	  
outcome	  measure	  in	  pain	  research	  is	  now	  discouraged.	  	  
When	  designing	  models	  of	  experimental	  pain,	  the	  first	  approach	  is	  to	  recreate	  a	  condition	  known	  to	  
produce	  pain	   clinically;	   nerve	   trauma,	   inflammation,	   viral	   infection	   such	  as	  HIV	  and	  herpes	   zoster,	  
and	  certain	  drugs	  including	  many	  anti-­‐retroviral	  and	  chemotherapeutic	  agents,	  have	  all	  been	  used	  to	  
varying	  degrees	  of	  success.	  	  	  
Traumatic	   nerve	   injury	   models,	   such	   as	   spinal	   nerve	   ligation	   (SNL;	   Kim	   &	   Chung,	   1992;	   and	   the	  
related	  model,	  spinal	  nerve	  transection	  (SNT)),	  and	  chronic	  constriction	   injury	  (CCI,	   (Bennett	  &	  Xie,	  
1988)	  use	  unilateral	  nerve	  damage	  to	  produce	  hypersensitivity	  of	  the	  hind	  paw	  ipsilateral	  to	  the	  site	  
of	  injury,	  analogous	  with	  clinical	  neuropathic	  pain	  conditions	  associated	  with	  nerve	  injury.	  The	  exact	  
presentation	   varies	   between	   models,	   but	   in	   general	   involves	   both	   thermal	   and	   mechanical	  
hypersensitivities,	  as	  well	  as	  behavioural	  responses	  such	  as	  attending	  to	  the	  affected	  area.	  Figure	  1-­‐5	  
illustrates	  the	  involvement	  of	  the	  saphenous,	  tibial,	  sural,	  and	  peroneal	  nerves	  in	  the	  most	  common	  
models	   of	   traumatic	   neuropathy.	   These	   all	   target	   the	   lumbar	   spinal	   region	   which	   innervates	   the	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hindpaw,	  chosen	  for	  its	  well	  defined	  innervation,	  ease	  of	  testing,	  and	  commonality	  with	  the	  majority	  
of	  clinical	  peripheral	  neuropathies,	  which	  target	  the	  longest	  nerve	  in	  the	  body	  i.e.	  those	  innervating	  
the	  feet.	  Occasionally,	  cases	  of	  SNT	  are	  seen	  clinically,	  and	  are	  characterised	  by	  mechanical	  and	  cold	  
hypersensitivity	   in	   the	  affected	  dermatome	   (C7;	  Ali	  et	  al.,	   2002),	  as	  well	   as	  numbness	  and	   tingling	  
(Chuang	   et	   al.,	   1998),	   showing	   some	   overlap	   with	   the	   pre-­‐clinical	   model,	   but	   also	   highlighting	  
differences	  such	  as	  a	  lack	  of	  thermal	  abnormalities.	  	  	  
Chemically-­‐induced	   pain	   can	   be	   investigated	   via	   systemic	   models	   such	   as	   alcohol-­‐associated	  
peripheral	  neuropathy	   (Ferrari	  et	  al.,	   2013b),	   and	  chemotherapy	   (Barzegar-­‐Fallah	  et	  al.,	   2014)	  and	  
anti-­‐retroviral	   induced	   neuropathy	   (Blackbeard	   et	   al.,	   2012),	   or	   localised	   models	   e.g.	   turpentine-­‐
induced	  bladder	   inflammation	   (Jaggar	  et	  al.,	  1999;	  Farquhar-­‐Smith	  &	  Rice,	  2001),	  and	  CFA-­‐induced	  
peripheral	  inflammation	  (Fehrenbacher	  et	  al.,	  2012).	  Application	  of	  most	  known	  irritant	  compounds	  
will	  provoke	  a	  nociceptive	  response.	  The	  CFA,	  carrageenan	  (Iannitti	  et	  al.,	  2012),	  and	  inter-­‐peritoneal	  
AA	   (Kurihara	   et	   al.,	   2003)	   models	   of	   acute	   inflammation	   illustrate	   this	   well.	   These	   models	   result	  
observable	  changes	   in	  behaviour	   (e.g.	  paw	   lifting,	   licking,	  writhing)	  or	   in	  evoked	  measures	   such	  as	  
mechanical	  and	  thermal	  hypersensitivity.	  	  
Anti-­‐Retroviral-­‐Induced	  Neuropathy	  	  
HIV	  affects	  35	  million	  people	  worldwide,	  with	  39%	  currently	  on	  anti-­‐retroviral	   treatment	   regimens	  
(UNAIDS,	   2014).	   This	   represents	   a	   mixed	   population	   of	   patients	   taking	   first	   generation	   NRTIs	  
(nucleoside	  and	  nucleotide	  reverse	  transcriptase	   inhibitors;	  e.g.	  Zidovudine,	  Didanosine,	  Stavudine,	  
and	   Tenofovir),	   second	   generation	   NNTRIs	   (non-­‐nucleotide	   reverse	   transcriptase	   inhibitors;	   e.g.	  
Nevirapine,	   Efavirenz,	   and	   Rilpivirine),	   and	   protease	   inhibitors	   (e.g.	   Indinavir,	   Fortovase,	   and	  
Ritonavir).	  	  
Current	   treatment	   regimens	   recommended	   by	   the	   WHO	   start	   with	   a	   combination	   of	   two	   NTRIs	  
(Tenofovir,	  with	  either	  Lamivudine	  or	  Emtricitabane),	  and	  a	  protease	  inhibitor	  (Efavirenz),	  but	  older	  
drugs,	  such	  a	  Stavudine	  (d4T)	  are	  still	  widely	  used	  in	  the	  developing	  world	  due	  to	  their	  low	  costs	  (Hill	  
et	  al.,	  2007;	  Murphy	  et	  al.,	  2007).	  	  	  
d4T	  is	  a	  NRTI-­‐class	  drug,	  which	  was	  approved	  by	  the	  FDA	  in	  1994	  (Moyle	  &	  Gazzard,	  1997).	  In	  2009	  
the	   WHO	   recommended	   it	   be	   phased	   out	   due	   to	   adverse	   effects	   (WHO,	   2009),	   including	  
lipodystrophy	  (Kampira	  et	  al.,	  2013),	  and	  peripheral	  neuropathy	  characterised	  by	  pain	  and	  numbness	  
in	  the	  extremities	  (Maritz	  et	  al.,	  2010;	  Mullin	  et	  al.,	  2011).	  However,	  it	   is	  still	   included	  on	  the	  WHO	  
List	   of	   Essential	   Medicines	   (WHO,	   2013),	   a	   fact	   that	   recognises	   it	   is	   still	   a	   cheap	   and	   effective	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treatment	   widely	   used	   in	   the	   developing	   world,	   areas	   which	   show	   the	   highest	   infection	   rates	  
(UNAIDS,	  2014).	  	  	  
The	  neuropathic	  symptoms	  seen	  in	  some	  patients	  following	  Stavudine	  treatment	  are	  associated	  with	  
increased	  levels	  of	  fatigue	  (Wantland	  et	  al.,	  2011)	  and	  decreased	  quality	  of	   life	  (Mrus	  et	  al.,	  2005),	  
further	  increasing	  socioeconomic	  burden.	  	  	  
d4T	   a	   nucleoside	   analogue	   thymidine,	   and	   acts	   as	   both	   a	   chain	   terminator,	   directly	   inhibiting	   HIV	  
reverse	  transcriptase	  activity	  (Huang	  et	  al.,	  1992;	  Hurst	  &	  Noble,	  1999;	  Martin	  et	  al.,	  2010).	  In	  vitro,	  
it	   has	   been	   shown	   to	   reduce	  neurite	   growth	   (Cherry	  et	   al.,	   2010),	   inhibit	   stimulated	   autophagy	   in	  
hepatocytes	  (Stankov	  et	  al.,	  2012),	  and	   interfere	  with	  mitochondrial	  activity	  (Kakuda,	  2000;	  Moyle,	  
2000;	  Dalakas,	  2001;	  Gardner	  et	  al.,	  2013),	  all	  effects	  which	  contribute	  to	  neuropathy.	  	  
As	  HIV	  infection	  itself	  is	  capable	  of	  inducing	  sensory	  neuropathy,	  it	  is	  difficult	  to	  isolate	  the	  effects	  of	  
antiretroviral	   therapy	   in	   a	   clinical	   population	   (Dalakas	   &	   Cupler,	   1996;	   Manji,	   2000).	   Numerous	  
preclinical	  studies	  have	  been	  conducted,	  primarily	  investigating	  side	  effect	  profile	  (Guimarães	  et	  al.,	  
2010),	   but	   increasingly	   looking	   at	   potential	   mechanisms	   of	   anti-­‐retroviral-­‐induced	   peripheral	  
neuropathy.	   It	  has	  been	  shown	  that	   treatment	  with	  d4T	   is	  associated	  with	  evoked	  hypersensitivity	  
(Weber	  et	  al.,	   2007;	  Boateng	  et	  al.,	   2014),	   and	  behavioural	   alterations	   in	  paradigms	   such	  as	  open	  
field	   and	   burrowing	   in	   male	   rats	   (Huang	   et	   al.,	   2013).	   Other	   studies	   looking	   at	   non-­‐sensory	  
consequences	  of	  neuropathy,	   such	  as	   free-­‐wheel	   running	   (Weber	  et	  al.,	  2007)	  and	  acoustic	   startle	  
(Morse	  et	  al.,	  1997;	  Morse,	  1997)	  have	  been	  inconclusive.	  	  
Viral	  Models	  of	  Experimental	  Neuropathy	  	  
Pain	  syndromes	  are	  also	  associated	  with	  viral	  infection,	  such	  as	  HIV	  (Manji,	  2000;	  Maritz	  et	  al.,	  2010),	  
post-­‐herpetic	  neuralgia	  (varicella	  zoster	  virus,	  VZV;	  Daniel	  et	  al.,	  2008;	  Attal	  et	  al.,	  2010;	  Johnson	  &	  
Rice,	   2014),	   and	   Hansen’s’	   disease	   (leprosy;	   (Legendre	   et	   al.,	   2012;	   Haroun	   et	   al.,	   2012)	   are	   all	  
associated	  with	  distal	  peripheral	  neuropathy	  syndromes.	  Experimental	  models	  have	  been	  developed	  
based	  on	  HIV,	  particularly	  using	  the	  envelope	  glycoprotein	  GP120	  	  (Wallace	  et	  al.,	  2007a;	  Kamerman	  
et	  al.,	  2012)	  and	  VZV	  (Fleetwood-­‐Walker	  et	  al.,	  1999;	  Garry	  et	  al.,	  2005;	  Hasnie	  et	  al.,	  2007;	  Boateng	  
et	  al.,	  2014),	  with	  demonstrable	  phenotypes	  of	  peripheral	  hypersensitivity	  with	  affective	  behavioural	  
alterations.	   Although	   leprosy	   is	   still	   associated	  with	   a	   large	   clinical	   burden	   in	   low	   resource	   areas,	  
attempts	  to	  develop	  a	  pre-­‐clinical	  model	  have	  been	  thwarted	  by	  difficulties	  culturing	  Mycobacterium	  
leprae,	   the	   pathogen	   responsible	   (Rees,	   1988),	   with	   current	   models	   showing	   narrow	   application	  
(Gupta,	  1995).	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Other	   options	   open	   to	   in	   vivo	   pain	   research	   involve	   using	   endogenous	   conditions,	   such	   as	   feline	  
interstitial	   cystitis	   (FIC)	   and	   simian	   immunodeficiency	   virus	   (SIV)	   infection	   in	   primates.	   FIC	   is	   a	  
naturally	   occurring	   model	   of	   chronic	   idiopathic	   cystitis	   which	   parallels	   the	   human	   pathology	   well	  
(Buffington,	   2004;	   Rubio-­‐Diaz	   et	   al.,	   2009;	   Keay	   et	   al.,	   2014),	   whereas	   SIV	   models	   an	   HIV-­‐like	  
neuropathy	  in	  primates	  (Clements	  et	  al.,	  2008;	  Burdo	  et	  al.,	  2012;	  Mangus	  et	  al.,	  2014).	  	  	  
Both	  provide	  useful	  insight	  into	  commonality	  between	  human	  clinical	  evidence	  and	  an	  analogous	  non-­‐human	  
condition,	  leading	  to	  increased	  translation	  in	  other	  non-­‐human	  models.	  	  
Experimental	  Models	  of	  Urinary	  Bladder	  Pain	  	  
Most	  models	   of	   visceral	   pain	   involving	   the	   bladder	   tend	   to	   involve	   application	   of	   an	   irritant	   (e.g.	  
intra-­‐peritoneal	  acetic	  acid,	  or	   instillation	  of	   turpentine	   into	  the	  bladder),	  or	  make	  use	  of	  stressors	  
such	  as	  early	  maternal	  separation	  and	  chronic	  psychosocial	  stress	  to	  induce	  visceral	  hypersensitivity.	  
Other	   models	   use	   viral	   vectors	   such	   as	   pseudorabies	   to	   induce	   neurogenic	   cystitis	   (Rudick	   et	   al.,	  
2012),	  or	  make	  use	  of	  innate	  models,	  such	  as	  FIC	  (Westropp	  &	  Buffington,	  2002).	  As	  mentioned,	  FIC	  
is	  an	  endogenous	  model	  of	  cystitis,	  associated	  with	  increased	  ATP	  release	  (Birder	  et	  al.,	  2003),	  and	  it	  
is	   thought	   that	   the	   inflammatory	   stimuli	   present	   are	   capable	  of	   inducing	   chemosensory	   activity	   in	  
previously	   unresponsive	   afferents	   (Häbler	   et	   al.,	   1988).	   Interestingly,	   there	   is	   no	   evidence	   of	  
overactive	  bladder	  (i.e.	  increased	  contraction	  frequency)	  in	  FIC	  cats,	  only	  a	  decrease	  in	  void	  volume	  
(Wu	  et	  al.,	  2011).	  	  
Acetic	   acid	   (AA)	   is	   commonly	   used	   to	   test	   acute	   responses	   to	   visceral	   pain,	   and	   when	   given	  
intraperitoneally	   to	   rodents,	   it	   produces	   a	   characteristic	   writhing	   movement	   accompanied	   by	  
abdominal	   contractions	   that	   can	   be	   measured	   using	   electromyography.	   It	   is	   responsive	   to	  
pharmaceutical	  interventions	  such	  as	  milnacipran	  (Depoortère	  et	  al.,	  2011),	  and	  has	  also	  been	  used	  
as	  a	  conditioning	  stimulus	  producing	  suppression	  of	  somatic	  pain	  associated	  with	  formalin	  injection	  
(Kurihara	   et	   al.,	   2003).	   In	   addition	   to	   intraperitoneal	   administration,	   acetic	   acid	   can	   be	   instilled	  
directly	   into	   the	  bladder	   to	  produce	  a	  cystitis-­‐like	   syndrome	  with	  decreased	  bladder	  pressure,	  and	  
urine	  void	  volume,	  and	  increased	  inter-­‐contraction	  interval	  (ICI;	  Su	  et	  al.,	  2013),	  responsive	  to	  sacral	  
acupuncture	  (Hino	  et	  al.,	  2010),	  which	  shows	  subtle	  sex	  differences	   in	  mice,	  with	  the	  male	  urethra	  
being	  more	  sensitive	  to	  irritation,	  whereas	  in	  females,	  bladder	  tissue	  showed	  the	  greatest	  response	  
(Yoshiyama	  et	  al.,	  2008).	  Its	  potential	  as	  a	  model	  of	  testicular	  pain	  has	  also	  been	  investigated,	  with	  
intra-­‐testicular	  injection	  of	  2-­‐3%	  solutions	  resulting	  in	  bladder	  hypersensitivity	  and	  behavioural	  signs	  
of	  pain	  (Yoshioka	  et	  al.,	  2010).	  	  
Cyclophosphamide	   (CYP)	   is	   a	   chemotherapeutic	   agent	   associated	   with	   a	   poor	   side-­‐effect	   profile,	  
including	   haemorrhagic	   cystitis	   (Ahmed	   &	   Hombal,	   1984).	   It	   is	   taken	   orally	   and	   metabolised	   to	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acrolein,	   which	   is	   damaging	   to	   the	   mucosal	   layer	   of	   the	   bladder	   (Brade	   et	   al.,	   1986).	   Direct	  
instillation	  of	  acrolein	   is	   sometimes	  used	  and	   is	   associated	  with	  both	  abdominal	  hyperalgesia,	   and	  
referred	   hypersensitivity	   in	   the	   hind-­‐paw	   (Guerios	   et	   al.,	   2008),	   dependent	   on	   TRPV1	   activation	  
(Wang	   et	   al.,	   2008),	   and	   increased	   levels	   of	   FAAH	   (Merriam	   et	   al.,	   2010;	  Wang	   et	   al.,	   2014).	   It	   is	  
however	  responsive	  to	  lidocaine	  pre-­‐treatment	  (Guerios	  et	  al.,	  2009),	  as	  seen	  clinically	  (Theoharides	  
et	   al.,	   2008),	   and	   importantly,	   heart	   rate,	   body	   temperature,	   and	   general	   activity	   are	   not	  
documented	  as	  being	  altered	  by	  CYP	  treatment	  (Boudes	  et	  al.,	  2011).	  	  
Systemic	  treatment	  with	  CYP,	  using	  either	  acute	  or	  chronic	  dosing,	  has	  been	  cited	  as	  an	  experimental	  
model	  of	  bladder	  dysfunction	  akin	   to	  both	  OAB	  and	   IC/BPS.	  As	  with	  acrolein,	   it	  decreases	  bladder	  
pressure	   and	   volume,	   while	   increasing	   ICI	   (Pan	   et	   al.,	   2012;	   Dornelles	   et	   al.,	   2014),	   and	   is	   also	  
associated	  with	   increased	   bladder	  weight,	   and	   increased	   levels	   of	   inflammatory	  mediators,	   which	  
can	  be	  normalised	  by	  NSAID	   treatment	   (Tsukimi	  et	  al.,	   2004),	  whereas	  morphine	  ameliorates	  only	  
hypersensitivity	  (Takagi-­‐Matsumoto	  et	  al.,	  2004;	  Augé	  et	  al.,	  2013).	  
CYP-­‐induced	   experimental	   cystitis	   is	   associated	   with	   macrophage	   activation,	   with	   inhibition	   of	  
macrophage	  migration	  inhibitory	  factor	  (MIF)	  ameliorating	  the	  concurrent	  increase	  in	  inflammatory	  
mediators	   (Vera	  et	   al.,	   2010),	   and	   the	   cytokine	   CCL-­‐2	   implicated	   in	   the	   associated	   abdominal	   and	  
hind-­‐paw	   hypersensitivity	   (Arms	   et	   al.,	   2013).	   TRP1A	   antagonists	   (Meotti	   et	   al.,	   2013),	   and	  
prostaglandin	  antagonism	  (Wada	  et	  al.,	  2013)	  also	  inhibit	  CYP-­‐induced	  contractions.	  	  	  
Various	  neurotrophic	  agents	  such	  as	  NGF	  (Jaggar	  et	  al.,	  1999;	  Farquhar-­‐Smith	  et	  al.,	  2002;	  Guerios	  et	  
al.,	   2006),	   and	   BDNF	   (Frias	   et	   al.,	   2013)	   have	   been	   implicated	   in	   the	   mechanical	   hypersensitivity	  
produced	  by	  CYP,	  with	  minimal	  contribution	  from	  NFκB	  (Velasco	  et	  al.,	  2001).	  	  
There	  appear	  to	  be	  differences	  in	  the	  effect	  produced	  by	  acute	  and	  repeated	  treatment,	  with	  more	  
severe	  mucosal	  abrasion	  seen	  following	  acute	  CYP	  (Juszczak	  et	  al.,	  2010),	  which	  in	  itself	  is	  associated	  
with	   higher	   over-­‐activity	   (e.g.	   decreased	   ICI)	   whereas	   individuals	   with	   minimal	   mucosal	   abrasion	  
despite	  CYP	  treatment	  show	  contractility	   indices	  comparable	  with	  the	  control	  group	  (Andersson	  et	  
al.,	  2008).	  	  
Intravesicular	  instillation	  of	  agents	  such	  as	  acetone	  (Kato	  et	  al.,	  1990;	  Shimizu	  et	  al.,	  1999),	  mustard	  
oil	   (Häbler	   et	   al.,	   1988),	   croton	   oil	   (McMahon	   &	   Abel,	   1987;	   McMahon,	   1988),	   hydrochloric	   acid	  
(Hayashi	  et	  al.,	  2009),	  and	  turpentine	  (Ham	  &	  Hurley,	  1965;	  McMahon	  &	  Abel,	  1987)have	  been	  used	  
to	  model	  painful	  bladder	  conditions.	  Turpentine	  in	  particular	  has	  been	  show	  to	  involve	  pathological	  
levels	  of	  NOS	  (Rice,	  1995),	  and	  is	  associated	  with	  involvement	  of	  endocannabinoids	  (Farquhar-­‐Smith	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&	  Rice,	  2001),	  NGF	  (Jaggar	  et	  al.,	  1999),	  bradykinin	  (Jaggar	  et	  al.,	  1998a),	  TRPV1	  (Jaggar	  et	  al.,	  2001),	  
and	  NMDA	  receptors	  (Rice	  &	  McMahon,	  1994).	  	  
Neonatal	   bladder	   treatment	   with	   intravesical	   zymosan	   is	   associated	   with	   increased	   bladder	  
permeability,	  and	  hypersensitivity	  to	  visceral	  but	  not	  somatic	  stimuli	  (Randich	  et	  al.,	  2006),	  including	  
increased	  sensitivity	  to	  bladder	  instillation	  of	  ice-­‐water	  as	  an	  adult	  (Randich	  et	  al.,	  2009),	  although	  it	  
is	  important	  to	  note	  that	  clinically,	  the	  bladder	  cooling	  reflex	  (i.e.	  expulsion	  of	  liquid	  between	  0-­‐4°C)	  
is	   seen	   in	  OAB	  but	  not	   IC/BPS,	  although	   IC/BPS	  patients	  do	  report	  higher	   levels	  of	  pain	  during	   this	  
test	  (Mukerji	  et	  al.,	  2006),	  therefore	  it	  is	  possible	  that	  cold	  water	  responses	  seen	  in	  this	  model	  reflect	  
a	  dominant	  IC/BPS	  phenotype.	  	  	  
Wistar	  Kyoto	  rats	  (WKY)	  were	  originally	  bred	  as	  a	  control	  strain	  for	  the	  spontaneously	  hypertensive	  
rat,	   but	   it	  was	  quickly	  noted	   that	   they	  possess	   a	  high	  pre-­‐disposition	   towards	  affective	  alterations	  
(Langen	   &	   Dost,	   2011).	   Unlike	   Sprague	   Dawley	   rats,	   chronic	   water	   avoidance	   stress	   is	   capable	   of	  
increasing	   visceral	   hypersensitivity	   in	  WKY	   rats,	  with	   associated	   increases	   in	   referred	   hyperalgesia	  
(Robbins	  et	  al.,	  2007).	  	  
Other	  models	  which	  have	  been	  suggested	  as	  useful	  in	  the	  study	  of	  bladder-­‐associated	  pain	  disorders	  
include	   a	   model	   of	   fibromyalgia	   (bilateral	   gluteal	   intramuscular	   hydrochloric	   acid)	   which	   shows	  
lidocaine-­‐reversible	   bladder	   hypersensitivity	   (Roppolo	   et	   al.,	   2005),	   and	   numerous	   models	   based	  
around	   both	   direct	   bacterial	   inflammation	   of	   the	   bladder	   (Bjorling	   et	   al.,	   2008),	   or	   use	  
lipopolysaccharide	  (LPS)	  isolated	  from	  gram	  positive	  bacteria	  to	  evoke	  an	  immune	  response	  (Dupont	  
et	  al.,	  2001).	  Bacterial	   infection,	  unlike	  the	  majority	  of	  models	  mentioned	  above,	  is	  associated	  with	  
decreased	  thermal	  thresholds	  (Bjorling	  et	  al.,	  2008),	  whereas	  LPS	  alone	  decreases	  bladder	  capacity	  
and	  compliance,	  as	  well	  as	  affecting	  cytometry	  measures	  (Takezawa	  et	  al.,	  2014).	  	  
There	   is	  considerable	  evidence	  of	  pelvic	  cross-­‐sensitisation,	  with	  CYP	   increasing	   levels	  of	  colorectal	  
chemosensory	   afferents	   (Brumovsky	   et	   al.,	   2009),	   and	   colonic	   hypersensitivity	   (Bielefeldt	   et	   al.,	  
2006),	   and	   intracolonic	   TNBS	   (Trinitrobenzenesulfonic	   acid)	   increasing	   bladder	   afferent	   firing	   and	  
sensitivity	  to	  bradykinin,	  capsaicin	  and	  substance	  P	  (Ustinova	  et	  al.,	  2006).	  	  
General	  Comments	  	  
It	  is	  also	  important	  to	  bear	  in	  mind	  physiological	  and	  pharmacokinetic	  differences	  between	  rodents	  
and	  humans	  when	  translating	  findings	  from	  basic	  into	  clinical	  research	  –	  for	  example,	  opioid	  efficacy	  
is	  higher	  in	  humans	  than	  rodents	  (Morgan	  &	  Christie,	  2011),	  with	  higher	  binding	  observed	  for	  kappa	  
opioid	  agonists	   in	  clinical	  studies	   (Schattauer	  et	  al.,	  2012),	   therefore	   it	   is	   likely	   that	  kappa	  agonists	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tested	   in	   rodents	   may	   present	   as	   less	   effective	   than	   their	   actual	   clinical	   potential	   in	   the	   human	  
population.	  	  
Additionally,	   there	   are	   subtle	  differences	   in	  behaviour,	   pharmacokinetics,	   and	  physiology	  between	  
both	   different	   strains	   of	   experimental	   animals	   such	   as	   rats	   and	  mice,	   but	   also	   between	   different	  
suppliers	  (Rex	  et	  al.,	  1996;	  Swerdlow	  et	  al.,	  2000;	  Palm	  et	  al.,	  2011a;	  Palm	  et	  al.,	  2011b;	  Langer	  et	  al.,	  
2011;	  O’Bryant	  et	  al.,	  2011).	  Looking	  at	  rats	  in	  particular,	  differences	  have	  been	  documented	  in	  the	  
response	  to	  stimuli	  such	  as	  ultrasonic	  sound,	  with	  the	  commonly	  used	  Wistar	  rats	  freezing,	  and	  the	  
less	   commonly	   used	   Hooded	   Lister	   rats	   focussing	   more	   on	   escape	   (Neophytou	   et	   al.,	   2000).	  
Pharmacokinetic	   differences	   are	   also	   evident,	   with	   WKY	   rats	   showing	   reduced	   sensitivity	   to	  
serotonergic	   drugs	   in	   the	   forced	   swim	   test	   (López-­‐Rubalcava	   &	   Lucki,	   2000),	   enhanced	   codeine	  
metabolism	   seen	   in	   Sprague	   Dawley	   rats	   (Williams	   et	   al.,	   2004),	   and	   variation	   in	   apomorphine	  
sensitivity	  in	  numerous	  common	  strains	  of	  laboratory	  rat	  (Kinney	  et	  al.,	  1999;	  Swerdlow	  et	  al.,	  2000).	  
Physiological	  differences	  between	  strains	  are	  highlighted	  by	  a	  study	  which	  showed	  Wistar	  rats	  have	  a	  
greater	  L4	   involvement	  following	  sciatic	  nerve	   injury	  (Rigaud	  et	  al.,	  2008),	  whereas	  Lewis	  rats	  have	  
increased	   levels	  of	  reactive	  C-­‐fibres	  and	  a	  greater	  noradrenalin	  response	  to	   inflammation	  (Banik	  et	  
al.,	   2001).	   Of	   particular	   relevance	   to	   the	   pain	   field	   is	   the	   presence	   of	   differences	   in	   formalin	   test	  
response	  (Lariviere	  et	  al.,	  2006),	  hotplate	   latency	  (Schaap	  et	  al.,	  2013),	  mechanical	  hypersensitivity	  
(DeLeo	   &	   Rutkowski,	   2000;	   Zhang	   et	   al.,	   2003),	   stress-­‐potentiation	   of	   hyperalgesia	   (Woolfolk	   &	  
Holtzman,	  1995),	  and	  NO	  anti-­‐nociceptive	  response	  (Fender	  et	  al.,	  2000).	  Furthermore,	  studies	  have	  
demonstrated	  blunted	  sexual	  responses	  to	  a	  receptive	  female	  in	  albino	  rats	  (Sachs,	  1996),	  and	  also	  
differences	  in	  manual	  dexterity	  involved	  in	  forelimb	  reaching	  tasks,	  with	  naive	  Sprague	  Dawley	  rats	  
employing	  a	  visually	  more	  similar	   to	   injured	  Long	  Evans	  rats	   (Whishaw	  et	  al.,	  2003).	  An	   interesting	  
study	  in	  2012	  compared	  swimming	  and	  digging	  behaviour	  in	  small	  numbers	  of	   laboratory	  bred	  rats	  
with	  wild	  rats,	  and	  found	  that	  although	   laboratory	  strains	  were	   less	   likely	  to	  engage	   in	  exploratory	  
behaviour	   and	   swimming,	   there	   was	   considerable	   inter-­‐individual	   variation	   (Stryjek	   et	   al.,	   2012).	  
These	   strain	  and	  breeder-­‐associated	  differences	  are	   important	   to	  be	  aware	  of,	   as	   they	   can	  have	  a	  
significant	  influence	  on	  experimental	  outcome,	  therefore	  inclusion	  of	  such	  information	  in	  published	  
studies	  is	  crucial	  to	  maximise	  the	  potential	  contribution	  of	  research.	  	  	  
Another	  factor	  when	  developing	  models	  for	  the	  study	  of	  experimental	  pain	  in	  animals	  is	  the	  inclusion	  
of	   a	   suitable	   control	   group.	   In	  most	   cases,	   this	   necessitates	   both	   a	   naïve	   (i.e.	   un-­‐treated,	   normal	  
health),	  and	  an	  appropriate	  control	  that	  will	  allow	  identification	  of	  effects	  specific	  to	  manipulation	  of	  
the	  variable	  of	  interest.	  For	  example,	  sham	  surgery	  groups	  used	  in	  models	  of	  traumatic	  neuropathy,	  
involving	  exposure	  of	  the	  nerve	  but	  no	  manipulation,	  or	  a	  vehicle	  group	   that	  receives	   intra-­‐plantar	  
saline	   rather	   than	   CFA.	   This	   is	   particularly	   important	   as	   sham	   effects	   have	   been	   documented	   in	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traumatic	  models	  such	  as	  SNI,	  as	  manifest	  by	  decreased	  open	  field	  behaviour	  (Hu	  et	  al.,	  2009a;	  Wang	  
et	   al.,	   2011),	   and	   increased	   activation	   of	   the	   right	   amygdala	   (with	   bilateral	   activation	   seen	   in	   SNI	  
animals;	  (Bourbia	  et	  al.,	  2010).	  	  
In	  2010,	  the	  ARRIVE	  	  (Animal	  Research:	  Reporting	  of	  In	  Vivo	  Experiments)	  guidelines	  were	  published	  
in	   collaboration	   with	   the	   National	   Centre	   for	   the	   Replacement,	   Refinement,	   and	   Reduction	   of	  
Animals	   in	  Research	  (NC3Rs,	  2014),	  designed	  to	  encourage	  transparency	   in	  the	  reporting	  of	  animal	  
research	  (Kilkenny	  et	  al.,	  2010).	  They	  were	  developed	  following	  a	  survey	  on	  271	  published	  articles	  on	  
animal	   research	  which	   found	   severe	   shortcomings	   in	   reporting,	   with	   only	   59%	   of	   studies	   giving	   a	  
hypothesis	   and	   characteristics	   such	   as	   group	   size,	   sex,	   supplier,	   and	   housing	   of	   animals,	   and	   over	  
86%	  did	  not	  use	  bias	  reduction	  methods	  such	  as	  blinding	  and	  randomisation	  (Kilkenny	  et	  al.,	  2009).	  
The	  ARRIVE	  guidelines	  take	  the	  form	  of	  a	  20-­‐point	  check-­‐list	  outlining	  information	  which	  should	  be	  
included	  when	  reporting	  animal	  research	   in	  order	  to	  maximise	  clarity	  and	  enable	  readers	  to	  assess	  
the	   quality	   of	   the	   research	   objectively.	   The	   inclusion	   of	   information	   on	   group	   sizes,	   animal	  
characteristics	   (e.g.	   age,	   sex,	   strain,	   supplier),	   and	   environmental	   factors,	   and	   provision	   of	   error	  
estimation	  will	  also	  facilitate	  systematic	  review	  in	  the	  pre-­‐clinical	  field.	  	  	  
Systematic	  reviews	  have	  been	  conducted	  in	  clinical	  research,	  as	  a	  means	  of	  synthesising	  an	  answer	  
to	  a	  hypothesis	  by	  surveying	  the	   literature	   in	  an	  objective	  and	  systematic	  fashion,	  since	  the	  1980s,	  
prompted	  by	  Archie	  Cochrane,	  who	  wrote	  extensively	  on	  the	  value	  of	  randomized	  control	  trials	  (RCT)	  
to	   evidence-­‐based	  medicine	   (Chalmers,	   1993).	   In	   1996,	   the	   CONSORT	   (Consolidated	   Standards	   of	  
Reporting	  Trials)	  statement	  was	  published,	  providing	  clinicians	  and	  researchers	  involved	  in	  RCTs	  with	  
21-­‐point	  checklist	  on	  which	  the	  ARRIVE	  guidelines	  were	  based	  (Altman,	  1996).	  CONSORT	  has	  greatly	  
improved	  the	  quality	  of	  the	  reporting	  of	  clinical	  trials,	  and	  allowed	  numerous	  high	  quality	  systematic	  
reviews	   to	   be	   conducted,	   particularly	   associated	  with	   the	   Cochrane	   Collaboration,	  where	   the	   first	  
systematic	  review	  looking	  at	  pain	  was	  registered	  in	  1998	  (Kleijnen	  &	  Mackerras,	  2000).	  The	  Cochrane	  
Collaboration	  is	  a	  particularly	  important	  resource	  as	  it	  requires	  pre-­‐registration	  of	  systematic	  review	  
protocols,	  as	  has	  been	  the	  case	  for	  RCTs,	  reducing	  the	  opportunity	  to	  bias	  findings	  by	  changing	  the	  
protocol	   once	   data	   has	   been	   collected,	   and	   encourages	   regular	   updating	   of	   systematic	   reviews	  
within	  its	  archive	  to	  allow	  inclusion	  of	  articles	  published	  after	  the	  initial	  completion	  of	  the	  review.	  	  
It	  is	  unlikely	  a	  ‘Cochrane’	  style	  collaboration	  would	  be	  easy	  to	  establish	  in	  the	  animal	  research	  field	  
(Sena	  et	  al.,	  2014a;	  Sena	  et	  al.,	  2014b)	  –	  there	  is	  resistance	  to	  the	  requirement	  for	  pre-­‐registration	  of	  
basic	   research,	   particularly	   as	  many	   are	   pilot	   studies,	   in	   which	   low	   group	   sizes	   are	   used	   and	   the	  
object	   is	   to	  determine	  whether	  a	  hypothesis	   is	  valid	  before	   full	  exploration	   involving	  higher	  use	  of	  
resources.	   Additionally,	   it	   is	   suggested	   that	   such	   pre-­‐registration	   would	   crush	   the	   serendipitous	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discoveries	  often	  made	  during	  exploratory	  studies.	  One	  way	  of	  circumventing	  this	  issue	  would	  be	  to	  
distinguish	   pre-­‐clinical	   from	   basic	   research,	   encouraging	   some	   degree	   of	   pre-­‐registration,	  
implemented	   by	   either	   journals	   or	   funding	   bodies,	   perhaps	   kept	   private	   until	   publication	   of	   the	  
research	  to	  negate	  the	  opportunity	  for	  ‘scooping’,	  for	  studies	  prepared	  to	  adhere	  fully	  to	  the	  ARRIVE	  
guidelines.	   Thus	   defined,	   preclinical	   research	   would	  move	   closer	   to	   the	   standards	   seen	   in	   clinical	  
RCTs,	   and	   facilitate	   high	   quality	   systematic	   reviews	   of	   animal	   literature,	   whilst	   allowing	   for	   basic	  
research,	  akin	  to	  case	  studies	  in	  clinical	  research,	  where	  the	  focus	  is	  on	  descriptive	  and	  exploratory	  
studies	  which	  benefit	  from	  the	  freedom	  of	  being	  able	  to	  adapt	  protocols	  to	  maximise	  observations.	  
The	  ability	  to	  distinguish	  these	  two	  types	  of	  animal	  research	  would	  greatly	  benefit	  the	  progression	  of	  
research	   by	   allowing	   critical	   assessment	   of	   a	   study,	   appropriate	   to	   its	   design.	   This	   can	   only	   be	  
facilitated	   by	   inclusion	   of	   all	   relevant	   factors	   and	   transparency	   regarding	   protocol,	   particularly	  
exclusions.	  	  
1.6 Sex	  Differences	  	  
The	  majority	   of	   in	   vivo	   research	   is	   conducted	   in	  male	   animals,	   purportedly	   because	   the	   oestrous	  
cycle	   of	   female	   animals	   adds	   a	   further	   level	   complexity	   which	   must	   be	   controlled,	   or	   at	   least	  
accounted	  for.	  In	  terms	  of	  drug	  development,	  this	  makes	  little	  sense	  as	  women	  show	  differences	  in	  
drug	  metabolism	  compared	  to	  men,	  including	  higher	  prevalence	  of	  side-­‐effects	  (Campesi	  et	  al.,	  2012;	  
Franconi	   &	   Campesi,	   2014),	   and	   would	   benefit	   from	   drugs	   which	   are	   effective	   irrespective	   of	  
menstrual	  phase,	  with	  the	  exception	  being	  menstruation	  and	  pain	  conditions	  such	  as	  endometriosis	  
(Hassan	   et	   al.,	   2014),	   when	   maximum	   efficacy	   under	   particular	   hormonal	   conditions	   would	   be	  
advantageous.	  	  
In	   rats,	   the	   female	   oestrous	   cycle	   lasts	   4-­‐5	   days,	   and	   involves	   an	   initial	   small	   peak	   in	   follicle	  
stimulating	   hormone	   (FSH)	   during	   day	   1	   (metestrous),	   which	   stimulates	   a	   larger	   peak	   in	  
progesterone	   (day	   2;	   diestrous).	   During	   day	   3,	   or	   pro-­‐oestrous,	   there	   is	   a	   large	   spike	   in	   estradiol	  
levels,	   followed	   by	   a	   similarly	   large	   peak	   in	   luteinizing	   hormone	   (LH),	   progesterone,	   and	   FSH.	   The	  
cycle	   ends	  with	   a	   small	   peak	   in	   estradiol	   (oestrous)	   around	   day	   4	   or	   5.	   This	   cycle	   repeats	   for	   the	  
entirety	  of	  the	  reproductive	  lifetime	  of	  the	  animal,	  typically	  200	  days	  in	  rats	  (~40	  cycles)	  (Marcondes	  
et	  al.,	  2002).	  	  
Oestrous	  stage	  can	  be	  determined	  by	  taking	  vaginal	  smears	  and	  examining	  the	  cell	  populations	  present,	  as	  
indicated	  in	  Table	  1-­‐3.	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Table	  1-­‐3:	  Cell	  characteristics	  used	  in	  the	  staging	  of	  rat	  oestrus	  cycle	  
From	  Marcondes	  et	  al.,	  2002	  
Cell	  Type	   Characteristics	   Proestrus	   Oestrous	   Metestrous	   Diestrous	  
Epithelia	   Round,	  nucleated	   ✓	   -­‐	   ✓	   -­‐	  
Cornified	   Irregular,	  enucleated	   -­‐	   ✓	   ✓	   -­‐	  
Leukocytes	   Round,	  small	   -­‐	   -­‐	   ✓	   ✓	  
The	  measurement	  of	  oestrous	  stage	  requires	  consistency,	  and	  at	  least	  5	  days	  consecutive	  testing	  to	  
establish	  exact	  timings	  (Hubscher	  et	  al.,	  2005).	  This	  is	  not	  always	  practical,	  as	  all	  animals	  should	  be	  at	  
the	   same	   confirmed	   stage	   during	   testing,	   or	   group	   sizes	   determined	   for	   each	   stage	   of	   oestrous,	  
increasing	  the	  numbers	  of	  animals	  required.	  Housing	  conditions	  also	  influence	  oestrous	  cycle	  length,	  
with	  group	  housing	  increasing	  irregularity	  of	  cycles	  (Pallares	  &	  Gonzalez-­‐Bulnes,	  2009).	  Furthermore,	  
the	  taking	  of	  daily	  vaginal	  swabs	  is	  a	  stressor,	  which	  could	  possibly	  alter	  behavioural	  responses,	  with	  
some	  studies	  utilising	  i.p.	  injection	  as	  a	  comparable	  stressor	  when	  comparing	  with	  males	  (Nicotra	  et	  
al.,	  2014).	  	  
Sex	  differences	  have	  been	  documented	  in	  sensitivity	  to	  noxious	  stimuli	  and	  risk	  of	  developing	  chronic	  
pain	  syndromes.	  Therefore	  it	  is	  important	  to	  establish	  experimental	  results	  in	  both	  male	  and	  female	  
subjects,	   so	   as	   to	   be	   aware	   of	   any	   potential	   differences	   in	   response.	   In	   May	   2014,	   the	   NIH	  
announced	  an	  initiative	  to	  encourage	  studies	  which	  use	  female	  animals,	  recognising	  that	  awareness	  
of	   sex-­‐related	   differences	   is	   important	   in	   driving	   translational	   progress	   (National	   Institutes	   for	  
Health,	  2014).	  	  
It	  is	  clear	  there	  are	  sex-­‐related	  differences	  in	  the	  reporting	  of	  and	  sensitivity	  to	  pain.	  The	  reasons	  for	  
these	   are	   numerous	   but	   can	  broadly	   be	   divided	   into	   physiological	   differences,	   including	   hormonal	  
differences,	  and	  psychosocial	  factors	  related	  to	  upbringing	  and	  gender	   identity	  (Bartley	  &	  Fillingim,	  
2013).	  	  	  
Sex	   hormones,	   such	   as	   estradiol	   and	   testosterone	   are	   reported	   to	   have	   differing	   effects	   on	   pain	  
perception.	   The	   effects	   of	   reproductive	   hormones	   such	   as	   oestradiol	   and	   testosterone	   on	   pain	  
perception	   are	   well	   documented,	   due	   to	   a	   substantial	   body	   of	   research	   into	   the	   effects	   of	   the	  
menstrual	  cycle	  (Hassan	  et	  al.,	  2014).	  Most	  studies	  show	  increased	  sensitivity	  during	  the	  luteal	  phase	  
(Fillingim	  et	  al.,	  1997;	  Powell-­‐Boone	  et	  al.,	  2005),	  but	  the	  effect	  is	  small	  in	  magnitude.	  	  	  	  
Testosterone	   is	   largely	   anti-­‐nociceptive	   (Aloisi	   et	   al.,	   2010),	   although	   has	   been	   shown	   to	   sharply	  
decrease	   in	   both	  men	   and	  women	   in	   response	   to	  morphine	   (Aloisi	   et	   al.,	   2009),	   with	   long-­‐acting	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opioids	   implicated	   in	   hypogonadism	   in	   men	   with	   chronic	   pain	   (Rubinstein	   et	   al.,	   2013).	   Similar	  
findings	  have	  also	  been	  noted	  in	  the	  rat	  (Cicero	  et	  al.,	  1975).	  	  	  
Studies	   have	   shown	   mu-­‐opioid	   receptor	   density	   is	   sensitive	   to	   oestradiol	   levels,	   with	   increased	  
expression	   corresponding	   with	   decreased	   pain	   sensitivity	   during	   high-­‐oestradiol	   phases	   of	   the	  
menstrual	   cycle	   (Smith	  et	   al.,	   2006).	   Clinical	   data	   also	   suggests	   sex	   differences	   in	   opioid	   use,	  with	  
some	  studies	  suggesting	  lower	  post-­‐operative	  use	  among	  women	  (Aubrun	  et	  al.,	  2005;	  Periasamy	  et	  
al.,	   2014),	   and	   other	   showing	   no	   differences	   (Bartley	   &	   Fillingim,	   2013).	   There	   is	   also	   possible	  
evidence	  of	  a	  gender	  bias	   in	  opioid-­‐based	  pain	   treatment,	  with	  physicians	  more	   likely	   to	  prescribe	  
opioids	  to	  patients	  of	  the	  same	  sex	  (Weisse	  et	  al.,	  2001).	  	  
Genetic	   factors	   that	   predispose	   to	  pain	   also	   show	   sexual	   dimorphism.	   In	  women,	   the	  MC1R	  gene,	  
which	  also	  confers	  red	  hair	  and	  fair	  skin,	  is	  associated	  with	  higher	  levels	  of	  kappa	  opioid	  associated	  
analgesia	   (Bartley	   &	   Fillingim,	   2013),	   whereas	   a	   single	   nucleotide	   polymorphism	   in	   the	  mu-­‐opioid	  
receptor	  gene	  predisposes	  men,	  but	  not	  women,	  to	   increased	  pressure	  pain	  sensitivity	  (Fillingim	  et	  
al.,	  2005).	  	  
In	   terms	   of	   psychosocial	   factors,	   the	   picture	   becomes	  more	   complex,	   with	   gender	   stereotypes	   of	  
‘stoic	   men’	   and	   ‘emotional	   women’	   leading	   to	   suppression	   and	   enhancement	   of	   symptoms	  
respectively	   (Alabas	  et	  al.,	  2012).	  Non-­‐verbal	  communication	   (e.g.	  grimacing,	  utterances,	  and	  body	  
position)	   is	   an	   important	   part	   of	   a	   clinical	   pain	   diagnosis,	   and	   it	   has	   been	   suggested	   that	  women	  
more	   likely	   to	  display	  and	   recognise	  non-­‐verbal	  expressions	  of	  pain	  expression,	  and	  more	   likely	   to	  
seek	  assistance	  from	  'non-­‐kin'	  networks	  e.g.	  medical	  practitioners	  (Keogh,	  2014).	  	  	  
Overall,	  despite	  conflicting	  evidence	  regarding	  mechanisms,	  there	  is	  a	  case	  for	  increased	  sensitivity,	  
and	  particularly	  increased	  prevalence	  of	  a	  range	  of	  chronic	  pain	  conditions	  in	  women	  (Hassan	  et	  al.,	  
2014),	  and	  that	  these	  have	  serious	  economic	  and	  social	  implications	  (Beckett	  et	  al.,	  2014).	  	  
1.7 Neural	  Circuitry	  of	  Pain	  	  
Pain	   acts	   on	   multiple	   levels	   within	   the	   nervous	   system:	   sensory	   signals	   from	   the	   periphery	   are	  
received	  centrally	  and	   interpreted	   in	   relation	   to	  previous	  experience	  and	  current	   circumstances	   to	  
produce	  a	  behavioural	  response.	  	  	  
In	  the	  periphery,	  nociceptive	  stimuli	  such	  as	  damaging	  heat	  or	  cold,	  mechanical	  trauma,	  or	  chemical	  
irritants	   are	   detected	   by	   sensory	   afferents,	   specifically	   unmyelinated	   C-­‐fibres	   and	   myelinated	   Aδ	  
fibres.	   These	   fibres	   possess	   an	   array	   of	   nociceptors	   that	   each	   respond	   to	   a	   defined	   set	   of	   stimuli,	  
such	  as	  the	  thermal	  receptors	  detailed	  in	  Table	  1-­‐1.	  The	  cell	  bodies	  of	  these	  nociceptive	  fibres	  reside	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in	   the	   DRG.	   A	   recent	   study	   which	   used	   novel	   magnetic	   cell	   sorting	   techniques	   to	   study	   the	   cell	  
populations	   in	  the	  DRG	  found	  <10%	  of	  all	  cells	  are	  neurons,	  of	  which	  approximately	  38%	  are	  CGRP	  
positive,	   suggesting	   dominant	   peptidergic	   transmission,	   and	   used	   magnetic	   sorting	   to	   generate	   a	  
95%	  pure	  neuronal	  preparation	  featuring	  mainly	  Nav1.8	  positive	  nociceptive	  neurons	  (Thakur	  et	  al.,	  
2014).	  This	  was	  used	  to	  generate	  a	  transcriptome	  of	  genes	  expressed	  exclusively	  in	  this	  population,	  
providing	  a	  new	  technique	  useful	  in	  the	  study	  of	  how	  neuronal	  populations	  in	  the	  DRG	  are	  altered	  in	  
pathological	  pain	  conditions.	  	  	  
Peripheral	   afferents	   transmit	   sensory	   information	   to	   the	   spinal	   cord	   via	   the	  DRG.	   From	   the	  dorsal	  
horn	  of	  the	  spinal	  cord,	  innervation	  crosses	  the	  midline	  of	  the	  spinal	  cord	  and	  travels	  up	  the	  dorsal	  
column	  medial-­‐leminiscus	   (touch	  and	  proprioception)	  and	  anterolateral	   (pain)	   tracts	   to	   the	  ventral	  
posterior	  nucleus	  of	  the	  thalamus,	  and	  on	  to	  the	  corresponding	  areas	  of	  the	  somatosensory	  cortex.	  
Signals	   from	   the	   anterolateral	   tract	   also	   terminate	   in	   the	   parabrachial	   nucleus	   (PB)	   where	   higher	  
connections	   to	   the	   amygdala,	   insula,	   and	   cingulate	   cortex	   are	   associated	   with	   modulation	   of	   the	  
affective	  components	  of	  pain	  (Basbaum	  et	  al.,	  2009),	  as	  illustrated	  in	  figure	  1-­‐6.	  	  




Figure	  1-­‐5:	  Central	  pathways	  implicated	  in	  pain	  processing	  showing	  nociceptive	  input	  and	  the	  resultant	  descending	  pathways	  
PFC	  -­‐	  pre-­‐frontal	  cortex,	  S1/S2	  -­‐	  primary	  and	  secondary	  somatosensory	  cortices,	  ACC	  -­‐	  anterior	  cingulate	  cortex,	  Ins.	  -­‐	  insula,	  
Tha.	  -­‐	  thalamus,	  NAc	  -­‐	  nucleus	  accumbens,	  Hyp.	  -­‐	  hypothalamus,	  AMY	  –	  amygdala,	  PAG	  –	  periaqueductal	  grey,	  PB	  –	  
parabrachial	  nucleus,	  RVM	  –	  rostroventral	  medulla	  	  
Differential	   processing	   of	   somatic	   and	   visceral	   stimuli	   is	   indicated	   by	   fMRI	   studies	   in	   healthy	  
volunteers	   which	   showed	   activation	   of	   the	   RVM,	   PAG,	   VTA,	   PB,	   and	   nucleus	   cuniformis	   (NCF)	  
following	  both	  abdominal	   somatic	  nociceptive	  and	   rectal	  distension,	  with	  higher	  activation	  seen	   in	  
the	  PAG	  and	  NCF,	  and	  PAG	  activation	  correlating	  with	  reports	  of	  anxiety	  (Dunckley	  et	  al.,	  2005).	  	  
Lesion	  studies	  have	  assisted	  functional	   identification	  of	  brain	  areas	  involved	  with	  certain	  aspects	  of	  
the	   pain	   experience,	   and	   have	   largely	   focussed	   on	   the	   amygdala.	   Lesions	   to	   the	   central	   amygdala	  
(Ce)	  are	  capable	  of	  abolishing	  morphine’s	  anti-­‐nociceptive	  effects	  in	  rats	  (Manning	  &	  Mayer,	  1995),	  
which	   can	   be	   restored	   by	   transplantation	   of	   Ce	   tissue	   (Jain	   et	   al.,	   2000),	  whereas	   ablation	   of	   the	  
whole	   amygdala,	   or	   the	   basolateral	   (BL)	   nuclei	   alone,	   but	   not	   Ce	   prior	   to	   SNI	   abolished	  
hypersensitivity	   (Li	  et	  al.,	  2013).	  Lesions	  of	  noradrenergic	  neurons	   in	  the	   locus	  coeruleus	   in	  the	  rat	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reduce	  hot	  plate	  latency,	  but	  have	  no	  effect	  on	  tail	  flick	  latency,	  indicating	  a	  role	  in	  pain	  modulation	  
at	  the	  supra-­‐spinal	  but	  not	  spinal	  level	  (Kudo	  et	  al.,	  2010).	  	  
In	   the	   early	   1900s,	   Déjerine	   and	   Roussy	   described	   “Le	   syndrome	   thalamique”,	   or	   thalamic	   pain	  
syndrome,	  one	  of	  the	  first	  studies	  on	  central	  post-­‐stroke	  pain	  (CPSP),	  and	  which	  demonstrated	  the	  
importance	  of	  the	  thalamus	  in	  the	  generation	  of	  pain	  (Pearce,	  1988).	  It	  is	  now	  known	  that	  CPSP	  can	  
be	  caused	  by	  lesions	  at	  any	  level	  of	  the	  central	  somatosensory	  pathway,	  including	  the	  medulla	  (Klit	  
et	  al.,	  2009).	  Rat	  models	  of	  thalamic	  CPSP	  have	  demonstrated	  bilateral	  cold	  allodynia,	  which	  can	  be	  
ameliorated	  by	  high	  dose	  ketamine	  (Castel	  et	  al.,	  2013),	  although	  this	  is	  not	  reflected	  clinically,	  with	  
ketamine	  having	  poor	  efficacy	  in	  CPSP	  (Vranken	  et	  al.,	  2005).	  	  
In	   addition	   to	   central	   integration	  of	   the	  afferent	   signals	  of	  nociception	   signals	   from	   the	  periphery,	  
descending	   pathways	   originating	   in	   the	   RVM	   and	   PAG	   control	   endogenous	   analgesia	   by	   inhibiting	  
ascending	   pathways	   in	   the	   substantia	   gelatinosa	   (Basbaum	   et	   al.,	   2009).	   This	   role	   of	   the	   PAG	   in	  
endogenous	  analgesia	  is	  supported	  by	  high	  levels	  of	  mu	  opioid	  receptors	  (Bodnar,	  2013),	  in	  addition	  
to	   decreases	   in	   fMRI	   signal	   and	   PET	   detection	   of	   μ	   opioid	   receptors	   associated	   with	   placebo	  
analgesia	  in	  the	  PAG	  and	  several	  other	  brain	  areas	  including	  the	  thalamus,	   insula,	  and	  RVM	  (Qiu	  et	  
al.,	  2009).	  	  
	  The	  Amygdala	  	  
The	  amygdala	  or	  amygdaloid	  complex	   is	  a	  highly	  heterogeneous	  group	  of	  nuclei	  with	  wide-­‐ranging	  
and	  overlapping	  functional	  connections	  with	  the	  rest	  of	  the	  brain	  located	  near	  the	  temporal	  pole.	  It	  
is	  primarily	  implicated	  in	  regulation	  of	  emotional	  processes,	  and	  in	  this	  complex	  field,	  the	  amygdala	  
is	  not	  a	  single	  functional	  or	  structural	  unit.	  Therefore,	   in	  this	  discussion,	  areas	  will	  be	  distinguished	  
based	  on	  developmental	  origin,	  namely	  pallial	  and	  subpallial,	  as	  shown	  in	  Figure	  1-­‐7.	  	  	  
History	  	  
Karl	   Burdach	   named	   the	   amygdala	   for	   its	   almond-­‐like	   shape	   in	   the	   late	   19th	   century	   (McDonald,	  
2003),	  and	  although	  his	  initial	  discovery	  only	  covered	  what	  is	  now	  known	  to	  be	  the	  basolateral	  (BL)	  
nucleus,	   early	   anatomical	   study	   soon	   highlighted	   the	   heterogeneous	   nature	   of	   the	   amygdala	   by	  
describing	   extensions	   of	   the	   amygdala	   into	   surrounding	   claustral,	   lenticular,	   striatal,	   and	   olfactory	  
areas	   (Swanson	  &	  Petrovich,	  1998).	  A	   seminal	   study	  by	   J.B.	   Johnston	   in	   the	  early	  20th	   century	   laid	  
most	   of	   the	   groundwork	   now	   used	   in	   definition	   of	   amygdalar	   nuclei,	   and	   enabled	   a	   focus	   on	  
delineation	   based	   on	   function	   rather	   than	   spatial	   proximity	   (Johnston,	   1923).	   The	   complexities	  
encountered	   by	   early	   anatomical	   researchers	   explain	   the	   apparent	   misnomers	   associated	   with	  
regions	  now	  known	  to	  be	  cortical	  yet	  described	  as	  nuclear	  (e.g.	  anterior	  cortical	  nuclei).	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Pallial	  versus	  Sub-­‐Pallial	  Amygdala	  	  
The	  pallial	  amygdala	  is	  largely	  involved	  with	  socio-­‐sexual	  and	  olfactory	  associated	  function,	  and	  has	  
strong	  connections	  with	  the	  hypothalamus	  and	  both	  accessory	  and	  primary	  olfactory	  bulbs.	  It	  shows	  
allocortical	  composition,	  and	  can	  further	  be	  divided	  into	  two	  subgroups	  based	  on	  whether	  structures	  
show	  cortical	   (superficial)	  or	  nuclear	   (deep)	  characteristics.	  The	  cortical	  pallial	  amygdala	  comprises	  
the	   nucleus	   of	   the	   lateral	   olfactory	   tract	   (LOT),	   the	   bed	   nucleus	   of	   the	   accessory	   olfactory	   tract	  
(BAOT),	  the	  cortex-­‐amygdala	  transition	  zone	  (CxA),	  the	  amygdalopiriform	  transition	  area	  (APir),	  the	  
anterior	   cortical	   amygdaloid	  nucleus	   (ACo),	   the	  posteriolateral	   cortical	   amygdaloid	   nucleus	   (PLCo),	  
and	  the	  posteriomedial	  cortical	  amygdaloid	  nucleus	  (PMCo).	  The	  deep	  pallial	  nuclei	   include	  the	  BL,	  
basomedial	   (BM),	   and	   lateral	   (La)	   amygdalae	   (originally	   identified	   as	   the	   BL	   amygdala),	   and	   the	  
amygdalohippocampal	  transition	  area	  (AHi)	  (Olucha-­‐bordonau	  et	  al.,	  2015).	  	  
	  
Figure	  1-­‐6:	  The	  subnuclei	  of	  the	  amygdala	  
Subpallial:	  Me	  -­‐	  medial,	  CeC	  -­‐	  capsular	  central,	  CeL	  -­‐	  lateral	  central,	  CeM	  -­‐	  medial	  central,	  ICN	  -­‐	  intercalated	  cell	  nuclei,	  SLEA	  
–sublenticular	   extended	   amygdala,	   STIA	   –	   intraamygdalar	   bed	   nucleus	   of	   the	   stria	   terminalis.	   Pallial:	   La	   –	   lateral,	   BL	   –	  
basolateral,	   BM	   –	   basomedial,	   APir	   -­‐	   amygdalopiriform	   transition	   area,	   CxA	   –	   cortex-­‐amygdala	   transition	   zone,	   PLCo	   –	  
posteriolateral	  cortical	  amygdala,	  ACo	  –	  anterior	  cortical	  amygdala,	  PMCo	  –	  posteriomedial	  cortical	  amygdala,	  BAOT	  	  bed	  
nucleus	  of	  the	  accessory	  olfactory	  bulb,	  LOT	  –	  lateral	  olfactory	  tract.	  Note:	  not	  all	  nuclei	  are	  present	  at	  all	  levels,	  this	  is	  for	  
illustrative	  purposes	  only	  	  
One	   characteristic	   of	   pallial	   nuclei	   compared	   to	   subpallial	   is	   the	   predominance	   of	   glutamatergic	  
innervation,	  due	  to	  developmental	  origins	  in	  the	  pallial	  neuroepithelium	  (Guirado	  et	  al.,	  2008).	  The	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subpallial	   amygdala	   is	   also	   sometimes	  known	  as	   the	  extended	  amygdala	   (EA),	   and	   includes	   the	  Ce	  
and	  Me	  amygdaloid	  nuclei,	  in	  addition	  to	  further	  EA	  areas	  including	  the	  intercalated	  nuclei	  (ICN),	  bed	  
nucleus	   of	   the	   stria	   terminalis	   (ST),	   the	   bed	   nucleus	   of	   the	   anterior	   commissure	   (BAS),	   the	  
sublenticular	  extended	  amygdala	  (SLEA),	  and	  anterior	  amygdaloid	  area	  (AAA).	  	  	  
Subpallial	  areas	  such	  as	  the	  Ce	  and	  Me	  possess	  high	  levels	  of	  GABAergic	  cells	  (Swanson	  &	  Petrovich,	  
1998),	   which	   correlates	   with	   their	   common	   origin	   in	   the	   ganglion	   eminences,	   from	   where	   they	  
migrated	  to	  the	  cortex	  (Avila	  et	  al.,	  2011).	  This	  staining	  pattern	  emphasises	  the	  link	  with	  the	  caudate	  
putamen,	   which	   is	   also	   an	   area	   of	   high	   GABAergic	   activity	   (McGinty,	   2007).	   Subpallial	   areas	   also	  
contain	   the	   predominance	   of	   peptidergic	   amygdalar	   innervation,	   further	   emphasising	   the	   striatal	  
origins	  (Real	  et	  al.,	  2008).	  	  
Connectivity	  	  
Differences	  in	  connectivity	  reinforce	  the	  separation	  between	  the	  pallial	  and	  subpallial	  regions	  of	  the	  amygdala.	  	  
As	  could	  be	  predicted	  by	   their	  proximity,	  olfactory	  and	  accessory	  olfactory	  bulbs	   largely	  project	   to	  
pallial	   structures	   such	  as	   the	  CxA,	  ACo,	  and	  LOT.	  Projections	   to	   the	   subpallial	  Me	  convey	  olfactory	  
information	   from	  the	  accessory	  olfactory	  bulb	   (Scalia	  &	  Winans,	  1975;	  de	  Olmos	  et	  al.,	  1978).	  This	  
pathway	  to	  the	  Me,	  in	  conjunction	  with	  activity	  in	  the	  BM	  and	  AHi	  is	  associated	  with	  modulation	  of	  
sociosexual	  behaviour	  (Ikebuchi	  et	  al.,	  2009;	  Bergan	  et	  al.,	  2014;	  Hari	  Dass	  &	  Vyas,	  2014).	  	  
Sensory	   information	   reaches	   the	   amygdala	   via	   the	   thalamus,	   with	   auditory,	   visual,	   and	  
somatosensory	  data	   conveyed	   to	   the	   La	   and	  Ce	   from	   the	   thalamic	   posterior	   intralaminar	   complex	  
(Turner	  &	  Herkenham,	  1991).	  	  These	  areas	  also	  receive	  input	  from	  the	  parvicellular	  ventral	  posterior	  
thalamic	  nucleus	  with	  gustatory	  and	  oral	  somatosensory	  information,	  and	  visceroreceptive	  thalamic	  
nuclei	   innervation	   to	   the	  BL	   and	  BM,	   and	   La,	   Ce.	   Further	   viscero-­‐receptive	   input	   is	   provided	   from	  
primary	   and	   sensory	   insular	   cortex	   neurons	   to	   the	   same	   amygdaloid	   nuclei	   as	   the	   parvicellular	  
ventral	  posterior	  thalamus	  (McDonald,	  1998).	  	  	  
As	  the	  amygdala	  is	  implicated	  in	  emotional	  memory,	  numerous	  hippocampal	  inputs	  terminate	  in	  the	  
pallial	  nuclei,	  BL,	  La,	  AHi,	  and	  APir	  (Pitkänen	  et	  al.,	  2000),	  and	  provide	  contextual	  information	  used	  to	  
make	  behavioural	  decisions	   (Ergorul	  &	  Eichenbaum,	  2004).	  Orbitofrontal	  projections	   to	   the	   La,	  BL,	  
and	  Ce	  have	  been	  shown	  to	  convey	  information	  on	  outcome	  expectancy	  (Schoenbaum	  et	  al.,	  2009)	  
and	   so	   may	   contribute	   to	   behaviour	   in	   the	   open	   field	   by	   modifying	   emotional	   responses	   in	  
accordance	  with	  how	  external	  factors	  impact	  upon	  expectation.	  	  	  
Cholinergic	   basal	   forebrain	   projections	   to	   the	   Ce	   are	   involved	   in	   enhanced	   attentional	   processing	  
seen	   in	   conditioning	   paradigms	  when	   an	   objects	   predictive	   value	   is	   altered	   (Chiba	  &	  Wada,	   1995;	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Han	   et	   al.,	   1999).	   Dopaminergic	   inputs	   to	   similar	   areas	   show	   involvement	   in	   retrieval	   of	   fear	  
memories	  (Nader	  &	  LeDoux,	  1999).	  	  
The	  amygdala	  is	  involved	  in	  many	  behaviours	  with	  a	  hormonal	  element,	  and	  many	  neurons	  possess	  
receptors	  for	  steroid	  hormones	  such	  as	  oestrogen	  (Rasia-­‐Filho	  et	  al.,	  2012),	  testosterone	  (Pfaff	  et	  al.,	  
2011;	  Gabor	  et	  al.,	  2012),	  and	  corticosterone	  (Joëls	  et	  al.,	  2013;	  Kovács,	  2013;	  Myers	  et	  al.,	  2014a).	  	  
These	   cells	   are	  mainly	   found	   in	   the	  medial	   EA,	   but	   are	   also	   present	   in	   cortical	   pallial	   nuclei	   (ACo,	  
PLCo,	   and	   PMCo).	   The	   high	   levels	   in	   the	  Me	   suggest	   steroid	   hormone	  modulation	   of	   behavioural	  
responses,	  and	  even	  the	  sparse	  corticosterone	  innervation	  in	  the	  BL	  has	  been	  associated	  with	  stress	  
enhanced	  memory	  consolidation	  (Roozendaal	  &	  McGaugh,	  1997).	  	  
In	   addition	   to	   extrinsic	   inputs,	   there	   are	   numerous	   intra-­‐amygdala	   connections.	   Chemosensory	  
circuits	   in	   the	  cortical	  amygdala	  show	  high	   levels	  of	  exclusive	   interconnection	   (Martínez-­‐Marcos	  et	  
al.,	  1999;	  Krusemark	  et	  al.,	  2013),	  whereas	  networks	  involved	  in	  emotional	  behaviours	  connect	  both	  
pallial	  and	  subpallial	  nuclei.	  The	  majority	  of	  pallial-­‐subpallial	   interconnectivity	   involves	   the	  BL,	  BM,	  
and	   La	   projecting	   to	   the	   Ce	   and	  Me,	   and	   is	   variously	   associated	  with	   odour-­‐associated	   emotional	  
memory	   (Ferry,	  2014;	  Takahashi,	  2014),	   the	   interplay	  between	  behaviour,	  emotion	  and	  motivation	  
(Fudge	   &	   Tucker,	   2009),	   and	   gated	   control	   of	   fear	   associated	   behaviours.	   Further	   investigations	  
suggest	  projections	  to	  the	  Me	  are	  largely	  concerned	  with	  socio-­‐sexual	  elements	  of	  behaviour	  (Dixon,	  
2004;	  Brennan	  &	  Zufall,	  2006),	  whereas	  those	  involving	  the	  Ce	  mediate	  fear	  behaviours	  (Koo	  et	  al.,	  
2004;	  Ciocchi	  et	  al.,	  2010).	  	  
The	  majority	  of	  amygdala	  projection	  neurons	  originate	  in	  the	  pallial	  regions.	  Projections	  from	  the	  La,	  
BL,	  BM,	  and	  LOT	  to	  the	  perirhinal	  cortex	  are	  implicated	  in	  emotional	  gating	  of	  sensory	  input	  to	  the	  
hippocampus	  (Sacchetti	  et	  al.,	  1999).	  	  	  
The	  BL,	  and	  BM	  and	  La	  to	  a	  lesser	  extent,	  are	  reciprocally	  connected	  with	  the	  insula,	  and	  involved	  in	  
conditioned	   taste	   aversion	   (Clark	   &	   Bernstein,	   2009).	   An	   imaging	   study	   looking	   at	   activational	  
differences	  between	  sommeliers	  and	  untrained	  controls	  gives	  an	  interesting	  take	  on	  the	  amygdala’s	  
role	  in	  interpretation	  of	  taste	  and	  found	  untrained	  individuals	  showed	  greater	  amygdalar	  activation,	  
compared	   to	   the	   more	   analytical,	   non-­‐amygdala	   activation	   seen	   in	   trained	   sommeliers,	  
demonstrating	  the	  division	  between	  analytical,	  trained	  processes	  and	  emotional	  responses	  to	  stimuli	  
(Pazart	  et	  al.,	  2014).	  	  
The	  BL	  is	  also	  the	  origin	  of	  numerous	  projections	  to	  the	  prefrontal	  cortex,	  and	  it	  has	  been	  shown	  that	  
this	   relationship	   controls	   acquisition	   and	   extinction	   of	   conditioned	   fear	   behaviours	   (Schafe	   et	   al.,	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2001).	   BL	   connections	   with	   the	   hippocampal	   regions	   are	   also	   involved	   in	   fear	   extinction	   and	  
acquisition	  by	  providing	  context	  (Zelikowsky	  et	  al.,	  2014).	  
Projections	   from	   this	   same	   basolateral	   subgrouping	   target	   thalamic	   nuclei	   and	   are	   thought	   to	   be	  
involved	   in	   regulation	  of	  visceral	  emotional	  associations	   (Van	  der	  Werf	  et	  al.,	  2002).	  Again,	   the	  Ce	  
also	  provides	   input	  as	  part	  of	  this	  circuit,	  with	  projections	  originating	  from	  CRF-­‐positive	  cells	   in	  the	  
CeL	  (Otake	  &	  Nakamura,	  1995).	  	  
The	  majority	  of	  amygdaloid	  descending	  projections	  originate	  in	  the	  subpallial	  areas,	  and	  are	  involved	  
in	   expression	   of	   fear	   and	   anxiety	   (LeDoux	   et	   al.,	   1988).	   Generally,	   output	   from	   the	  medial	   EA	   to	  
descending	   pathways	   also	   involves	   return	   projections	   through	   the	   central	   EA	   (Rizvi	   et	   al.,	   1991).	  
Projections	   from	   the	   Me	   proper	   and	   extended	   Me	   (primarily	   the	   STL)	   show	   different	   functional	  
outcomes,	  with	  Me	  involved	  in	  short-­‐term	  fear	  reactions,	  and	  STL	  activity	  associated	  with	  sustained	  
fear	  or	  anxiety-­‐like	  behaviours	  (Walker	  et	  al.,	  2009).	  	  
The	  Ce	  is	  also	  the	  origin	  of	  projections	  to	  the	  hypothalamus,	  but	  unlike	  those	  from	  the	  Me,	  these	  are	  
associated	  with	   control	   of	   fear-­‐associated	   stress	   responses.	   Ablation	   is	   associated	  with	   decreased	  
circulating	  corticosterone	  (Feldman	  &	  Conforti,	  1985),	  and	  the	  inverse	  is	  seen	  during	  Ce	  stimulation	  
(Redgate	  &	  Fahringer,	  1973).	  	  
The	   PAG	   is	   implicated	   in	   pain	   pathways,	   and	   receives	   amygdala	   input	   via	   the	   Ce,	   specifically	   CRF,	  
somatostatin,	  and	  substance	  P	  immunoreactive	  cells	  in	  the	  CeM	  and	  CeL	  (Chen	  et	  al.,	  2009;	  Zhao	  et	  
al.,	   2009;	   Penzo	   et	   al.,	   2014)	   are	   involved	   in	   controlling	   the	   expression	   of	   endogenous	   analgesia	  
(Nakamura	   et	   al.,	   2013),	   fear	   (Canteras	   et	   al.,	   2012),	   and	   foraging	   behaviour	   (Mota-­‐Ortiz	   et	   al.,	  
2009).	  	  
Sex	   differences	   have	   been	   noted	   in	   strength	   of	   pain-­‐associated	   connectivity	   between	   the	   Ce	   and	  
PAG,	   with	   men	   showing	   increased	   connectivity,	   despite	   similar	   increases	   in	   activation	   and	   VAS	  
ratings	  in	  response	  to	  heat	  stimuli	  seen	  in	  both	  men	  and	  women	  (Linnman	  et	  al.,	  2012).	  	  
The	  PB	  receives	  input	  from	  the	  central	  CeL,	  and	  sends	  projections	  back	  via	  the	  CeC	  (Bray,	  2000)	  involving	  
gustatory	  circuits	  implicated	  in	  the	  development	  of	  conditioned	  taste	  aversion	  (Yamamoto,	  2007),	  in	  addition	  
to	  homeostatic	  control	  of	  water	  and	  sodium	  intake	  (Johnson	  et	  al.,	  1999).	  
The	  CeL/CeM	  and	  central	  EA	  areas	  such	  as	  the	  STL	  also	  project	  to	  the	  dorsal	  vagal	  complex,	  modulating	  stress-­‐
induced	  gastrointestinal	  activity	  (Johnson	  et	  al.,	  2012).	  	  	  	   	  
	  	  	  
	  	  
64	  
Table	   1-­‐4	   summarises	   the	   immunohistological	   characterisation	   of	   the	   Ce	   subdivisions	   in	   the	   rat.	  
Other	   studies	   investigating	   immunohistology	   in	   the	   amygdala	   often	   fail	   to	   distinguish	   the	  
subdivisions	   (Katona	  et	   al.,	   2001;	   Badowska-­‐Szalewska	  et	   al.,	   2006),	   or	   use	   simplified	   schema	   e.g.	  
medial	   and	   lateral	   areas	   of	   the	   Ce	   (Równiak	   et	   al.,	   2008).	   It	   is	   also	   worth	   bearing	   in	   mind	   that	  
amygdala	   outputs	   are	   less	   extensive	   in	   the	   rat	   compared	   to	   primates,	   suggesting	   caution	   when	  
translating	  what	  is	  seen	  in	  the	  rat	  to	  the	  clinical	  population	  as	  neurochemical	  differences	  may	  also	  be	  
present	  (Amaral	  &	  Price,	  1984),	  and	  additionally,	  some	  transmitters	  such	  as	  relaxin3	  show	  extensive	  
receptor	  staining	  without	  detectable	  relaxin3	  innervation	  (Ma	  et	  al.,	  2007).	  	  
Functionality	  	  
As	   this	   study	   is	   looking	   at	   amygdala	   activity	   associated	   with	   nociception	   and	   how	   this	   influences	  
behavioural	   responses	   to	   a	   contextual	   evaluation	   of	   the	   environment,	   the	   majority	   of	   amygdala	  
functionality	  discussed	  will	  relate	  to	  this.	  	  
The	  amygdala	  is	  a	  key	  centre	  for	  control	  and	  generation	  of	  emotional	  behavioural	  responses	  in	  both	  mammals	  
(LeDoux,	  2000;	  Price,	  2006)	  and	  other	  organisms	  (Moreno	  &	  González,	  2007).	  	  
Table	  1-­‐4:	  Immunohistochemical	  properties	  of	  the	  nuclei	  of	  the	  central	  amygdala	  
Highlighting	  similarities	  between	  lateral	  and	  capsular	  areas.	  ++	  indicates	  dense	  staining,	  +	  positive	  staining,	  -­‐	  negative	  staining.	  Data	  
from	  Cassell	  et	  al.,	  1986;	  Gray	  &	  Magnuson,	  1987;	  Ma	  et	  al.,	  2007;Spicer	  2013	  (unpublished	  data))	  	  
	   Medial	   Lateral	   Capsular	  
General	  description	   Small	  clustered	  cells	   Small	  dense	  cells	   Loosely	  packed	  cells	  
NAPDHd	   ++	   -­‐	   -­‐	  
AChE	   +	   -­‐	   -­‐	  
Substance	  P	   ++	   ++	   +	  
Somatostatin	   ++	   +	   +	  
Galanin	   ++	   	   	  
Calbindin	   	   +	   	  
CRF	   	   +	   	  
Neurotensin	   	   +	   	  
CCK	   	   ++	   +	  
CGRP	   	   +	  (perineuronal	  nests)	   +	  
Relaxin3	   	   ++*	   ++	  
Enkephalin	   	   	   +	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Early	  studies	  in	  primates	  identified	  a	  syndrome	  named	  Kluver	  Bucy	  associated	  with	  functional	  loss	  of	  amygdala	  
activity	  due	  to	  temporal	  lobe	  damage	  characterised	  by	  placidity,	  hypersexuality,	  and	  hyperorality	  (Terzian	  &	  
Ore,	  1955;	  Bucy	  &	  Kluver,	  1955),	  although	  to	  date,	  little	  is	  known	  about	  the	  pain	  phenotype	  associated	  with	  
this	  condition	  (Muller	  et	  al.,	  2005).	  Other	  studies	  into	  amygdala	  function	  have	  investigated	  individuals	  with	  
bilateral	  amygdala	  damage	  and	  noted	  an	  apparent	  lack	  of	  fear	  (Adolphs	  et	  al.,	  2005),	  however	  this	  only	  seems	  
to	  apply	  to	  externally	  initiated	  fearful	  stimuli	  as	  studies	  looking	  at	  responses	  to	  low	  CO2	  were	  able	  to	  evoke	  
fear	  in	  patients	  with	  bilateral	  amygdala	  defects	  (Feinstein	  et	  al.,	  2013),	  suggesting	  some	  other	  brain	  areas	  must	  
also	  be	  capable	  of	  evoking	  feelings	  of	  fear	  to	  internally-­‐generated	  physiologically-­‐induced	  stimuli,	  separate	  
from	  the	  contribution	  from	  the	  amygdala.	  	  
The	  lateral	  amygdala	  (La)	  is	  strongly	  implicated	  in	  development	  of	  fear	  conditioned	  responses,	  with	  
lesions	  abolishing	  development	  of	  such	  responses	   (Amano	  et	  al.,	  2011),	  and	  studies	  demonstrating	  
synaptic	  potentiation	  in	  the	  La	  enables	  fear-­‐conditioned	  responses	  (Lazzaro	  et	  al.,	  2010;	  Hong	  et	  al.,	  
2012).	  The	  La	  also	  projects	  to	  the	  Ce	  (direct	  and	  via	  the	  BM),	  mediating	  fear-­‐associated	  behaviours	  
such	  as	  freezing	  (Duvarci	  et	  al.,	  2011).	  The	  BL	  is	  also	  involved	  in	  some	  elements	  of	  fear	  conditioned	  
behaviour,	  particularly	  learning-­‐related	  aspects	  (Roche	  et	  al.,	  2010),	  whereas	  the	  Me	  is	  implicated	  in	  
unconditioned	   neuroendocrine	   responses	   to	   stress	   (Masini	   et	   al.,	   2009).	   Some	   studies	   have	   also	  
shown	   involvement	   of	   the	   BM	   in	   responses	   to	   live	   predators,	   emphasising	   the	   refinement	   of	   the	  
amygdaloid	   system,	  with	   differential	   responses	   to	   present	   and	   unseen	   dangers	   (Takahashi,	   2014).	  
Cortical	  nuclei	  are	  not	  exempt	   from	   fear	  associated	  behavioural	  modulation,	  and	  are	   suggested	   to	  
play	  a	  role	  in	  processing	  aversive	  chemosensory	  stimuli	  (Dhungel	  et	  al.,	  2011).	  Furthermore,	  a	  recent	  
study	   demonstrated	   the	   ability	   of	   toxoplasma	   gondii	   to	   supress	   predator-­‐odour	   evoked	   fear	  
behaviours	   in	   rats	   via	   epigenetic	   modulation	   of	   the	   medial	   amygdala	   (Hari	   Dass	   &	   Vyas,	   2014),	  
emphasising	  how	  the	  amygdala’s	  role	  in	  behavioural	  modulation	  can	  be	  hijacked.	  	  
Few	  studies	  have	  considered	  the	  direct	  effect	  of	  open	  field	  exposure	  on	  amygdala	  activity,	  and	  how	  
this	  contributes	  to	  behaviours	  observed.	  However,	  studies	  looking	  at	  response	  to	  predators	  implicate	  
the	  Me	  and	  BL/BM	  in	  generating	  evasive	  behavioural	  responses,	  with	  little	  involvement	  of	  the	  Ce	  –	  
the	   Ce	   is,	   however	   activated	   in	   response	   to	   a	   compound	   extracted	   from	   fox	   faeces,	  
trimethylthiazoline	  (TMT),	  although	  ablation	  studies	  have	  shown	  this	  activation	  is	  not	  required	  for	  a	  
behavioural	  response	  (Day	  et	  al.,	  2004;	  Fendt	  &	  Endres,	  2008).	  	  
Numerous	   functional	   imaging	   studies	   have	   also	   shown	   increased	   activation	   in	   the	   amygdala	  
associated	  with	  pain	  states	  (Bornhovd	  et	  al.,	  2002;	  Hadjikhani	  et	  al.,	  2013),	  however,	  variation	  in	  the	  
areas	  defined	  as	  “the	  amygdala”,	  a	   lack	  of	   spatial	  precision	   (Chen	  et	  al.,	  2003;	  Soher	  et	  al.,	  2007),	  
and	  statistical	  complications	  associated	  with	  analysing	  large	  interdependent	  data	  sets	  (Bennett	  et	  al.,	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2011)	   suggest	   caution	   is	   required	   when	   interpreting	   such	   data.	   It	   was	   recently	   shown	   that	   the	  
accuracy	   of	   diffusion-­‐weighted	   MRI	   in	   determining	   connectivity	   is	   very	   low,	   and	   dependent	   on	  
analysis	  algorithms	  used	  when	  compared	  to	  traditional	  tract	  tracing	  (Thomas	  et	  al.,	  2014).	  	  
The	  evidence	  for	  lateralisation	  in	  amygdala	  activation	  is	  inconclusive,	  with	  studies	  showing	  left	  (Baas	  
et	  al.,	  2004;	  Beraha	  et	  al.,	  2012),	  right	  (Carrasquillo	  &	  Gereau,	  2008),	  or	  variable	  dominance	  (Dyck	  et	  
al.,	   2010).	  With	  unilateral	   peripheral	   stimulation,	   activation	   is	   often	  observed	  on	   the	   contralateral	  
side	   (Brügger	   et	   al.,	   2011),	   but	   there	   is	   evidence	   of	   functional	   division	   between	   left	   and	   right	  
amygdalae	  (Chen	  et	  al.,	  2014).	  	  
From	  Table	   1-­‐5,	   it	   is	   clear	   there	   is	   low	  overall	   consistency	   in	   lateralisation	  of	   amygdala	   activation,	  
with	  both	  left	  and	  right	  showing	  dominance	  in	  different	  studies.	  The	  problem	  with	  comparing	  such	  
information	   is	   that	   the	  amygdala	   is	   such	  a	  heterogeneous	  brain	  area	   that	   studies	   reporting	   simply	  
activation	  are	  actually	  giving	  very	  little	  useful	  information.	  In	  studies	  related	  to	  pain	  and	  associated	  
behavioural	   responses,	   activity	   in	   the	  Ce	   appears	   to	   show	  a	   left	   bias,	   although	  bilateral	   activation	  
dependent	   on	   time	   after	   SNT	   injury	   has	   been	   described	   (Gonçalves	   &	   Dickenson,	   2012),	   with	  
implantation	  of	  corticosterone	  pellets	  into	  either	  Ce	  resulting	  in	  hypersensitivity	  and	  decreased	  open	  
arm	   activity	   in	   the	   elevated	   plus	   maze,	   but	   bilateral	   implantation	   was	   required	   for	   expression	   of	  
visceral	  hypersensitivity	  (Tran	  &	  Greenwood-­‐Van	  Meerveld,	  2012).	  	  
Connections	   between	   the	   PFC	   and	   amygdala	   are	   implicated	   in	   top-­‐down	   control	   of	   behavioural	  
responses,	  with	  an	  indirect	  pathway	  involving	  excitation	  of	  the	  BL	  by	  the	  medial	  PFC,	  which	  in	  turn	  
leads	  to	  inhibition	  of	  the	  Me	  and	  associated	  brainstem	  connections	  (Likhtik	  et	  al.,	  2005).	  	  
The	  different	   subdivisions	  of	   the	  amygdala	   receive	   sensory	   input	   from	  areas	   such	  as	   the	   thalamus	  
and	   spinal	   cord	   (capsulo-­‐lateral	   portion	  of	   the	  Ce,	   via	   the	   La	   and	  BL),	   and	  provides	  output	   via	   the	  
medial	  nucleus	  of	  the	  central	  amygdala	  to	  the	  PFC	  and	  hypothalamus,	  suggesting	  involvement	  in	  the	  
assessment	   and	   generation	   of	   emotional	   associations	   that	   form	   an	   integral	   part	   of	   the	   pain	  
experience	   (Neugebauer	   et	   al.,	   2009).	   Studies	   have	   shown	   pain-­‐associated	   increases	   in	   amygdala	  
activity	  both	  clinically	  and	  pre-­‐clinically:	  	  Pancreatitis	  	  (Frøkjær	  et	  al.,	  2011),	  cluster	  headache	  (Seifert	  
et	  al.,	  2011),	  back	  pain	  and	  arthritis	  (Baliki	  et	  al.,	  2008),	  fibromyalgia	  (Harris	  et	  al.,	  2009),	  menstrual	  
pain	  (Tu	  et	  al.,	  2010).	  	  
c-­‐Fos	  	  
c-­‐fos	  is	  a	  proto-­‐oncogene	  from	  the	  Fos	  family	  of	  transcription	  factors	  that	  encodes	  a	  62kDa	  nuclear	  
protein	   (c-­‐Fos).	   It	   forms	   a	   heterodimer	  with	   c-­‐Jun	   (also	   a	   transcription	   factor),	   known	  as	   activator	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protein	  1	  (AP-­‐1),	  which	  binds	  DNA	  and	  enables	  the	  conversion	  of	  extracellular	  signals	  into	  changes	  in	  
gene	  expression	  (Bullitt,	  1990).	  	  
Within	   30-­‐40	  minutes	   of	   neurotransmitter	   stimulation,	   c-­‐Fos	  mRNA	   is	   rapidly	   induced	   in	   neurons,	  	  
with	   protein	   levels	   peaking	   90-­‐120min	   after	   the	   initial	   stimulation.	   It	   is	   involved	   in	   early	   cell	  
responses	  to	  growth	  factors	  (Biały	  &	  Kaczmarek,	  1996),	  and	  has	  been	  shown	  to	  be	  up	  regulated	   in	  
cancer	   (Durchdewald	  et	   al.,	   2009;	  Healy	  et	   al.,	   2013).	   Additionally,	   	   it	   is	   also	   commonly	   used	   as	   a	  
marker	  of	  neuronal	  activation,	  with	  increased	  levels	  associated	  with	  stimuli	  including	  drug	  of	  abuse	  
(Armario,	   2010),	   stress	   (Nishi	   et	   al.,	   2013;	   Reul,	   2014),	   and	   pain	   (Hunt	   et	   al.,	   1987;	   Harris,	   1998;	  
Coggeshall,	  2005).	  	  
In	   studies	   investigating	   nociceptive	   stimuli,	   up-­‐regulation	   of	   c-­‐fos	   RNA	   or	   c-­‐Fos	   protein	   has	   been	  
shown	   in	   the	   spinal	   cord	   following	   both	   visceral	   inflammation	   (Dinis	   et	   al.,	   2004)	   and	   CCI.	   In	   the	  
brain,	  the	  type	  of	  noxious	  insult	  influences	  the	  areas	  activated:	  visceral	  models	  of	  acute	  CYP-­‐induced	  
haemorrhagic	  cystitis	  (Bon	  et	  al.,	  1998),	  colorectal	  distension	  (Traub	  et	  al.,	  1996)	  and	  intraperitoneal	  
acetic	   acid	   increase	   c-­‐Fos	   immunoreactivity	   in	   the	   Ce,	  whereas	   intradermal	   formalin	   is	   associated	  
with	  c-­‐Fos	  activity	   in	   the	  BL	  but	  not	   the	  Ce	  of	   the	  amygdala	   (Nakagawa	  et	  al.,	  2003).	  Formalin	  has	  
also	  been	  shown	  to	  increase	  activation	  in	  the	  hippocampus	  and	  RVM	  (Roche	  et	  al.,	  2010),	  whereas	  
studies	  looking	  at	  central	  activation	  following	  SNT	  have	  shown	  both	  increases	  in	  the	  Ce	  on	  one	  hand	  
(Morland	  et	  al.,	  Manuscript	  in	  Preparation)	  and	  no	  change	  in	  the	  amygdala	  or	  hypothalamus	  (Narita	  
et	  al.,	  2003).	  This	  2003	  study	  also	   found	  higher	   levels	  of	  c-­‐Fos	   in	   the	   frontal	  cortex,	   thalamus,	  and	  
PAG,	   with	   decreases	   in	   the	   nucleus	   accumbens	   (NAc)	   and	   VTA	   following	   SNT	   in	   male	   rats.	   Non-­‐
nociceptive	  stressors	  are	  also	  capable	  of	  inducing	  up	  regulation	  of	  c-­‐Fos.	  Restraint	  stress	  increases	  c-­‐
Fos	   immunoreactivity	   in	   the	  paraventricular	   nucleus	  of	   the	  hypothalamus	   (PVN)	   (Umriukhin	  et	   al.,	  
2012),	   and	   also	   in	   the	   prefrontal	   cortex,	   and	   amygdala	   (Shoji	   &	  Mizoguchi,	   2013).	   There	   is	   some	  
evidence	   that	   open	   field	   exposure	   increases	   c-­‐Fos	   immunoreactivity	   in	   a	   number	   of	   brain	   areas,	  
including	   the	   Ce,	   enhanced	   by	   chlordiazepoxide	   treatment,	   but	   the	   authors	   failed	   to	   include	  
information	  on	  activation	  period	  allowed	  for	  c-­‐Fos,	  so	  it	  is	  possible	  these	  increases	  were	  due	  to	  other	  
factors	  (Shaw	  et	  al.,	  2011).	  	  
Levels	  of	  amygdala	  c-­‐Fos	  activation	  have	  been	  shown	  both	  sensitive	  to	  behavioural	  phenotype,	  with	  
dominant	   animals	   showing	   higher	   levels	   following	   open	   field	   exposure	   (Wrona	   et	   al.,	   2013),	   and	  
dominant	  males,	   but	   not	   females	   exhibiting	   sensitivity	   to	   early	   life	   ‘Denial	   of	   Expectation	  Reward’	  
experiences	  resulting	  in	  increased	  adult	  Ce	  c-­‐Fos	  response	  to	  fear	  conditioning	  (Diamantopoulou	  et	  
al.,	  2013).	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Increases	  in	  Ce	  c-­‐Fos	  have	  been	  observed	  4	  hours	  after	  initiation	  of	  CYP	  treatment,	  but	  not	  at	  later	  
stages,	  indicating	  an	  acute	  amygdala	  response	  to	  bladder	  insult	  (Bon	  et	  al.,	  1997;	  Bon	  et	  al.,	  1998).	  	  
It	   is	   important	   to	  be	  aware	  of	   the	   limitations	  associated	  with	  using	  c-­‐Fos	  as	  a	  marker	   for	  neuronal	  
activation.	  Firstly,	  c-­‐Fos	  alone	  will	  only	  detect	  recent	  cell	  activation,	  giving	  no	  indication	  whether	  the	  
signal	  transmitted	  was	  excitatory	  or	  inhibitory,	  a	  limitation	  also	  seen	  in	  imaging	  techniques	  such	  as	  
MRI.	  Additionally,	  not	  all	   cells	  express	  c-­‐Fos	   (Dragunow	  &	  Faull,	  1989),	   such	  as	   those	   in	   the	  dorsal	  
root	   ganglia	   (Hunt	  et	  al.,	   1987).	   Studies	  have	  also	   found	  unexpectedly	   low	   levels	  of	   c-­‐Fos	   in	   areas	  
previously	   identified	   as	   involved	   in	   pain	  mechanisms	   such	   as	   the	   ventral	   postero-­‐lateral	   thalamus	  
(Bullitt,	  1990).	  Together,	  this	  evidence	  suggests	  caution	  in	  the	  interpretation	  of	  negative	  results,	  as	  
the	  absence	  of	  evidence	  of	  neuronal	  activation	  following	  nociceptive	  stimulation	  cannot	  be	  taken	  as	  
evidence	  that	  the	  brain	  area	  in	  question	  is	  not	  being	  activated.	  
	  
	  	  
Table	  1-­‐5:	  Summary	  of	  evidence	  for	  lateralisation	  of	  amygdala	  activation,	  showing	  the	  variation	  present	  in	  studies	  to	  date	  
ABBREVIATIONS	   –	   AMY:	   amygdala,	   PET:	   positron	   emission	   tomography,	   fMRI:	   functional	  magnetic	   resonance	   imaging,	   LORETA:	   Low	  Resolution	   Electromagnetic	   Tomography,	   Ce:	   central	  
amygdala,	   CeL:	   lateral	   central	   amygdala,	   PHN:	   post-­‐herpetic	   neuralgia,	   CRF:	   corticotrophin-­‐releasing	   factor,	   IBS:	   irritable	   bowel	   syndrome,	   OCD:	   obsessive	   compulsive	   disorder,	   ERK:	  
extracellular	  signal-­‐regulated	  kinase,	  mGluR5:	  metabotropic	  glutamate	  receptor	  5,	  EPhys:	  electrophysiology,	  CORT:	  corticosterone,	  SNT:	  spinal	  nerve	  transection,	  SR:	  systematic	  review,	  IHC:	  
immunohistochemistry	  	  
	  Study	  Details	  	   	  Type	  	   Condition	  	   Method	  	   Area	  	   Details	  	   Left	  	   Right	  	   Both	  	  
(Sutherland	  et	  al.,	  2010)	   Basic	  	   Stress	  	   Gene	  Expr.	  	   AMY	  	   CRF	  	   ✓	  	   	  	   	  	  
(Naliboff	  et	  al.,	  2003)	   Clinical	  	   Visceral	  	   PET	  	   AMY	  	   IBS;	  Enhanced	  in	  women	  	   ✓	  	   	  	   	  	  
(Hindi	  Attar	  et	  al.,	  2010)	   Clinical	  	   Psychiatric	  	   fMRI	  	   AMY	  	   Facial	  processing	  	   ✓	  	   	  	   	  	  
(Beraha	  et	  al.,	  2012)	   Clinical	  	   Negative	  Affect	  	   fMRI	  	   AMY	  	   	  	   ✓	  	   	  	   	  	  
(Liu	  et	  al.,	  2013)	   Clinical	  	   Neuropathic	  Pain	  	   fMRI	  	   AMY	  	   PHN	  	   ✓	  	   	  	   	  	  
(Baas	  et	  al.,	  2004)	   SR	  	   Emotional	  processing	  -­‐	  54	  studies	  	   fMRI/PET	  	   AMY	  	   	  	   ✓	  	   	  	   	  	  
(Akitsuki	  &	  Decety,	  2009)	   Clinical	  	   Psychiatric	  	   fMRI	  	   AMY	  	   Social	  context	  	   ✓	  	   	  	   	  	  
(Kwon	  et	  al.,	  2003)	   Clinical	  	   Psychiatric	  	   MRI	  	   AMY	  	   OCD	  compared	  to	  schizophrenia	  	   ✓size	  	   	  	   	  	  
(Carrasquillo	  &	  Gereau,	  2008)	   Basic	  	   Inflammation	  	   IHC	  	   Ce	  	   ERK	  	   	  	   ✓	  	   	  	  
(Ji	  &	  Neugebauer,	  2009)	   Basic	  	   Inflammation	  	   EPhys	  	   CeL	  	   Monoarthritis	  	   	  	   ✓	  	   	  	  
(Kolber	  et	  al.,	  2010)	   Basic	  	   Inflammation	  	   IHC/behaviour	  	   Ce	  	   mGluR5	  	   	  	   ✓	  	   	  	  
(Veltman	  et	  al.,	  2004)	   Clinical	  	   Psychiatric	  	   PET	  	   AMY	  	   Phobia	  	   	  	   ✓	  	   	  	  
(Strigo	  et	  al.,	  2008)	   Clinical	  	   Depression	  	   fMRI	  	   AMY	  	   Painful	  Stimuli	  	   	  	   ✓	  	   	  	  
(Proverbio	  et	  al.,	  2009)	   Clinical	  	   Empathy	  	   LORETA	  	   AMY	  	   Effect	  seen	  only	  in	  women	  	   	  	   ✓	  	   	  	  
(Farahbod	  et	  al.,	  2010)	   Clinical	  	   Depression	  	  	   LORETA	  	   AMY	  	   Facial	  processing	  	   	  	   ✓	  	   	  	  
(Gaffrey	  et	  al.,	  2011)	   Clinical	  	   Depression	  	  	   fMRI	  	   AMY	  	   Juveniles	  -­‐	  facial	  processing	  	   	  	   ✓	  	   	  	  
(Kim	  et	  al.,	  2014)	   Clinical	  	   Alcohol	  Dependence	  	   fMRI	  	   AMY	  	   	  	   	  	   ✓	  ê	  	   	  	  
(van	  der	  Plas	  et	  al.,	  2010)	   Clinical	  	   Fear	  	   MRI	  	   AMY	  	   Juveniles	  -­‐	  enhanced	  in	  women	  w/history	  of	  depression	  	   	  	   ✓size	  	   	  	  
(Tran	  &	  Greenwood-­‐Van	  Meerveld,	  
2012)	   Basic	  	   CORT-­‐implantation	  	   Behaviour	  	   Ce	  	  
Affective,	  behaviour	  &	  	  
somatic/visceral	  hypersensitivity	  	  	   	  	   	  	   ✓	  	  
(Gonçalves	  &	  Dickenson,	  2012)	   Basic	  	   Neuropathic	  Pain	  	   EPhys	  	   Ce	  	   SNT	  -­‐	  differential	  effect	  of	  time	  	   	  	   	  	   ✓	  	  
(Dyck	  et	  al.,	  2010)	   Clinical	  	   Psychiatric	  	   fMRI	  	   AMY	  	   Dependent	  on	  stimuli	  	  	   	  	   	  	   ✓	  	  
(Chen	  et	  al.,	  2014)	   Clinical	  	   Depression	  	   fMRI	  	   AMY	  	   6	  right	  -­‐	  12	  left	  	   	  	   	  	   ✓	  	  
(Rosenberger	  et	  al.,	  2009)	   Clinical	  	   Stress	  	   fMRI	  	   AMY	  	   Rectal	  distension	  and	  stress	  	   	  	  	   	  	  	   ✓	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1.8 Inflammation	  in	  Pain	  	  
Inflammation	  describes	  the	  reaction	  of	  the	  body	  to	  tissue	  damage.	  It	  can	  be	  divided	  into	  innate	  and	  
adaptive	   responses:	   innate	   immune	   responses	   are	   the	   first	   line	   of	   defence	   and	   are	   most	   active	  
within	  the	  first	  12	  hours	  of	  an	   insult.	   Innate	   immunity	   involves	  natural	  barrier	  systems	  such	  as	  the	  
epithelium	   and	   endothelium,	   phagocytic	   cells	   such	   as	   monocytes	   and	   macrophages,	   granulocytic	  
cells,	   including	   neutrophils,	   eosinophils,	   and	   basophils,	   and	   other	   cells	   types	   including	  mast	   cells,	  
dendritic	  cells,	  complement	  protein	  systems,	  and	  natural	  killer	  (NK)	  cells.	  In	  response	  to	  damage	  to	  
epithelial	  barriers,	   these	  cells	   release	  a	   range	  of	  cytokines	  and	   inflammatory	  mediators	   that	  act	   to	  
isolate	   and	   limit	   damage	   caused	   by	   insults	   including	   bacterial	   infection,	   and	   chemical	   or	   physical	  
trauma.	  	  	  
Adaptive	   immunity,	   a	  more	   specialised	   form	   of	   immune	   response,	   becomes	   involved	   a	   day	   or	   so	  
after	   the	   original	   insult.	   It	   involves	   highly	   specialised	   cells	   known	   as	   T	   and	   B	   lymphocytes,	   which	  
generate	   antibodies	   towards	   foreign	   agents	   such	   as	   bacteria,	   and	   possess	   ‘memory’	   whereby	  
previously	  encountered	  antigens	  elicit	  a	  stronger	  response.	   In	  terms	  of	   inflammation	  and	  pain,	  the	  
contribution	  of	  adaptive	  immunity	  is	  minimal.	  	  
Released	  during	  innate	  immune	  reactions,	  cytokines	  are	  small	  protein	  molecules	  involved	  in	  a	  broad	  
range	   of	   activities	   associated	  with	   cell	   signalling.	   There	   are	   various	   specific	   subtypes	   of	   cytokines,	  
including	   chemokines	   and	   interleukins.	   Chemokines	   are	   cytokines	   specifically	   involved	   in	   cell	  
chemotaxis,	   acting	   to	   guide	   and	   modulate	   cell	   migration,	   whereas	   interleukins	   were	   initially	  
identified	   in	   leukocytes	  and	  act	  prominently	   in	   the	   immune	   response.	  There	  are	  also	  a	  number	  of	  
other	  mediators	  involved	  in	  the	  inflammatory	  response,	  including	  growth	  factors	  and	  enzymes	  such	  
as	   inducible	   nitric	   oxide	   synthase	   (iNOS),	   and	   prostaglandin-­‐endoperoxide	   synthase	   2	  
(PTGES2/COX2),	   which	   catalyse	   reactions	   producing	   the	   potent	   vasodilators	   nitric	   oxide	   and	  
prostaglandin	  respectively.	  	  	  
Tumour	   necrosis	   factor	   (TNF),	   interleukin-­‐1β	   (IL-­‐1β),	   and	   IL-­‐6	   are	   endogenous	   pyrogens	   and	   are	  
involved	  in	  the	  increase	  in	  body	  temperature	  that	  occurs	  during	  inflammatory	  processes.	  In	  general,	  
inflammatory	  mediators	  can	  be	  pro-­‐inflammatory	  (e.g.	  IL-­‐1β),	  anti-­‐inflammatory	  (e.g.	  IL-­‐10),	  or	  show	  
activity	  in	  both	  directions	  dependent	  on	  pathways	  activated	  (e.g.	  IL-­‐6)	  (Arango	  Duque	  &	  Descoteaux,	  
2014).	  	  
As	  many	  painful	  situations	  involve	  tissue	  damage	  without	  foreign	  bodies	  present,	  innate	  immunity	  is	  
more	  prominent	  compared	  to	  adaptive,	  and	  as	  there	  is	  no	  ‘memory’	  involved	  in	  an	  innate	  response,	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the	   magnitude	   of	   response	   is	   modulated	   by	   factors	   including	   severity	   and	   spread	   of	   insult,	   not	  
familiarity.	  	  
Neurogenic	   inflammation,	   where	   release	   of	   neuropeptides	   such	   as	   substance	   P	   and	   CGRP	   from	  
peripheral	   sensory	   afferents	   acts	   on	   local	   vasculature	   and	   soft	   tissue	   to	   increase	   vasodilation	   and	  
inflammation	  levels,	  is	  also	  implicated	  in	  chronic	  pain	  conditions	  such	  as	  CRPS	  (Krämer,	  2012).	  	  
The	   TRPA1	   receptor	   is	   thought	   to	   be	   involved	   in	   the	   neurogenic	   process	   via	   peripheral	   axon	   and	  
central	   dorsal	   root	   reflexes	   (Koivisto	   et	   al.,	   2014),	   and	   has	   been	   suggested	   as	   a	   drug	   target	   in	  
neurogenic	  and	  central	  pain	  conditions	  (Pertovaara	  &	  Koivisto,	  2011).	  	  
The	   triple	   response	   of	   Lewis	   is	   a	   classic	   example	   of	   an	   inflammatory	   response	   whereby	   a	   non-­‐
penetrative	  scratch	  on	  the	  skin	  initially	  turns	  red	  due	  to	  capillary	  dilation,	  followed	  by	  a	  wider	  area	  of	  
reddening	   (flare)	   caused	   by	   neurogenic	   reflex	   activity	   resulting	   in	   arteriole	   dilation,	  with	   the	   final	  
component	   of	   the	   response	   being	   oedema/wheal	   following	   the	   shape	  of	   the	   initial	   scratch	   (Kong,	  
1960).	  	  
Inflammation	  has	  been	  shown	  to	  play	  an	   important	  role	   in	  many	  pain	  conditions	   including	  arthritis	  
(Lee	  et	   al.,	   2014),	   CRPS	   (Borchers	  &	  Gershwin,	   2014),	   and	  migraine	   (Bruno	  et	   al.,	   2007).	   Systemic	  
e.coli-­‐induced	  inflammation	  has	  been	  shown	  to	  decrease	  pain	  thresholds	  to	  pressure	  and	  electrical	  
stimulation,	  whilst	  also	   increasing	  the	  pain	  experience	  during	  the	  cold	  pressor	  test	  (de	  Goeij	  et	  al.,	  
2013).	   Numerous	   studies	   have	   investigated	   the	   cytokine	   profile	   associated	   with	   pain	   conditions	  
including	   chronic	   pelvic	   pain	   syndrome	   (Murphy	   et	   al.,	   2014),	   IC/BPS	   (Schrepf	   et	   al.,	   2014),	   and	  
neuropathic	   pain	   (Ellis	   &	   Bennett,	   2013).	   In	   particular,	   Dawes	   and	   co-­‐workers	   demonstrated	  
commonality	   between	   cytokines	   up-­‐regulated	   following	   UVB-­‐irradiation	   in	   clinical	   and	   pre-­‐clinical	  
models,	   showing	   the	   pro-­‐inflammatory	   cytokine	   CXCL5	   is	   up-­‐regulated	   and	   capable	   of	   producing	  
hypersensitivity	   in	  otherwise	  naïve	  rats	  (Dawes	  et	  al.,	  2011).	  Further,	   it	  has	  been	  documented	  that	  
following	  surgery,	  innate	  immunity	  suffers	  stress-­‐associated	  suppression	  (Cardinale	  et	  al.,	  2011;	  Cata	  
et	  al.,	  2013),	  emphasising	  the	  complexity	  of	  the	  inflammatory	  contribution	  to	  pain.	  	  
Mast	  cells	  are	  myeloid	  stem	  cell	  derived	  immune	  cells	  actively	  involved	  in	  the	  inflammatory	  response	  
(Sant	   et	   al.,	   2007).	   They	   produce	   a	   range	   of	   mediators	   including	   nitric	   oxide	   (NO),	   COX-­‐2,	   NGF,	  
serotonin,	   and	   histamine,	   in	   response	   to	   inflammatory	   mediators,	   including	   NGF	   itself	   via	   TrkA	  
receptors	  (Rice	  et	  al.,	  2002),	  and	  also	  in	  response	  to	  bradykinin	  (Cochrane	  et	  al.,	  1982).	  Bradykinin	  is	  
associated	   with	   increased	   pain	   sensitivity	   (Paterson	   et	   al.,	   2013),	   and	   acts	   to	   balance	   the	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inflammatory	   response	   in	   tandem	   with	   other	   mast-­‐cell	   secretions,	   such	   as	   interleukin-­‐10	   (IL-­‐10)	  
possessing	  anti-­‐inflammatory	  properties	  (Gautam	  et	  al.,	  2011).	  
Other	  mediators	  such	  as	  NO	  are	  released	  from	  other	  cells,	  including	  neurons,	  during	  tissue	  damage	  
and	   are	   involved	   in	   vasodilatation	   (Cirino,	   1998).	   NO	   is	   highly	   expressed	   in	   healthy	   bladder	   tissue	  
(Austin	  et	  al.,	  2003),	  and	  has	  been	   implicated	   in	  bladder	  cancer	  (Ryk	  et	  al.,	  2010;	  Ryk	  et	  al.,	  2011),	  
and	  ESSIC	  type	  3	  IC/BPS	  (IC	  featuring	  Hunner’s	  ulcers)	  (Logadottir	  et	  al.,	  2012).	  The	  high	  expression	  in	  
neurons,	   is	   implicated	   in	   modulation	   of	   motor	   behaviour	   in	   mice,	   with	   systemic,	   intra-­‐
cerebroventricular	   and	   intra-­‐striatal	   administration	   of	   a	   NOS	   inhibitor	   associated	   with	   anxiolytic	  
effects	   in	  the	  elevated	  plus	  maze,	  as	  well	  as	  reduced	  locomotion	  and	  rearing	   in	  the	  open	  field	  (Del	  
Bel	  et	  al.,	  2005).	  It	  also	  has	  similar	  effects	  in	  rats,	  with	  studies	  identifying	  the	  PAG	  as	  a	  site	  with	  high	  
NO	  activity,	  wherein	  application	  of	  NOS	  inhibitors	  induced	  anxiolytic	  effects,	  with	  NO	  donors	  having	  
the	  opposite	  effect	  (Guimarães	  et	  al.,	  2005).	  	  
Interleukin-­‐1β	  (IL-­‐1β)	  is	  also	  highly	  implicated	  in	  behavioural	  changes	  associated	  with	  inflammation.	  
It	   stimulates	   the	   release	  of	  CXCL8,	  CCL2,	   and	  CSF2,	   and	   is	   supressed	  by	  prostaglandin	  E2,	   another	  
inflammatory	  mediator	  (Mosher	  et	  al.,	  2012).	  Behaviourally,	  systemic	  IL-­‐1β	  reduces	  ambulation	  and	  
rearing	  activity	  in	  both	  male	  and	  female	  rats,	  with	  female	  rats	  in	  oestrous	  showing	  greater	  sensitivity	  
compared	  to	  non-­‐oestrous	  and	  male	  rats	   (Avitsur	  et	  al.,	  1995).	  Furthermore,	  socially	   isolated	  mice	  
show	   increased	   pre-­‐frontal	   expression	   of	   IL-­‐1β	   following	   spared	   nerve	   injury	   (SNI),	   a	   situation	  
replicated	   by	   application	   of	   an	   oxytocin-­‐inhibitor	   (Norman	  et	   al.,	   2010).	   IL-­‐1β	   is	   also	   up	   regulated	  
following	  Stavudine	  treatment	  (Lagathu	  et	  al.,	  2007)	  and	  implicated	  in	  numerous	  autoinflammatory	  
pain	  conditions	  (Chen	  &	  Meckfessel,	  2013).	  	  
It	   is	   clear	   that	   inflammatory	   mediators	   are	   involved	   to	   different	   degrees	   in	   numerous	   pain	  
conditions,	   and	   offer	   attractive	   targets	   for	   drug	   development;	   therefore	   identification	   of	  
characteristic	  inflammatory	  profiles	  is	  important	  in	  the	  study	  of	  pain.	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2 Study	  Aims	  and	  Statement	  of	  Hypothesis	  	  
Aims	  	  
Affective	  dysfunction	  associated	  with	  chronic	  pain	   is	  a	  major	  obstacle	  to	  successful	   treatment.	  The	  
aims	   of	   this	   thesis	   are	   to	   investigate	   the	   behavioural	   alterations	   associated	   with	   the	   turpentine	  
model	  of	  visceral	  inflammation,	  and	  determine	  whether	  such	  changes	  are	  correlated	  with	  activation	  
in	   the	   central	   amygdala,	   an	   area	   implicated	   in	   pain-­‐related	   behavioural	   responses.	   The	   secondary	  
aims	   are	   to	   examine	   differences	   between	   visceral	   inflammation	   and	   a	   model	   of	   anti-­‐retroviral-­‐
associated	   neuropathy,	   and	   further	   investigate	   open	   field	   phenotype	   in	   naïve	   animals	   to	   increase	  
translational	  understanding	  of	  affective	  aspects	  of	  the	  pain	  experience.	  	  
Hypotheses	  	  
1. Variation	   seen	   in	   Naïve	   animals	   is	   due	   to	   trait	   differences	   associated	   with	   defined	  
behavioural	  phenotypes	  
2. Urinary	   bladder	   inflammation	   in	   the	   female	   laboratory	   rat	   is	   associated	   with	   pain-­‐related	  
changes	   in	   ethologically-­‐relevant	   behaviours,	   which	   are	   accompanied	   by	   increases	   in	  
activation	  in	  the	  central	  nucleus	  of	  the	  amygdala	  
3. d4T-­‐induced	   peripheral	   neuropathy	   in	   female	   rats	   is	   associated	   with	   evoked	   mechanical	  
hypersensitivity	  and	  increases	  in	  thigmotactic	  behaviour	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3 Materials	  and	  Methods	  	  
3.1 Ethical	  Statement	  	  
All	   animal	   experiments	   conformed	   to	   the	   British	   Home	   Office	   Regulations	   (Animals	   (Scientific	  
Procedures)	  Act	  1986	  Amendment	  Regulations	  2012	  (SI	  2012/3039))	  under	  the	  authority	  of	  United	  
Kingdom	   Home	   Office	   Project	   Licence	   70/7162	   and	   the	   IASP	   guidelines	   for	   in	   vivo	   research	  
(Zimmermann,	  1983;	  and	  http://www.iasp-­‐pain.org).	  	  Experiments	  were	  designed	  according	  to	  Good	  
Laboratory	  Practice	   standards	   (Macleod	  et	  al.,	   2009)	   and	   reported	   in	   accordance	  with	   the	  ARRIVE	  
Guidelines	  (Kilkenny	  et	  al.,	  2010;	  Rice	  et	  al.,	  2013).	  	  
3.2 Experimental	  Animals	  	  
Adult	  female	  Wistar	  rats	  (Charles	  River,	  UK)	  were	  housed	  in	  groups	  of	  2-­‐4	  in	   individually	  ventilated	  
cages	  with	  free	  access	  to	  tap	  water	  and	  standard	  rat	  chow	  (RM1	  (P),	  Special	  Diet	  Services,	  UK).	  Male	  
Wistar	  rats	   (Charles	  River,	  UK)	  housed	  under	  the	  same	  conditions	  were	  used	   in	  the	  repeated	  open	  
field	  study.	  	  
Animals	   were	   maintained	   under	   a	   12-­‐hour	   light	   cycle	   (07:00-­‐19:00)	   under	   temperature	   and	  
humidity-­‐controlled	  conditions	  (25°C,	  30%	  ±	  5).	  Cages	  were	  cleaned	  weekly	  on	  a	  Tuesday	  (p.m.),	  and	  
housed	   in	  a	  holding	   room	  containing	  mice	  and	   rats	  of	  both	   sexes.	   	  Rats	  and	  mice	  were	  housed	  at	  
opposite	  ends	  of	  the	  holding	  room,	  and	  each	  cage	  was	  individually	  ventilated	  to	  avoid	  exposure	  to	  
olfactory	   stressors.	   Animals	   were	   habituated	   to	   the	   holding	   room	   for	   a	   minimum	   48	   hours	   after	  
delivery.	  Weight,	  estimated	  age,	  and	  sex	  of	  experimental	  animals	  used	  in	  each	  study	  are	  detailed	  in	  
Table	  3-­‐1.	  	  
Table	  3-­‐1:	  Weight	  details	  of	  experimental	  animals	  	  
Estimated	  age	  taken	  from	  UK	  growth	  chart	  (http://www.criver.com/products-­‐services/basic-­‐research/find-­‐
amodel/wistar-­‐rat)	  	  
Study	   Sex	   Weight	  at	  start	  of	  
study	  
(median	  (95%	  CI))	  
Estimated	  
age*	  
1	  	   	  Naïve	  repeated	  Open	  Field	   Male	   235.2g	  (231.6-­‐238.8)	   7	  weeks	  
2	  	  A	  Acute	  Bladder	  Inflammation	  +	  Open	  Field	   Female	   237.4g	  (232.6-­‐242.2)	   11	  weeks	  
B	  Acute	  Bladder	  Inflammation	  +	  Burrowing	  
Female	   248.6g	  (242.1-­‐255.1)	   11	  weeks	  
C	  Repeated	  Bladder	  Inflammation	  +	  Open	  Field	   Female	   231.3g	  (228.3-­‐234.2)	   11	  weeks	  
3	  	   	  d4T	  anti-­‐retroviral	  neuropathy	  +	  Open	  Field	   Female	   229.7g	  (216.0-­‐243.4)	   11	  weeks	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3.3 Study	  Design	  	  
Table	  3-­‐2	  highlights	  the	  major	  domains	  of	  good	  laboratory	  practice,	  including	  bias	  reduction.	  	  	  
Table	  3-­‐2:	  Major	  Domains	  of	  Good	  Laboratory	  Practice	  (Macleod	  et	  al.,	  2009)	  
Characteristic	   Description	  of	  procedures	  
Sample	  size	  calculation	  	   Group	  size	  was	  determined	  by	  sample	  size	  estimation	  for	  each	  experiment	  using	  SigmaStat	  software,	  version	  3.5	  
(ANOVA	  sample	  size,	  desired	  power	  =	  0.8,	  α	  =	  0.05).	  Effect	  sizes	  for	  estimation	  were	  derived	  from	  previous	  studies	  
in	  our	  group.	  Details	  of	  sample	  size	  calculation	  can	  be	  found	  in	  the	  appropriate	  study	  design	  sections	  	  
Inclusion	  and	  exclusion	  criteria	  	   Animals	  that	  died	  prior	  to,	  or	  during	  model	  induction	  were	  excluded	  from	  further	  study.	  Animals	  were	  only	  
excluded	  from	  open	  field	  analysis	  if	  video	  footage	  was	  compromised;	  animals	  were	  excluded	  from	  c-­‐Fos	  analysis	  if	  
>90min	  elapsed	  between	  open	  field	  and	  perfusion,	  or	  if	  hemisphere	  were	  indistinguishable.	  	  
Randomization	  	   Animals	  were	  randomised	  to	  model	  group	  by	  cage	  using	  a	  pseudorandom	  ABCBCACAB	  labelling	  system.	  	  
Allocation	  concealment	  	   To	  maintain	  concealment	  of	  group	  allocation,	  a	  second	  experimenter	  prepared	  the	  syringes	  with	  either	  olive	  oil	  or	  
turpentine.	  Although	  I	  (model	  creator)	  was	  theoretically	  unaware	  of	  the	  allocation	  to	  treatment	  group,	  due	  to	  the	  
pungent	  odour	  of	  turpentine,	  allocation	  concealment	  was	  difficult	  to	  maintain.	  Procedures	  were	  still	  followed,	  
using	  the	  blinding	  procedure	  described	  below,	  as	  well	  as	  masking	  cage	  labels	  or	  turning	  around	  the	  cages	  before	  
each	  behavioural	  assessment	  session.	  	  
Reporting	  of	  animals	  excluded	  from	  analysis	  	   All	  animals	  excluded	  are	  reported	  in	  the	  relevant	  tables	  below.	  	  
Blinded	  measurement,	  assessment,	  and	  
analysis	  of	  outcome	  	  
Codes	  were	  assigned	  to	  different	  treatments	  by	  an	  independent	  person	  and	  kept	  in	  a	  sealed	  envelope.	  The	  codes	  
were	  not	  broken	  until	  the	  analysis	  had	  been	  completed.	  The	  experimenter	  was	  blinded	  to	  the	  experimental	  group	  
to	  which	  an	  animal	  was	  randomized.	  In	  addition,	  open	  field	  videos	  were	  renamed	  by	  an	  independent	  person	  
before	  analysing,	  and	  immunohistochemistry	  sections	  were	  identified	  by	  animal	  not	  group	  code.	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Study	  1	  	  
Naïve,	  male	  Wistar	  rats	  were	  used	  to	  test	  the	  effects	  of	  repeated	  open	  field	  exposure	  on	  behavioural	  
outcome	  measures	  commonly	  used	  in	  pain	  research.	  There	  were	  no	  differences	  in	  how	  the	  animals	  
were	   handled	   over	   the	   three-­‐week	   testing	   period.	   Each	   animal	  was	   exposed	   to	   the	   open	   field	   on	  
three	  occasions,	  exactly	  1	  week	  apart.	  26	  animals	  were	  used	  in	  this	  study,	  with	  no	  exclusions.	  Figure	  
3-­‐1	  illustrates	  the	  experimental	  timeline.	  	  
	  	  
Figure	  3-­‐1:	  Experimental	  timeline	  for	  the	  repeated	  open	  field	  study	  using	  naïve	  male	  rats.	  No	  interventions	  were	  involved,	  with	  
open	  field	  outcomes	  measured	  at	  three	  points	  during	  the	  study.	  	  
Table	   3-­‐3	   details	   the	   information	   used	   when	   calculating	   sample	   sizes.	   As	   this	   was	   an	   explorative	  
study	   looking	  at	   longitudinal	  changes	  over	  time,	  rather	  than	  comparing	  the	  effects	  of	  treatment,	   it	  
was	  not	  possible	  to	  do	  a	  classic	  sample	  size	  calculation.	  Instead,	  the	  following	  equation	  was	  used:	  	  
	  	  
Where	  z	  is	  the	  critical	  value	  (1.96	  for	  a	  95%	  confidence	  interval),	  σ	  represents	  the	  standard	  deviation	  
of	  duration	  in	  the	  inner	  zone	  for	  naïve	  male	  rats	  (5.11),	  and	  MOE	  representing	  the	  margin	  of	  error,	  
(2).	  Using	  data	  from	  12	  naïve	  male	  rats,	  this	  calculation	  yielded	  a	  sample	  size	  of	  25.	  26	  animals	  were	  
used	   in	   the	   study	   to	  avoid	  uneven	  group	  housing.	   This	  was	  an	  approximate	  method	  of	   estimating	  
sample	  size	  based	  on	  confidence	  interval	  (CI),	  as	  the	  sample	  size	  calculator	  used	  (OriginPro)	  did	  not	  
account	   for	   repeated	   testing,	   and	   as	   this	   study	   utilised	   repeated	   testing,	   the	   sample	   size	   was	  
deemed	  appropriate	  for	  detecting	  phenotypic	  alterations	  in	  this	  study.	  	  
Table	  3-­‐3:	  Information	  used	  when	  calculating	  sample	  sizes	  for	  study	  1	  	  
	  	   Duration	  	   Frequency	  	  
Mean/Median	  	   8.9s	  	   13.5	  	  
Standard	  Deviation/IQR	  	   5.11	  	   8.5-­‐19.5	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Study	  2	  	  
In	   the	   bladder	   inflammation	   experiments,	   there	  were	   three	  main	   experimental	   groups:	  Naïve	   (N),	  
Instrumentation	  (I),	  and	  Turpentine	  (T).	  Two	  forms	  of	  bladder	  inflammation	  were	  employed	  –	  acute	  
(tested	  24	  hours	  following	  induction	  of	  inflammation),	  and	  repeated	  (tested	  24	  hours	  following	  the	  
final	  session	  of	  inflammation,	  two	  weeks	  after	  initial	  induction).	  In	  the	  repeated	  model,	  there	  was	  an	  
additional	   Anaesthesia	  Only	   (AO)	   group,	   subjected	   to	   a	   two-­‐hour	   period	  of	   isoflurane	   anaesthesia	  
with	  no	  other	  intervention.	  This	  group	  was	  introduced	  to	  determine	  the	  contribution	  of	  anaesthesia	  
to	   behavioural	   alteration.	   Twenty-­‐four	   hours	   following	   model	   completion,	   animals	   were	   either	  
exposed	   to	   the	   open	   field	   (acute	   and	   repeated)	   or	   burrowing	   (acute	   only)	   paradigms.	   Tissue	   for	  
immunohistochemistry	  (brain)	  and	  cytokine	  analysis	  (bladder)	  was	  harvested	  within	  90-­‐120	  minutes	  
of	  open	  field	  exposure	  to	  capture	  peak	  c-­‐Fos	  activation.	  	  	  
For	  full	  details	  of	  exclusions	  and	  group	  sizes,	  see	  Table	  3-­‐5	  and	  Figure	  3-­‐2	  for	  experimental	  timelines.	  	  	  
	  	  
Figure	   3-­‐2	   -­‐	   Experimental	   timeline	   for	   Bladder	   Inflammation	   studies,	   illustrating	   the	   three	   substudies	   –	   A)	   acute	   bladder	  
inflammation	  with	  a	  single	  open	  field	  exposure,	  B)	  baseline	  burrowing	  measurements	  followed	  by	  a	  single	  session	  of	  bladder	  
inflammation	  and	  four	  testing	  sessions	  for	  burrowing,	  C)	  Repeated	  bladder	   inflammation	  (x3)	   followed	  by	  a	  single	  open	  field	  
exposure.	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Table	  3-­‐4:	  Group	  sizes	  and	  exclusions	  for	  study	  2,	  acute	  and	  repeated	  bladder	  inflammation	  	  
	  	  
	  	  
Acute	  Bladder	  Inflammation	  	  
	   Naïve	  	   Instrumentation	  	   Turpentine	  	  
Model	  Induction	  	   	   14	  	   9	  	   17	  	  
Exclusions	  	   1	  found	  dead	  in	  cage	  prior	  to	  study	  start	  	   	  	  	   3	  died	  during	  model	  induction	  	  
Open	  Field	  	  
Exclusions	  	  
	   13	  	   9	  	   14	  	  
	  	  	   	  	  	   	  	  	  
c-­‐Fos	  
immunoreactivity	  	  
	   9	  	   8	  	   13	  	  
Exclusions	  	   	   3	  due	  to	  quality	  of	  	   1	  due	  to	  quality	  of	  staining	  	   1	  due	  to	  quality	  of	  	  
	   staining,	  1	  due	  to	  timing	  	   staining	  	  
Cytokine	  
Microarray	  	  
	   4	  	   4	  	  
Exclusions	  	   Animals	  chosen	  based	  on	  behaviour	  	   Animals	  chosen	  based	  on	  behaviour	  (close	  to	  
median	  frequency)	  	  	   (close	  to	  median	  frequency)	  	  
	  
Acute	  Bladder	  Inflammation	  and	  Burrowing	  
Model	  	  
Induction	  	  
14	  	   14	  	   14	  	  
Exclusions	  	   	  	   3	  died	  during	  model	  induction	  	  	   2	  died	  during	  model	  
induction	  	  
Burrowing	  	   14	  	   11	  	   12	  	  
Exclusions	  	   	  2	  	   2	  (all	  due	  to	  baseline	  
burrowing	  <500g)	  	  
2	  	  	  
	  
Repeated	  Bladder	  Inflammation	  
	   Naive	   AO	   Instrumentation	   Turpentine	  
Model	  	  
Induction	  	  
16	  (20	  inc.	  *)	  	  	   8	  	   10	  	   14	  (18	  inc.	  *)	  	  
Exclusions	  	   	  	  	   	  	   	  	   2	  died	  during	  model	  
induction	  	  
Open	  Field	  	  
Exclusions	  	  
16	  	  






	  	  	  
c-­‐Fos	  IR	  	   15	  	   8	  	   10	  	   8	  	  






4*	  	   4*	  	  
Exclusions	  	   1	  due	  to	  PCR	  replication	  
failure;	  as	  above	  	  
	  	   As	  above	  	   As	  above	  	  
*	  n=4/group	  extra	  animals	  in	  repeated	  model	  for	  cytokines	  only;	  NT,	  not	  tested	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Table	  3-­‐5	  details	  the	  information	  used	  when	  calculating	  sample	  sizes.	  Frequency	  of	  entry	  to	  the	  inner	  
zone	  data	  from	  a	  previous	  study	  conducted	  in	  this	  laboratory	  looking	  at	  thigmotaxis	  in	  the	  open	  field	  
following	  SNT	  (Morland	  et	  al.,	  Manuscript	  in	  Preparation).	  Using	  a	  power	  of	  0.08	  and	  alpha	  value	  of	  
0.05,	  a	  sample	  size	  of	  8	  was	  calculated	  using	  OriginPro	  (applicable	  to	  both	  1-­‐Way	  ANOVA	  and	  t-­‐test).	  	  
Table	  3-­‐5:	  Information	  from	  previous	  work	  into	  the	  spinal	  nerve	  transection	  model	  (SNT)	  used	  when	  calculating	  sample	  sizes	  for	  
study	  2	  	  
	  	   Naïve	  	   SNT	  	   	  	  
Mean	  	   7.67	  	   4.17	  	   Difference	  =	  4.17	  	  
Standard	  Deviation	  	   3.84	  	   1.65	  	   Mean	  =	  2.745	  	  
Study	  3	  	  
In	   the	   study	   of	   d4T-­‐induced	   neuropathy,	   there	   were	   three	   main	   experimental	   groups:	   Naïve	   (N),	  
Vehicle	  (V),	  and	  d4T.	  Animals	  were	  tested	  for	  hindpaw	  sensitivity	  (mechanical,	  thermal,	  cold)	  on	  days	  
4,	  7,	  10,	  and	  13,	  and	  exposed	  to	  the	  open	  field	  on	  post-­‐injection	  day	  14.	  Table	  3-­‐6	  shows	  group	  sizes,	  
Table	  3-­‐7	  gives	  the	  data	  used	  to	  calculate	  sample	  sizes,	  and	  Figure	  3-­‐3	   illustrates	  the	  experimental	  
timeline.	  	  
Table	  3-­‐6:	  Group	  sizes	  used	  in	  the	  d4T	  study	  	  
Group	  	   Initial	  Group	  Size	  	   Open	  Field	  	   Evoked	  Nocifensive	  Measures	  	  
Naïve	  	   12	  	   12	  	   12	  	  
Saline	  	   12	  	   12	  	   12	  	  
d4T	  	   12	  	   12	  	   12	  	  
	  	  
Figure	   3-­‐3:	   Experimental	   timeline	   for	   the	   d4T	   study	   illustrating	   the	   measurement	   of	   baseline	   evoked	   measures	   before	   two	  
injections	  of	  d4T.	  Evoked	  measures	  were	  tested	  at	  a	  further	  4	  points,	  completed	  with	  a	  single	  open	  field	  exposure.	  
Frequency	  of	  entry	  to	  the	  inner	  zone	  data	  from	  a	  previous	  study	  conducted	  in	  this	  laboratory	  looking	  at	  
thigmotaxis	  in	  the	  open	  field	  following	  d4T	  (Stavudine)	  treatment	  in	  male	  rats	  (Huang	  et	  al.,	  2013)	  was	  
used.	  Using	  a	  power	  of	  0.08	  and	  alpha	  value	  of	  0.05,	  a	  sample	  size	  of	  12	  was	  calculated	  using	  SigmaStat	  
(applicable	  to	  both	  1-­‐Way	  ANOVA	  and	  t-­‐test).	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Table	  3-­‐7:	  Information	  used	  when	  calculating	  sample	  sizes	  for	  study	  3	  	  
	  	   Naïve	  	   d4T	  	   	  	  
Mean	  	   15.67	  	   4.71	  	   Difference	  =	  10.96	  	  
Standard	  Deviation	  	   2.87	  	   1.13	  	   Mean	  =	  2	  	  
	  
3.4 Test	  Environment	  	  
All	   behavioural	   experiments	   were	   conducted	   during	   the	   light	   phase	   (08:00-­‐18:00)	   in	   a	   dedicated	  
behavioural	   laboratory,	   with	   surgical	   procedures	   carried	   out	   in	   a	   separate	   but	   adjacent	   surgical	  
room.	   In	   vivo	   studies	   were	   conducted	   in	   batches	   of	   2-­‐3	   animals	   per	   group	   (n=6-­‐9/batch)	   due	   to	  
capacity	   and	   protocol	   constraints.	   Humidity	   and	   temperature	   were	   maintained	   at	   25°C	   and	   30%	  
respectively.	   Light	   levels	   outside	   the	   isolation	   chamber	   during	   open	   field	   paradigms	   ranged	   from	  
70300	   lux,	   measured	   using	   an	   IsoTech	   ILM350	   lux	   meter	   (IsoTech,	   Industrial	   Partner,	   USA).	   As	  
rodents	  have	  a	  greater	  auditory	  range	  than	  humans,	  ultrasonic	  sound	  recordings	  were	  taken	  using	  a	  
Mini-­‐3	  Bat	  Detector	  (Ultra	  Sound	  Advice,	  UK)	  to	  determine	  the	  background	  levels	  of	  high	  frequency	  
sound	   generated	   by	   equipment.	   Fluorescent	   lighting	   and	   computer	   equipment	   emitted	   signals	  
within	  the	  20-­‐50	  kHz	  range	  -­‐	   this	  equipment	  was	  switched	  on	  for	  the	  duration	  of	  each	  experiment	  
and	  animals	  were	  allowed	  to	  acclimatise	  to	  the	  testing	  room	  for	  30	  min	  prior	  to	  testing.	  	  
3.5 Model	  Induction	  	  
Study	  1:	  Repeated	  Open	  Field	  	  
Naïve	  animals	  were	  used	  without	  prior	  intervention.	  	  
Study	  2:	  Bladder	  Inflammation	  	  
Visceral	   inflammation	  was	   induced	  via	   turpentine	   inflammation	  of	   the	  urinary	  bladder.	   Turpentine	  
inflammation	  has	  been	  previously	  shown	  to	  induce	  both	  cytometric	  changes	  in	  bladder	  activity	  (Rice	  
&	   McMahon,	   1994;	   Jaggar	   et	   al.,	   1998b;	   Farquhar-­‐Smith	   et	   al.,	   2002),	   and	   referred	   thermal	  
hyperalgesia	  in	  the	  hind	  paws	  (Jaggar	  et	  al.,	  1999;	  Farquhar-­‐Smith	  &	  Rice,	  2001)	  but	  this	  is	  the	  first	  
study	   looking	   at	   the	   effect	   on	   ethological	   behaviours	   such	   as	   thigmotaxis	   following	   turpentine	  
inflammation	   of	   the	   bladder.	   Female	   rats	   were	   used	   for	   anatomical	   reasons	   associated	   with	  
catheterisation.	  	  
Under	   isoflurane	   anaesthesia,	   (1.5-­‐3%	   in	   2	   L/min	   O2),	   bladder	   inflammation	   was	   induced	   as	  
described	  by	  McMahon	  and	  Abel	  (1987).	  With	  the	  rat	  in	  a	  supine	  position,	  a	  transurethral	  catheter	  
(diameter	   1.02mm)	   was	   introduced	   into	   the	   bladder	   and	   position	   verified	   by	   applying	   gentle	  
abdominal	   pressure	   to	   empty	   the	   bladder.	   0.5	   ml	   olive	   oil	   (instrumentation	   control;	   Marks	   &	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Spencer,	   UK)	   or	   turpentine	   (50%	   in	   olive	   oil;	   Rustins	   Pure	   Turpentine,	   Rustins,	   UK)	   was	   slowly	  
introduced	   to	   the	   bladder	   using	   a	   0.5ml	   syringe	   attached	   to	   the	   catheter	   with	   a	   luer	   lock.	   The	  
instillation	  was	  maintained	  under	  anaesthesia	  for	  2	  hours	  before	  removal	  of	  the	  catheter.	  The	  animal	  
was	  allowed	  to	  recover	  in	  a	  separate	  area	  before	  returning	  to	  the	  home	  cage.	  To	  avoid	  hypothermia,	  
a	   warming	   mat	   was	   used,	   and	   1ml	   sterile	   saline	   (B.	   Braun	   Melsungen	   AG,	   Germany)	   was	  
subcutaneously	   administered	   at	   hourly	   intervals	   (start,	   middle,	   and	   end)	   to	   prevent	   dehydration.	  
Isoflurane	  levels	  were	  monitored	  and	  adjusted	  throughout	  the	  procedure	  to	  maintain	  an	  appropriate	  
depth	  of	  anaesthesia.	  	  
Based	  on	  the	  above	  protocol,	  a	  model	  of	  persistent	  bladder	  inflammation	  was	  developed,	  involving	  
three	   instillations,	   each	   one	  week	   apart.	   Animals	  were	  weighed	   at	   the	   start	   of	   each	   experimental	  
session	  to	  monitor	  changes	  in	  weight.	  	  	  
Study	  3:	  d4T-­‐induced	  Neuropathy	  	  
d4T	  is	  an	  antiretroviral	  known	  to	  induce	  peripheral	  neuropathy.	  Patients	  are	  generally	  administered	  
d4T	   orally,	   and	   previous	   studies	   have	   demonstrated	   in	   rats	   that	   both	   oral	   gavage	   and	   i.v.	  
administration	  routes	  produce	  similar	  nocifensive	  behavioural	  profiles	  (Weber	  et	  al.,	  2009;	  Huang	  et	  
al.,	  2013).	  We	  selected	  i.v.	  administration	  as	  it	   is	  a	  comparatively	  less	  stressful	  procedure	  than	  oral	  
gavage,	   and	   is	   more	   consistent	   in	   terms	   of	   absorption	   rates	   (Kaul	   et	   al.,	   1999).	   The	   treatment	  
regimen	   (two	   50mg/kg	   i.v.	   injections)	   was	   chosen	   on	   the	   basis	   of	   previous	   studies	   (Huang	   et	   al.,	  
2013),	  which	   showed	  a	   robust	  phenotype	  of	  mechanical	  hypersensitivity	   in	  male	   rats.	   Female	   rats	  
were	  used	  to	  enable	  comparison	  with	  the	  repeated	  model	  of	  bladder	  inflammation,	  and	  contrast	  the	  
effects	   with	   that	   seen	   following	   d4T-­‐associated	   neuropathy,	   to	   investigate	   differences	   and	  
similarities	  between	  two	  models	  of	  non-­‐unilateral	  pain	  with	  differing	  aetiologies.	  	  
Animals	  were	  briefly	  anaesthetised	  (isoflurane,	  1.5-­‐3%	  in	  2	  L/min	  O2),	  and	  their	  tail	  placed	  in	  warm	  
water	   to	   facilitate	   i.v.	   injection.	   Once	   the	   tail	   vein	  was	   sufficiently	   dilated,	   the	   needle	  was	   gently	  
inserted,	   bevel-­‐up	   into	   the	   tail	   vein,	   and	   0.5	  mL	   of	   either	   0.9%	   saline	   (sterile	   10ml	   ampoules,	   B.	  
Braun	  Melsungen	  AG,	  Germany)	  or	  d4T	   (a	  gift	   from	  Pfizer	  Ltd.,	  UK;	  50	  mg/kg	   in	  sterile	  saline)	  was	  
slowly	  injected.	  A	  second	  identical	  i.v.	  injection	  was	  given	  4	  days	  later.	  	  	  
3.6 Outcome	  Measures	  	  
All	  Studies:	  Thigmotaxis	  	  
Thigmotaxis	   is	   an	   ethological	   outcome	   measure	   that	   detects	   changes	   in	   the	   innate	   behavioural	  
conflict	   between	   exploration	   and	   predator	   avoidance.	   It	   has	   been	   shown	   effective	   in	   detecting	  
negative	  behavioural	  responses	  associated	  with	  traumatic	  peripheral	  nerve	  injury	  (Leite-­‐Almeida	  et	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al.,	   2009;	   Blackbeard	  et	   al.,	   2012),	   HIV-­‐induced	   (Wallace	  et	   al.,	   2008),	   VZV-­‐associated	   neuropathy	  
(Hasnie	  et	  al.,	  2007)	  and	  d4T-­‐induced	  (Huang	  et	  al.,	  2013)	  neuropathies	  in	  male	  rats.	  This	  is	  the	  first	  
study	  to	  investigate	  whether	  visceral	  inflammation	  is	  also	  capable	  of	  inducing	  thigmotactic	  changes,	  
and	  also	  the	  first	  investigating	  effects	  in	  female	  animals.	  	  
The	  open	  field	  paradigm	  was	  used	  to	  assess	  thigmotaxis.	  Animals	  were	  exposed	  to	  the	  open	  field	  at	  the	  
following	  points	  in	  each	  study:	  	  
1. Naïve	  Study:	  At	  weekly	  intervals	  over	  three	  weeks	  in	  naïve	  animals	  	  
2. Bladder	  Inflammation:	  24	  hours	  after	  acute	  model	  induction	  and	  the	  final	  session	  of	  
bladder	  inflammation	  	  (repeated)	  
3. d4T-­‐associated	  neuropathy:	  14	  days	  after	  the	  final	  injection	  of	  d4T	  	  
Rats	  were	  taken	  from	  their	  home	  cage	  using	  a	  gloved	  hand	  and	  introduced	  into	  the	  near	  corner	  of	  a	  
matt	   black	   100	   cm2	   arena,	   enclosed	   in	   an	   isolation	   chamber	   (115	   x	   115	   x	   255	   cm)	   to	   minimise	  
fluctuations	  in	   light	  and	  sound	  levels	  and	  minimise	  observer	  effects	  on	  behaviour	  (i.e.	  the	  effect	  of	  
observation	   on	   that	   which	   is	   being	   observed).	   Light	   levels	   within	   the	   open	   field	   were	   12	   lux	  
(measured	  in	  the	  centre	  of	  the	  arena).	  Animals	  were	  positioned	  in	  the	  near	  corner	  facing	  the	  centre	  
of	  the	  arena	  floor,	  and	  allowed	  to	  explore	  for	  15	  minutes.	  The	  arena	  was	  cleaned	  with	  0.02%	  Distel	  
(formerly	  Trigene,	  Tristel	  Solutions	  Ltd.,	  UK)	  between	  trials.	  Behaviour	  was	  captured	  during	  the	  15-­‐
minute	  exploration	  session	  by	  high	  sensitivity	  camera	  (VCB	  3372;	  Sanyo,	  Japan),	  and	  analysed	  using	  
Ethovision	   XT	   10.1	   (Tracksys,	   UK	   (for	   Noldus,	   Netherlands)).	   The	   primary	   outcome	   measure	   was	  
frequency	  of	  entry	  to	  a	  virtual	  central	  zone	  (40	  cm2;	  defined	  using	  Ethovision	  software).	  Secondary	  
outcome	  measures	  were	  duration	  in	  the	  central	  zone,	  and	  rearing.	  Total	  distance	  travelled	  was	  used	  
as	  a	  measure	  of	  general	   locomotor	  activity,	  and	  was	  compared	  to	  a	  range	  derived	  from	  previously	  
published	  studies	  of	  6000-­‐8000	  cm.	  The	  distance	  travelled	  by	  naïve	  animals	  was	  used	  as	  an	  internal	  
control,	   allowing	   identification	   of	   data	   that	   may	   be	   compromised,	   either	   due	   to	   environmental	  
conditions,	  or	   issues	  with	  the	  animals	  themselves.	  Rearing	  was	  defined	  as	  both	  forelimbs	  elevated,	  
either	  against	  a	  wall,	  or	  freestanding,	  and	  measured	  under	  blinded	  conditions	  by	  a	  trained	  observer	  
watching	   at	   4	   x	   playback	   speed.	   Animals	   were	   excluded	   if	   the	   environmental	   conditions	   were	  
disrupted	  during	  testing	  (e.g.	  noise).	  	  
In	  study	  1,	  investigating	  the	  effects	  of	  repeated	  open	  field	  exposure,	  StopWatch+	  software	  (Georgia	  
State	   University,	   USA;	   http://www.cbn-­‐atl.org/research/stopwatch.shtml)	   was	   used	   to	   collect	  
rearing	   behaviour	   data,	   allowing	   differentiation	   of	   free-­‐standing	   and	   wall-­‐supported	   rearing,	   in	  
addition	   to	   recording	   duration	   and	   latency	   behaviour.	   Furthermore,	  mean	   velocity	   and	   latency	   to	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enter	   the	   inner	   zone	   were	   also	   analysed	   using	   Ethovision,	   to	   enhance	   characterization	   of	   the	  
response	  to	  repeated	  open	  field	  exposure.	  	  	  
Study	  2:	  Burrowing	  	  
Burrowing	  activity	  was	  measured	  using	  a	  protocol	  developed	  within	  the	  IMI	  Europain	  work	  package	  
2	   burrowing	   sub	   group	   (IMI	   Europain,	   2012;	   Rutten	   et	   al.,	   2014b),	   and	   cross-­‐validated	   across	   10	  
separate	   laboratories	   covering	   five	   countries,	   with	   both	   academic	   and	   pharmaceutical	   industry	  
participants.	   The	   protocol	   involves	   training,	   baseline,	   and	   testing	   phases.	   During	   training,	   animals	  
were	  allowed	  to	  acclimatize	  to	  the	  testing	  room	  before	  being	  transferred,	  in	  pairs,	  to	  empty,	  tissue	  
paper-­‐lined	  burrowing	  cages.	  After	  30	  minutes	  habituation,	  a	  burrowing	  tube	  (grey	  plastic,	  320mm	  x	  
100mm	  diameter)	  containing	  2.5kg	  clean,	  dry	  pea	  shingle	  gravel	  (2-­‐4mm	  diameter)	  was	  introduced	  
to	  each	  cage,	  and	  left	  in	  situ	  for	  60	  minutes,	  after	  which	  it	  was	  removed	  and	  weight	  displaced	  noted.	  
If	   the	   pair	   did	   not	   burrow,	   one	  member	   of	   the	   pair	  was	   swapped	   an	   individual	   rat	   from	  a	   known	  
burrowing	  pair	  during	  subsequent	  habituation	  sessions	  as	  required.	  This	  was	  based	  on	  the	  idea	  that	  
a	  non-­‐burrower	  may	  be	  encouraged	  to	  burrow	  in	  the	  presence	  of	  a	  burrower.	  Baseline	  and	  testing	  
involved	  a	  similar	  protocol	  as	  habituation,	  but	  animals	  were	  singly	  placed	  into	  the	  burrowing	  cages.	  
After	  three	  baseline	  sessions,	  animals	  were	  randomized	  into	  three	  groups	  using	  a	  balanced	  design	  to	  
ensure	   consistent	   baseline	   burrowing	   activity	   between	   groups.	   Burrowing	   activity	   was	   tested	   on	  
days	  1,	  2,	  3,	  and	  7	  following	  acute	  bladder	  inflammation,	  and	  weight	  displaced	  recorded.	  Following	  
each	  trial,	  the	  gravel	  was	  rinsed	  under	  clean	  tap	  water	  and	  allowed	  to	  air-­‐dry	  overnight.	  At	  the	  end	  
of	  the	  study,	  gravel	  was	  sterilized	  before	  storage.	  	  
Animals	  were	  excluded	  from	  final	  analysis	  if	  their	  mean	  baseline	  weight	  displaced	  was	  less	  than	  500	  g.	  	  
Study	  2:	  Cytokine	  Activation	  	  	  
Increased	  production	  of	   inflammatory	  mediators	  have	  been	  shown	   in	  models	  of	  experimental	  pain	  
(Cunha	  et	  al.,	  2008;	  Dawes	  et	  al.,	  2011;	  de	  Oliveira	  et	  al.,	  2014).	  Collaboration	  with	  John	  Dawes	  and	  
co-­‐workers	   at	   Kings	   College,	   London,	   enabled	   the	   inclusion	   of	   a	   qRT-­‐PCR	   Array	   study,	   looking	   at	  
changes	   in	  mRNA	   levels	  of	   92	  different	   inflammatory	  mediators	   (compared	   to	   four	  house-­‐keeping	  
genes).	  Cytokines	  were	  categorized	  into	  cytokines,	  chemokines,	  growth	  factors,	  enzymes,	  and	  ‘other’	  
(Table	  3-­‐8).	  	  
Tissue	  from	  whole	  bladders,	  which	  were	  snap	  frozen	  during	  the	  saline	  phase	  of	  perfusion,	  was	  used	  
for	   RNA	   extraction.	   Samples	   were	   homogenized	   while	   still	   frozen,	   and	   total	   RNA	   obtained	   using	  
“hybrid”	   method	   of	   phenol	   extraction	   (Trizol,	   Invitrogen,	   USA)	   and	   column	   purification	   (RNeasy,	  
Qiagen,	  USA).	  All	   samples	  were	  deoxyribonuclease	   (DNase,	  Qiagen,	  USA)	  treated	  to	  avoid	  genomic	  
contamination,	   and	   purity	   and	   integrity	   confirmed	   with	   an	   RNA	   6000	   Nano	   Chip	   (Agilent,	   USA).	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Complementary	  DNA	  (cDNA)	  was	  synthesized	  from	  RNA	  with	  the	  SuperScript	  II	  reverse	  transcriptase	  
kit	  (Invitrogen,	  USA).	  Each	  cDNA	  sample	  was	  diluted	  with	  PCR-­‐grade	  water	  and	  added	  in	  a	  1:1	  ratio	  
to	  TaqMan®	  Universal	  master	  mix	  to	  produce	  a	  final	  concentration	  of	  1	  ng/µl	  cDNA.	  Samples	  were	  
loaded	   into	   the	   appropriate	   ports	   (1	   µl/well)	   according	   to	  manufacturer’s	   guidelines.	   Cards	   were	  
placed	  into	  a	  7900HT	  Fast	  Real-­‐Time	  PCR	  system	  (Applied	  Biosystems,	  USA),	  and	  samples	  subjected	  
to	  40	  cycles	  of	  amplification.	  Expression	  of	  each	  transcript	  was	  measured	  with	  the	  ΔΔCt	  (cycling	  time)	  
method	   normalised	   to	   the	   geometric	  mean	   of	   the	   four	   housekeeping	   genes	   using	   the	   R	   package	  
NormqPCR	  (Perkins	  et	  al.,	  2012).	  Relative	  changes	   in	  transcript	   levels	  are	  presented	  as	  fold	  change	  
(FC).	  When	   transcript	   numbers	   were	   undetermined	   for	   a	   given	   detector	   in	   <50%	   of	   samples,	   the	  
average	   Ct	   value	   was	   calculated	   with	   the	   remaining	   data	   values.	   If	   transcript	   numbers	   were	  
undetermined	   in	   >50%	  of	   transcripts	   for	   a	   given	   sample,	   a	   default	  Ct	   of	   38	  was	   assigned.	   If	   these	  
conditions	   coincided,	   no	   FC	   value	  was	   calculated.	   Significant	   differences	   in	   gene	   expression	  were	  
detected	   using	   significance	   analysis	   of	   microarray	   (SAM)	   technique,	   involving	   calculation	   of	   false	  
discovery	  rates	  (FDR),	  represented	  as	  a	  q	  statistic	  describing	  the	  %	  probability	  of	  the	  result	  observed	  
being	  a	  false	  positive	  (Xiao	  et	  al.,	  2002;	  Lin	  et	  al.,	  2008).	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Table	  3-­‐8:	  Cytokine	  qRT-­‐PCR	  Array	  Card	  Targets	  	  
Chemokines	  	   Cytokines	  	  	   Growth	  Factors	  	   Enzymes	  	  
Complement	  



























CXCL4	  /	  PF4	  
CXCL5	  /	  CXCL6	  









CSF1	  /	  MCSF	  
CSF2	  /	  GMCSF	  
















IL-­‐14	  /	  TXLNA	  
IL-­‐15	  
IL-­‐16	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Study	  2:	  Amygdala	  Activation	  	  
Animals	  were	  humanely	  killed	  with	  0.65ml	  pentobarbitone	  sodium	  given	  via	   i.p	   injection	   (20%	  w/v	  
Solution	   for	   Injection,	   Pentoject,	   AnimalCare	   Ltd,	   UK)	   and	   transcardially	   perfused	   with	   0.9%	  
heparinized	   saline	   followed	   by	   4%	   paraformaldehyde,	   both	   at	   4°C.	   The	   brain	   was	   removed	   and	  
postfixed	  in	  4%	  paraformaldehyde	  for	  6	  hours	  and	  cryoprotected	  in	  30%	  sucrose	  for	  at	  least	  3	  days	  
prior	   to	   sectioning	   (50	   µm)	   on	   a	   freezing	  microtome	   (model	   no.	   HM450,	   Thermo	   Scientific,	   USA).	  
Staining	  of	  sections	  took	  place	  over	  several	  consecutive	  weeks	  due	  to	  capacity	  constraints.	  12	  sets	  of	  
sections	   were	   processed	   during	   each	   batch.	   Sections	   were	   washed	   in	   phosphate	   buffered	   saline	  
(PBS;	   1(NaH2PO4.2H2O):9(Na2HPO4.12H2O):7(NaCl)	   in	   dH2O),	   quenched	   with	   0.03%	   H2O2	   (Sigma-­‐
Aldrich,	  UK),	  washed	  again	   in	  PBS,	  blocked	   for	  one	  hour	   in	  5%	  normal	  goat	   serum	   (NGS,	  Millipore,	  
UK;	   PBS	  with	   0.3%	   TX	   (Triton	   X-­‐100,	   BDH,	   UK)),	   before	   incubation	   overnight	   at	   4°C	  with	   1:20,000	  
polyclonal	   rabbit	   IgG	  anti-­‐c-­‐Fos	   (sc-­‐52,	  Santa	  Cruz,	  USA;	  0.3%	  PBS-­‐TX,	  2%	  NGS).	  The	   following	  day,	  
sections	  were	  washed	  in	  PBS	  and	  incubated	  for	  two	  hours	  at	  room	  temperature	  with	  1:250	  Biotin-­‐
SP-­‐conjugated	  Affinipure	  goat	  anti-­‐rabbit	  IgG	  (F(ab’)2	  fragment	  specific;	  Jackson,	  USA;	  0.3%	  PBS-­‐TX,	  
2%	   NGS).	   Staining	   was	   visualised	   using	   a	   Vectastain	   ABC	   kit	   (avidin-­‐biotin-­‐peroxidase	   complex,	  
VectorLabs,	   UK)	   and	   DAB	   (3,3ʹ′-­‐Diaminobenzidine)	  with	   nickel	   salt	   intensification	   (VectorLabs,	   UK).	  
Sections	  were	  mounted,	  counterstained	  with	  toluidine	  blue	  to	  enhance	  cyto-­‐architecture,	  and	  cover-­‐
slipped	  using	  DePex	  mounting	  media	  (VWR,	  UK)	  prior	  to	  image	  capture.	  The	  bregma	  position	  of	  each	  
mounted	   section	  was	   determined	  with	   reference	   to	   Paxinos	  &	  Watson	  Rat	   Brain	  Atlas	   (Paxinos	  &	  
Watson,	  2006),	  and	  only	  those	  between	  -­‐1.44mm	  and	  3.36mm	  (range	  of	  the	  central	  amygdala)	  were	  
captured	  using	   a	   Leica	  DM	  R	   light	  microscope	   (Leica	  Microsystems,	  Germany).	   Image	  analysis	  was	  
conducted	  using	  Photoshop	  CS5	  (Adobe,	  USA),	  and	  the	  mean	  number	  of	  positively	  stained	  cells	  per	  
mm2	   calculated	   for	   each	   subdivision	   of	   the	   central	   amygdala	   (medial,	   lateral,	   and	   capsular),	   with	  
lateralization	  and	   rostro-­‐caudal	  axis	  position	  noted.	  A	  positively	   stained	  cell	  was	  defined	  as	  having	  
clear	  round	  dark	  nuclei	  (blue/black)	  -­‐	  sections	  without	  cFos	  positive	  cells	  in	  areas	  out	  with	  the	  central	  
amygdala	   were	   excluded.	   Staining	   areas	   outside	   distinct	   round	   puncta	   with	   a	   strong	   blue-­‐black	  
colour	  were	  ignored.	  Image	  analysis	  was	  conducted	  blind	  to	  intervention.	  Animals	  were	  excluded	  if	  
the	  open	  field-­‐perfusion	  interval	  exceeded	  120	  minutes.	  Sections	  were	  excluded	  from	  analysis	  if	  the	  
area	   containing	   the	   amygdala	   was	   bilaterally	   damaged,	   or	   if	   there	   were	   no	   c-­‐Fos	   positive	   cells	  
present	  in	  the	  section.	  	  
Study	  3:	  Evoked	  Measures	  of	  Hypersensitivity	  	  
To	   detect	   signs	   of	   neuropathy	   associated	   with	   anti-­‐retroviral	   treatment,	   evoked	   responses	   to	  
mechanical,	  thermal,	  and	  cold	  stimuli	  were	  assessed.	  These	  measures	  are	  thought	  to	  correlate	  with	  
qualitative	  sensory	  testing	  procedures	  used	  to	  assess	  neuropathic	  and	  chronic	  pain	  conditions	  in	  the	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clinical	   setting.	  Testing	  was	  conducted	   in	   the	   following	  order:	  Mechanical,	   thermal,	   cold,	  and	   sites	  
selected	  as	  shown	  in	  Figure	  1-­‐4,	  and	  Figure	  1-­‐5.	  
Mechanical	  Sensitivity	  	  
Hind-­‐paw	   withdrawal	   threshold	   in	   response	   to	   punctuate	   static	   mechanical	   stimulation	   was	  
measured	  with	  an	  electronic	  von	  Frey	  device	  of	  0.5	  mm2	  probe	  tip	  area	  (SENSEBox	  System,	  Somedic	  
Sales	  AB,	  Sweden).	  Before	  each	  habituation	  or	  testing	  session,	  animals	  were	  allowed	  to	  acclimatise	  
to	  the	  testing	  room	  for	  20	  minutes	  before	  being	  transferred	  individually	  to	  Perspex	  testing	  chambers	  
(20	  x	  20	  x	  14	  cm).	  	  Rats	  were	  allowed	  to	  acclimatize	  until	  exploratory	  behaviour	  ceased.	  During	  two	  
habituation	   sessions,	   animals	   were	   left	   undisturbed	   in	   the	   chamber	   for	   50min.	   During	   the	   two	  
baseline	  sessions	  that	  followed,	  and	  all	  subsequent	  testing	  sessions,	  the	  probe	  tip	  was	  used	  to	  apply	  
force	  to	  the	  mid-­‐plantar	  hind	  paw,	  which	  increased	  gradually	  at	  a	  rate	  of	  8–15	  g/s	  until	  the	  paw	  was	  
withdrawn.	   The	   application	   was	   performed	   5	   times	   with	   a	   minimum	   interval	   of	   1	   min	   between	  
applications.	  The	  hind	  paw	  reflex	  thresholds	  were	  determined	  at	  days	  four,	  seven,	  ten,	  and	  thirteen	  
after	  initial	  d4T	  injection	  for	  inclusion	  and	  exclusion	  purposes.	  We	  only	  measured	  hypersensitivity	  in	  
the	   hind	   paws	   as	   anti-­‐retroviral-­‐induced	   neuropathy	   predominantly	   affects	   the	   feet	   and	   is	   less	  
frequent	  in	  the	  hands	  due	  to	  increased	  vulnerability	  with	  increasing	  nerve	  length.	  	  	  
Thermal	  Sensitivity	  	  
Thermal	   sensitivity	   was	   measured	   using	   the	   Hargreaves	   Test	   (Hargreaves	   et	   al.,	   1988).	   	   The	  
apparatus	   was	   calibrated	   using	   a	   radiometer	   before	   first	   use	   to	   ensure	   consistent	   IR	   emissions.	  
Before	  each	  habituation	  or	  testing	  session,	  animals	  were	  allowed	  to	  acclimatise	  to	  the	  testing	  room	  
for	   20	  minutes	  before	  being	   transferred	   individually	   to	  Perspex	   testing	   chambers	   (20	   x20	   x14	   cm)	  
placed	   on	   the	   Hargreaves	   apparatus	   (Ugo	   Basile,	   Italy).	   	   Rats	   were	   allowed	   to	   acclimatize	   until	  
exploratory	  behaviour	  ceased.	  During	  two	  habituation	  sessions,	  animals	  were	  left	  undisturbed	  in	  the	  
chamber	   for	   50min.	   	   During	   the	   two	   baseline	   sessions	   that	   followed,	   and	   all	   subsequent	   testing	  
sessions,	   thermal	   stimuli	   were	   directed	   at	   the	   mid-­‐plantar	   hind	   paw	   and	   latency	   to	   withdraw	  
recorded.	  To	  avoid	   thermal	  damage,	   the	  heat	   source	  had	  an	  automatic	   cut-­‐off	  of	  20	   seconds.	  The	  
application	  was	  performed	  5	  times	  with	  a	  minimum	  interval	  of	  1	  min	  between	  applications.	  The	  hind	  
paw	   thermal	   sensitivity	   thresholds	   were	   determined	   at	   days	   four,	   seven,	   ten,	   and	   thirteen	   after	  
initial	  d4T	  injection	  for	  inclusion	  and	  exclusion	  purposes.	  	  	  
Cold	  Sensitivity	  	  	  
The	  acetone	  drop	  test	  was	  used	  to	  assess	  cold	  hypersensitivity.	  Before	  each	  habituation	  or	   testing	  
session,	   animals	   were	   allowed	   to	   acclimatise	   to	   the	   testing	   room	   for	   20	   minutes	   before	   being	  
transferred	  individually	  to	  Perspex	  testing	  chambers	  (20	  x	  20	  x14	  cm)	  placed	  on	  plastic	  mesh.	  	  Rats	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were	   allowed	   to	   acclimatize	   until	   exploratory	   behaviour	   ceased.	   During	   two	   habituation	   sessions,	  
animals	   were	   undisturbed	   in	   the	   chamber	   for	   50min.	   	   During	   the	   two	   baseline	   sessions	   that	  
followed,	  and	  all	  subsequent	  testing	  sessions,	  a	  syringe	  was	  used	  to	  apply	  a	  drop	  of	  acetone	  to	  the	  
mid-­‐plantar	   hind	   paw	   and	   latency	   to	  withdraw	   recorded.	   The	   application	  was	   performed	   5	   times	  
with	   a	  minimum	   interval	   of	   1	  min	   between	   applications.	   The	   hind	   paw	   cold	   sensitivity	   thresholds	  
were	  determined	  at	   four,	   seven,	   ten,	  and	   thirteen	  days	  after	   initial	  d4T	   injection	   for	   inclusion	  and	  
exclusion	  purposes.	  	  	  
3.7 Statistical	  Analysis	  	  
Sample	   size	   calculations	   were	   performed	   to	   determine	   group	   sizes	   in	   all	   studies.	   For	   the	   bladder	  
inflammation	  studies,	  data	  from	  previous	  studies	  involving	  male	  SNT	  animals	  (n=8,	  open	  field	  and	  c-­‐
Fos),	  and	  CFA	  inflammation	  (n=12,	  burrowing)	  was	  used;	  for	  the	  d4T	  study,	  data	  from	  previous	  d4T	  
studies	  using	  male	  animals	  was	  used	  (n=12);	  for	  the	  naïve	  behavioural	  characterization	  study,	  pooled	  
naïve	   data	   from	   previous	   studies	   was	   examined	   and	   sample	   size	   calculations	   designed	   to	   detect	  
difference	  in	  behavioural	  phenotype	  based	  on	  frequency	  of	  entry	  to	  the	  inner	  zone	  were	  conducted	  
using	  this	  pooled	  naïve	  data	  (n=26).	  
Normally	   distributed,	   continuous	   outcome	   measures	   was	   analysed	   using	   1-­‐way	   ANOVA,	   with	  
Kruskal-­‐Wallis	  ANOVA	  on	  ranks	  utilised	  for	  data	  that	  was	  not	  normally	  distributed	  or	  non-­‐continuous	  
(e.g.	  activity	  count	  in	  the	  open	  field).	  2-­‐way	  ANOVA	  was	  used	  to	  investigate	  the	  interaction	  between	  
group	  and	  hemisphere,	  rostro-­‐caudal	  axis	  position,	  and	  nuclear	  subdivisions	  of	  the	  central	  amygdala	  
(CeA),	   and	  also	   to	   investigate	   the	  effect	  of	  behavioural	  phenotype.	  2-­‐way	   repeated	  measure	   (RM)	  
ANOVA	   was	   additionally	   used	   to	   study	   the	   difference	   across	   time	   and	   between	   behavioural	  
phenotypes	   in	   the	   naïve	   open	   field	   study.	  Where	   overall	   ANOVA	   detected	   significant	   differences,	  
multiple	  comparison	  procedures	  were	  used	   -­‐	  Holm-­‐Sidak	   for	  normally	  distributed	  data	  and	  Dunn’s	  
multiple	   comparison	   for	   non-­‐parametric	   tests.	   Correlations	   between	   behavioural	   and	  
immunohistological	   outcomes	   were	   assessed	   using	   Pearson	   correlation	   coefficients.	   Inflammatory	  
mediator	   analysis	   was	   conducted	   using	   Significance	   Analysis	   of	   Microarrays	   (SAM),	   and	   the	   false	  
discovery	   method	   (FDR),	   which	   take	   into	   account	   dependence	   between	   transcripts	   and	   uses	  
nonparametric	  techniques.	  Significance	  was	  taken	  as	  q=0%.	  	  
Exploratory	   secondary	   analysis	   to	   look	   for	   thigmotactic	   phenotype	   based	   on	   open	   field	   was	   also	  
conducted	  during	   the	  bladder	   inflammation	  study.	  Animals	  were	  classified	  as	  “Low	  Thigmotaxis”	   if	  
they	   entered	   the	   central	   zone	  more	   than	   the	   pooled	  median	   or	   “High	   Thigmotaxis”	   if	   they	   were	  
below	   the	   pooled	   median.	   Pooled	   medians	   were	   calculated	   separately	   for	   acute	   and	   repeated	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studies.	   2-­‐way	   ANOVA	   was	   used	   to	   investigate	   the	   effect	   of	   responder	   phenotype	   on	   other	  
behavioural	  outcomes,	  and	  cFos	  immunoreactivity	  in	  the	  central	  amygdala.	  	  	  
When	   examining	   responder	   phenotype	   in	   the	   naïve	   repeated	   exposure	   study,	   a	   further	   level	   of	  
differentiation	  was	   required,	   to	   take	   into	   account	   both	   behavioural	   phenotype,	   and	   changes	   over	  
time.	  Therefore,	  the	  pattern	  of	  high	  or	   low	  phenotype	  across	  the	  three	  sessions	  was	  assessed,	  and	  
animals	  categorised	  further	  into	  one	  of	  4	  categories,	  as	  shown	  in	  Table	  3-­‐9.	  
Table	   3-­‐9:	   Behavioural	   Phenotypes	   defined	   by	   thigmotactic	   activity,	   showing	   the	   four	   different	   behavioural	   phenotypes	  
involved	  and	  the	  progression	  of	  increasing	  levels	  of	  thigmotaxis	  
Week	  of	  testing	   1	   2	   3	  
Low	  Thigmotaxis	   Low	   Low	   Low	  
Slow	  Thigmotaxis	   Low	   Low	   High	  
Rapid	  Thigmotaxis	   Low	   High	   High	  
High	  Thigmotaxis	   High	   High	   High	  
Summary	  statistics	  are	  expressed	  as	  mean	  (95%	  CI)	  when	  data	  was	  normally	  distributed,	  or	  median	  
(Interquartile	   Range:	   IQR)	   when	   data	   failed	   normality	   testing.	   Significance	   was	   taken	   at	   p<0.05.	  
Biological	  limitations	  were	  taken	  into	  account	  when	  expressing	  data	  e.g.	  cell	  density	  c-­‐Fos	  data	  given	  
to	  one	  significant	  figure.	  	  
Graphical	  representation	  of	  data	  using	  box	  and	  dot	  plots	  involved	  display	  of	  both	  median	  and	  mean	  
(black)	  lines,	  a	  box	  covering	  the	  IQR	  (25-­‐75%),	  and	  whiskers	  indicating	  the	  extent	  of	  the	  95%	  CI.	  	  
All	  statistical	  tests	  were	  performed,	  sample	  sizes	  calculated,	  and	  appropriate	  graphs	  generated	  using	  
OriginPro	  v9.1	  (OriginLab,	  USA)	  and	  SigmaPlot	  v10	  (Systat	  Software	  Inc.,	  USA).	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4 Results	  -­‐	  Study	  1:	  Repeated	  Open	  Field	  Exposure	  in	  Naïve	  Rats	  	  
The	   aim	   of	   this	   study	   was	   to	   characterise	   naïve	   behaviour	   in	   the	   open	   field	   to	   enable	   better	  
interpretation	   of	   study	   data,	   and	   gain	   understanding	   into	   how	   rat	   behaviour	   in	   the	   open	   field	  
changes	  with	  repeated	  exposure.	  This	  will	  allow	  improved	  design	  of	  experiments	  utilising	  the	  open	  
field	   paradigm	   by	   enabling	   baseline	   testing	   so	   changes	   in	   thigmotaxis	   can	   be	   related	   to	   trait	  
behavioural	  phenotype.	  Naïve	  male	  Wistar	  rats	  were	  used	  as	  male	  rats	  are	  most	  commonly	  used	  in	  
research,	  and	  were	  repeatedly	  exposed	  to	  the	  paradigm	  over	  three	  weeks.	  In	  addition	  to	  the	  primary	  
(frequency	   of	   entry)	   and	   secondary	   (duration	   in	   inner	   zone,	   latency	   to	   enter	   inner	   zone,	   rearing,	  
velocity,	   and	   distance	   travelled)	   parameters,	  weight	   and	   faecal	   count	   during	   open	   field	  were	   also	  
monitored.	  	  	  
Exclusions	  	  
No	  animals	  were	  excluded	  from	  this	  study.	  The	  total	  number	  of	  animals	  studied	  was	  26.	  	  
All	  animals	  gained	  weight	  over	  the	  course	  of	  the	  three-­‐week	  experiment,	  from	  235.2g	  (8.84)	  during	  
week	   one,	   to	   285.0g	   (16.71)	   in	  week	   2,	   and	   326.91g	   (17.28)	   in	   the	   final	  week	   (1-­‐way	   RM	  ANOVA	  	  
p<0.001).	  There	  was	  no	  difference	  in	  faecal	  count	  during	  the	  open	  field	  paradigm	  (1-­‐way	  RM	  ANOVA	  
p=0.314).	  	  
4.1 Open	  Field	  	  
Thigmotaxis	  	  
Activity	  in	  the	  inner	  zone	  of	  the	  open	  field	  decreased	  over	  time.	  Frequency	  of	  entry	  decreased	  from	  
4	  (1-­‐7)	   in	  week	  one	  to	  1	  (0-­‐3)	   in	  week	  three	  (1-­‐way	  RM	  ANOVA	  p=0.022).	  There	  was	  no	  difference	  
between	  week	   two	   activity	   (1.5	   (6-­‐0)),	   and	   either	  week	   one	   or	  week	   three	   activity.	   There	  was	   no	  
significant	   difference	   in	   duration	   in	   the	   inner	   zone	   (p=0.88),	   with	   durations	   of	   6.48s	   (3.58-­‐9.39),	  
4.65s	  (2.59-­‐6.70),	  and	  3.66s	  (1.01-­‐6.32)	  recorded	  for	  weeks	  one,	  two,	  and	  three	  respectively	  (Figure	  
4-­‐1).	  	  
Rearing	  	  
In	  contrast	  with	  studies	  2	  (bladder	  inflammation)	  and	  3	  (d4T	  peripheral	  neuropathy),	  rearing	  analysis	  
for	   this	   study	   was	   done	   using	   StopWatch+	   software,	   enabling	   free-­‐standing	   and	   wall-­‐supported	  
rearing	  to	  be	  distinguished,	  in	  addition	  to	  recording	  duration	  and	  latency	  of	  rearing	  activity.	  	  	  
2-­‐way	  RM	  ANOVA	  was	  performed	  to	  compare	  wall-­‐supported	  with	  free-­‐standing	  rearing	  across	  time.	  	  
During	   the	   first	   exposure	   to	   the	  open	   field,	   animals	  made	  52.5	   (39-­‐70)	  wall-­‐supported	   (WS)	   rears,	  
and	  20	  (13-­‐28)	  free-­‐standing	  (FS)	  rears.	  This	  decreased	  significantly	  to	  35	  (21-­‐47)	  WS	  and	  8	  (4-­‐16)	  FS	  
during	  the	  second	  exposure	  (p<0.001),	  and	  even	  further	  to	  22.5	  (13-­‐38)	  WS	  and	  8	  (3-­‐16)	  FS	  during	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week	   3	   (p<0.001	  WS).	   There	  was	   also	   a	   significant	   difference	   between	  weeks	   2	   and	   3	   in	  WS	   rear	  
frequency	  (p=0.017),	  which	  was	  not	  seen	  in	  FS	  rears.	  There	  were	  significantly	  more	  WS	  rears	  than	  FS	  
(p<0.001).	  	  
Duration	  spent	  engaging	  in	  wall-­‐supported	  rearing	  activity	  also	  decreased	  over	  time.	  WS	  rears	  
dropped	  from	  34.28s	  (29.46-­‐39.10)	  in	  week	  1	  to	  24.81s	  (19.42-­‐30.21)	  during	  week	  2,	  and	  even	  
further	  to	  19.08	  (13.93-­‐24.22)	  in	  week	  3	  (p<0.001).	  FS	  rearing	  duration	  was	  significantly	  lower	  than	  
WS	  (p<0.001)	  but	  showed	  no	  difference	  over	  time.	  No	  difference	  between	  weeks	  2	  and	  3	  was	  seen	  in	  
either	  form	  of	  rearing	  behaviour	  (Figure	  4-­‐1).	  	  
Latency	   to	  perform	  WS	   rearing	  was	  not	   significantly	   changed	  over	   time	   (p=0.341),	   but	   in	   FS	   there	  
was	   a	   significant	   increase	   from	   28.75s	   (22.88-­‐34.62)	   during	   week	   1,	   to	   118.56s	   (70.09-­‐167.03)	   in	  
week	  2	  (p<0.001),	  and	  94.68s	  (39.46-­‐149.91)	  in	  week	  3	  (p=0.008,	  Figure	  4-­‐2).	  	  
There	  was	  no	  effect	  of	  time	  on	  average	  rear	  duration,	  but	  there	  was	  a	  significant	  difference	  between	  
WS	  and	  FS	  during	  week	  3,	  with	  a	  significant	  decrease	  in	  duration	  of	  FS	  rears	  (p=0.001).	  	  
Locomotor	  Activity	  	  
Both	  total	  distance	  travelled,	  and	  mean	  velocity	  decreased	  over	  time.	  Distance	  travelled	  decreased	  
significantly	   from	   5802cm	   (5117.95-­‐6487.58)	   during	   week	   1,	   to	   4410.25cm	   (3615.81-­‐5204.69)	   in	  
week	   2,	   and	   3188.59cm	   (2458.77-­‐3918.41)	   in	  week	   3	   (1-­‐way	   RM	  ANOVA	  p<0.001).	  Mean	   velocity	  
also	   showed	  a	   significant	  difference,	  decreasing	   from	  6.45cm/s	   (5.69-­‐7.21)	   in	  week	  1,	   to	  4.94cm/s	  
(4.07-­‐5.82)	  in	  week	  2,	  and	  3.54cm/s	  (2.73-­‐4.35)	  in	  week	  3	  (1-­‐way	  RM	  ANOVA	  p<0.001).	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Figure	  4-­‐1:	  Frequency	  and	  duration	  of	  inner	  zone	  and	  rearing	  activity	  in	  the	  open	  field	  following	  repeated	  open	  field	  exposure	  	  
	  Activity	  significantly	  reduced	  over	  time,	  with	  decreases	  noted	  in	  frequency	  of	  inner	  zone	  activity	  and	  rearing,	  and	  a	  
decrease	   in	   time	   spent	   engaging	   in	  wall-­‐supported	   rearing	   behaviour	  All	   outcomes	   tested	   using	   1-­‐way	   repeated	  
measures	  ANOVA	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Figure	  4-­‐2:	  Latency	  to	  enter	  in	  the	  inner	  zone	  and	  rearing	  behaviour	  following	  repeated	  open	  field	  exposure	  	  
	  Latency	  to	  exhibit	  free-­‐standing	  rearing	  increased	  between	  weeks	  1	  and	  2.	  There	  were	  no	  other	  significant	  differences.	  All	  
outcomes	  tested	  using	  1-­‐way	  repeated	  measures	  ANOVA	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Figure	   4-­‐3:	   Distance	   travelled	   and	   velocity	   in	   the	   open	   field	   following	   repeated	   exposure	  	  
Significant	   decreases	   were	   observed	   in	   both	   outcome	   measures.	   All	   outcomes	   tested	  
using	  1-­‐way	  repeated	  measures	  ANOVA	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Responder	  Analysis	  	  
The	   sample	   size	   of	   this	   study	   was	   calculated	   to	   take	   into	   account	   the	   potential	   for	   different	  
behavioural	  phenotypes	  present	  in	  the	  naïve	  population	  (n=26).	  Based	  on	  frequency	  of	  entry	  to	  the	  
inner	  zone,	  the	  animals	  were	  classified	  as	   low	  (>2)	  or	  high	  (≤2)	  thigmotaxis.	  The	  pattern	  of	  high	  or	  
low	  phenotype	  across	  the	  three	  sessions	  was	  assessed,	  and	  animals	  categorised	  further	  into	  one	  of	  4	  
categories,	  as	  shown	  in	  Table	  3-­‐9.	  3	  animals	  showed	  low	  thigmotaxis,	  8	  showed	  a	  slow	  thigmotactic	  
phenotype,	  10	  a	  rapid	  thigmotactic	  phenotype,	  and	  5	  showing	  consistently	  high	  levels	  of	  thigmotaxis	  
across	  the	  three	  weeks	  of	  testing.	  	  	  
Behavioural	  outcomes	  were	  then	  analysed	  using	  2-­‐way	  RM	  ANOVA,	  with	  week	  of	  exposure,	  and	  the	  
thigmotactic	  phenotypes	  as	  factors.	  	  
Frequency	  of	  inner	  zone	  entry	  was	  significantly	  different	  between	  low	  (11	  (6-­‐16))	  and	  high	  (0	  (0-­‐1)),	  
slow	  (3	  (1-­‐6.5)),	  and	  rapid	  (1.5	  (0-­‐5))	  thigmotactic	  groups,	  and	  between	  high	  and	  slow	  thigmotactic	  
groups	   (p<0.001).	  Within	   groups,	   there	  was	   an	   effect	   of	  week,	  with	   low	   and	   both	   rapid	   and	   high	  
thigmotactic	  animals	  showing	  significantly	  different	  frequency	  of	  entry	  each	  week	  tested	  (p=0.003).	  
High	   and	   slow	   thigmotactic	   animals	   were	   only	   significantly	   different	   during	   week	   1	   (p=0.02),	   and	  
there	  were	   differences	   between	   low	   and	   slow	   thigmotaxis	   groups	   during	  week	   1	   (p=0.007)	   and	   3	  
(p=0.001,	  Figure	  4-­‐4).	  	  
Duration	   spent	   in	   the	   inner	   zone	  was	   significantly	   different	   between	   the	   low	   thigmotaxis	   (14.73s	  
(7.23-­‐22.23)),	   and	   slow	   (4.87s	   (3.12-­‐6.61)),	   rapid	   (3.97s	   (2.00-­‐5.94)),	   and	   high	   (1.08s	   (0.03-­‐2.13))	  
thigmotaxis	  groups.	  No	  effect	  of	  week	  was	  detected.	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Figure	   4-­‐4:	   Frequency	   in	   inner	   zone	   and	   total	   distance	   travelled	   in	   the	   open	   field	   by	   thigmotactic	   phenotype	  	  
There	  were	   significant	   differences	   between	   responder	   groups	   at	   all	   three	   time	   points.	   	   All	   outcomes	  
tested	  using	  2-­‐way	  repeated	  measures	  ANOVA	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Figure	   4-­‐5:	   Frequency	   of	   wall-­‐supported	   and	   free-­‐standing	   rearing	   behaviour	   in	   the	   repeated	   open	   field	   by	   thigmotactic	  
phenotype.	  All	  outcomes	  tested	  using	  2-­‐way	  repeated	  measures	  ANOVA	  
	  Wall-­‐supported	  but	  not	  free-­‐standing	  rear	  frequency	  showed	  significant	  differences	  	  
Behavioural	   phenotype	   contributed	   significantly	   to	   frequency	   of	   wall-­‐supported	   rearing	   (p=0.02),	  
with	   multiple	   comparison	   procedure	   indicating	   a	   significant	   difference	   between	   high	   and	   low	  
thigmotactic	   groups	   (p=0.003).	   Differences	   between	  week	   1	   and	   subsequent	   weeks	   were	   seen	   in	  
both	  high	  thigmotaxis	  (vs.	  week	  3;	  p=0.01)	  and	  rapid	  thigmotaxis	  groups	  (vs.	  week	  2	  and	  3;	  p<0.001).	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A	   similar	   effect	  was	   seen	   in	  duration	  of	  wall-­‐supported	   rears	   (p=0.04),	   again	  with	   strongest	   effect	  
between	  high	  and	  low	  thigmotaxis	  groups	  (p=0.007),	  and	  an	  effect	  of	  week	  observable	  in	  the	  rapid	  
thigmotaxis	  groups	   (vs.	  2:	  p=0.002;	  vs.	  3:	  p<0.001).	  Free-­‐standing	  rearing	  only	  showed	  an	  effect	  of	  
behavioural	   phenotype	  on	   latency	   to	   rear	   in	   the	   slow	   thigmotaxis	   group	   (p=0.009).	  No	   effect	  was	  
seen	  on	  average	  rear	  duration	  for	  either	  free	  standing	  or	  wall-­‐supported	  rears,	  or	  on	  frequency	  and	  
duration	  of	  free-­‐standing	  rears	  (Figure	  4-­‐5).	  	  
Distance	  travelled	  revealed	  significant	  effects	  of	  group	  between	  low	  (6355.23cm	  (5148.78-­‐7581.68))	  
and	  high	   (3045.55	   (2060.58cm	  (2060.58-­‐4030.53)),	   rapid	   (4046.08cm	   (3280.51-­‐4811.66)),	  and	  slow	  
(5170.37cm	   (4418.00-­‐5922.74))	   thigmotaxis	   groups	   (p<0.001),	   and	   between	   slow	   and	   both	   rapid	  
(p=0.01),	  and	  high	  thigmotaxis	  (p<0.001).	  There	  were	  significant	  effects	  seen	  between	  weeks	  in	  both	  
slow	  and	  rapid	  thigmotactic	  groups	  (p<0.01	  Figure	  4-­‐4).	  	  
Velocity	   in	   the	   inner	   zone	   also	   showed	   an	   effect	   of	   behavioural	   phenotype,	   with	   significant	  
difference	  between	  high	  and	   low	   thigmotactic	   animals	  present	  overall	   (p<0.001)	  and	  at	  each	   time	  
point	  tested	  (p=0.004,	  p=007,	  and	  p=0.006	  respectively.	  Overall	  effects	  were	  also	  detected	  between	  
high	   and	   slow	   thigmotaxis	   (p=0.003,	   week	   1:	   p=0.004),	   and	   low	   and	   rapid	   thigmotactic	   groups	  
(p=0.0004,	  week	  2:	  p=0.002,	  Figure	  4-­‐3).	  	  
Key	  findings	  	  
• Activity	  in	  the	  open	  field	  gradually	  decreases	  with	  repeated	  exposure	  	  
• Four	  behavioural	  phenotypes	  were	  detected,	  which	  take	  into	  account	  both	  frequency	  of	  inner	  
zone	  entry	  during	  each	  session,	  and	  the	  pattern	  of	  behaviour	  over	  time	  –	  the	  majority	  of	  
animals	  showed	  high	  inner	  zone	  activity	  during	  the	  first	  and/or	  second	  exposures,	  with	  a	  
significant	  minority	  exhibiting	  consistently	  high	  or	  low	  levels	  of	  thigmotaxis	  across	  the	  three	  
trials	  	  
• Frequency	  and	  duration	  of	  inner	  zone	  entry,	  distance	  travelled,	  and	  velocity	  showed	  consistent	  
phenotypes	  	  
• Thigmotactic	  outcomes	  (frequency	  and	  duration)	  showed	  highest	  re-­‐test	  stability	  between	  
weeks	  1	  and	  2	  	  
4.2 Correlations	  	  
To	   gain	   further	   understanding	   of	   open	   field	   behaviour	   and	   the	   relationships	   between	   different	  
behaviours,	  Pearson’s	  correlation	  coefficients	  were	  calculated.	  As	  numerous	  significant	  correlations	  
were	   detected,	   only	   those	   equal	   to	   or	   greater	   than	   ρ=0.8	   will	   be	   discussed.	   Full	   details	   of	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correlations	  between	  behavioural	  outcomes	  are	  shown	  in	  Table	  4-­‐1,	  with	  between-­‐week	  correlation	  
data	  shown	  in	  Table	  4-­‐2.	  	  
Highlighting	   the	   strongest	   correlations	   in	   the	   overall	   data,	   velocity	   and	   distance	   travelled	   were	  
significantly	  correlated	  (ρ=1,	  p<0.001),	  and	  frequency	  of	  inner	  zone	  entry	  was	  significantly	  correlated	  
with	   duration	   spent	   in	   the	   inner	   zone	   (ρ=0.89,	   p<0.001).	   Both	   distance	   and	   velocity	   were	   also	  
significantly	  correlated	  with	  the	  frequency	  (ρ=0.85,	  p<0.001)	  and	  duration	  (ρ=0.80,	  p<0.001)	  of	  wall-­‐
supported	   rearing.	  Duration	   and	   frequency	  were	   significantly	   correlated	  with	   both	  wall-­‐supported	  
(ρ=0.91,	  p<0.001)	  and	  free-­‐standing	  rearing	  (ρ=0.87,	  p<0.001).	  	  
Comparing	   correlations	  week	  by	  week	   revealed	   a	   time-­‐dependent	   increase	   in	   ρ,	  with	   4	   significant	  
correlations	  greater	  than	  ρ=0.8	  observed	  in	  data	  from	  week	  1,	  compared	  to	  8	  in	  week	  3.	  However,	  
correlations	  between	  weeks	  were	  poor,	  showing	  commonality	  only	  with	  the	  adjacent	  time	  point	  (i.e.	  
week	  1	  with	  2,	  and	  2	  with	  3,	  but	  not	  1	  with	  3).	  	  
Looking	   at	   correlations	   within	   thigmotactic	   phenotypes,	   velocity	   and	   distance	   were	   strongly	  
correlated	   in	   all	   subgroups(ρ=1,	   p<0.001).	   Correlations	   between	   distance	   travelled	   and	   frequency	  
and	   duration	   of	   wall-­‐supported	   rearing	   were	   strongest	   in	   the	   rapid	   (ρ=0.90,	   p<0.01),	   and	   high	  
(ρ=0.87,	   p<0.001)	   thigmotaxis	   animals.	   Low	   thigmotaxis	   animals	   also	   showed	   a	   correlation	   with	  
frequency	  of	  wall-­‐supported	  rears	  (ρ=0.95,	  p<0.001).	  	  
Combining	   responder	   type	   with	   across	   week	   comparison	   to	   investigate	   the	   relationship	   between	  
week	   1	   behaviour	   and	   that	   observed	   during	   subsequent	  weeks	   revealed	   differences	   between	   the	  
thigmotactic	  phenotypes	  as	  would	  be	  expected	  by	  their	  temporal	  phenotype	  e.g.	  those	  in	  the	  rapid	  
thigmotaxis	   group	   showed	  negative	   correlations	   between	  weeks	   1	   and	  2,	  whereas	   in	   the	   low	  and	  
slow,	  there	  were	  positive	  correlations.	  	  
Duration	  in	  the	  inner	  zone	  was	  consistently	  correlated	  over	  time,	  suggesting	  use	  as	  a	  predictor	  of	  
behavioural	  phenotype.	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Key	  findings	  	  
• Duration	  in	  the	  inner	  zone	  was	  the	  only	  outcome	  measure	  consistently	  correlated	  with	  itself	  
over	  repeated	  testing	  	  
• Velocity	  and	  distance	  travelled	  was	  strongly	  correlated	  in	  every	  phenotype	  and	  time	  point	  
tested	  	  
• Frequency	  and	  duration	  measures	  of	  the	  same	  outcome	  (e.g.	  rearing,	  inner	  zone	  entry)	  show	  
strong	  correlations	  	  
• Repeated	  exposure	  to	  the	  open	  field	  strengthens	  correlations	  observed	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Table	  4-­‐1:	  Overall	  Pearson’s	  correlation	  coefficients	  between	  open	  field	  behavioural	  outcomes	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Table	  4-­‐2:	  Summary	  of	  Pearson's	  correlation	  coefficients	  calculated	  between	  weeks	  	  
To	  investigate	  predictive	  value	  of	  previous	  behaviours.	  	  *	  denotes	  significant	  correlations	  present	  between	  parameters	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5 Results	  -­‐	  Study	  2:	  Bladder	  Inflammation	  	  
Acute	  and	  repeated	  turpentine	  bladder	  inflammation	  was	  induced	  in	  female	  Wistar	  rats	  to	  
investigate	  the	  behavioural	  consequences	  of	  visceral	  inflammation.	  	  	  
Bladder	   inflammation	   as	   a	   model	   of	   visceral	   inflammation	   was	   well	   tolerated;	   the	  main	   cause	   of	  
mortality	  was	  surgical	  complications	  relating	  to	  technical	   issues	  associated	  with	  anaesthesia.	   In	  the	  
repeated	  model,	  all	  deaths	  occurred	  during,	  or	  immediately	  following	  the	  final	  inflammation	  session.	  
Following	  recovery	  from	  anaesthesia	  and	  return	  to	  the	  home	  cage,	  animals	  were	  alert	  and	  outwardly	  
indistinguishable	  from	  naïve.	  	  
5.1 Inflammatory	  Mediator	  mRNA	  	  
Intensity	  of	  inflammatory	  response	  was	  assayed	  using	  whole	  bladder	  tissue	  and	  a	  qRT-­‐PCR	  array	  
featuring	  92	  inflammatory	  mediator	  transcripts	  and	  four	  house-­‐keeping	  genes.	  	  	  
Acute	  Bladder	  Inflammation	  	  
Both	  bladder	  weight	  and	  RNA	  concentration	  were	  increased	  following	  turpentine	  bladder	  
inflammation	  as	  shown	  in	  Table	  5-­‐1.	  	  
Table	  5-­‐1:	  Bladder	  weight	  and	  total	  RNA	  concentration	  following	  a	  single	  episode	  of	  turpentine	  bladder	  inflammation.	  Mean	  
(IQR)	  	  
	  	   Bladder	  Weight	  (g)	  	   Total	  RNA	  (ng/nl)	  	   Relative	  to	  Naive	  	  
Naïve	  	  	   0.13	  (0.01-­‐0.25)	   368.35	  (195.8-­‐540.9)	   1	  
Turpentine	  	   0.28	  (0.18-­‐0.35)	   615.03	  (250.7-­‐979.3)	   1.67	  
A	   total	   of	   81/92	   cytokine	   transcripts	   were	   analysed	   for	   magnitude	   and	   significance	   of	   transcript	  
upregulation	   following	  acute	  bladder	   inflammation,	  as	  measured	  by	   fold	  change	   (FC)	   compared	   to	  
naïve	  tissue.	  11	  markers	  (CCL1,	  CCL28,	  CTLA-­‐8,	  CCXL17,	  IFNG,	  IL-­‐2,	   IL-­‐3,	   IL-­‐4,	   IL-­‐9,	   IL-­‐13,	  IL-­‐27)	  were	  
excluded	  from	  the	  acute	  inflammation	  model	  due	  to	  high	  cycle	  time	  (>38),	  indicative	  of	  low	  levels	  or	  
issues	   in	   detection.	   The	   top	   ten	   up-­‐regulated	   transcripts	   were	   iNOS	   (159,110.28	   FC),	   PROK2	  	  
(11,060.01	  FC),	  CXCl2	  (3,679.32	  FC),	  CCL3	  (2,541.99	  FC),	  IL-­‐1α	  (1,827.32	  FC),	  IL-­‐1β	  (403.78	  FC),	  CSF3	  
(350.52	   FC),	   CXCL3	   (254.33	   FC),	   IL-­‐10	   (222.75	   FC),	   and	   IL-­‐6	   (153.21	   FC)	   (see	   Table	   5-­‐2).	   Figure	   5-­‐1	  
shows	   the	   rank	   FC	   for	   all	   markers	   analysed.	   SAM	   was	   used	   to	   identify	   25	   mRNAs	   significantly	  
different	  in	  the	  turpentine	  group	  compared	  to	  naive	  (FC	  >1.5,	  Δ	  =	  1.61,	  FDR=0%).	  Of	  these,	  13	  were	  
classified	   as	   chemokines	   (CCL2,	   CCL3,	   CCL4,	   CCL6,	   CCL7,	   CCL12,	   CCL20,	   CXCL1,	   CXCL2,	   CXCL3,	  
CXCL5/6,	   XCL1),	   9	   as	   cytokines	   (CSF2,	   CSF3,	   IL-­‐1α,	   IL-­‐1β,	   IL-­‐6,	   IL-­‐10,	   IL-­‐24,	   IL-­‐35/EBI1,	   TNF),	   2	   as	  
enzymes	  (iNOS,	  COX-­‐2),	  2	  as	  growth	  factors	  (ARTN,	  EREG),	  and	  1	  as	  ‘other’	  (PROK2),	  as	  seen	  in	  Table	  
5-­‐4.	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Figure	  5-­‐1:	  Fold	  change	  of	  inflammatory	  mediators	  following	  acute	  and	  repeated	  turpentine	  bladder	  inflammation.	  
Markers	  were	  ranked	  by	  fold	  change.	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Table	  5-­‐2:	  Top	  10	  up-­‐regulated	  transcripts	  in	  bladder	  tissue	  from	  turpentine	  group	  	  
Ranked	  by	  mRNA	  FC,	  and	  normalised	  to	  naive	  values.	  Data	  presented	  as	  mean	  FC	  (95%	  CI),	  n=3-­‐4,	  *	  Significant	  
difference	  (p<0.05)	  
	   Acute	  Bladder	  Inflammation	  	   Repeated	  Bladder	  Inflammation	  	  
Rank	  	   Gene	  	   FC	  	   	   95%	  CI	  	   	  	  	   Gene	  	   FC	  	   95%	  CI	  	  
1	  	   NOS2	  	   159110.28	  	   	  	  -­‐127366.6-­‐445587.2	  	  
	  	  
CCL12	  	   169.65	  	   67.05-­‐272.25	  	  
2	  	   PROK2	  	   11060.01	  	   	  -­‐12741.5-­‐34861.5	  	  
	  	  
CTLA-­‐8	  	   75.098	  	   -­‐56.21-­‐206.4	  	  
3	  	   CXCL2	  	   3679.32	  	   	  -­‐4618.0-­‐11976.7	  	  
	  	  
CXCL17	  	   71.2	  	   -­‐22.64-­‐165.03	  	  
4	  	   CCL3	  	   2541.99	  	   	  -­‐1417.4-­‐6501.3	  	  
	  	  
CXCL11	  	   53.27	  	   -­‐71.05-­‐177.6	  	  
5	  	   IL-­‐1α	  	   1827.32	  	   	  -­‐2717.6-­‐6372.2	  	  
	  	  
NOS2	  	   14.2	  	   -­‐9.46-­‐37.87	  	  
6	  	   IL-­‐1β	  	   403.78	  	   	  -­‐328.2-­‐1135.7	  	  
	  	  
BDNF	  	   11.9	  	   -­‐2.06-­‐25.86	  	  
7	  	   	  CSF3	  	   350.52	  	   	  -­‐269.9-­‐971.0	  	  
	  	  
CXCL2	  	   9.94	  	   -­‐9.78-­‐29.65	  	  
8	  	   CXCL3	  	   254.33	  	   	  -­‐131.8-­‐640.5	  	  
	  	  
PROK2	  	   9.12	  	   	  -­‐10.24-­‐28.49	  	  
9	  	   IL-­‐10	  	   222.75	  	   	  -­‐399.6-­‐845.1	  	  
	  	  
IL-­‐21	  	   8.88	  	   	  -­‐17.20-­‐34.96	  	  
10	  	   IL-­‐6	  	   153.21	  	   	   	  -­‐42.8-­‐349.3	  	   	  	  	   IL-­‐1β	  	   8.63*	  	   	  4.62-­‐12.65	  	  
	  
Repeated	  Bladder	  Inflammation	  	  
Both	  bladder	  weight	  and	  RNA	  concentration	  were	  increased	  in	  the	  turpentine	  and	  instrumentation	  
groups	  as	  shown	  in	  Table	  5-­‐3.	  	  
Table	  5-­‐3:	  Bladder	  weight	  and	  RNA	  concentration	  in	  the	  repeated	  bladder	  inflammation	  model	  showing	  mean	  (IQR)	  
	  	   Bladder	  Weight	  (g)	  	   [RNA]	  (ng/nl)	  	  	   RNA	  relative	  to	  Naïve	  	  
Naïve	  	  	   0.15	  (0.07-­‐0.22)	  	   2082.75	  (-­‐1164.7-­‐5330.2)	  	   1	  	  
Instrumentation	  	   0.30	  (0.16-­‐0.44)	  	   3548.5	  (-­‐172-­‐7269)	  	   1.70	  	  
Turpentine	  	   0.30	  (0.16-­‐0.43)	  	   2600.25	  (165.1-­‐5035.4)	  	   1.25	  	  
A	  total	  of	  75/92	  cytokine	  transcripts	  were	  analysed	  for	  magnitude	  and	  significance	  of	  transcript	  up-­‐
regulation	  following	  repeated	  bladder	  inflammation.	  16	  markers	  (CCL1,	  CCL3,	  CCL25,	  CCL26,	  CXCL12,	  
IL-­‐2,	   IL-­‐3,	   IL-­‐4,	   IL-­‐4,	   IL-­‐9,	   IL-­‐13,	   IL-­‐19,	   IL-­‐20,	   IL-­‐27,	   C5,	   and	   IFNG)	  were	   excluded	   from	   the	   repeated	  
inflammation	  model	  due	  to	  high	  cycle	  time	  (>38).	  One	  housekeeping	  gene	  (18s)	  was	  excluded	  as	   it	  
was	   significantly	   up-­‐regulated	   in	   the	   turpentine	   group.	   FC	  was	   therefore	   calculated	   normalized	   to	  
the	  remaining	  housekeeping	  genes	  (HPRT,	  ACTB,	  and	  GAPDH).	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Figure	   5-­‐1	   shows	   FC	   rank	   for	   all	   cytokines	   analysed	   in	   the	   turpentine	   groups.	   The	   top	   10	   mRNA	  
transcripts	   up-­‐regulated	   following	   repeated	   bladder	   inflammation	   with	   turpentine	   (normalised	   to	  
naïve	   data)	   were	   CCL12	   (169.65	   FC),	   CTLA-­‐8	   (75.10	   FC),	   CXCL17	   (71.20	   FC),	   CXCL11	   (53.27),	   iNOS	  
(14.2	  FC),	  BDNF	  (11.9	  FC),	  CXCL2	  (9.94	  FC),	  PROK2	  (9.12	  FC),	  IL-­‐21	  (8.88	  FC),	  and	  IL-­‐1β	  (8.63	  FC)	  (see	  
Table	   5-­‐2).	   Using	   SAM,	   we	   identified	   4	   mRNAs	   that	   were	   significantly	   different	   in	   turpentine	  
compared	   to	   naive	   (FC	   >1.5,	   Δ	   =	   1.61,	   FDR=0%).	  Of	   these,	   3	  were	   classified	   as	   chemokines	   (CCL7,	  
CCL12,	  CXCL17),	  and	  1	  as	  cytokine	  (IL-­‐1β),	  as	  seen	  in	  Table	  5-­‐4.	  	  	  
Analysis	  of	  bladders	  from	  the	  repeated	  instrumentation	  group	  also	  revealed	  significant	  up-­‐regulation	  
of	  CCL12	  (108.55	  FC),	  and	  of	  PPBP	  (FC	  34.42)	  compared	  to	  naïve	  animals	  (FC	  >1.5,	  Δ	  =	  1.67,	  FDR=0%).	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Table	  5-­‐4:	  Significance	  analysis	  of	  qRT-­‐PCR	  array	  (SAM)	  results	  for	  acute	  and	  repeated	  bladder	  inflammation	  	  
Significant	  fold	  difference	  in	  acute	  modela,	  repeated	  modelb,	  or	  bothc;	  Significance	  level,	  FDR	  q=0%	  	  
	   	   Acute	  	   Repeated	  	  
	  




CCL2a	  	   43.47	   4.63	   0	   3.36	   1.43	   8.44	  
CCL3a	  	   1656.98	   8.89	   0	   transcript	  excluded	  
CCL4a	  	   95.66	   2.55	   0	   6.74	   1.13	   8.44	  
CCL6a	  	   14.34	   2.52	   0	   3.98	   1.9	   5.52	  
CCL7c	  	   17.96	   2.37	   0	   5.44	   3.47	   0	  
CCL12c	  	   149.46	   3.7	   0	   120.42	   8.28	   0	  
CCL20a	  	   66.21	   3.69	   0	   9.71	   1.4	   8.44	  
CXCL1a	  	   218.46	   2.71	   0	   3.42	   1.21	   8.44	  
CXCL2a	  	   9412.93	   5.23	   0	   5.63	   1.22	   8.44	  
CXCL3a	  	   75.99	   2.61	   0	   transcript	  excluded	  
CXCL6a	  	   106.35	   4.74	   0	   5.24	   1.17	   8.44	  
CXCL17b	  	   transcript	  excluded	  	   34.53	   4.15	   0	  
XCL1a	  	   0.01	   -­‐4.93	  	  0.00	  	   0	   2.38	   0.45	   15.95	  
Cytokines	  	  
	  CSF2a	  	   91.78	   5.87	   0	   2.2	   0.57	   15.95	  
	  CSF3a	  	   1355.83	   4.75	   0	   5.23	   0.87	   10.67	  
IL-­‐1αa	  	   2857.26	   4.63	   0	   5.46	   1.6	   5.52	  
IL-­‐1βc	  	   272.74	   5.88	   0	   7.15	   2.68	   0	  
IL-­‐6a	  	   522.18	   4.78	   0	   4.57	   1.11	   8.44	  
IL-­‐10a	  	   334.63	   3.67	   0	   2.83	   0.48	   15.95	  
IL-­‐24a	  	   233.58	   4.22	   0	   0.11	   -­‐0.98	   21.98	  
IL-­‐35	  /	  
Ebi3a	  	   45.77	   2.46	   0	   3.15	   1.1	   8.44	  	  	  
TNFa	  	   20.44	   3.2	   0	   2.42	   1.13	   8.44	  
Enzymes	  	  
NOS2a	  	   81737.07	   11.43	   0	   13.87	   1.98	   5.52	  
COX-­‐2	  /	  
PTGS2a	  	   8.42	   2.66	   0	   0.96	   -­‐0.07	   21.98	  
Growth	  
Factors	  	  
ARTNa	  	   0.37	   -­‐2.46	   2.26	   0.39	   -­‐1.61	   20.25	  
EREGa	  	   140.2	   3.15	   0	   24.38	   1.91	   5.52	  
Other	  	   PROK2a	  	   4443.04	   7.25	   0	   8.52	   1.34	   8.44	  
Comparison	  of	  Inflammatory	  mediator	  up-­‐regulation	  in	  Acute	  and	  Repeated	  Bladder	  
Inflammation	  	  
From	  a	  possible	   list	  of	  92	  transcripts,	  73	  were	  detected	  in	  both	  models.	  Table	  5-­‐5	  shows	  the	  mean	  
rank,	  standard	  deviation,	  and	  super	  rank	  value	  (SRV)	  for	  the	  top	  ten	  transcripts.	  Of	  these	  IL-­‐1β	  was	  
significantly	   up-­‐regulated	   in	   both	   (FDR	   q=0%).	   Two	   other	   chemokines,	   CCL7	   (acute:	   272.74	   FC;	  
repeated:	   7.15	   FC),	   and	   CCL12	   (acute:	   17.96	   FC;	   repeated:	   7.15	   FC),	   were	   also	   significantly	  
upregulated	  in	  both	  models	  (FDR	  q=0%).	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  Table	  5-­‐5:	  Super	  rank	  values	  (SRV)	  for	  cytokines	  in	  bladder	  tissue	  up-­‐regulated	  following	  acute	  and	  repeated	  bladder	  
inflammation	  	  	  
SRV	   Gene	   Mean	  Rank	   SD	  
1	   NOS2	   3	   1.41	  
2	   CXCL2	   5	   0.71	  
3	   PROK2	   5	   7.07	  
4	   IL-­‐1β	   8	   2.83	  
5	   CCL12	   9.5	   4.24	  
6	   IL-­‐1α	   13.5	   7.07	  
7	   BDNF	   15	   8.49	  
8	   C3	   18.5	   4.95	  
9	   IL-­‐35	  /	  EBI3	   19	   4.95	  
10	   EREG	   19.5	   10.6	  
Comparison	  of	  Repeated	  Instrumentation	  and	  Turpentine	  	  
CCL12	   was	   significantly	   up-­‐regulated	   in	   both	   turpentine	   and	   instrumentation	   groups	   following	  
repeated	   bladder	   inflammation.	   PPBP	   was	   up-­‐regulated	   in	   instrumentation	   but	   not	   turpentine	  
groups.	  
Key	  findings	  	  
• Both	  acute	  and	  repeated	  visceral	  inflammation	  increase	  levels	  of	  4	  inflammatory	  mediators	  	  
• Number	  of	  inflammatory	  mediators	  up-­‐regulated	  by	  repeated	  inflammation	  is	  lower	  than	  
that	  seen	  in	  acute	  inflammation,	  suggesting	  habituation	  to	  the	  stimuli	  	  
• CCL12	  is	  also	  up-­‐regulated	  in	  the	  instrumentation	  group,	  suggesting	  involvement	  in	  a	  general	  
inflammatory	  response,	  rather	  than	  irritant-­‐specific	  (i.e.	  turpentine)	  	  
5.2 Open	  Field	  Behaviour	  	  
Thigmotaxis	   in	   the	   open	   field	   has	   been	   observed	   in	   traumatic	   and	   HIV/ART-­‐associated	  models	   of	  
neuropathic	  pain	   (Hasnie	  et	  al.,	  2007;	  Wallace	  et	  al.,	  2007a;	  Huang	  et	  al.,	  2013),	  but	  as	  yet	  not	   in	  
models	  of	  visceral	  inflammation.	  Therefore,	  open	  field	  behaviour	  was	  assessed	  24	  hours	  after	  either	  
a	  single	  (acute),	  or	  the	  third	  (repeated)	  session	  of	  bladder	  inflammation.	  Behaviour	  was	  recorded	  for	  
15	  minutes.	  	  
Acute	  Bladder	  Inflammation	  	  
Animals	  in	  both	  the	  instrumentation	  (7,	  0-­‐12,	  p=0.004),	  and	  the	  turpentine	  (11,	  1-­‐16,	  p=0.03)	  groups	  
entered	  the	  inner	  zone	  significantly	  less	  frequently	  than	  naïve	  (10,	  2-­‐27)	  (Kruskal-­‐Wallis	  overall	  1way	  
ANOVA,	  p=0.045,	  Figure	  5-­‐2).	  	  	  
Duration	   in	   the	   inner	   zone	   was	   not	   significantly	   different	   between	   groups	   (Kruskal-­‐Wallis	   1-­‐way	  
ANOVA,	  p=0.216).	  The	  time	  spent	  in	  the	  inner	  zone	  was	  11.52	  s	  (6.88-­‐26.88),	  6.8	  s	  (2.88-­‐12.96),	  and	  
8.64	  s	  (2.72-­‐13.92)	  for	  naïve,	  instrumentation,	  and	  turpentine	  groups	  respectively	  (Figure	  5-­‐2).	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Rearing	   behaviour	   was	   not	   significantly	   different	   between	   groups	   either	   (Kruskal-­‐Wallis	   1-­‐way	  
ANOVA,	   p=0.179),	   with	   median	   rear	   counts	   of	   58	   (40-­‐61),	   45	   (32-­‐55),	   and	   44	   (26-­‐50)	   for	   naïve,	  
instrumentation,	  and	  turpentine	  groups	  respectively	  (Figure	  5-­‐3).	  	  
In	  the	  turpentine	  group,	  distance	  travelled	  significantly	  reduced	  from	  8964.82	  cm	  (8153.48-­‐9776.16)	  
in	   naïve	   animals	   to	   6204.49cm	   (4513.71-­‐7895.26)	   in	   turpentine	   (p=0.0018).	   No	   difference	   was	  
observed	   between	   instrumentation	   (7038.95	   cm	   (6011.39-­‐8066.50)	   and	   naïve	   (p=0.1029)	   or	  
turpentine	  (overall	  1-­‐way	  ANOVA	  p=0.0045,	  Figure	  5-­‐3).	  	  	  
Repeated	  Bladder	  Inflammation	  	  
No	   significant	   differences	   in	   inner	   zone	   activity	   (frequency	   or	   duration)	   were	   seen	   between	   any	  
groups,	   with	   naïve	   animals	   entering	   the	   inner	   zone	   12	   (8-­‐14)	   times	   for	   13.76s	   (9.12-­‐24),	  
instrumentation	   entering	   7.5	   (5-­‐14)	   times	   with	   a	   duration	   of	   14.48	   (6.56-­‐27.2),	   and	   turpentine	  
animals	   entering	   the	   inner	   zone	   8.5	   (1.5-­‐10)	   times	   with	   a	   median	   duration	   of	   6.96s	   (1.76-­‐16.72)	  
(Kruskal-­‐Wallis	   1-­‐way	  ANOVA	  p=0.39,	   and	  p=0.348;	   Figure	   5-­‐4).	  No	  difference	  was	   seen	   in	   rearing	  
activity	   (p=0.241),	  with	  median	  rear	  counts	  of	  58	   (49-­‐71),	  48	   (44-­‐63.5),	  and	  53.5	   (45-­‐56)	   for	  naïve,	  
instrumentation,	  and	  turpentine	  groups	  respectively	  (Figure	  5-­‐4).	  	  
A	   decrease	   in	   distance	   travelled	   was	   seen	   in	   both	   instrumentation	   (p=0.016,	   6797.29	   cm	  
(5626.187968.39))	   and	   turpentine	   (p=0.00091,	   5974.04	   cm	   (4678.10-­‐726.99))	   groups	   compared	   to	  
naïve	  (8432.59	  cm	  (7904.75-­‐8960.42);	  overall	  1-­‐way	  ANOVA	  p=0.002,	  Figure	  5-­‐5).	  	  
To	  control	   for	   the	  effects	  of	   repeated	  anaesthesia,	  an	  additional	   control	  group	  was	   introduced	   for	  
the	   repeated	   model.	   These	   “anaesthesia	   only”	   (AO)	   animals	   were	   not	   significantly	   different	  
compared	  to	  control,	  with	  an	  average	  distance	  travelled	  of	  8316.25cm	  (95%	  CI:	  7852.49-­‐8780.01),	  13	  
inner	  zone	  entries	  (IQR:	  8-­‐18),	  and	  a	  median	  duration	  in	  the	  inner	  zone	  of	  14.24s	  (IQR:	  11.04-­‐24.32).	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Figure	  5-­‐2:	  Inner	  zone	  activity	  (frequency	  and	  duration)	  following	  acute	  bladder	  inflammation	  	  
There	  was	  a	  significant	  decrease	  in	  inner	  zone	  entry	  in	  both	  turpentine	  and	  instrumentation	  groups.	  
Frequency	  analysed	  using	  Kruskal-­‐Wallis	  ANOVA	  on	  ranks,	  Duration	  by	  1-­‐way	  ANOVA	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5-­‐3:	  Total	  distance	  travelled	  (cm),	  and	  rearing	  activity	  in	  the	  open	  field	  following	  acute	  bladder	  inflammation	  	  
Significant	  decreases	  in	  total	  distance	  travelled	  were	  seen	  in	  both	  turpentine	  and	  instrumentation	  groups.	  
Distance	  by	  1-­‐way	  ANOVA	  ,	  Rearing	  analysed	  using	  Kruskal-­‐Wallis	  ANOVA	  on	  ranks.	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Figure	  5-­‐4:	  Inner	  zone	  activity	  following	  repeated	  bladder	  inflammation	  No	  significant	  differences	  in	  inner	  
zone	  activity	  were	  recorded.	  Frequency	  analysed	  using	  Kruskal-­‐Wallis	  ANOVA	  on	  ranks,	  Duration	  by	  1-­‐way	  
ANOVA	  





Figure	  5-­‐5:	  Distance	  travelled	  (cm)	  and	  rearing	  activity	  in	  the	  open	  field	  following	  repeated	  bladder	  inflammation	  	  
Significant	  decreases	  in	  total	  distance	  travelled	  were	  seen	  in	  both	  turpentine	  and	  instrumentation	  groups	  when	  compared	  
to	  naïve.	  Distance	  by	  1-­‐way	  ANOVA	  ,	  Rearing	  analysed	  using	  Kruskal-­‐Wallis	  ANOVA	  on	  ranks.	  
	  




Comparison	  of	  Acute	  and	  Repeated	  Bladder	  Inflammation	  	  
2-­‐way	   ANOVA	  was	   conducted	   to	   investigate	   how	   these	  models	   compare	   in	   terms	   of	   behavioural	  
outcomes.	  No	  significant	  difference	  between	  acute	  and	   repeated	  bladder	   inflammation	  were	  seen	  
for	  distance	  travelled	   (p=0.4),	   frequency	  of	   inner	  zone	  entry	   (p=0.8),	  or	  duration	   in	   the	   inner	  zone	  
(p=0.4).	   Rearing	   was	   significantly	   higher	   in	   the	   repeated	   model	   (54,	   46-­‐60)	   compared	   to	   acute	  
(p=0.01;	  45,	  35-­‐58.5).	  Turpentine	  inflammation	  had	  a	  significant	  effect	  on	  behaviour,	  independent	  of	  
the	   number	   of	   instillations,	   with	   significant	   decreases	   seen	   in	   distance	   (p<0.001),	   frequency	  
(p=0.004),	   duration	   (p=0.01),	   and	   rearing	   (p=0.01),	   with	   higher	   rear	   frequencies	   in	   repeated	  
turpentine	  when	  compared	   to	  acute	   turpentine	   (p=0.03).	   	   Instrumentation	  had	  a	   less	  pronounced	  
effect,	  significantly	  decreasing	  distance	  travelled	  (p=0.001),	  and	  frequency	  of	  entry	  to	  the	  inner	  zone	  
(p=0.004)	   only.	   Figure	   5-­‐6	   and	   Figure	   5-­‐7	   illustrate	   the	   overall	   behavioural	   effects	   of	   acute	   and	  
repeated	  bladder	  inflammation.	  	  
Key	  findings	  	  
• Acute	  but	  not	  repeated	  bladder	  inflammation	  significantly	  increases	  thigmotaxis	  	  
• Both	  acute	  and	  repeated	  models	  showed	  a	  decrease	  in	  locomotor	  activity	  	  
• There	  was	  a	  strong	  effect	  of	  instrumentation,	  suggesting	  catheterisation	  alone	  is	  sufficient	  to	  
induce	  behavioural	  alterations	  such	  as	  thigmotaxis	  	  
• 2-­‐way	  ANOVA	  found	  no	  differences	  between	  acute	  and	  repeated	  inflammation	  on	  distance	  
travelled,	  frequency	  of	  entry	  to	  the	  inner	  zone,	  and	  duration	  in	  the	  inner	  zone	  	  	  
• Rearing	  activity	  was	  higher	  in	  the	  repeated	  model	  than	  in	  the	  acute	  	  
	  	  





Figure	  5-­‐6:	  Comparison	  of	  thigmotactic	  outcomes	  (frequency	  and	  duration	  in	  the	  open	  field)	  following	  acute	  and	  repeated	  bladder	  
inflammation	  p-­‐values	  shown	  for	  2-­‐Way	  ANOVA	  comparison	  between	  acute	  and	  repeated	  inflammation	  	  





Figure	   5-­‐7:	   Comparison	   of	   distance	   travelled	   and	   rearing	   activity	   following	   acute	   and	   repeated	   bladder	   inflammation.	   p-­‐
values	  shown	  for	  2-­‐Way	  ANOVA	  comparison	  between	  acute	  and	  repeated	  inflammation	  	  




5.3 Burrowing	  Paradigm	  	  
Burrowing	   is	   a	   relatively	   new	   ethological	   assay,	   which	   has	   detected	   deficits	   associated	   with	  
experimental	   models	   of	   pain	   such	   as	   CFA	   inflammation	   (Rutten	   et	   al.,	   2014a),	   and	   spinal	   nerve	  
transection	   (Andrews	   et	   al.,	   2012).	   It	   models	   burrow	   maintenance	   behaviour,	   and	   deficits	   in	  
burrowing	  have	  been	  associated	  with	  decreases	  in	  quality	  of	   life	  measures	  such	  as	   impaired	  ability	  
to	   maintain	   activities	   around	   the	   home	   and	   workplace	   seen	   in	   many	   chronic	   clinical	   conditions	  
(Breivik	  et	  al.,	  2006).	  	  	  
A	  separate	  group	  of	  female	  rats	  had	  burrowing	  activity	  assessed	  following	  acute	  turpentine	  bladder	  
inflammation.	   Briefly,	   three	   paired	   training,	   and	   three	   individual	   baseline	   sessions	   of	   burrowing	  
were	  conducted	  prior	  to	  model	   induction.	  2500g	  gravel	  was	  used,	  and	  the	  weight	  displaced	  during	  
each	  hour-­‐long	  session	  recorded.	  Bladder	  induction	  was	  induced	  as	  previously	  described,	  with	  naïve,	  
instrumentation,	   and	   turpentine	   groups.	   24	   hours	   later,	   animals	   were	   re-­‐introduced	   to	   the	  
burrowing	  paradigm	  and	  weight	  displaced	  recorded.	  	  
This	  was	  repeated	  at	  2,	  3,	  and	  7	  days	  after	  bladder	   inflammation.	   	  Data	  was	  analysed	  using	  2-­‐way	  
Repeated	  Measure	  ANOVA	  and	  showed	  equal	  variance	  but	  was	  not	  distributed	  normally.	  Data	  below	  
presented	  as	  median	  (IQR).	  	  
Exclusions:	  	  
Animals	  were	  assigned	  to	  experimental	  group	  based	  on	  mean	  baseline	  burrowing	  activity,	  and	  those	  
with	  baseline	   values	  below	  500g	  were	  equally	  distributed	  between	  groups	  but	  excluded	   following	  
completion	   of	   the	   study	   (n=2/group).	   5	   animals	   in	   total	  were	   lost	   during	  model	   induction	   due	   to	  
surgical	   complications,	   yielding	   final	   group	   sizes	   of	   14	   (naïve),	   12,	   (instrumentation),	   and	   11	  
(turpentine).	  	  
Bladder	  inflammation	  did	  not	  significantly	  influence	  weight	  displaced	  during	  the	  burrowing	  paradigm	  
(p=0.46)	   as	   shown	   in	   Figure	   5-­‐8.	   There	  was	   a	   significant	   effect	   of	   time,	  with	   animals	   in	   all	   groups	  
significantly	   decreasing	   gravel	   displacement	   between	   baseline	   (Naïve:	   1214.6g	   (1006.0-­‐1274.4g),	  
Instrumentation:	  1169.9g	   (998.5-­‐1415.9g),	  and	  Turpentine:	  1155.0g	   (901.8-­‐1363.7g))	  and	  24	  hours	  
post-­‐inflammation	   (Naïve:	   849.6g	   (499.3-­‐1110.3g),	   Instrumentation:	   834.6g	   (178.84-­‐1781.0g),	   and	  
Turpentine:	  812.2g	  (231.0-­‐1331.5g))	  (p=0.001).	  No	  other	  differences	  were	  observed.	  	  
	  





Figure	  5-­‐8:	  Weight	  displaced	  during	  1hr	  burrowing	  session	  24hrs	  after	  acute	  bladder	  inflammation	  	  
A) data	  from	  baseline	  (average	  of	  3	  measurements),	  to	  1,	  2,	  3,	  and	  7	  days.	  All	  groups	  burrowed	  significantly	  less	  during	  the	  first	  test	  
session	  (1	  day)	  	  
B) Box	  and	  Dot	  representation	  of	  the	  significant	  difference	  seen	  between	  baseline	  activity	  and	  that	  24hrs	  following	  acute	  bladder	  
inflammation	  
Data	  analysed	  using	  1-­‐way	  Repeated	  Measures	  ANOVA	  
	  
Key	  findings	  	  
• Acute	  bladder	  inflammation	  has	  no	  effect	  on	  burrowing	  activity	  	  
• Burrowing	  activity	  is	  highly	  variable	  	  




5.4 c-­‐Fos	  Immunoreactivity	  in	  the	  Central	  Amygdala	  Following	  Open	  Field	  	  	  
c-­‐Fos	  is	  an	  immediate-­‐early	  oncogene	  specific	  to	  neurons.	  It	  shows	  up-­‐regulation	  associated	  
with	   neuronal	   activation	   (Gao	   &	   Ji,	   2009),	   with	   a	   window	   of	   expression	   90-­‐120	   minutes	   after	   a	  
stimulus	   (Hunt	   et	   al.,	   1987).	   Numerous	   studies	   have	   demonstrated	   up-­‐regulation	   of	   c-­‐Fos	   in	   the	  
central	  amygdala	  in	  response	  to	  nociceptive	  stimuli	  such	  as	  intra-­‐peritoneal	  acetic	  acid	  (Tanimoto	  et	  
al.,	   2003),	   intra-­‐plantar	   formalin	   (Nakagawa	  et	   al.,	   2003),	   adjuvant-­‐induced	   arthritis	   (Jawed	  et	   al.,	  
2014),	   and	   dental	   pain	   (Yamashiro	   et	   al.,	   1998).	   In	   addition,	   studies	   have	   showed	   social	   stress	  
influences	   cFos	   expression	   in	   the	   central	   amygdala	   (Daskalakis	   et	   al.,	   2014),	   and	   that	   c-­‐Fos	  
expression	   in	   the	   central	   amygdala	   correlates	  with	   novelty-­‐seeking	   behaviour	   (Majkutewicz	  et	   al.,	  
2012).	   Therefore,	   cFos	   immunoreactivity	   in	   the	   central	   amygdala	   was	   investigated	   to	   determine	  
whether	  alterations	  in	  activation	  mirror	  the	  effect	  of	  visceral	  noxious	  inflammatory	  stimuli	  on	  open	  
field	  behaviour.	  	  
Acute	  Bladder	  Inflammation	  	  
Levels	   of	   c-­‐Fos	   immunoreactivity	   were	   higher	   in	   the	   left	   hemisphere,	   with	   observed	   densities	  
(cells/mm2)	  of	  19.7	   (2.8-­‐36.6),	  23.1	   (11.5-­‐34.7),	  and	  27.6	   (5.1-­‐50.1)	   compared	   to	  12.2	   (2.4-­‐22),	  7.4	  
(1.4-­‐13.3),	   and	   12.5	   (2.8-­‐22.2)	   in	   naïve,	   instrumentation,	   and	   turpentine	   groups	   respectively	  
(p=0.024).	  	  Overall,	  c-­‐Fos	  immunoreactivity	  was	  present	  at	  densities	  of	  23.9	  (14.1-­‐33.6)	  cells/mm2	  in	  
the	  left	  hemisphere,	  compared	  to	  10.9	  (6.2-­‐15.5)	  in	  the	  right,	  as	  shown	  in	  Figure	  5-­‐9.	  	  
No	  other	  differences	  in	  c-­‐Fos	  immunoreactivity	  were	  observed	  in	  the	  central	  amygdala	  at	  the	  overall	  level	  
(Figure	  5-­‐10).	  	  
Figure	  5-­‐11	  show	  examples	  of	  c-­‐Fos	  staining	  and	  amygdala	  delineation	  in	  sections	  from	  rostral,	  
intermediate,	  and	  caudal	  areas.	  	  
	  	   	  	  





Figure	  5-­‐9:	   c-­‐Fos	   immunoreactivity	   in	   the	   central	  amygdala	  globally	  and	   in	   left/right	  hemispheres	   following	  open	   field	  exposure	  
(Acute	  bladder	  inflammation).	  Analyses	  conducted	  using	  1-­‐way	  and	  2-­‐way	  ANOVA	  for	  global	  and	  hemispheric	  respectively.	  	  





Figure	   5-­‐10:	   c-­‐Fos	   immunoreactivity	   in	   the	   three	   subdivisions	   of	   the	   central	   amygdala	   (Medial,	   CeM;	   Lateral,	   CeL;	   Capsular,	  
CeC),	  and	  along	  the	  rostro-­‐caudal	  axis	  (acute	  bladder	  inflammation).	  Analysis	  conducted	  using	  2-­‐way	  ANOVA.	  





Figure	   5-­‐11:	   Examples	   of	   c-­‐Fos	   immunoreactivity	   in	   the	   central	   amygdala	   following	   acute	   (left)	   and	   repeated	   (right)	   bladder	  
inflammation.	  Examples	  from	  rostral	  (1st	  row)	  to	  caudal	  (3rd	  row)	  x50	  magnification	  (x100	  used	  for	  quantification	  purposes),	  with	  
magnified	  sections	  to	  show	  examples	  of	  positive	  c-­‐Fos	  staining	   (4th	   row).	  Toluidine	  blue	  counterstain	  used,	  with	  nickel-­‐enhanced	  
DAB	  visualisation	  of	  c-­‐Fos	  protein.	  





Figure	   5-­‐12:	   c-­‐Fos	   immunoreactivity	   in	   the	   central	   amygdala	   and	   left/right	   hemispheres	   following	   repeated	   bladder	  
inflammation.	  Analyses	  conducted	  using	  1-­‐way	  and	  2-­‐way	  ANOVA	  for	  global	  and	  hemispheric	  respectively.	  	  	  





Figure	  5-­‐13:	  c-­‐Fos	  immunoreactivity	  in	  the	  central	  amygdala	  within	  the	  three	  subdivisions	  of	  the	  amygdala	  (medial,	  CeM;	  lateral,	  
CeL;	  capsular,	  CeC),	  and	  along	  the	  rostro-­‐caudal	  axis	  following	  repeated	  bladder	  inflammation.	  Analysis	  conducted	  using	  2-­‐way	  
ANOVA.	  	  




Repeated	  Bladder	  Inflammation	  	  
There	  was	  no	  overall	  difference	  between	  left	  and	  right	  hemisphere,	  and	  no	  effect	  of	  group	  on	  c-­‐Fos	  
immunoreactivity	  (Figure	  5-­‐12).	  	  
A	   rostro-­‐caudal	   gradient	  was	   present	  with	   significantly	   higher	   levels	   of	   activation	   observed	   in	   the	  
caudal	   regions	   (Overall:	   123.1	   (86.0-­‐127.1),	  N:	   107.3	   (31.6-­‐182.9),	   AO:	   167.5	   (78.5-­‐256.4),	   I:	   114.6	  
(40.9-­‐188.2),	   T:	   120.6	   (31.4-­‐209.8))	   when	   compared	   to	   both	   rostral	   (p<0.001;	   Overall:	   56.9	  
(38.475.3),	  N:	  38.2	   (15.7-­‐60.8),	  AO:	  68.9	   (13.9-­‐124.0),	   I:	  68.9	   (3.5-­‐134.3),	  T:	  62.5	   (22.7-­‐102.3)),	  and	  
intermediate	  (p=0.005;	  Overall:	  76.8	  (52.4-­‐101.1),	  N:82.0	  (21.6-­‐142.4),	  AO:	  85.3	  (25.4-­‐145.2),	  I:	  75.8	  
(26.4-­‐125.2),	  T:	  64.8	  (22.7-­‐106.8))	  as	  shown	  in	  Figure	  5-­‐13.	  	  
c-­‐Fos	  immunoreactivity	  in	  the	  CeM	  (61.1	  (43.7-­‐78.5))	  was	  significantly	  lower	  than	  that	  detected	  in	  both	  the	  
CeL	  (p=0.007;	  115.1	  (81.3-­‐148.9))	  and	  the	  CeC	  (p=0.005;	  108.1	  (76.7-­‐139.5)).	  	  
To	  check	  reliability	  of	  measurements,	  delineated	  amygdala	  area	  was	  analysed.	  No	  group	  differences	  were	  
observed	  in	  measured	  area	  of	  central	  amygdala	  nuclei	  (data	  not	  shown).	  	  
To	  control	   for	   the	  effects	  of	   repeated	  anaesthesia,	  an	  additional	  control	  group	  was	   introduced	   for	  
the	   repeated	   model.	   These	   AO	   animals	   showed	   no	   significant	   effect	   of	   repeated	   isoflurane	  
anaesthesia	  on	  c-­‐Fos	  immunoreactivity	  in	  the	  central	  amygdala.	  	  
Examples	  of	  c-­‐Fos	  staining	  can	  be	  seen	  on	  the	  right	  panel	  of	  Figure	  5-­‐11	  showing	  c-­‐Fos	  immunoreactivity	  
and	  amygdala	  delineation	  in	  sections	  from	  rostral,	  intermediate,	  and	  caudal	  areas.	  	  
Key	  findings	  	  
• Bladder	  inflammation	  has	  no	  effect	  on	  c-­‐Fos	  immunoreactivity	  in	  the	  central	  amygdala	  	  
• Increased	  caudal	  activation	  of	  the	  central	  amygdala	  was	  observed	  in	  the	  repeated	  model	  only	  	  
• Some	  lateralisation	  was	  observed	  following	  acute	  inflammation,	  with	  immunoreactivity	  of	  the	  left	  
hemisphere	  higher	  than	  right	  	  
5.5 Relationship	  between	  Thigmotaxis	  and	  Central	  Amygdala	  Activity	  	  
Responder	  Analysis	  	  
When	   behaviour	  was	   analysed	   by	   responder	   phenotype,	   significant	   differences	   between	   high	   and	  
low	   activity	   animals	   was	   seen	   in	   frequency	   and	   duration	   (p<0.001	   for	   both	   acute	   and	   repeated	  
models,	  Table	  5-­‐6).	  	  	  
A	  significant	  difference	  between	  high	  and	  low	  responders	  was	  also	  seen	  for	  distance	  travelled	  in	  the	  
repeated	  group	  (p=0.009),	  with	  an	  effect	  of	  group	  (p=0.012),	  but	  no	  interaction	  (p=0.732,	  Figure	  5-­‐7).	  	  	  




In	  the	  acute	  model,	  high/low	  thigmotactic	  phenotype	  influenced	  c-­‐Fos	  immunoreactivity	  in	  the	  right	  
intermediate	   central	   amygdala	   (p=0.05).	   In	   the	   repeated	   model,	   thigmotaxis	   showed	   an	   inverse	  
relationship	   with	   findings	   of	   increased	   c-­‐Fos	   immunoreactivity	   in	   the	   medial	   central	   amygdala	  
(global:	   p=0.03,	   rostral:	   p<0.001,	   intermediate:	   p=0.006),	   and	   in	   the	   intermediate	   region	   of	   the	  
lateral	   central	   amygdala	   (p=0.03)	   in	   low	   thigmotaxis	   animals.	   Multiple	   comparison	   procedures	  
identified	   significant	   differences	   between	   c-­‐Fos	   immunoreactivity	   of	   high	   and	   low	   thigmotaxis	  
animals	  in	  the	  turpentine	  (Global	  CeM:	  p0.03,	  rostral	  CeM:	  p=0.004,	  intermediate	  CeM:	  p=0.04)	  and	  
instrumentation	  groups	  (Rostral	  CeM:	  p=0.003,	  intermediate	  CeM:	  p=0.01).	  	  	  
Table	  5-­‐6:	  Responder	  data	  for	  thigmotactic	  outcomes	  in	  both	  models	  	  
*	  denotes	  p<0.05	  between	  high	  and	  low	  thigmotactic	  groups	  	  
	   	  	   n	  	   Low	  Thigmotaxis	  	   High	  Thigmotaxis	  	  
Acute	   hi-­‐lo	   Frequency	   Duration	  (s)	   Frequency	   Duration	  (s)	  
Naïve	   9-­‐4	   19	  (10.5-­‐22)*	   18.2	  (11.5-­‐36.2)*	   9	  (7-­‐9)	   5.7	  (4.4-­‐6.8)	  
Instrumentation	   2-­‐8	   11	  (10-­‐12)*	   7.6	  (6.7-­‐8.5)*	   6.5	  (2.5-­‐7.5)	   5.5	  (2.5-­‐13.4)	  
Turpentine	   8-­‐5	   12.5	  (11.5-­‐14.5)*	   13.8	  (10.5-­‐15.6)*	   2	  (1-­‐2)	   2.1	  (1.6-­‐2.7)	  
Repeated	   	   	   	   	   	  
Naïve	   9-­‐6	   14	  (13-­‐16)*	   22.9	  (12.5-­‐31.8)*	   6.5	  (3-­‐9)	   8.6	  (4.2-­‐13.8)	  
Instrumentation	   4-­‐6	   15	  (13.5-­‐16)*	   28	  (20.2-­‐30)*	   5	  (2-­‐6)	   8	  (1.4-­‐15.7)	  
Turpentine	   3-­‐9	   12	  (11-­‐12)*	   17.28	  (8.3-­‐45.4)*	   3	  (1-­‐9)	   4.3	  (1.1-­‐9.1)	  
Key	  findings	  	  
• Possible	  existence	  of	  distinct	  behavioural	  phenotypes	  based	  on	  frequency	  of	  entry	  to	  inner	  
zone,	  which	  show	  significant	  differences	  across	  the	  other	  open	  field	  outcomes	  measures	  	  
• Increased	  c-­‐Fos	  immunoreactivity	  observed	  in	  the	  medial	  subdivision	  of	  the	  central	  
amygdala	  in	  animals	  exhibiting	  a	  low	  thigmotaxis	  phenotype	  in	  the	  repeated	  model,	  with	  the	  
reverse	  observed	  in	  the	  right	  intermediate	  central	  amygdala	  in	  the	  acute	  model	  	  
	   	  




Correlations	  	  	  
Acute	  Bladder	  Inflammation	  	  
Overall	  	  
There	  were	  no	  significant	  correlations	  between	  c-­‐Fos	  immunoreactivity	  and	  behaviour	  in	  the	  open	  field	  
at	  the	  overall	  level.	  	  
Within	  Groups	  	  
In	  naïve	  animals,	  duration	  in	  the	  inner	  zone	  significantly	  correlated	  with	  c-­‐Fos	  immunoreactivity	  in	  the	  
intermediate	  CeL	  (ρ=0.76,	  p=0.05).	  	  
In	  the	  instrumentation	  group,	  rearing	  behaviour	  was	  correlated	  with	  c-­‐Fos	  immunoreactivity	   in	  the	  
CeC	   (overall	   ρ=0.73,	   right	   ρ=0.76,	   rostral	   ρ=0.80;	   p<0.05)	   and	   CeM	   (caudal	   ρ=0.71	   p=0.03),	   and	  
distance	   travelled	   was	   correlated	   with	   immunoreactivity	   in	   the	   caudal	   levels	   of	   the	   left	   central	  
amygdala	  (ρ=0.80,	  p=0.02).	  	  
There	  were	  no	  significant	  correlations	  seen	  in	  the	  turpentine	  group.	  	  
Table	  5-­‐7:	  Responder	  data	  for	  locomotor	  activity	  and	  rearing	  in	  both	  models	  	  
No	  significant	  differences	  in	  rearing	  or	  distance	  travelled	  were	  detected	  	  
	   	  	   n	  	   Low	  Thigmotaxis	  	   High	  Thigmotaxis	  	  
Acute	   hi-­‐lo	   Distance	  (cm)	   Rearing	   Distance	  (cm)	   Rearing	  





















Repeated	   	   	   	   	   	  






















	   	  




Correlations	  Based	  on	  Thigmotactic	  Phenotype	  	  
No	  significant	  correlations	  were	  observed	  in	  low	  thigmotactic	  animals.	  In	  those	  showing	  higher	  levels	  
of	   thigmotaxis,	  duration	   in	   the	   inner	  zone	  was	  significantly	  correlated	  with	   intermediate	  CeL	  c-­‐Fos	  
immunoreactivity	   (ρ=0.61,	   p=0.034),	   distance	   travelled	   correlated	   with	   c-­‐Fos	   immunoreactivity	   in	  
the	   caudal	   regions	   of	   the	   left	   central	   amygdala	   (ρ=0.62,	   p=0.031),	   and	   rearing	   was	   significantly	  
correlated	  with	  central	  amygdala	  activation	  in	  the	  left	  hemisphere	  (ρ=0.52,	  p=0.045).	  	  
Correlations	  were	  seen	  between	  central	  amygdala	  activation	  and	  bladder	  inflammation	  (Table	  5-­‐7)	  and	  
behavioural	  phenotype	  (Table	  5-­‐8).	  No	  overall	  patterns	  were	  observed.	  
Table	  5-­‐8:	  Correlations	  between	  behavioural	  outcomes	  and	  c-­‐Fos	   immunoreactivity	   in	  the	  central	  amygdala	  following	  acute	  bladder	  
inflammation	  R:	  Right,	  L:	  Left;	  glob:	  Global	  
	  	   	  	   Naïve	  	   Instrumentation	  	   Turpentine	  	  


































































































ρ	  	   -­‐0.05	   0.16	   -­‐0.07	   0.14	   0.28	   0.15	   -­‐0.24	   0.66*	  	   0.34	   0.17	   0.05	   0.19	  
Sig.	  	   0.90	   0.68	   0.87	   0.71	   0.47	   0.71	   0.54	   0.05	   0.25	   0.59	   0.87	   0.53	  
LCeL	  	  
ρ	  	   0.41	   -­‐0.13	   0.22	   -­‐0.07	   0.60	   0.55	   0.57	   0.13	   0.26	   0.25	   0.37	   -­‐0.14	  
Sig.	  	   0.27	   0.74	   0.58	   0.86	   0.09	   0.12	   0.11	   0.74	   0.41	   0.44	   0.24	   0.66	  
LCeC	  	  
ρ	  	   -­‐0.21	   -­‐0.31	   -­‐0.43	   -­‐0.42	   0.12	   -­‐0.07	   -­‐0.26	   0.48	   0.23	   0.17	   0.22	   0.26	  
Sig.	  	   0.58	   0.42	   0.25	   0.26	   0.76	   0.85	   0.51	   0.19	   0.45	   0.58	   0.48	   0.38	  
Left	  	  
ρ	  	   0.14	   -­‐0.14	   -­‐0.06	   -­‐0.13	   0.50	   0.42	   0.16	   0.49	   0.39	   0.32	   0.35	   0.06	  
Sig.	  	   0.71	   0.72	   0.88	   0.73	   0.17	   0.26	   0.68	   0.18	   0.18	   0.29	   0.24	   0.85	  
RCeM	  	  
ρ	  	   -­‐0.34	   -­‐0.15	   -­‐0.34	   -­‐0.27	   0.23	   -­‐0.33	   -­‐0.40	   0.38	   0.06	   0.02	   0.08	   0.24	  
Sig.	  	   0.37	   0.69	   0.36	   0.48	   0.55	   0.39	   0.29	   0.31	   0.86	   0.95	   0.79	   0.42	  
RCeL	  	  
ρ	  	   -­‐0.09	   -­‐0.33	   -­‐0.37	   -­‐0.39	   -­‐0.13	   -­‐0.07	   -­‐0.37	   0.23	   0.30	   0.11	   0.15	   0.16	  
Sig.	  	   0.81	   0.39	   0.33	   0.29	   0.73	   0.85	   0.33	   0.55	   0.32	   0.71	   0.63	   0.60	  
RCeC*	  	  
ρ	  	   -­‐0.34	   -­‐0.18	   -­‐0.43	   -­‐0.18	   0.52	   0.32	   -­‐0.22	   0.76*	  	   0.22	   0.06	   0.02	   0.30	  
Sig.	  	   0.37	   0.64	   0.25	   0.65	   0.15	   0.40	   0.57	   0.02	   0.47	   0.86	   0.94	   0.32	  
Right	  	  
ρ	  	   0.09	   -­‐0.10	   -­‐0.28	   -­‐0.14	   0.33	   -­‐0.10	   -­‐0.43	   0.62	   0.24	   0.08	   0.11	   0.29	  
Sig.	  	   0.82	   0.79	   0.47	   0.71	   0.39	   0.80	   0.25	   0.07	   0.42	   0.81	   0.71	   0.33	  
CeM	  	  
ρ	  	   -­‐0.10	   0.12	   -­‐0.12	   0.08	   0.28	   -­‐0.10	   -­‐0.36	   0.58	   0.25	   0.12	   0.08	   0.27	  
Sig.	  	   0.80	   0.77	   0.76	   0.84	   0.46	   0.79	   0.35	   0.10	   0.41	   0.71	   0.78	   0.36	  
CeL	  	  
ρ	  	   0.27	   -­‐0.24	   0.01	   -­‐0.22	   0.56	   0.53	   0.45	   0.21	   0.38	   0.28	   0.39	   0.01	  
Sig.	  	   0.48	   0.53	   0.99	   0.56	   0.12	   0.14	   0.22	   0.59	   0.20	   0.36	   0.19	   0.97	  
CeC*	  	  
ρ	  	   -­‐0.29	   -­‐0.34	   -­‐0.52	   -­‐0.44	   0.40	   0.17	   -­‐0.27	   0.73*	  	   0.23	   0.12	   0.13	   0.29	  
Sig.	  	   0.44	   0.37	   0.15	   0.23	   0.29	   0.66	   0.48	   0.02	   0.44	   0.70	   0.68	   0.34	  
Global	  	  
ρ	  	   0.12	   -­‐0.15	   -­‐0.14	   -­‐0.18	   0.51	   0.29	   -­‐0.07	   0.65	   0.35	   0.22	   0.27	   0.18	  
Sig.	  	   0.75	   0.70	   0.72	   0.65	   0.16	   0.46	   0.87	   0.06	   0.24	   0.46	   0.37	   0.56	  
	  	  




	  	   	  	  
Table	  5-­‐8	  (continued):	  Correlations	  between	  behavioural	  outcomes	  and	  c-­‐Fos	   immunoreactivity	   in	  the	  central	  amygdala	  following	  acute	  
bladder	  inflammation	  	  	  
r:	  Rostral,	  i:	  Intermediate,	  c:	  Caudal;	  glob:	  Global	  	  
	   	  































































































ρ	   -­‐0.21	   -­‐0.01	   -­‐0.21	   -­‐0.08	   0.23	   -­‐0.08	   -­‐0.34	   0.53	   -­‐0.06	   -­‐0.13	   -­‐0.09	   0.32	  
Sig.	   0.59	   0.98	   0.58	   0.84	   0.55	   0.84	   0.37	   0.14	   0.84	   0.66	   0.76	   0.29	  
rLeft	  
ρ	   -­‐0.23	   -­‐0.13	   -­‐0.32	   -­‐0.19	   -­‐0.16	   -­‐0.15	   -­‐0.32	   0.39	   -­‐0.25	   -­‐0.17	   -­‐0.15	   0.22	  
Sig.	   0.54	   0.74	   0.40	   0.62	   0.68	   0.70	   0.40	   0.29	   0.41	   0.58	   0.63	   0.47	  
rRight	  
ρ	   0.03	   0.48	   0.22	   0.40	   0.35	   -­‐0.03	   -­‐0.34	   0.52	   0.02	   -­‐0.09	   -­‐0.05	   0.30	  
Sig.	   0.94	   0.19	   0.57	   0.28	   0.35	   0.94	   0.37	   0.15	   0.94	   0.77	   0.88	   0.31	  
rCeM	  
ρ	   -­‐0.02	   0.28	   0.01	   0.26	   0.23	   -­‐0.28	   -­‐0.18	   0.12	   -­‐0.21	   -­‐0.12	   -­‐0.01	   -­‐0.16	  
Sig.	   0.97	   0.46	   0.98	   0.50	   0.56	   0.47	   0.64	   0.75	   0.54	   0.72	   0.97	   0.63	  
rCeL	  
ρ	   0.20	   -­‐0.22	   -­‐0.04	   -­‐0.23	   -­‐0.20	   -­‐0.08	   -­‐0.48	   0.39	   -­‐0.01	   -­‐0.14	   -­‐0.10	   0.24	  
Sig.	   0.64	   0.60	   0.93	   0.58	   0.61	   0.83	   0.19	   0.30	   0.97	   0.64	   0.76	   0.43	  
rCeC*	  
ρ	   0.14	   0.49	   0.00	   0.40	   0.36	   0.13	   -­‐0.37	   0.80*	   0.00	   -­‐0.10	   -­‐0.10	   0.32	  
Sig.	   0.72	   0.18	   0.99	   0.29	   0.34	   0.74	   0.33	   0.01	   1.00	   0.75	   0.75	   0.29	  
Inter.*	  
ρ	   0.13	   -­‐0.11	   0.21	   -­‐0.18	   0.44	   0.35	   -­‐0.05	   0.66*	   0.31	   0.18	   0.28	   0.14	  
Sig.	   0.74	   0.79	   0.59	   0.65	   0.24	   0.36	   0.91	   0.05	   0.30	   0.56	   0.35	   0.66	  
iLeft	  
ρ	   0.22	   0.05	   0.40	   -­‐0.01	   0.34	   0.41	   0.09	   0.50	   0.23	   0.13	   0.22	   -­‐0.09	  
Sig.	   0.58	   0.91	   0.29	   0.99	   0.37	   0.27	   0.81	   0.17	   0.47	   0.70	   0.50	   0.79	  
iRight	  
ρ	   -­‐0.27	   -­‐0.42	   -­‐0.49	   -­‐0.48	   0.27	   -­‐0.22	   -­‐0.43	   0.52	   0.18	   0.07	   0.12	   0.28	  
Sig.	   0.47	   0.26	   0.18	   0.19	   0.49	   0.57	   0.25	   0.15	   0.57	   0.83	   0.68	   0.35	  
iCeM	  
ρ	   -­‐0.45	   -­‐0.18	   -­‐0.57	   -­‐0.16	   0.09	   -­‐0.26	   -­‐0.39	   0.62	   0.04	   -­‐0.02	   -­‐0.01	   0.36	  
Sig.	   0.26	   0.66	   0.14	   0.70	   0.82	   0.49	   0.30	   0.07	   0.89	   0.94	   0.98	   0.23	  
iCeL*	  
ρ	   0.33	   0.16	   0.76*	   0.05	   0.44	   0.49	   0.17	   0.47	   0.25	   0.11	   0.25	   -­‐0.25	  
Sig.	   0.47	   0.74	   0.05	   0.92	   0.24	   0.19	   0.66	   0.20	   0.46	   0.74	   0.46	   0.46	  
iCeC	  
ρ	   0.29	   -­‐0.10	   -­‐0.10	   -­‐0.07	   0.38	   0.19	   -­‐0.18	   0.61	   0.15	   -­‐0.02	   0.02	   0.22	  
Sig.	   0.44	   0.80	   0.81	   0.86	   0.31	   0.62	   0.64	   0.08	   0.64	   0.95	   0.96	   0.50	  
	   	  




Table	  5-­‐8	  (continued):	  Correlations	  between	  behavioural	  outcomes	  and	  c-­‐Fos	  immunoreactivity	  in	  the	  central	  amygdala	  following	  acute	  
bladder	  inflammation	  	  
r:	  Rostral,	  i:	  Intermediate,	  c:	  Caudal;	  glob:	  Global	  	  
	  	  
	  	  	   Naïve	   Instrumentation	   Turpentine	  















































































































































































	  	   	  	  





























































































































Table	  5-­‐9:	  Correlations	  between	  behavioural	  phenotype	  and	  c-­‐Fos	  immunoreactivity	  following	  acute	  bladder	  
inflammation	  *	  denotes	  parameters	  with	  significant	  correlation	  L:	  Left,	  R:	  Right;	  glob:	  Global	  	  
	   	   Low	  Thigmotaxis	  	   	   	   High	  Thigmotaxis	  	  
	  	  	   	  	  	  











































































































































































































































	  	   	  	  
















































































	  	  	  




Table	  5-­‐9	   (continued):	   	   Correlations	  between	  behavioural	  phenotype	  and	   c-­‐Fos	   immunoreactivity	   following	  acute	  
bladder	  inflammation.	  *	  denotes	  parameters	  with	  significant	  correlation;	  r:	  Rostral,	  i:	  Intermediate,	  c:	  Caudal;	  glob:	  
Global	  	  
	   	   Low	  Thigmotaxis	  	   High	  Thigmotaxis	  	  






































































ρ	  	   -­‐0.06	   0.05	   -­‐0.09	   0.16	   0.13	   0.08	   -­‐0.17	   0.39	  
Sig.	  	   0.82	   0.86	   0.74	   0.55	   0.65	   0.79	   0.54	   0.15	  
rLeft	  	  
ρ	  	   -­‐0.32	   -­‐0.07	   -­‐0.18	   0.22	   0.12	   0.08	   -­‐0.14	   0.10	  
Sig.	  	   0.23	   0.79	   0.49	   0.41	   0.68	   0.78	   0.62	   0.72	  
rRight	  	  
ρ	  	   0.07	   0.11	   -­‐0.05	   0.12	   0.11	   0.03	   -­‐0.14	   0.50	  
Sig.	  	   0.78	   0.68	   0.85	   0.66	   0.71	   0.92	   0.62	   0.06	  
rCeM	  	  
ρ	  	   -­‐0.02	   -­‐0.13	   -­‐0.04	   -­‐0.10	   0.17	   0.36	   0.08	   0.29	  
Sig.	  	   0.94	   0.66	   0.88	   0.74	   0.54	   0.19	   0.78	   0.29	  
rCeL	  	  
ρ	  	   -­‐0.22	   -­‐0.11	   -­‐0.28	   -­‐0.02	   0.14	   -­‐0.05	   -­‐0.10	   0.41	  
Sig.	  	   0.41	   0.69	   0.29	   0.95	   0.63	   0.87	   0.75	   0.15	  
rCeC	  	  
ρ	  	   0.02	   0.15	   -­‐0.14	   0.43	   0.15	   0.04	   -­‐0.21	   0.47	  
Sig.	  	   0.95	   0.58	   0.59	   0.10	   0.59	   0.88	   0.46	   0.08	  
iGlob	  	  
ρ	  	   0.04	   0.00	   -­‐0.07	   -­‐0.24	   0.18	   0.02	   0.00	   0.47	  
Sig.	  	   0.89	   0.99	   0.79	   0.37	   0.53	   0.93	   0.99	   0.07	  
iLeft	  	  
ρ	  	   0.07	   0.12	   0.04	   -­‐0.26	   0.29	   0.21	   0.22	   0.47	  
Sig.	  	   0.78	   0.65	   0.90	   0.33	   0.32	   0.48	   0.44	   0.09	  
iRight	  	  
ρ	  	   -­‐0.03	   -­‐0.13	   -­‐0.15	   0.02	   0.12	   -­‐0.05	   -­‐0.25	   0.40	  
Sig.	  	   0.92	   0.64	   0.58	   0.95	   0.68	   0.87	   0.38	   0.14	  
iCeM	  	  
ρ	  	   -­‐0.16	   -­‐0.12	   -­‐0.13	   0.22	   0.09	   -­‐0.06	   -­‐0.27	   0.42	  
Sig.	  	   0.56	   0.67	   0.62	   0.40	   0.75	   0.84	   0.36	   0.13	  
iCeL*	  	  
ρ	  	   0.08	   0.01	   -­‐0.02	   -­‐0.31	   0.24	   0.25	   0.61*	  	   0.31	  
Sig.	  	   0.77	   0.97	   0.95	   0.27	   0.46	   0.43	   0.03	   0.32	  
iCeC	  	  
ρ	  	   0.09	   0.12	   -­‐0.08	   -­‐0.09	   0.12	   -­‐0.02	   -­‐0.19	   0.43	  
Sig.	  	   0.74	   0.66	   0.77	   0.75	   0.67	   0.95	   0.51	   0.12	  
	  
	   	  




Table	  5-­‐9	  (continued):	  Correlations	  between	  behavioural	  phenotype	  and	  c-­‐Fos	  immunoreactivity	  
following	   acute	   bladder	   inflammation.	   *	   denotes	   parameters	   with	   significant	   correlation	   r:	  
Rostral,	  i:	  Intermediate,	  c:	  Caudal;	  glob:	  Global	  	  
	   	   Low	  Thigmotaxis	  	   	   High	  Thigmotaxis	  	  
	  	  	   	  	  	  









































































































































































































	  	  	  




Repeated	  Bladder	  Inflammation	  	  
Overall	  	  
Duration	  in	  the	  inner	  zone	  significantly	  correlated	  with	  c-­‐Fos	  immunoreactivity	  in	  the	  left	  CeC	  (ρ=0.30,	  
p=0.04).	  	  
Within	  Groups	  	  
In	  naïve	  animals,	  rearing	  activity	  was	  significantly	  correlated	  with	  c-­‐Fos	  immunoreactivity	  in	  the	  rostral	  
CeM	  (ρ=0.59,	  p=0.02).	  	  
Animals	   in	   the	   anaesthesia-­‐only	   group	   showed	   significant	   negative	   correlations	   between	   duration	  
and	   c-­‐Fos	   immunoreactivity	   in	   the	  CeC	   (right:	   ρ=-­‐0.73,	   p=0.04,	   intermediate:	   ρ=-­‐0.73	  p=0.04),	   CeL	  
(caudal:	  ρ=-­‐0.79,	  p=0.02),	  right	  hemisphere	  (overall:	  ρ=-­‐0.79,	  p=0.02,	  intermediate:	  ρ=-­‐0.80,	  p=0.02,	  
caudal:	   ρ=-­‐0.76,	   p=0.03),	   and	   in	   the	   intermediate	   (ρ=-­‐0.71,	   p=0.05)	   and	   caudal	   (ρ=-­‐0.76,	   p=0.03)	  
levels	  of	  the	  central	  amygdala.	  	  
In	   instrumentation	   animals,	   duration	   in	   the	   inner	   zone	   was	   significantly	   correlated	   with	   c-­‐Fos	  
immunoreactivity	   in	   the	   CeM	   (right	   hemisphere:	   ρ=0.64,	   p=0.04),	   and	   rostral	   (ρ=0.64,	   p=0.04)	  
regions	   of	   the	   central	   amygdala,	  with	   frequency	   also	   showing	   a	   correlation	  with	   activation	   in	   the	  
rostral	  central	  amygdala	  (overall:	  ρ=0.75,	  p=0.01,	  right:	  ρ=0.68,	  p=0.03).	  	  
In	   turpentine	   animals,	   frequency	   in	   the	   inner	   zone	   was	   significantly	   correlated	   with	   c-­‐Fos	  
immunoreactivity	   in	   the	   left	   CeC	   (ρ=0.67,	   p=0.02),	   and	   caudal	   regions	   of	   the	   central	   amygdala	  
(overall:	  ρ=0.68,	  p=0.01,	   left:	  ρ=0.72,	  p=0.01,	  CeL:	  ρ=0.65	  p=0.02).	  Duration	   in	   the	   inner	   zone	  was	  
also	  significantly	  correlated	  with	  c-­‐Fos	  immunoreactivity	  overall	  (ρ=0.58,	  p=0.05),	  in	  the	  CeC	  (overall:	  
ρ=0.60	  p=0.04,	  caudal:	  ρ=0.60,	  p=0.04),	  CeL	  (overall:	  ρ=0.63,	  p=0.03,	  caudal:	  ρ=0.61,	  p=0.03),	  and	  in	  
the	  rostral	  (right:	  ρ=0.60,	  p=0.04)	  and	  caudal	  (overall:	  ρ=0.78,	  p<0.001,	  left:	  ρ=0.68,	  p=0.01.	  	  
Looking	  at	  correlations	  within	  thigmotactic	  phenotypes,	  low	  thigmotactic	  animals	  showed	  significant	  
negative	  correlations	  between	  distance	  travelled	  and	  left	  hemispheric	  c-­‐Fos	  activation	  in	  the	  central	  
amygdala	   (Caudal:	   ρ=-­‐0.51,	   p=0.02,	   CeC:	   ρ=-­‐0.56,	   p=0.006).	   In	   the	   high	   thigmotaxis	   animals,	   a	  
negative	   correlation	   between	   rearing	   activity	   and	   c-­‐Fos	   immunoreactivity	   in	   the	   CeC	   (ρ=-­‐0.44,	  
p=0.04).	  	  
Table	  5-­‐10	  and	  Table	  5-­‐11	  summarise	  the	  correlations	  detected	  in	  the	  repeated	  bladder	  inflammation	  
model.	  	  
	  




Key	  findings	  	  
• More	  correlations	  between	  behaviour	  and	  immunoreactivity	  were	  seen	  in	  the	  repeated	  
compared	  to	  acute	  model	  of	  bladder	  inflammation	  	  
• The	  majority	  of	  correlations	  involved	  measures	  of	  thigmotaxis	  (frequency	  and	  duration	  in	  the	  
inner	  zone)	  associated	  with	  activation	  in	  the	  CeC	  and	  CeL	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   0.79	  	  	  
Table	  5-­‐10:	  Pearson	  Correlation	  Coefficients	  between	  behaviour	  and	  open	  field	  following	  repeated	  bladder	  inflammation	  *	  denotes	  significant	  correlation	  within	  parameter,	  †	  denotes	  
significant	  correlation	  also	  seen	  in	  acute	  model	  	  
	  	   	  	  	   	   Naïve	  	   	   	   AO	  	   	   	   Instrumentation	  	   	   	   Turpentine	  	   	  

















LCeM	  	   ρ	  	   0.34	  	   0.06	  	   0.09	  	   -­‐0.02	  	   -­‐0.48	  	   -­‐0.34	  	   -­‐0.30	  	   -­‐0.70	  	   0.12	  	   0.19	  	   0.24	  	   0.16	  	   -­‐0.37	  	   0.20	  	   0.17	  	   -­‐0.19	  	  








































































ρ	  	   -­‐0.09	  	   0.13	  	   0.08	  	   0.13	  	   -­‐0.61	  	   -­‐0.53	  	   -­‐0.56	  	   0.59	  	   0.28	  	   0.44	  	   0.51	  	   0.06	  	   -­‐0.28	  	   0.54	  	   0.47	  	   -­‐0.47	  	  
	   Sig.	  	   0.75	  	   0.64	  
-­‐0.13	  	  
0.64	  	   0.10	  	  
0.72	  	  
0.64	  	   0.11	  	   0.17	  	   0.15	  	   0.22	  	   0.43	  	   0.20	  	   0.13	  	   0.87	  	   0.37	  	   0.07	  	   0.12	  	   0.12	  
0.10	  



































































































Right*†	  	   ρ	  	  
-­‐0.02	  	   0.26	  	   0.27	  	   -­‐0.07	  	   -­‐0.51	  	   -­‐0.42	  	   -­‐0.79*	  	   0.68	  	   0.55	  	   0.49	  	   0.24	  	   -­‐0.17	  	   -­‐0.50	  	   0.26	  	   0.44	  	   0.03	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Table	  5.10	  (continued):	  Pearson	  Correlation	  Coefficients	  between	  behaviour	  and	  open	  field	  following	  repeated	  bladder	  inflammation.	  *	  denotes	  significant	  correlation	  within	  parameter,	  †	  	  
denotes	  significant	  correlation	  also	  seen	  in	  acute	  model	  	  
	   	   Naïve	  	   AO	  	   Instrumentation	  	   Turpentine	  	  




























































CeM	  	   ρ	  	   -­‐0.21	   -­‐0.04	   0.14	   -­‐0.07	   -­‐0.53	   -­‐0.39	   -­‐0.47	   -­‐0.62	   0.13	   0.36	   0.46	   -­‐0.07	   -­‐0.05	   0.42	   0.48	   -­‐0.14	  
	   Sig.	  	  
0.45	   0.88	   0.62	   0.80	   0.17	   0.34	   0.25	   0.19	   0.72	   0.31	   0.18	   0.84	   0.87	   0.17	   0.11	   0.67	  
CeL*	  	   ρ	  	   0.04	   0.28	   0.27	   0.03	   -­‐0.18	   -­‐0.29	   -­‐0.56	   0.54	   0.25	   0.46	   0.56	   -­‐0.23	   -­‐0.24	   0.57	   0.63*	  	   -­‐0.33	  
	   Sig.	  	  
0.89	   0.32	   0.33	   0.92	   0.66	   0.48	   0.15	   0.27	   0.49	   0.18	   0.09	   0.51	   0.45	   0.05	   0.03	   0.29	  
CeC*†	  	   ρ	  	   -­‐0.08	   0.33	   0.21	   -­‐0.01	   -­‐0.55	   -­‐0.45	   -­‐0.64	   0.69	   0.50	   0.52	   0.32	   -­‐0.43	   -­‐0.13	   0.52	   0.60*	  	   -­‐0.31	  
	   Sig.	  	  
0.79	   0.24	   0.46	   0.96	   0.16	   0.27	   0.08	   0.13	   0.14	   0.12	   0.37	   0.21	   0.69	   0.08	   0.04	   0.32	  
Global*	  	   ρ	  	   -­‐0.06	   0.26	   0.24	   -­‐0.01	   -­‐0.58	   -­‐0.50	   -­‐0.70	   0.71	   0.36	   0.51	   0.49	   -­‐0.31	   -­‐0.23	   0.48	   0.58*	  	   -­‐0.32	  
	  
Sig.	  	   0.84	   0.34	   0.39	   0.98	   0.13	   0.21	   0.05	   0.12	   0.31	   0.13	   0.15	   0.39	   0.48	   0.11	   0.05	   0.31	  
Rostral*	  	   ρ	  	   0.07	   0.23	   0.28	   0.12	   -­‐0.51	   -­‐0.37	   -­‐0.43	   -­‐0.62	   0.61	   0.75*	  	   0.64*	  	   -­‐0.31	   -­‐0.03	   0.32	   0.40	   -­‐0.03	  
	   Sig.	  	   0.81	   0.40	   0.31	   0.67	   0.19	   0.37	   0.28	   0.19	   0.06	   0.01	   0.04	   0.39	   0.92	   0.31	   0.20	   0.92	  
rLeft	  	   ρ	  	   0.07	   0.16	   0.21	   0.10	   -­‐0.53	   -­‐0.41	   -­‐0.36	   -­‐0.68	   0.27	   0.37	   0.41	   -­‐0.08	   -­‐0.41	   -­‐0.29	   -­‐0.30	   0.10	  
	   Sig.	  	   0.81	   0.57	   0.45	   0.73	   0.17	   0.32	   0.38	   0.14	   0.44	   0.29	   0.23	   0.83	   0.19	   0.36	   0.35	   0.76	  
rRight*	  	   ρ	  	   -­‐0.01	   0.09	   0.05	   0.30	   -­‐0.44	   -­‐0.26	   -­‐0.52	   -­‐0.35	   0.57	   0.68*	  	   0.50	   -­‐0.25	   -­‐0.13	   0.56	   0.60*	  	   0.05	  
	   Sig.	  	   0.99	   0.76	   0.85	   0.27	   0.28	   0.53	   0.18	   0.49	   0.09	   0.03	   0.14	   0.48	   0.69	   0.06	   0.04	   0.88	  
rCeM*	  	   ρ	  	   -­‐0.21	   0.09	   -­‐0.04	   0.59*	  	   -­‐0.60	   -­‐0.43	   -­‐0.42	   -­‐-­‐	  	   0.20	   0.49	   0.55	   -­‐0.04	   0.05	   0.31	   0.39	   -­‐0.06	  
	   Sig.	  	   0.45	   0.74	   0.90	   0.02	   0.11	   0.28	   0.30	   -­‐-­‐	  	   0.57	   0.15	   0.10	   0.91	   0.88	   0.33	   0.21	   0.85	  
rCeL	  	   ρ	  	   0.30	   0.29	   0.30	   -­‐0.08	   0.38	   0.35	   -­‐0.02	   -­‐0.53	   0.27	   0.35	   0.49	   -­‐0.12	   -­‐0.25	   -­‐0.12	   -­‐0.05	   0.06	  
	   Sig.	  	   0.28	   0.29	   0.28	   0.79	   0.36	   0.40	   0.97	   0.28	   0.46	   0.32	   0.16	   0.75	   0.43	   0.70	   0.87	   0.86	  
rCeC	  	   ρ	  	   -­‐0.19	   0.27	   0.32	   0.25	   -­‐0.54	   -­‐0.42	   -­‐0.48	   -­‐0.66	   0.63	   0.38	   0.01	   -­‐0.36	   0.02	   0.01	   -­‐0.01	   -­‐0.08	  
	  	   Sig.	  	   0.49	   0.34	   0.25	   0.38	   0.17	   0.30	   0.22	   0.15	   0.05	   0.28	   0.97	   0.31	   0.96	   0.98	   0.98	   0.80	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Table	  5.10	  	  (continued):	  Pearson	  Correlation	  Coefficients	  between	  behaviour	  and	  open	  field	  following	  repeated	  bladder	  inflammation.	  *	  denotes	  significant	  correlation	  within	  parameter,	  †	  	  
denotes	  significant	  correlation	  also	  seen	  in	  acute	  model	  	  
	   	  	   Naïve	  	   AO	  	   Instrumentation	  	   Turpentine	  	  









































Inter.*†	  	   ρ	  	   -­‐0.14	   -­‐0.01	   0.11	   0.31	   -­‐0.51	   -­‐0.51	   -­‐0.71*	  	   -­‐0.53	   -­‐0.03	   0.01	   0.16	   -­‐0.01	   -­‐0.03	   0.36	   0.37	   -­‐0.26	  
	  	   Sig.	  	   0.61	   0.96	   0.68	   0.25	   0.19	   0.20	   0.05	   0.28	   0.93	   0.99	   0.66	   0.97	   0.93	   0.25	   0.23	   0.41	  
iLeft	  	   ρ	  	   0.01	   -­‐0.09	   -­‐0.03	   0.17	   -­‐0.49	   -­‐0.54	   -­‐0.59	   -­‐0.68	   0.06	   0.09	   0.21	   0.11	   -­‐0.03	   0.49	   0.31	   -­‐0.55	  
	  	   Sig.	  	   0.96	   0.76	   0.91	   0.54	   0.22	   0.16	   0.12	   0.14	   0.87	   0.80	   0.57	   0.76	   0.92	   0.11	   0.32	   0.06	  
iRight	  	   ρ	  	   -­‐0.21	   -­‐0.08	   0.23	   0.24	   -­‐0.47	   -­‐0.40	   -­‐0.80*	  	   -­‐0.16	   0.10	   0.27	   0.38	   0.00	   -­‐0.54	   0.25	   0.34	   0.15	  
	  	   Sig.	  	   0.46	   0.77	   0.41	   0.38	   0.24	   0.33	   0.02	   0.76	   0.77	   0.46	   0.27	   0.99	   0.07	   0.43	   0.28	   0.64	  
iCeM	  	   ρ	  	   0.27	   0.19	   0.32	   -­‐0.09	   -­‐0.36	   -­‐0.24	   -­‐0.33	   -­‐0.67	   -­‐0.11	   -­‐0.11	   0.02	   -­‐0.10	   -­‐0.46	   -­‐0.03	   0.07	   0.14	  
	   Sig.	  	   0.33	   0.51	   0.24	   0.75	   0.38	   0.56	   0.42	   0.15	   0.76	   0.77	   0.95	   0.79	   0.14	   0.93	   0.84	   0.65	  
	  iCeL	  	   ρ	  	   0.05	   0.02	   -­‐0.05	   0.35	   -­‐0.46	   -­‐0.53	   -­‐0.64	   -­‐0.47	   0.07	   0.13	   0.24	   0.09	   0.00	   0.43	   0.54	   0.00	  
	  	   Sig.	  	   0.87	   0.94	   0.85	   0.21	   0.25	   0.17	   0.09	   0.35	   0.84	   0.72	   0.50	   0.81	   0.99	   0.17	   0.07	   0.99	  
iCeC*	  	   ρ	  	   0.00	   -­‐0.08	   0.13	   -­‐0.05	   -­‐0.47	   -­‐0.41	   -­‐0.73*	  	   -­‐0.43	   -­‐0.06	   0.01	   0.20	   -­‐0.15	   0.12	   0.21	   0.21	   -­‐0.28	  
	  	   Sig.	  	   0.99	   0.79	   0.65	   0.85	   0.24	   0.31	   0.04	   0.39	   0.87	   0.98	   0.59	   0.68	   0.70	   0.51	   0.51	   0.38	  
Caudal*†	  	   ρ	  	   0.05	   0.29	   0.27	   -­‐0.23	   -­‐0.65	   -­‐0.57	   -­‐0.76*	  	   0.70	   0.18	   0.41	   0.53	   -­‐0.19	   -­‐0.13	   0.68*	   0.78*	   -­‐0.25	  
	  	   Sig.	  	   0.86	   0.29	   0.33	   0.42	   0.08	   0.14	   0.03	   0.12	   0.63	   0.24	   0.12	   0.59	   0.68	   0.01	   0.00	   0.44	  
cLeft*†	  	   ρ	  	   -­‐0.10	   0.20	   0.10	   0.16	   -­‐0.58	   -­‐0.57	   -­‐0.67	   0.70	   0.26	   0.43	   0.50	   0.01	   -­‐0.15	   0.72*	  	   0.68*	  	   -­‐0.28	  
	  	   Sig.	  	   0.73	   0.47	   0.73	   0.56	   0.13	   0.14	   0.07	   0.12	   0.47	   0.21	   0.14	   0.97	   0.64	   0.01	   0.01	   0.38	  
cRight	  	   ρ	  	   0.14	   0.33	   0.25	   -­‐0.19	   -­‐0.61	   -­‐0.53	   -­‐0.76*	  	   0.57	   0.05	   0.17	   0.23	   0.17	   -­‐0.34	   0.36	   0.56	   0.05	  
	  	   Sig.	  	   0.63	   0.23	   0.36	   0.50	   0.11	   0.17	   0.03	   0.24	   0.89	   0.64	   0.52	   0.64	   0.29	   0.25	   0.06	   0.89	  
cCeM	  	   ρ	  	   -­‐0.29	   -­‐0.26	   -­‐0.02	   0.03	   -­‐0.66	   -­‐0.51	   -­‐0.63	   -­‐0.31	   0.19	   0.42	   0.55	   0.08	   0.17	   0.14	   0.14	   -­‐0.18	  
	  	   Sig.	  	   0.30	   0.34	   0.94	   0.90	   0.08	   0.20	   0.09	   0.55	   0.60	   0.23	   0.10	   0.83	   0.60	   0.67	   0.66	   0.58	  
cCeL*	  	   ρ	  	   0.10	   0.32	   0.36	   -­‐0.23	   -­‐0.59	   -­‐0.56	   0.79*	  	   0.51	   0.12	   0.23	   0.22	   -­‐0.44	   -­‐0.19	   0.65*	  	   0.61*	  	   -­‐0.41	  
	  	   Sig.	  	   0.73	   0.24	   0.18	   0.42	   0.13	   0.15	   0.02	   0.30	   0.75	   0.52	   0.54	   0.20	   0.56	   0.02	   0.03	   0.19	  
cCeC*	  	   ρ	  	   0.02	   0.24	   0.13	   -­‐0.13	   -­‐0.62	   -­‐0.55	   -­‐0.67	   0.67	   0.08	   0.21	   0.22	   -­‐0.27	   -­‐0.48	   0.36	   0.60*	  	   0.04	  
	  	   Sig.	  	   0.94	   0.38	   0.64	   0.64	   0.10	   0.16	   0.07	   0.14	   0.83	   0.56	   0.55	   0.45	   0.11	   0.25	   0.04	   0.90	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5-­‐11:	  Correlation	  coefficients	  between	  behavioural	  phenotype	  and	  c-­‐Fos	  activation	  in	  the	  central	  amygdala	  	  
	   	   Low	  Thigmotaxis	  	   High	  Thigmotaxis	  	  
	  	  	   	  	  	   Dist.*	   Freq	   Duration	   Rearing*	   Dist.	   Freq	   Duration	   Rearing*	  
LCeM	  	   ρ	  	   -­‐0.05	   -­‐0.13	   -­‐0.03	   0.13	   0.03	   0.04	   0.12	   -­‐0.01	  
	   Sig.	  	   0.82	   0.56	   0.89	   0.58	   0.88	   0.84	   0.60	   0.95	  
LCeL	  	   ρ	  	   -­‐0.31	   -­‐0.08	   -­‐0.13	   0.05	   0.06	   -­‐0.13	   -­‐0.09	   -­‐0.04	  
	   Sig.	  	   0.16	   0.74	   0.55	   0.81	   0.77	   0.56	   0.70	   0.86	  
LCeC*	  	   ρ	  	   -­‐0.56*	   -­‐0.04	   0.13	   0.16	   -­‐0.08	   0.08	   0.16	   -­‐0.02	  
	   Sig.	  	   0.01	   0.85	   0.55	   0.48	   0.71	   0.72	   0.47	   0.94	  
Left	  	   ρ	  	   -­‐0.41	   -­‐0.09	   -­‐0.03	   0.15	   -­‐0.02	   -­‐0.03	   0.07	   -­‐0.06	  
	  	   Sig.	  	   0.06	   0.68	   0.89	   0.51	   0.93	   0.88	   0.76	   0.81	  
RCeM	  	   ρ	  	   -­‐0.38	   0.05	   0.22	   0.21	   0.01	   0.08	   0.15	   -­‐0.05	  
	   Sig.	  	   0.09	   0.81	   0.33	   0.35	   0.98	   0.71	   0.49	   0.83	  
RCeL	  	   ρ	  	   -­‐0.25	   0.01	   0.32	   0.21	   -­‐0.35	   -­‐0.40	   -­‐0.28	   0.03	  
	   Sig.	  	   0.25	   0.97	   0.15	   0.34	   0.10	   0.06	   0.20	   0.91	  
RCeC	  	   ρ	  	   0.12	   0.11	   -­‐0.14	   0.04	   -­‐0.14	   -­‐0.18	   -­‐0.05	   -­‐0.13	  
	   Sig.	  	   0.58	   0.64	   0.53	   0.85	   0.52	   0.40	   0.80	   0.56	  
Right	  	   ρ	  	   -­‐0.03	   0.11	   0.03	   0.14	   -­‐0.24	   -­‐0.25	   -­‐0.10	   -­‐0.10	  
	  	   Sig.	  	   0.89	   0.62	   0.88	   0.55	   0.28	   0.26	   0.64	   0.66	  
CeM	  	   ρ	  	   -­‐0.24	   -­‐0.03	   0.10	   0.19	   0.09	   0.24	   0.38	   -­‐0.3	  
	   Sig.	  	   0.28	   0.90	   0.65	   0.38	   0.70	   0.26	   0.08	   0.18	  
CeL	  	   ρ	  	   -­‐0.27	   0.04	   0.07	   0.16	   -­‐0.14	   -­‐0.13	   0.04	   -­‐0.36	  
	   Sig.	  	   0.22	   0.87	   0.75	   0.47	   0.53	   0.54	   0.85	   0.11	  
CeC	  	   ρ	  	   -­‐0.12	   0.08	   -­‐0.07	   0.11	   -­‐0.07	   0.16	   0.36	   -­‐0.44	  
	   Sig.	  	   0.58	   0.74	   0.76	   0.63	   0.74	   0.47	   0.09	   0.04	  
Global*	  	   ρ	  	   -­‐0.23	   0.04	   0.02	   0.19	   -­‐0.11	   0.04	   0.26	   -­‐0.43*	  	  
	  	   Sig.	  	   0.29	   0.86	   0.92	   0.40	   0.61	   0.85	   0.23	   0.05	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5-­‐11	  (continued):	  Correlation	  coefficients	  between	  behavioural	  phenotype	  and	  c-­‐Fos	  activation	  in	  the	  
central	  amygdala	  	  
	   	   Low	  Thigmotaxis	   High	  Thigmotaxis	  
	  	  	   	  	  	   Dist.*	   Freq	   Dur.	   Rear*	   Dist.	   Freq	   Dur.	   Rear*	  
Rostral	  	   ρ	  	   -­‐0.11	   0.01	   0.10	   0.27	   0.06	   0.15	   0.18	   -­‐0.31	  
	   Sig.	  	   0.63	   0.98	   0.67	   0.22	   0.77	   0.49	   0.41	   0.17	  
rLeft	  	   ρ	  	   0.00	   -­‐0.09	   0.04	   0.41	   0.03	   -­‐0.02	   0.00	   -­‐0.21	  
	   Sig.	  	   0.98	   0.69	   0.84	   0.06	   0.88	   0.91	   0.99	   0.35	  
rRight	  	   ρ	  	   -­‐0.22	   0.05	   0.03	   0.07	   -­‐0.06	   0.15	   0.04	   -­‐0.13	  
	   Sig.	  	   0.34	   0.83	   0.88	   0.76	   0.78	   0.51	   0.84	   0.56	  
rCeM2	  	   ρ	  	   -­‐0.33	   0.01	   0.06	   0.33	   -­‐0.03	   0.21	   0.26	   -­‐0.13	  
	   Sig.	  	   0.13	   0.96	   0.79	   0.13	   0.88	   0.33	   0.23	   0.58	  
rCeL2	  	   ρ	  	   0.08	   -­‐0.04	   0.07	   0.26	   0.06	   0.03	   0.01	   -­‐0.34	  
	   Sig.	  	   0.72	   0.86	   0.76	   0.25	   0.78	   0.91	   0.97	   0.13	  
rCeC2	  	   ρ	  	   0.14	   -­‐0.10	   -­‐0.18	   0.14	   0.02	   0.17	   0.20	   -­‐0.16	  
	  	   Sig.	  	   0.54	   0.65	   0.42	   0.52	   0.94	   0.45	   0.35	   0.49	  
Interm.	   ρ	  	   -­‐0.22	   -­‐0.18	   -­‐0.06	   0.26	   0.04	   0.04	   0.20	   -­‐0.13	  
	   Sig.	  	   0.33	   0.42	   0.81	   0.24	   0.85	   0.87	   0.36	   0.59	  
iLeft	  	   ρ	  	   -­‐0.15	   -­‐0.17	   -­‐0.07	   0.06	   0.16	   -­‐0.07	   0.03	   0.07	  
	   Sig.	  	   0.52	   0.45	   0.76	   0.80	   0.48	   0.76	   0.90	   0.77	  
iRight	  	   ρ	  	   -­‐0.22	   -­‐0.07	   0.12	   0.27	   -­‐0.22	   -­‐0.20	   -­‐0.05	   0.26	  
	   Sig.	  	   0.32	   0.76	   0.59	   0.23	   0.32	   0.36	   0.81	   0.25	  
iCeM	  	   ρ	  	   -­‐0.01	   -­‐0.05	   0.17	   0.29	   -­‐0.09	   0.00	   -­‐0.01	   -­‐0.34	  
	   Sig.	  	   0.95	   0.82	   0.46	   0.19	   0.68	   1.00	   0.95	   0.13	  
iCeL	  	   ρ	  	   -­‐0.13	   -­‐0.11	   -­‐0.06	   0.17	   0.00	   0.01	   0.13	   0.11	  
	   Sig.	  	   0.58	   0.62	   0.80	   0.44	   0.98	   0.97	   0.54	   0.63	  
iCeC	  	   ρ	  	   -­‐0.15	   -­‐0.05	   0.03	   -­‐0.13	   0.07	   0.17	   0.32	   -­‐0.21	  
	  	   Sig.	  	   0.49	   0.81	   0.90	   0.57	   0.75	   0.44	   0.13	   0.35	  
Caudal	  	   ρ	  	   -­‐0.35	   0.05	   0.13	   0.00	   -­‐0.09	   0.12	   0.31	   -­‐0.38	  
	   Sig.	  	   0.11	   0.84	   0.56	   0.99	   0.67	   0.58	   0.16	   0.09	  
cLeft	  	   ρ	  	   -­‐0.51	   0.00	   0.05	   0.00	   -­‐0.03	   0.16	   0.16	   0.30	  
	   Sig.	  	   0.02	   0.98	   0.83	   0.99	   0.88	   0.47	   0.46	   0.19	  
cRight	  	   ρ	  	   -­‐0.05	   0.22	   0.15	   0.15	   -­‐0.14	   -­‐0.21	   -­‐0.09	   -­‐0.19	  
	   Sig.	  	   0.84	   0.33	   0.50	   0.50	   0.52	   0.34	   0.70	   0.41	  
cCeM	  	   ρ	  	   -­‐0.30	   -­‐0.15	   0.02	   -­‐0.09	   0.08	   0.26	   0.38	   -­‐0.09	  
	   Sig.	  	   0.18	   0.50	   0.92	   0.69	   0.73	   0.24	   0.08	   0.69	  
cCeL*	  	   ρ	  	   -­‐0.21	   0.15	   0.13	   -­‐0.01	   -­‐0.16	   -­‐0.04	   0.08	   -­‐0.43*	  	  
	   Sig.	  	   0.35	   0.52	   0.58	   0.97	   0.48	   0.86	   0.73	   0.05	  
cCeC	  	   ρ	  	   -­‐0.24	   0.11	   0.06	   0.18	   -­‐0.29	   -­‐0.11	   0.11	   -­‐0.31	  
	  	   Sig.	  	   0.27	   0.62	   0.80	   0.41	   0.18	   0.63	   0.62	   0.18	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6 Results	  -­‐	  Study	  3:	  Stavudine-­‐associated	  Neuropathy	  in	  Female	  Rats	  	  
To	   induce	   anti-­‐retroviral	   associated	   neuropathy,	   two	   intravenous	   tail	   vein	   injections	   of	   Stavudine	  
(d4T)	  were	  given	  to	  adult	  female	  Wistar	  rats	  under	  isoflurane	  anaesthesia.	  Control	  animals	  received	  
an	   equal	   volume	   of	   sterile	   0.9%	   saline	   solution	   (B.	   Braun	   Melsungen	   AG,	   Germany),	   and	   naïve	  
animals	   were	   untreated	   but	   similarly	   handled.	   Baseline	   evoked	   hypersensitivity	  measurements	   to	  
mechanical,	  thermal,	  and	  cold	  stimuli	  were	  taken	  prior	  to	  d4T	  treatment,	  and	  on	  days	  4,	  7,	  10,	  and	  
13	  post-­‐injection.	  Animals	  were	  subsequently	  exposed	  to	  the	  open	  field	  paradigm	  for	  15	  minutes	  on	  
day	  14	  post-­‐injection,	  and	  behaviour	  analysed	  for	  thigmotaxis.	  	  
Exclusions	  	  
One	  animal	  was	  excluded	  from	  the	  naïve	  group	  due	  to	  technical	  failure	  during	  video	  capture	  of	  open	  
field	  behaviour.	  A	  priori	  exclusion	  criteria	  for	  evoked	  measures	  were	  discarded	  when	  no	  significant	  
effect	  of	  treatment	  was	  observed,	  and	  results	  are	  reported	  for	  the	  entire	  data	  set.	  	  
6.1 Mechanical	  Hypersensitivity	  	  
Electronic	  von	  Frey	  apparatus	  was	  used	  to	  test	  hind	  paw	  hypersensitivity	  to	  mechanical	  stimuli.	  Each	  
data	  point	  represents	  an	  average	  of	  five	  measurements.	  	  
No	  significant	  effect	  of	  d4T	  treatment	  on	  mechanical	  hypersensitivity	  was	  found	  (2-­‐way	  RM	  ANOVA	  
p=0.685	   left,	  p=0.367	  right),	  and	  there	  was	  no	   interaction	  between	  group	  and	  time-­‐point	   (p=0.820	  
left,	  p=0.983	  right).	  There	  was	  an	  effect	  of	  time-­‐point	  (p<0.001),	  with	  all	  animals	  reducing	  baseline	  
mechanical	  withdrawal	  from	  48.42g	  (45.27-­‐51.57),	  50.90g	  (47.17-­‐54.62),	  and	  50.35	  (47.05-­‐53.63),	  to	  
40.79g	   (35.82-­‐45.74),	   42.33g	   (37.94-­‐46.71),	   and	   44.82g	   (40.34-­‐49.30)	   at	   4	   days	   post-­‐injection	   in	  
naïve,	  saline,	  and	  d4T	  animals	  respectively	  (Figure	  6-­‐1).	  	  
6.2 Thermal	  Hypersensitivity	  	  
Hargreaves	  apparatus	  was	  used	  to	  investigate	  thermal	  withdrawal	  thresholds,	  with	  each	  data	  point	  
representing	  an	  average	  of	  three	  measurements.	  	  
No	   significant	   differences	   in	   thermal	   hypersensitivity	   were	   detected	   due	   to	   group	   (p=0.351	   left,	  
p=0.867	  right),	  time-­‐point	  (p=0.380	  left,	  p=0.090	  right),	  or	  an	  interaction	  between	  the	  two	  (p=0.902	  
left,	   p=0.264	   right).	   Baseline	   and	   day	   13	   withdrawal	   latencies	   were	   11.0s	   (10.1-­‐11.8)	   and	   11.5s	  
(10.112.8)	  for	  naïve	  animals,	  11.9s	  (10.9-­‐12.9)	  and	  11.2s	  (10.2-­‐12.2)	  for	  the	  saline	  group,	  and	  11.1s	  
(10.3-­‐11.9)	   and	   11.2s	   (10.2-­‐12.3)	   in	   the	   d4T	   treated	   group	   (Figure	   6-­‐1).





Figure	  6-­‐1:	  Mechanical	  and	  thermal	  hypersensitivity	  following	  d4T	  treatment	  	  
All	  groups	  showed	  reduced	  mechanical	   thresholds	  on	  the	   first	  day	  of	   testing	   (mean	  ±	  95%	  CI).	  There	  were	  no	  
differences	  in	  thermal	  hypersensitivity	  	  Data	  analyses	  conducted	  using	  1-­‐way	  Repeated	  Measures	  ANOVA	  
6.3 Cold	  Hypersensitivity	  	  
A	  drop	  of	  acetone	  was	  applied	  to	  each	  hind	  paw	  in	  turn,	  and	  flinch	  responses	  frequency	  noted.	  
Each	  data	  point	  represents	  an	  average	  of	  five	  measurements.	  	  




No	  flinch	  responses	  to	  acetone	  were	  observed	  (p=1	  for	  all	  tests	  performed,	  data	  not	  shown).	  	  
6.4 Open	  Field	  Behaviour	  	  
No	  differences	  in	  open	  field	  behaviour	  were	  associated	  with	  d4T	  treatment	  in	  female	  rats.	  	  
Frequency	  of	  entry	  to	  the	  inner	  zone	  was	  17	  (8-­‐21)	  in	  naïve	  animals,	  12	  (8-­‐21)	  in	  saline	  vehicle,	  and	  
14.5	   (12.5-­‐20)	   in	   d4T	   (1-­‐way	   ANOVA	   on	   ranks	   p=0.56).	   Duration	   in	   the	   inner	   zone	   was	   not	  
significantly	   altered	   (1-­‐way	   ANOVA	   p=0.607),	   with	   naïve	   animals	   spending	   23.4s	   (9.8-­‐25.6),	  
compared	  to	  7.1s	  (15.5-­‐22.3)	  in	  vehicle,	  and	  17.4s	  (22.16-­‐26.24)	  in	  d4T	  groups	  (Figure	  6-­‐2).	  Rearing	  
behaviour	  was	  also	  not	   significantly	  different	  between	  groups	   (1-­‐way	  ANOVA	  on	   ranks	  p=0.174),	  
with	  naïve	  animals	  rearing	  a	  median	  of	  79	  (61.5-­‐82.5)	  times,	  compared	  to	  66	  (58-­‐80)	  in	  saline,	  and	  
59	  (52-­‐71)	   in	  d4T	  treated	  animals.	  Distance	  travelled	  was	  8847.99cm	  (7665.70-­‐10030.28)	   in	  naïve	  
animals,	  8967.27cm	  (8063.93-­‐9870.61)	  in	  saline	  vehicle,	  and	  9254.44cm	  (8482.54-­‐10026.34)	  in	  the	  
d4T	  group	  (1-­‐way	  ANOVA	  p=0.793)	  (Figure	  6-­‐3).	  	  
Key	  findings	  	  
• No	  evidence	  of	  mechanical,	  thermal,	  or	  cold	  hypersensitivity	  within	  14	  days	  of	  d4T	  
antiretroviral	  	  
• No	  effect	  of	  d4T	  on	  open	  field	  behaviour	  	  
• Sex	  differences	  could	  explain	  unexpectedly	  negative	  result	  	  
	  	   	  	  





Figure	  6-­‐2:	  Inner	  zone	  activity	  (frequency	  and	  duration)	  in	  the	  open	  field	  following	  d4T	  treatment	  
No	   significant	   differences	   were	   observed.	   Data	   analysed	   using	   1-­‐way	   Kruskal-­‐Wallis	  
ANOVA	  on	  Ranks	  (frequency)	  and	  1-­‐way	  ANOVA	  (duration)	  





Figure	  6-­‐3:	  Total	  distance	  travelled	  and	  rearing	  activity	  in	  the	  open	  field	  following	  d4T	  treatment	  
No	  significant	  differences	  were	  observed.	  Data	  analysed	  using	  1-­‐way	  ANOVA	  (distance)	  and	  
1-­‐	  way	  Kruskal-­‐Wallis	  ANOVA	  on	  Ranks	  (rearing)	  




7 Discussion	  	  
These	   studies	   have	   shown	   robust	   behavioural	   phenotypes	   are	   present	   in	   naïve	   rats	   in	   terms	   of	  
open	  field	  behaviour.	  The	  data	  also	   indicates	  catheterisation,	  with	  or	  without	  turpentine-­‐induced	  
bladder	   inflammation	   is	   capable	   of	   inducing	   thigmotaxis,	   and	   this	   is	   not	   accompanied	   by	   clear	  
changes	   in	   amygdala	   activation,	   but	   is	   associated	   with	   robust	   upregulation	   of	   inflammatory	  
mediators.	   There	  was	  no	  effect	   of	   bladder	   inflammation	  on	  burrowing	  behaviour.	  Unexpectedly,	  
Stavudine	  treatment	  in	  female	  rats	  did	  not	  cause	  the	  hypersensitivity	  and	  thigmotactic	  alterations	  
observed	  in	  male	  rats.	  	  	  
7.1 Repeated	  Open	  Field	  	  
The	   Open	   Field	   paradigm	  was	   developed	   to	   detect	   behavioural	   alterations	   in	   the	   rat	   associated	  
with	   emotionality	   (Walsh	   &	   Cummins,	   1976).	   This	   study	   was	   designed	   to	   investigate	   how	   the	  
behaviour	   of	   male	   Wistar	   rats	   changes	   with	   repeated	   exposure	   to	   the	   open	   field.	   The	   primary	  
outcome	   of	   interest	   was	   thigmotaxis,	   a	   predation	   risk	   avoidance	   behaviour	   characterised	   by	  
preference	   for	   movement	   close	   to	   the	   walls.	   Thigmotaxis	   is	   an	   ethological	   outcome	   measure,	  
investigating	   the	   balance	   between	   exploratory	   drive	   and	   heightened	   risk	   awareness	   associated	  
with	  a	  vulnerable	  physical	  state,	  e.g.	  pain.	  By	  looking	  at	  behaviour	  in	  naïve	  animals,	  it	  is	  possible	  to	  
characterise	  naïve	  behaviour,	  and	  determine	  whether	  all	  animals	  behave	   in	  the	  same	  way,	  and	   if	  
not,	  characterise	  behavioural	  phenotypes	  present.	  	  
As	  the	  Open	  Field	  has	  been	  used	  for	  over	  80	  years,	  there	  are	  a	  number	  of	  outcomes	  measures	  that	  
have	  been	  used.	   Table	  7-­‐1	   summarises	   the	  most	   common	  outcomes	  measures	  used	   in	   the	  open	  
field.	  	  
Table	  7-­‐1:	  Summary	  of	  outcome	  measures	  commonly	  used	  in	  the	  Open	  Field	  Paradigm	  	  






General	  Activity	  	  
General	  Activity	  	  
Automated	  	  
Automated	  	  
	   Rearing	  	   Exploratory/Escape	  /	  High	  Arousal	  	   Manual	  	  
	   Grooming	  	   Arousal	  	   Manual	  	  
	   Freezing	  	   Fear	  	   Automated	  	  
	   Sleeping/Immobility	  	   Low	  Arousal	  	   Automated/Manual	  	  




Frequency	  of	  Entry	  	  
Thigmotaxis	  /	  ‘Timidity’	  /	  ‘Anxiety’	  	  
Thigmotaxis	  /	  ‘Timidity’	  /	  ‘Anxiety’	  	  
Automated	  	  
Automated	  	  
	   Duration	  in	  Zone	  	   Thigmotaxis	  /	  ‘Timidity’	  /	  ‘Anxiety’	  	   Automated	  	  
	   Velocity	  	   Thigmotaxis	  /	  ‘Timidity’	  /	  ‘Anxiety’	  	   Automated	  	  
In	   naïve	   animals	   repeatedly	   exposed	   to	   the	   open	   field,	   behavioural	   outcomes	   decreased	   with	  
exposure,	  as	  previously	  reported	  (Walsh	  &	  Cummins,	  1976).	  To	  minimise	  this	  effect,	  I	  designed	  this	  
study	  to	  maximise	  time	  between	  exposures,	  and	  minimise	  the	  number	  of	  exposures	  required.	  	  




Four	   behavioural	   phenotypes	  were	   identified,	   based	   on	   initial	   thigmotactic	   phenotype,	   and	   how	  
that	  changed	  over	   time.	  There	  were	  a	  minority	  of	  animals	   that	  consistently	  exhibited	  either	  high	  
(n=5)	   or	   low	   (n=3)	   thigmotaxis,	   but	   in	   the	   majority	   of	   animals,	   thigmotaxis	   was	   initially	   low,	  
increasing	  over	  time.	  The	  speed	  of	  this	  decrease	  distinguishes	  the	  two	  majority	  phenotypes	  as	  slow	  
(n=8)	   or	   rapid	   (n=10)	   thigmotaxis,	   based	   primarily	   on	   thigmotactic	   activity	   during	   their	   second	  
exposure	  to	  the	  open	  field.	  This	  distribution	  pattern,	  with	  a	  minority	  exhibiting	  extreme	  behaviours	  
and	  the	  majority	  occupying	  an	  intermediate	  phenotype	  was	  also	  noted	  in	  much	  earlier	  open	  field	  
studies	  into	  the	  non-­‐specific	  excitability	  level	  of	  rats	  in	  the	  open	  field	  (Lát	  &	  Gollová-­‐Hémon,	  1969).	  	  
One	  of	  the	  purposes	  of	  conducting	  this	  study	  was	  to	  investigate	  the	  feasibility	  of	  utilising	  the	  open	  
field	   paradigm	   in	   a	   test-­‐re-­‐test	   manner,	   allowing	   a	   ‘baseline’	   session,	   during	   which	   behavioural	  
phenotype	  can	  be	  assessed,	  prior	   to	   testing.	  This	  would	   improve	  understanding	  of	  how	  different	  
stimuli	  influence	  open	  field	  behaviour,	  and	  whether	  all	  behavioural	  phenotypes	  react	  in	  the	  same	  
way.	  Numerous	   studies	  have	   shown	  biochemical	  differences	  between	  animals	  with	  high	  and	   low	  
innate	  activity	  levels,	  suggestive	  of	  these	  being	  trait	  rather	  than	  state	  characteristics	  (Cools	  et	  al.,	  
1993;	  Borta	  &	  Schwarting,	  2005;	  Mällo	  et	  al.,	  2007).	  The	  noted	  changes	   in	  phenotype	  during	   the	  
first	  two	  open	  field	  sessions	  is	  in	  keeping	  with	  early	  work	  suggesting	  a	  change	  in	  factor	  loading	  of	  
ambulation	  during	  initial	  exposure	  (Whimbey	  &	  Denenberg,	  1967b),	  and	  based	  on	  this,	  it	  would	  be	  
advantageous	   to	   test	  open	   field	  behaviour	  on	   two	  consecutive	  days	  prior	   to	   intervention,	  with	  a	  
further	  two	  sessions	  occurring	  over	  the	  48	  hours	  following	  bladder	  inflammation.	  This	  time	  period	  
is	   within	   the	   current	   Home	   Office	   project	   license	   permissions	   relating	   to	   induction	   of	   bladder	  
inflammation,	   and	   would	   allow	   investigation	   of	   the	   time-­‐course	   of	   the	   behavioural	   response	   to	  
such	  stimuli.	  Baseline	  open	  field	  testing,	  preferably	  over	  2	  sessions,	  would	  allow	  prior	  behavioural	  
phenotyping	   of	   the	   experimental	   animals,	   which	   could	   then	   be	   randomised	   to	   treatment	   in	   a	  
balanced	   manner.	   This	   behavioural	   phenotyping	   would	   allow	   distinction	   of	   effects	   due	   to	  
experimental	  pain	  from	  innate	  variation	  in	  trait	  behavioural	  phenotype,	  and	  enable	  researchers	  to	  
investigate	   how	   individual	   differences	   influence	   behavioural	   outcome.	   This	   is	   important	   in	   pain	  
research	   as	   the	   factors	   that	   predispose	   an	   individual	   to	   developing	   chronic	   pain	   are	   thought	   to	  
involve	  complex	  interplay	  between	  physiological	  factors	  and	  psychological	  profile.	  	  
When	  behavioural	  phenotype	  based	  on	  frequency	  of	  inner	  zone	  activity	  was	  applied,	  this	  produced	  
sub-­‐groups	   that	  were	  different	  both	   in	   terms	  of	   thigmotaxis,	   and	  other	  behaviours	   such	  as	   total	  
distance	   travelled,	   velocity,	   and	   rearing.	   These	   subgroups	  may	   reflect	   innate	   differences	   in	   trait	  
phenotype.	  	  




Thigmotactic	   outcomes	   of	   frequency	   and	   duration	   in	   the	   open	   field	   showed	   greatest	   predictive	  
value	  between	  weeks	  one	  and	  two,	  with	  the	  majority	  of	  animals	  exhibiting	  a	  consistent	  thigmotaxis	  
phenotype.	  However,	  there	  was	  a	  group	  of	  animals	  (“rapid	  thigmotaxis”)	  that	  dramatically	  reduced	  
their	   inner	   zone	   activity	   between	  week	   1	   and	   2,	   and	   this	   could	   skew	   attempts	   to	   interpret	   the	  
effect	  of	   any	   intervention	  between	  open	   field	  exposures,	   as	   some	  animals	  would	  naturally	   show	  
reduced	  thigmotaxis.	  However,	  as	  significant	  differences	  in	  thigmotaxis	  are	  detectable	  at	  an	  overall	  
level,	   this	   is	  unlikely	   to	  be	  a	  deciding	   factor,	  although	   future	   studies	   into	  how	  experimental	  pain	  
affects	   repeated	  open	   field	  exposure	  would	   increase	  understanding	  of	  how	  different	  behavioural	  
phenotypes	  respond	  to	  nociceptive	  stimuli.	  	  	  
This	  study	   indicated	  duration	   in	  the	  open	  field	  showed	  the	  greatest	  consistency	  across	  re-­‐testing,	  
with	   strong	   correlations	   seen	   between	   consecutive	   testing,	   and	   also	   between	   initial	   and	   second	  
exposure.	   However,	   experimental	   findings	   from	   this	   lab	   have	   shown	   frequency	   is	   more	   reliably	  
modulated	   by	   experimental	   pain	   states	   (Wallace	   et	   al.,	   2007b;	   Huang	   et	   al.,	   2013),	   suggesting	  
further	  investigation	  into	  the	  relationship	  between	  frequency	  and	  duration	  is	  warranted.	  	  
The	  fact	  that	  correlations	  were	  strengthened	  by	  repeated	  exposure	  to	  the	  open	  field	  strengthens	  
the	  assertion	  that	  the	  behavioural	  phenotypes	  are	  indicative	  of	  trait	  differences.	  	  
Strong	  correlations	  were	  seen	  between	  both	  velocity	  and	  distance	  travelled,	  and	  duration	  and	  
frequency	  in	  the	  inner	  zone,	  indicative	  of	  a	  link	  between	  these	  behaviours.	  	  	  	  
Additionally,	   rearing	   activity	   was	   shown	   to	   be	   robust	   and	   stable,	   with	   differences	   noted	   in	  
freestanding	   and	   wall-­‐supported	   rearing.	   It	   is	   likely	   that	   these	   two	   forms	   of	   rearing	   are	  
representative	   of	   exploration	   and	   escape	   attempts	   respectively,	   particularly	   as	   wall-­‐supported	  
rearing	  was	  shown	  to	  be	  higher	  when	  the	  open	  field	  apparatus	  featured	  lower	  walls,	  i.e.	  increasing	  
the	  potential	  for	  escape	  (Walsh	  &	  Cummins,	  1976).	  	  
7.2 Bladder	  Inflammation	  	  
Bladder	  inflammation	  induced	  via	  instillation	  of	  a	  50%	  turpentine	  solution	  has	  been	  shown	  to	  cause	  
referred	  somatic	  hyperalgesia	  and	  bladder	  hyper-­‐reflexia	  (Rice,	  1995;	  Jaggar	  et	  al.,	  1999),	  but	  until	  
this	   study,	   investigations	   into	   affective	   alterations	   associated	   with	   this	   model	   of	   visceral	  
inflammation	   were	   lacking.	   Therefore,	   this	   study	   was	   designed	   to	   investigate	   the	   presence	   of	  
affective	   changes,	   such	   as	   increased	   thigmotactic	   behaviour	   in	   the	   open	   field,	   or	   decreased	  
burrowing	  activity,	  and	  determine	  whether	  correlations	  between	  neural	  activation	  of	  the	  amygdala	  
(as	   measured	   by	   c-­‐Fos	   immunoreactivity)	   and	   behaviour	   are	   present.	   Levels	   of	   inflammatory	  
mediators	   in	   the	  bladder	  were	  determined	   in	  order	   to	  provide	   a	  measure	  of	   insult	   severity,	   and	  




demonstrate	   the	   presence	   of	   nociceptive	   stimuli	   in	   the	   absence	   of	   measuring	   evoked	  
hypersensitivity.	  	  
Bladder	  inflammation	  with	  turpentine,	  both	  acute	  and	  repeated,	  had	  effects	  on	  both	  inflammatory	  
mediator	   levels	   in	   bladder	   tissue	   and	   activity	   in	   the	   open	   field.	   Additionally,	   there	  was	   a	   strong	  
effect	  seen	  in	  the	  instrumentation	  group,	  with	  inflammatory	  changes	  and	  alterations	  in	  open	  field	  
behaviour	  present,	  suggesting	  catheterization	  alone	  is	  responsible	  for	  part	  of	  the	  effect	  seen	  in	  the	  
turpentine	  group.	  	  
Up-­‐regulation	   of	   inflammatory	   mediators	   was	   observed	   in	   both	   acute	   and	   repeated	   models	   of	  
visceral	   inflammation.	   Bladder	   weights	   were	   increased	   in	   both	   models,	   with	   the	   magnitude	  
increase	   in	   total	   RNA	  higher	   following	   repeated	  bladder	   inflammation,	   likely	   associated	  with	   the	  
extended	  duration,	  as	  changes	  were	  also	  seen	  in	  naïve	  animals.	  The	  magnitude	  of	  fold	  change,	  and	  
the	   number	   of	   mediators	   affected	   was	   higher	   in	   the	   acute	   model	   compared	   to	   the	   repeated,	  
suggesting	   a	   possible	   habituation	   to	   inflammatory	   stimuli	   occurs.	   The	   difference	   in	   expression	  
could	  also	  reflect	  bladder	  re-­‐modelling	  in	  response	  to	  repeated	  inflammatory	  stimuli	  (Tseng	  et	  al.,	  
2009),	  with	  remodelling	  seen	  in	  both	  urothelial	  (Lucon	  et	  al.,)	  and	  sensory	  innervation	  (Forrest	  et	  
al.,	  2013).	  Alternatively,	  it	  could	  simply	  be	  associated	  with	  the	  presence	  of	  a	  non-­‐linear	  relationship	  
between	  RNA	  and	  protein	  levels	  (Heumann	  et	  al.,	  1984;	  Gygi	  et	  al.,	  1999;	  Chen,	  2002).	  In	  the	  rat,	  
compared	  to	  a	  single	  acute	  treatment,	  repeated	  i.p.	  injections	  of	  LPS	  decrease	  the	  responsiveness	  
of	   ACTH	   and	   corticosterone,	   decreased	   the	   corticosterone	   response	   to	   stress,	   and	   increased	  
expression	   of	   vasopressin	   (AVP)	   in	   parvocellular	   neurons	   (Grinevich	   et	   al.,	   2001),	   with	   similar	  
suppression	   observed	   in	   studies	   on	   lung	   tissue	   following	   repeated	   ovalbumin,	   specifically	  
decreased	  in	  inflammatory	  cell	  involvement	  (e.g.	  neutrophils	  &	  eosinophils)	  (Tigani	  et	  al.,	  2007).	  	  
CCL-­‐12	   is	   up-­‐regulated	   in	   both	   acute	   and	   repeated	   turpentine	   inflammation,	   and	   also	   following	  
repeated	  instrumentation,	  suggesting	  involvement	  in	  a	  general	  inflammatory	  response,	  rather	  than	  
irritant-­‐specific	   (i.e.	   turpentine).	   It	   is	   also	   known	   as	  monocyte	   chemotactic	   protein	   (MCP-­‐5)	   and	  
acts	  during	   the	  early	   stages	  of	   inflammation	   to	  attract	   eosinophils,	  monocytes,	   and	   lymphocytes	  
(Lam	  et	  al.,	  2013a)	  as	  shown	  in	  Figure	  7-­‐1.	  Production	  by	  macrophages	  is	  stimulated	  by	  interleukin	  
(IL)-­‐13	  (Cho	  et	  al.,	  2006),	  and	  NGF	  (Susaki	  et	  al.,	  1996),	  and	  it	  is	  strongly	  up-­‐regulated	  by	  infection	  
(Benítez-­‐Hernández	  et	  al.,	   2010;	   Li	  et	  al.,	   2014a).	   IL-­‐7	  aggravation	  of	   collagen-­‐induced	  arthritis	   is	  
associated	   with	   CCL-­‐12	   up-­‐regulation	   (Hartgring	   et	   al.,	   2012),	   and	   in	   another	   study	   looking	   at	  
thioglycollate-­‐elicited	   peritonitis	   in	  mice,	   it	  was	   found	   that	   CCL-­‐12	   is	   up-­‐regulated	   at	   three	   days	  
post-­‐insult,	   although	   it	   is	   worth	   noting	   CCL-­‐12	   was	   also	   one	   of	   the	   few	   mediators	   investigated	  




which	   had	   baseline	   detection	   levels	   above	   zero	   (Lam	   et	   al.,	   2013a),	   suggesting	   the	   presence	   of	  
constant	  low-­‐level	  activation.	  	  	  
	  
Figure	   7-­‐1:	   Inflammation	   in	   the	   bladder,	   comparing	   inflamed	   (red/left)	   and	   normal	   (right).	   1)	   Integrity	   of	   tight	  
junctions	  and	  basal	   lamina	   is	   lost;	  2)	  NGF	   is	  produced	  by	  mast	   cells	  and	  neutrophils,	  which	  activates	   sensory	  nerve	  
endings	  and	  3)	  macrophages	   to	  produce	   IL-­‐1β	  and	  CCL-­‐12;	   4)	  CCL-­‐12	  and	  CCL-­‐7	  attract	  monocytes,	   eosinophils,	   and	  
lymphocytes	  (CCL-­‐12	  only).	  	  
In	  this	  study,	  CCL-­‐12	  was	  most	  highly	  up-­‐regulated	  in	  the	  acute	  turpentine	  group	  (149	  fold	  change,	  
FC),	  although	  levels	  seen	  in	  the	  repeated	  turpentine	  (120FC)	  and	  repeated	  instrumentation	  (109FC)	  
were	  very	  similar,	  and	  as	  the	  acute	  and	  repeated	  RT-­‐qPCR	  array	  cards	  were	  not	  run	  simultaneously,	  
it	  is	  likely	  that	  up-­‐regulation	  of	  CCL-­‐12	  is	  not	  significantly	  different	  across	  all	  groups,	  and	  associated	  
with	  a	  general	   inflammatory	  response	  to	  trauma	  due	  to	  catheterisation,	  or	  some	  other	  aspect	  of	  
the	  surgical	  induction	  such	  as	  anaesthesia.	  	  
The	  other	  inflammatory	  mediators	  significantly	  up-­‐regulated	  in	  both	  turpentine	  groups	  were	  CCL-­‐7,	  
and	  IL-­‐1β.	  




CCL-­‐7	   is	   also	   a	   monocyte	   attractant	   (AKA	  MCP-­‐3)	   as	   seen	   in	   Figure	   7-­‐1,	   and	   is	   associated	   with	  
various	   conditions	   involving	   inflammatory	   and	   immune	   processes.	   It	   is	   one	   of	   a	   number	   of	  
cytokines	   associated	  with	   a	   poor	   prognosis	   in	   gastric	   cancer	   patients	   (Chang	  et	   al.,	   2014),	   is	   up-­‐
regulated	  serum	  from	  asthma	  patients	  (Pelikan,	  2013),	  and	  found	  in	  increased	  levels	  in	  fibroblasts	  
from	  patients	  with	  systemic	  sclerosis	  	  
(Distler	  et	  al.,	  2009).	  CCL-­‐7	  has	  been	  suggested	  as	  a	  biomarker	  for	   IC/BPS	  (Corcoran	  et	  al.,	  2013),	  
and	  OAB	  (Ghoniem	  et	  al.,	  2011).	  However,	  a	  study	  has	  also	  shown	  that	  a	  common	  treatment	  for	  
nonmuscle	   invasive	   bladder	   cancer,	   bacillus	   Calmette-­‐Guérin	   (BCG,	   from	   Mycobacterium	   bovis),	  
upregulates	  a	  number	  of	  cytokines	  including	  CCL-­‐7,	  which	  was	  still	  up-­‐regulated	  4	  weeks	  following	  
instillation	  (Seow	  et	  al.,	  2008).	  Furthermore,	  it	  is	  also	  up-­‐regulated	  in	  vaginal	  (Woo	  et	  al.,	  2007)	  and	  
urethral	   (Woo	   et	   al.,	   2009)	   tissue	   following	   a	   simulated	   childbirth	   model	   involving	   vaginal	  
distension.	  As	  cross-­‐sensitisation	  has	  previously	  been	  observed	  between	  pelvic	  organs	  (Ustinova	  et	  
al.,	   2006),	   it	   is	   interesting	   that	   the	   first	   study	   (Woo	   et	   al.,	   2007)	   also	   noted	   no	   up-­‐regulation	   in	  
bladder	  or	  rectal	  tissue.	  	  
The	  presence	  of	  significant	  up-­‐regulation	  of	  CCL-­‐7	  following	  turpentine	  inflammation	  (acute:	  18FC,	  
repeated:	  5FC),	  with	  very	  low	  levels	  detected	  in	  the	  repeated	  instrumentation	  group	  is	  in	  keeping	  
with	   turpentine	   producing	   a	   cystitis-­‐like	   state,	   and	   suggests	   the	   acute	  model	   is	   associated	   with	  
higher	  levels	  of	  immune	  activation.	  	  
IL-­‐1β	   is	  highly	  up-­‐regulated	  following	  acute	  turpentine	   inflammation	  (273FC),	  and	  was	   less	  so	  but	  
still	   significantly	   increased	   in	   the	  repeated	  turpentine	  group	  (7FC).	   It	   is	  an	   important	  mediator	  of	  
the	   inflammatory	   process	   and	   is	   produced	   by	   macrophages	   in	   autoimmune	   disorders	   (Chen	   &	  
Meckfessel,	  2013),	  CRPS	  (Cooper	  &	  Clark,	  2013),	  and	  neuropathic	  pain	  (Ramesh	  et	  al.,	  2013).	   It	   is	  
also	  associated	  painful	  bladder	  conditions	  such	  as	  IC/PBS	  (Schrepf	  et	  al.,	  2014),	   is	  up-­‐regulated	  in	  
tissue	   from	  CYP	   treated	  mice	   (Girard	  et	  al.,	  2008),	  and	   looking	  at	  other	  painful	  pelvic	  conditions,	  
IL1-­‐	   β	   is	   significantly	   up-­‐regulated	   in	   menstrual	   blood	   from	   a	   group	   of	   primary	   dysmenorrhea	  
patients	   compared	   to	   healthy	   control	   (Ma	  et	   al.,	   2013).	   The	   increased	   levels	   observed	   following	  
turpentine	   inflammation	  are	   in	  keeping	  with	  an	   intense	   inflammatory	   response,	  especially	   in	   the	  
first	  twenty	  four	  hours.	  	  
Alterations	   in	   thigmotactic	   behaviour	  were	   only	   seen	   following	   acute	   bladder	   inflammation,	   but	  
were	  seen	  in	  both	  turpentine	  and	  instrumentation	  groups’,	  suggesting	  that	  the	  trauma	  associated	  
with	  catheterisation	  is	  sufficient	  to	  induce	  behavioural	  alterations.	  This	  acute	  effect	  is	  in	  agreement	  
with	  the	  majority	  of	  literature	  on	  bladder	  inflammation,	  which	  shows	  stronger	  acute	  effects	  of	  CYP	  
compared	  to	  chronic	  (Juszczak	  et	  al.,	  2010),	  and	  in	  the	  original	  turpentine	  inflammation	  studies	  by	  




McMahon	   &	   Abel,	   the	   greatest	   thermal	   responses	   were	   seen	   in	   the	   first	   few	   hours	   of	  
inflammation,	  with	  tail	  and	  abdominal	  sensitivity	  showing	  more	  sustained	  sensitisation	  compared	  
to	  the	  lateral	  hindpaw	  (McMahon	  &	  Abel,	  1987).	  	  
Decreases	   in	   locomotor	   activity	   were	   seen	   in	   both	   intervention	   groups	   for	   acute	   and	   repeated	  
models.	   Whether	   this	   can	   be	   interpreted	   as	   a	   sign	   of	   on-­‐going	   nociception	   in	   these	   animals	   is	  
unclear	   –	   decreased	   locomotor	   activity	   has	   been	   documented	   in	   other	   studies	   of	   experimental	  
models	  of	  visceral	  pain	  and	  neuropathy,	  suggesting	  it	  is	  an	  effect	  worth	  understanding.	  It	  could	  be	  
a	  pure	  ‘locomotor	  inhibition	  effect’	  associated	  with	  non-­‐nociceptive	  symptoms,	  but	  it	  seems	  likely	  
that	   it	   could	   reflect	   increased	  vigilance,	  and	  an	   indication	  of	   increased	  environmental	  awareness	  
expressed	   through	   reduction	   of	   ‘unnecessary’	   movements	   akin	   to	   extended	   freezing	   noted	  
following	  exposure	   to	  predators	   (Hofer,	  1970).	  Furthermore,	   systemic	   inflammation	   is	  associated	  
with	   constitutional	   symptoms	   such	   as	   decreased	   activity	   and	   general	   ‘malaise’,	   associated	   with	  
both	  cytokine	  release	  and	  peripheral	  nerve	  activation	  (Poon	  et	  al.,	  2013),	  meaning	  it	   is	   important	  
when	   studying	   inflammation	   to	   fully	   characterise	   behavioural	   responses	   and	   inflammatory	  
mediator	  levels	  to	  enable	  distinction	  of	  systemic	  inflammatory	  effects	  from	  behavioural	  depression	  
associated	  with	  nociceptive	  stimuli.	  	  
Burrowing	  has	  been	  mooted	  as	  an	  ethological	  outcome	  measure	  sensitive	  to	  disruptions	  in	  general	  
wellbeing	   (Deacon,	  2009).	  Rats,	  being	  primary	  excavator	  burrowers	   (i.e.	  build	   their	  own	  burrows	  
rather	   than	  occupying	   those	  built	  by	  other	  animals),	   readily	  burrow	  when	  given	   the	  opportunity,	  
and	   decreases	   in	   burrowing	   activity	   have	   been	   documented	   in	   association	   with	   models	   of	  
peripheral	   neuropathy	   (Andrews	   et	   al.,	   2012),	   and	   somatic	   inflammation	   (Rutten	   et	   al.,	   2014b),	  
with	   reversal	   of	   deficits	   following	   analgesic	   treatment	   (Rutten	  et	   al.,	   2014a).	   No	   studies	   to	   date	  
have	   investigated	   the	  effect	  of	   visceral	   inflammation	  on	  burrowing	  outcomes,	  and	   the	   little	  data	  
available	  on	  differences	  in	  burrowing	  activity	  between	  male	  and	  female	  rats	  comes	  from	  a	  largely	  
observational	  study	  utilising	  small	  sample	  sizes,	  which	  found	  no	  significant	  differences	  (Stryjek	  et	  
al.,	  2012).	  Therefore,	  this	  study	  of	  burrowing	  behaviour	  following	  bladder	  inflammation	  in	  female	  
rats	  provides	  useful	  information	  on	  both	  the	  effect	  of	  visceral	  inflammation,	  and	  also	  on	  whether	  
burrowing	  shows	  sex-­‐associated	  variation.	  	  
There	  was	  no	  significant	  effect	  of	  bladder	  inflammation	  on	  burrowing	  activity,	  in	  contrast	  with	  the	  
reported	  decreases	  associated	  with	  acute	  somatic	  inflammation	  following	  intraplantar	  CFA	  (Rutten	  
et	  al.,	  2014a).	  However,	  this	  was	  the	  first	  study	  looking	  at	  burrowing	  activity	  in	  female	  rats,	  and	  it	  is	  
possible	  that	  sex	  differences	  are	  present	  in	  this	  behavioural	  response.	  It	  could	  also	  be	  argued	  that	  
abdominal	   sensitivity	   contributes	   less	   than	   hind-­‐paw	   sensitivity	   to	   decreases	   in	   burrowing,	  




however	  this	  was	  not	  quantified	   in	  this	  study.	  So	  far,	   the	  majority	  of	  studies	  showing	  burrowing-­‐
related	   deficits	   have	   focused	   on	   conditions	   predominantly	   affecting	   the	   hindlimbs,	   such	   as	  
peripheral	   neuropathy	   (Andrews	   et	   al.,	   2012),	   or	   those	   involving	   central	   lesions	   such	   as	   prion	  
disease	   (Cunningham	  et	   al.,	   2005),	   so	   it	   is	   possible	   that	   conditions	  with	   less	   severe	   neurological	  
implications,	   and	   those	   evoking	   non-­‐peripheral	   pain	   and	   therefore	   not	   impairing	   limb	   function	  
implicitly	  may	  not	  show	  such	  clear	  burrowing	  deficits.	  Burrowing	  is	  still	  a	  relatively	  new	  paradigm,	  
and	   studies	   investigating	   the	   contribution	   of	   environmental	   factors	   are	   still	   on-­‐going,	   so	   it	   is	  
possible	   that	   future	   refinements	  may	   increase	   sensitivity	   and	   reduce	   the	   high	   levels	   of	   variation	  
currently	  observed.	  	  
c-­‐Fos	  is	  an	  immediate	  early	  oncogene	  which	  is	  frequently	  used	  as	  a	  marker	  of	  neural	  activation	  due	  
to	  its	  rapid	  induction	  following	  stimuli	  including	  pain	  (Hunt	  et	  al.,	  1987).	  To	  capture	  the	  peak	  of	  c-­‐
Fos	   activation,	   animals	  were	   sacrificed	   one	   hour	   and	   thirty	  minutes	   after	   exposure	   to	   the	   open	  
field,	  and	  activity	  within	  the	  central	  amygdala	  (Ce)	  was	  determined.	  	  
There	   was	   no	   effect	   of	   turpentine	   inflammation	   on	   c-­‐Fos	   immunoreactivity	   in	   the	   amygdala.	  
Increased	   activation	   of	   the	   left	   amygdala	  was	   seen	   in	   both	  models,	   potentially	   indicative	   of	   left	  
amygdala	   involvement	  in	  processing	  input	  related	  to	  open	  field	  exposure.	  Lateralisation	  has	  been	  
seen	  in	  studies	  of	  amygdala	  activation,	  although	  there	  is	  no	  clear	  indication	  of	  generalisation,	  with	  
both	  pain	  and	  social	  processing	  showing	  differential	  lateralisation,	  as	  shown	  in	  Table	  1-­‐5.	  However,	  
there	   is	   evidence	   that	   lateralisation	   shows	   a	   time-­‐dependent	   phenotype,	   with	   increased	   left	  
activation	   in	   early	   stages	   of	   spinal	   nerve	   ligation	   (<day	   6),	   and	   increased	   right	   Ce	   activation	  
corresponding	  with	  expression	  of	  hypersensitivity	  (>day	  14)	  (Gonçalves	  &	  Dickenson,	  2012).	  Caudal	  
activation	  of	  Ce,	  particularly	  CeL	  and	  CeC	  was	  observed	  in	  both	  models.	  Caudal	  activation	  has	  also	  
been	  observed	  following	  acute	  CYP	  treatment	  in	  male	  rats,	  although	  higher	  intensities	  of	  staining	  
were	   observed	   in	   the	   bed	   nucleus	   of	   the	   stria	   terminalis	   (Bon	   et	   al.,	   1998),	   and	   following	   SNT,	  
caudal	  activation	  of	  the	  CeL	  and	  CeC	  was	  also	  observed	  in	  male	  rats	  exposed	  to	  the	  open	  field	  using	  
the	   same	   protocol	   this	   study	   was	   based	   on	   (Morland	   et	   al.,	   Manuscript	   in	   Preparation).	   Both	  
studies	  observed	   increases	  of	  c-­‐Fos	   in	  saline-­‐treated	  animals,	  but	  as	  the	  former	  did	  not	   include	  a	  
naïve	  control,	  and	  the	  later,	  as	  with	  this	  study,	  was	  without	  a	  “No	  Open	  Field”	  control,	  it	  is	  difficult	  
to	  conclude	  whether	  this	   is	  due	  to	  the	   injection	  process/experimental	  neuropathy	  or	  some	  other	  
element	  of	  the	  experimental	  experience	  such	  as	  handling	  or	  environmental	  factors.	  	  	  
The	  difference	  in	  c-­‐Fos	  immunoreactive	  cell	  density	  between	  acute	  and	  repeated	  models	  is	  curious.	  
That	   the	   levels	   are	   consistent	   within	   each	   model	   suggests	   it	   is	   not	   due	   to	   inconsistencies	   in	  
counting,	  but	  it	  is	  unlikely	  that	  the	  difference	  in	  model	  duration	  (2	  days	  compared	  to	  15	  days)	  could	  




be	   responsible	   for	   the	   differences.	   It	   is	   possible	   there	   was	   some	   other	   environmental	   factor	  
present	  during	  the	  repeated	  model,	  which	  could	  increase	  baseline	  c-­‐Fos	  activity	  in	  all	  animals.	  
To	  determine	  whether	  the	  changes	  in	  behaviour	  observed	  were	  related	  to	  activation	  of	  the	  Ce,	  
correlations	  were	  performed	  between	  density	  of	  c-­‐Fos	  immunoreactivity	  and	  open	  field	  behaviour.	  	  
Increased	   correlations	   between	   thigmotaxis	   in	   the	   open	   field	   and	   Ce	   c-­‐Fos	   immunoreactivity,	  
particularly	  the	  CeC	  and	  CeL,	  were	  seen	  in	  the	  repeated	  model,	  despite	  no	  significant	  differences	  in	  
thigmotaxis	  being	  observed.	  	  
Interestingly,	  when	  open	  field	  behaviour	  following	  both	  acute	  and	  repeated	  bladder	  inflammation	  
was	   compared	   and	   analysed	   using	   2-­‐Way	   ANOVA,	   overall	   differences	   in	   behavioural	   influence	  
between	   turpentine	   and	   instrumentation	   group	   became	   clear	   –	   turpentine	   treatment	   was	  
associated	  with	   decreases	   in	   all	   outcomes	  measures,	   whereas	   instrumentation	   only	   significantly	  
decreased	  distance	  travelled	  and	  frequency	  of	  entry	  to	  the	  inner	  zone,	  emphasising	  the	  increased	  
severity	   of	   the	   inflammation	   associated	   with	   turpentine.	   Additionally,	   in	   the	   overall	   analysis,	  
rearing	  behaviour	  was	  the	  only	  outcome	  influenced	  by	  repeated	  bladder	  inflammation,	  showing	  an	  
overall	   increase	   compared	   to	   the	   acute	   model,	   likely	   an	   effect	   associated	   with	   the	   longer	  
experimental	  time-­‐course	  due	  to	  increased	  handling.	  This	  analysis	  firstly	  suggests	  that	  much	  larger	  
group	   sizes	   are	   required	   to	   detect	   the	   behavioural	   changes	   produced	   by	   turpentine	   and	  
differentiate	  them	  from	  the	  effects	  of	  catheterisation.	  The	  group	  sizes	  were	  based	  on	  data	  from	  a	  
model	   of	   traumatic	   peripheral	   neuropathy,	   and	   it	   is	   likely	   that	   the	   increased	   inflammatory	  
component	   of	   bladder	   inflammation	   resulted	   in	   higher	   variation	   than	   that	   seen	   in	   nerve	   injury	  
models.	  	  
Secondly,	  it	  shows	  that	  examining	  behavioural	  change	  as	  a	  whole,	  rather	  than	  individual	  outcome	  
measures,	  can	  be	  more	  sensitive	  when	  determining	  the	  contribution	  from	  the	  control	  condition,	  in	  
this	  case,	  catheterisation.	  Looking	  at	  data	  from	  both	  experiments,	  rearing	  activity	  and	  duration	  in	  
the	  inner	  zone	  appear	  to	  distinguish	  the	  effect	  of	  turpentine	  from	  that	  of	  the	  catheterisation	  (i.e.	  
distance	  travelled	  and	  frequency	  of	  inner	  zone	  entry).	  	  
7.3 d4T	  in	  female	  rats	  	  
The	  d	  nucleoside	  reverse	  transcriptase	  (dNRTI)	  family	  of	  anti-­‐retroviral	  drugs	  such	  as	  ddC	  and	  ddI	  
are	   associated	  with	   poor	   side-­‐effect	   profiles,	   including	   peripheral	   neuropathy	   and	   lipodystrophy	  
(Dubinsky	   et	   al.,	   1989;	   Joseph	   et	   al.,	   2004).	   d4T,	   or	   Stavudine,	   is	   another	   dNRTI	  which	   is	   still	   in	  
widespread	  used	  as	  cheap	  an	  effective	  ART	  in	  the	  developing	  world	  but	  it	  is	  associated	  with	  a	  drug	  
induced	   peripheral	   neuropathy	   (McGrath	   et	   al.,	   2012),	   and	   to	   date,	   the	   few	   studies	   which	  




investigate	   the	  effect	  of	   such	  agents	  on	  behaviours	  such	  as	   thigmotaxis	   (Huang	  et	  al.,	  2013),	  use	  
exclusively	   male	   animals.	   This	   study	   investigated	   thigmotaxis	   following	   a	   previously	   validated	  
treatment	  regime,	  aiming	  to	  determine	  firstly	  whether	  female	  rats	  respond	  in	  the	  same	  manner	  as	  
male	   rats,	   and	   secondly,	   whether	   behavioural	   alterations	   correlate	   with	   sensory	   nociceptive	  
measures	  of	  evoked	  hypersensitivity.	  	  
d4T,	   administered	   twice	   over	   4	   days	   via	   tail	   vein	   injection,	   failed	   to	   evoke	   spontaneous	  
hypersensitivity,	  and	  had	  no	  effect	  on	  open	  field	  behaviour.	  This	  was	  unexpected	  as	  the	  protocol	  
was	  previously	  validated	  (Huang	  et	  al.,	  2013;	  Denk	  et	  al.,	  2013),	  with	  the	  only	  difference	  from	  this	  
study	  being	  the	  use	  of	  male,	  rather	  than	  female	  rats.	  	  	  
A	  pilot	  study	  was	  initially	  conducted	  to	  determine	  whether	  the	  dosing	  regimen	  of	  two	  intravenous	  
injections	   was	   sufficient	   to	   induce	   peripheral	   neuropathy	   in	   female	   rats.	   After	   this	   pilot	   study	  
showed	  no	  effect,	  small	  trials	  were	  conducted	  using	  both	  male	  and	  female	  rats	  and	  d4T	  from	  both	  
a	  new	  batch,	  and	  a	  batch	  with	  proven	  efficacy	  in	  causing	  peripheral	  neuropathy	  in	  male	  Wistar	  rats	  
of	  comparable	  weight	  (Huang	  et	  al.,	  2013).	  The	  new	  batch	  appeared	  to	  be	  effective	  in	  male	  rats	  at	  
comparable	  doses,	  with	  a	  mild	  decrease	  was	   seen	   in	   female	   rats,	   and	  as	   there	  was	  no	   literature	  
suggesting	  differences	  in	  d4T	  metabolism	  between	  males	  and	  females,	  the	  study	  went	  ahead	  using	  
the	  second	  batch	  of	  d4T.	  	  	  
However,	   in	   contrast	   with	   previous	   studies	   investigating	   d4T-­‐associated	   hypersensitivity	   and	  
thigmotaxis	  in	  the	  open	  field	  in	  male	  rats	  (Huang	  et	  al.,	  2013),	  d4T	  treatment	  failed	  to	  significantly	  
alter	  female	  behaviour.	  No	  deficits	   in	  open	  field	  behaviour	  were	  observed,	  and	  evoked	  measures	  
were	  similarly	  unaffected,	  with	  all	  animals	  showing	  significantly	  decreased	  mechanical	   thresholds	  
four	  days	  after	  the	  final	  d4T	  injection.	  	  	  
Previous	   studies	   have	   shown	   hypersensitivity	   following	   d4T	   treatment,	   although	   this	   used	   oral	  
dosing	  via	  gelatin	  cubes,	  resulting	  in	  a	  higher	  dose	  of	  87.5mg	  (assuming	  rat	  weight	  of	  250g)	  at	  the	  
start	  of	  testing,	  compared	  to	  50mg	  in	  this	  study	  (Weber	  et	  al.,	  2007).	  They	  also	  continued	  dosing	  
throughout	  the	  testing	  period,	  which	  started	  7	  days	  after	  the	  start	  of	  dosing,	  and	  didn’t	  see	  evoked	  
hypersensitivity	   until	   3	  weeks,	   or	   21	   days	   of	   dosing.	   Therefore,	   it	   is	   possible	   that	   there	   is	   a	   sex	  
difference	   in	   sensitivity	   to	   the	   neuropathic	   effects	   of	   d4T,	   with	   female	   rats	   requiring	   a	   chronic	  
dosing	  regimen,	  compared	  to	  the	  more	  acute	  sensitivity	  seen	  in	  male	  rats.	  	  
d4T	  is	  thought	  to	  instigate	  neuropathic	  symptoms	  by	  disrupting	  mitochondrial	  activity	  leading	  to	  an	  	  
increase	  in	  reactive	  oxygen	  species	  (ROS)	  (Velsor	  et	  al.,	  2004;	  Lagathu	  et	  al.,	  2007),	  although	  it	  has	  




also	  been	  shown	  that	  d4T	  has	  no	  effect	  on	  oxidative	  stress	  levels	  in	  vitro	  (Cui	  et	  al.,	  1997;	  Kline	  et	  
al.,	  2009).	  	  
There	   is	   some	   evidence	   of	   increased	  mitochondrial	   resistance	   in	   women	   (Lagranha	   et	   al.,	   2010;	  
Guevara	  et	  al.,	  2011),	  which	  could	  explain	  the	  lack	  of	  effect	  we	  observed,	  but	  as	  there	  are	  no	  long	  
term	   studies	   of	   d4T	   effects	   in	   healthy	   individuals,	   it	   is	   difficult	   to	   compare	   this	   directly	   to	   the	  
clinical	   situation	   as	   patients	   on	  d4T	   exhibiting	   peripheral	   neuropathy,	  will	   all	   have	  HIV	   infection,	  
which	  in	  itself	  causes	  peripheral	  neuropathy,	  but	  may	  also	  have	  been	  previously	  treated	  with	  older	  
antiretrovirals	   (e.g.	   AZT),	   making	   it	   very	   difficult	   to	   accurately	   determine	   the	   contribution	   d4T	  
makes	  to	  neuropathic	  phenotype.	  	  	  
Further	  studies	  are	  required	  to	  determine	  whether	  the	  lack	  of	  effect	  observed	  represents	  increased	  
resistance	  in	  females	  to	  d4T-­‐induced	  neuropathy.	  It	  is	  possible	  that	  the	  differences	  between	  male	  
and	   female	   metabolism	   result	   in	   a	   different	   time	   course,	   with	   peak	   behavioural	   and	   sensory	  
alterations	   present	   at	   a	   later	   time	  point,	   and	   requiring	   higher	   dosages	   than	   tested	   in	   this	   study.	  
Investigations	  into	  epidermal	  nerve	  fibre	  density	  in	  the	  hindpaw,	  and	  circulating	  levels	  of	  both	  d4T	  
and	  of	  inflammatory	  cytokines	  would	  enable	  better	  interpretation	  of	  these	  findings.	  It	  is	  useful	  to	  
note	   that	  distance	   travelled	  by	   these	   animals	  was	   comparable	  with	  naïve	  data	   from	   the	  bladder	  
inflammation	  studies,	  suggesting	  activity	  levels	  were	  within	  the	  normal	  range	  and	  therefore	  not	  a	  
factor	  in	  the	  results	  observed.	  	  
8 Limitations	  	  
There	  are	  a	  number	  of	  limitations	  present	  in	  the	  methods	  and	  data	  presented.	  	  
First,	   the	   c-­‐Fos	   experiments	   could	   benefit	   from	   the	   inclusion	   of	   additional	   control	   groups.	   To	  
determine	  whether	  c-­‐Fos	  immunoreactivity	  seen	  following	  open	  field	  exposure	  is	  influenced	  by	  the	  
inflammatory	  pain	  condition,	  an	  additional	  set	  of	  animals,	  with	   identical	  handling	  and	  treatment,	  
but	  without	  open	  field	  exposure,	  could	  have	  been	  included.	  However,	  as	  this	  would	  have	  doubled	  
the	   experimental	   group	   sizes	   and	   considerably	   increased	   the	   workload	   in	   terms	   of	  
immunohistochemical	  analysis,	  this	  was	  omitted	  from	  the	  experimental	  design.	  	  
Immunohistochemical	   controls,	   including	   negative	   (lacking	   primary	   and/or	   secondary	   antibodies)	  
and	   positive	   (including	   c-­‐Fos	   antigen)	   controls	   were	   not	   conducted,	   as	   the	   protocol	   had	   been	  
previously	   validated	   in	   the	   laboratory	   at	   Chelsea	   &	   Westminster	   Hospital	   (Morland	   et	   al.,	  
Manuscript	   in	   Preparation;	   Farquhar-­‐Smith	   et	   al.,	   2002)	   and	   elsewhere	   (Moncho-­‐Bogani	   et	   al.,	  
2005).	  	  	  




Due	  to	  cost	  constraints,	  inflammatory	  mediator	  levels	  were	  initially	  only	  assessed	  in	  bladder	  tissue	  
from	   naïve	   and	   turpentine-­‐inflamed	   animals	   following	   acute	   bladder	   inflammation,	   whereas	  
instrumentation	   tissue	   was	   included	   in	   the	   repeated	   inflammation	   model.	   This	   restricts	   the	  
conclusions	   that	   can	   be	   drawn	   from	   up-­‐regulation	   in	   the	   acute	  model,	   as	   demonstrated	   by	   the	  
differential	  up-­‐regulation	  seen	   in	   the	   repeated	   instrumentation	  group	  compared	   to	   the	   repeated	  
turpentine,	  with	  some	  markers	  in	  common,	  and	  some	  only	  seen	  in	  instrumentation	  and	  turpentine	  
groups.	  	  
Male	   rats	  were	   chosen	   for	   the	   repeated	  open	   field	   investigation,	  despite	   female	   rats	  being	  used	  
throughout	   the	   remainder	   of	   studies.	   They	   were	   selected	   to	   maximise	   comparison	   with	   the	  
literature,	   however	   it	   would	   have	   also	   been	   informative	   for	   this	   series	   of	   experiments	   to	   use	  
female	  rats.	  The	   initial	  plans	  were	  to	   investigate	   in	  both	  males	  and	  females,	  but	  time-­‐constraints	  
prevented	  this.	  	  
Measurement	  of	  oestrous	  cycle	  was	  not	  conducted,	  as	  it	  would	  have	  greatly	  increased	  the	  number	  
of	  animals	  required,	  and	  involved	  an	  additional	  stressor	  not	  present	  in	  studies	  using	  male	  rats	  (i.e.	  
vaginal	  swabs),	  reducing	  comparison	  with	  the	  published	  literature.	  	  
Dual-­‐staining	   of	   sections,	   using	   a	   marker	   such	   as	   Galanin	   (Gray	   &	   Magnuson,	   1987)	   or	   CGRP	  
(D’Hanis	  et	  al.,	  2007)	  would	  have	  aided	  identification	  of	  the	  amygdalar	  sub-­‐divisions,	  in	  addition	  to	  
providing	  insight	  into	  the	  classification	  of	  cells	  activated.	  	  
Behavioural	  alterations	  following	  d4t	  treatment	  failed	  to	  detect	  an	  effect.	  In	  hindsight,	  further	  pilot	  
studies	   to	   determine	   the	   optimal	   dose	   to	   induce	   hypersensitivity	   would	   have	   been	   advisable.	  
Hypersensitivity	  has	  been	  demonstrated	   in	   female	   rats	   following	  a	  more	   intense	  dosing	   regimen	  
(Weber	   et	   al.,	   2007).	   Oral	   dosing	   is	   not	   optimal,	   due	   to	   imprecision	   regarding	   the	   actual	   dose	  
delivered,	  but	  additional	  d4T	   i.v.	  administration	  could	  have	  enhanced	  effects	  seen,	   in	  addition	  to	  
providing	   valuable	   information	   regarding	   sex-­‐related	   differences	   in	   sensitivity	   in	   peripheral	  
neuropathy	  development.	  	  
In	   contrast	   with	   the	   other	   interventional	   studies,	   the	   effect	   of	   acute	   bladder	   inflammation	   on	  
burrowing	   activity	   involved	   mixed	   housing,	   as	   opposed	   to	   the	   block	   design	   employed	   in	   other	  
studies.	  This	  was	  a	  consequence	  of	  group	  randomisation	  based	  on	  baseline	  burrowing	  activity,	  and	  
block	   randomisation	   would	   have	   required	   either	   ignoring	   baseline	   activity	   or	   re-­‐distributing	  
animals	   between	   cages,	   which	   would	   introduce	   undesirable	   social	   stress	   effects	   potentially	  
associated	   with	   stranger	   interactions	   (Martin	   et	   al.,	   2014).	   Further,	   it	   has	   been	   suggested	   that	  




mixed	   housing	   of	   naïve	   animals	   with	   those	   exposed	   to	   experimental	   nociceptive	   stimuli	   can	  
influence	  open	  field	  outcome,	  although	  the	  effects	  are	  subtle	  (Legg,	  2011).	  	  
Experimental	  design	  and	  laboratory	  capacity	  restricted	  the	  size	  of	  experimental	  batches,	  potentially	  
introducing	  additional	  variation	  both	  in	  terms	  of	  seasonality,	  and	  time	  frame.	  Open	  Field	  exposure	  
in	  study	  1	  was	  performed	  over	  the	  course	  of	  an	  entire	  day,	  introducing	  the	  potential	  for	  circadian	  
variation,	   although	  as	   the	   time-­‐frame	   involved	  did	  not	   cross	  between	   the	   light	   and	  dark	  phases,	  
this	  effect	  is	  likely	  minimal	  (Eidman	  et	  al.,	  1990).	  	  
9 Further	  Studies	  	  
There	   are	   numerous	   directions	   this	   research	   could	   now	   go	   in.	   The	   first	   studies	   required	   should	  
address	   the	   limitations	   mentioned	   in	   the	   previous	   section.	   Investigation	   of	   c-­‐Fos	   expression	   in	  
animals	   without	   open	   field	   exposure	   would	   enable	   untangling	   of	   the	   activation	   due	   to	   bladder	  
stimuli	   from	  those	  associated	  with	  open	  field	  exposure.	  Also,	  c-­‐Fos	  expression	   in	  other	  amygdala	  
nuclei	   such	   as	   the	  BL,	  Me,	   and	   ST,	   and	  extra-­‐amygdala	   areas	   such	   as	   the	   insula,	   PAG,	   and	  RVM,	  
which	   are	   also	   involved	   in	   response	   to	   nociceptive	   and	   environmental	   stimuli,	   would	   further	  
elucidate	  the	  neural	  networks	  involved	  in	  the	  expression	  of	  thigmotactic	  behaviour.	  	  
A	   study	  examining	   inflammatory	  mediator	  up-­‐regulation	   in	  acute	   instrumentation	  animals	   is	   also	  
required,	  as	  many	  more	  mediators	  were	  affected	   in	   the	  acute	  turpentine,	  compared	  to	  repeated	  
turpentine,	   and	   there	  was	   some	   degree	   of	   over	   overlap	   between	   repeated	   instrumentation	   and	  
repeated	  turpentine.	  As	  behaviour	  was	  significantly	  different	  in	  these	  animals,	  it	  is	  likely	  that	  a	  high	  
level	  of	  differential	  regulation	  would	  be	  observed	  in	  acute	  instrumentation.	  	  	  
Additionally,	   examination	   of	   inflammatory	   profiles	   associated	  with	   all	   animals	   in	   a	   study,	   rather	  
than	   a	   selected	   subgroup,	  would	   enable	   identification	  of	  mediators	  whose	   expression	   correlates	  
with	   behavioural	   changes,	   and	   provides	   the	   potential	   for	   identification	   of	   biomarkers	   for	   such	  
changes,	   although	   this	   would	   currently	   be	   an	   expensive	   study	   to	   carry	   out.	   Studies	   looking	   at	  
cytokines	   in	   urine	   or	   blood	  would	   also	   enable	   examination	   of	   changes	   over	   time,	   distinguishing	  
mediators	  involved	  in	  initiation	  of	  inflammatory	  response	  from	  those	  responsible	  for	  maintenance	  
of	  long-­‐term	  inflammation.	  	  
Studies	  have	  shown	  systemic	  inflammation	  induces	  changes	  in	  central	  activation	  (Fan	  et	  al.,	  2014),	  
and	   that	   central	   changes	   can	   drive	   peripheral	   inflammation	   in	   a	   neurogenic	   model	   of	   cystitis	  
(Jasmin	   et	   al.,	   1998),	   and	   changes	   in	   inflammatory	   mediator	   expression	   have	   been	   observed	  
centrally,	   including	   amygdala	   nuclei,	   following	   LPS-­‐induced	   systemic	   inflammation	   (Skelly	   et	   al.,	  




2013;	  Araki	  et	  al.,	  2014).	   It	  would	  therefore	  be	  interesting	  to	  examine	  central	   levels	  of	  mediators	  
seen	   local	   to	   inflammation	   (e.g.	  CCL-­‐2,	   IL-­‐1β,	   and	   iNOS)	   in	  areas	   such	  as	   the	  amygdala.	  As	   it	  has	  
been	   shown	   that	   isoflurane	   is	   capable	   of	   producing	   an	   inflammatory	   response	   in	   the	   brain	  
independent	   of	   other	   stimuli	   (Wu	   et	   al.,	   2012),	   it	   would	   also	   important	   to	   also	   include	   the	  
inflammatory	   profile	   of	   anaesthesia-­‐only	   animals	   to	   allow	   differentiation	   of	   effects	   due	   to	  
anaesthesia	  from	  those	  associated	  with	  peripheral	  inflammation.	  	  
In	  this	  study,	  oestrous	  cycle	  was	  not	  considered,	  as	  identification	  of	  stage	  is	  not	  only	  a	  potentially	  
stressful	  experience,	  but	  also	  it	  would	  necessitate	  larger	  group	  sizes	  to	  allow	  for	  analysis	  between	  
stages.	  However,	   there	   is	  evidence	  of	  sex	  differences	   in	   the	  role	  of	  nitric	  oxide	  and	  transforming	  
growth	   factor	   beta	   (TGF-­‐β)	   following	   CYP-­‐induced	   cystitis,	  with	   females	   showing	   higher	   baseline	  
levels	  of	  NO2/3,	  compared	  to	  a	  greater	  TGF-­‐β	  response	  in	  males	  (Tyagi	  et	  al.,	  2009).	  Furthermore,	  
oestrous	   cycle	   has	   been	   shown	   to	   influence	   centrally-­‐mediated	   cross-­‐sensitisation	   between	   the	  
bladder,	   colon,	   and	   uterus	   (Winnard	   et	   al.,	   2006).	   However,	   there	   is	   debate	   in	   clinical	   research	  
regarding	  different	  methods	  of	  determining	  menstrual	  phase,	  with	  poor	  correlations	  between	  cell	  
and	   hormonal	  markers,	   suggesting	  monitoring	   circulating	   hormone	   levels	  may	   yield	  more	   useful	  
information,	   as	   demonstrated	   by	   greater	   correlation	   between	   hormonal	   levels	   and	   heart	   rate	   in	  
healthy	   women,	   not	   seen	   when	   looking	   strictly	   at	   menstrual	   cycle	   (Leicht	   et	   al.,	   2003).	  
Furthermore,	   there	   is	   considerable	   variation	   in	   cycle	   length	   in	   healthy	   women,	   but	   a	   relatively	  
restricted	  range	  of	  peak	  progesterone	  levels	  (Landgren	  et	  al.,	  1980).	  Studies	  have	  shown	  decreased	  
testosterone	   in	   a	   subgroup	   of	   women	   taking	   the	   combined	   oral	   contraceptive	   (COCP)	   show	  
increased	  pain	  sensitivity	  compared	  to	  both	  women	  taking	  COCP	  with	  elevated	  testosterone	  levels,	  
and	  those	  not	  taking	  COCP	  at	  all	  (Vincent	  et	  al.,	  2013).	  	  
Comparison	  of	   the	  hyper-­‐reflexia	  and	  referred	  hypersensitivity	   response	   to	  bladder	   inflammation	  
in	   female	   rats	   with	   male	   rats	   would	   also	   yield	   valuable	   information	   on	   sex	   differences	   in	  
behavioural	   responses.	   Female	   animals	   have	   been	   documented	   as	   having	   higher	   sensitivity	   to	  
visceral	  stimuli	   (Aloisi	  et	  al.,	  2010),	  higher	  activity	  and	  lower	  defecation	   in	  the	  open	  field	  (Slob	  et	  
al.,	  1981),	  and	  the	  opposite	  effect	  of	  social	  isolation	  on	  open	  field	  compared	  to	  males,	  with	  females	  
showing	  reduced	  ambulation	  and	  increased	  ‘anxiety’	  (Palanza,	  2001).	  	  	  
The	  majority	  of	  animals	  in	  this	  study	  were	  randomised	  to	  group	  by	  the	  block	  method,	  meaning	  they	  
were	  housed	  with	   cage-­‐mates	   in	   the	   same	  experimental	   group.	   Studies	  have	   shown	  a	  degree	  of	  
‘empathy’	   or	   altered	   social	   responses	   both	   between	   animals	   in	   experimental	   pain,	   and	   between	  
control	   animals	   and	   those	   in	   experimental	   pain	   groups,	   with	   non-­‐pain	   observers	   demonstrating	  
hypersensitivity	  only	  if	  they	  were	  cage-­‐mates	  in	  a	  model	  of	  acute	  bee	  venom	  pain	  (Li	  et	  al.,	  2014b),	  




and	  although	  it	  has	  been	  suggested	  that	  there	  is	  no	  effect	  on	  naïve	  open	  field	  behaviour	  associated	  
with	  mixed	   group	   housing,	  male	   rats	  with	   transection	   of	   L5	   spinal	   nerve	   only	   show	   behavioural	  
alterations	   when	   house	   in	   mixed	   groups	   (Legg,	   2011).	   As	   sex-­‐related	   effects	   have	   been	  
demonstrated	   in	   expression	  of	   social	   behaviour,	   it	   is	   likely	   that	   female	   rats	  may	  exhibit	   a	  higher	  
degree	   of	   ‘empathic’	   behaviour	   (Langford	   et	   al.,	   2010b),	   which	   could	   impact	   comparisons	   of	  
behavioural	   outcomes	   dependent	   on	   whether	   housing	   is	   heterogeneous	   or	   homogeneous.	   The	  
majority	  of	   animals	   in	   this	   study	  were	   randomised	   to	   group	  by	   the	  block	  method,	  meaning	   they	  
were	  housed	  with	   cage-­‐mates	   in	   the	   same	  experimental	   group.	   Studies	  have	   shown	  a	  degree	  of	  
‘empathy’	   or	   altered	   social	   responses	   both	   between	   animals	   in	   experimental	   pain,	   and	   between	  
control	   animals	   and	   those	   in	   experimental	   pain	   groups,	   with	   non-­‐pain	   observers	   demonstrating	  
hypersensitivity	  only	  if	  they	  were	  cage-­‐mates	  in	  a	  model	  of	  acute	  bee	  venom	  pain	  (Li	  et	  al.,	  2014b),	  
and	  although	  it	  has	  been	  suggested	  that	  there	  is	  no	  effect	  on	  naïve	  open	  field	  behaviour	  associated	  
with	  mixed	   group	   housing,	  male	   rats	  with	   transection	   of	   L5	   spinal	   nerve	   only	   show	   behavioural	  
alterations	   when	   house	   in	   mixed	   groups	   (Legg,	   2011).	   Additionally,	   the	   concept	   of	   empathy	   or	  
emotional	   contagion	   is	   controversial,	   as	   the	   use	   of	   words	   such	   as	   emotion/empathy	   can	   be	  
misleading,	   as	  previously	  discussed	   in	   relation	   to	   ‘anxiety’	   and	   ‘allodynia’.	   Empathy	  and	  emotion	  
are	  human	  constructs	  per	  se,	  and	  their	  use	   implies	  a	  degree	  of	   insight	   into	  subjective	  experience	  
that	  is	  not	  currently	  possible	  when	  the	  subjects	  are	  unable	  to	  communicate	  their	  perspective.	  	  As	  
sex-­‐related	   effects	   have	   been	   demonstrated	   in	   expression	   of	   social	   behaviour,	   it	   is	   likely	   that	  
female	   rats	  may	   exhibit	   a	   higher	   degree	  of	   ‘empathic’	   behaviour	   (Langford	  et	   al.,	   2010b),	  which	  
could	   impact	   comparisons	   of	   behavioural	   outcomes	   dependent	   on	   whether	   housing	   is	  
heterogeneous	  or	  homogeneous.	  	  
Increasing	  group	  sizes	  would	  facilitate	  investigation	  of	  behavioural	  phenotypes,	  such	  as	  those	  seen	  
in	   the	   study	  of	   repeated	  open	   field	  exposure.	  This	  would	  allow	   full	   correlations	   to	  be	  conducted	  
into	   expression	   of	   mediators	   implicated	   in	   protective	   pain-­‐associated	   modulation	   of	   behaviour,	  
with	   the	   potential	   for	   identification	   of	   useful	   biomarkers	   indicative	   of	   negative	   consequences	   in	  
situations	  where	  the	  occurrence	  of	  pain	  can	  be	  predicted	  (e.g.	  post-­‐operative	  pain).	  	  
Examination	  of	  morphological	  changes	  in	  the	  bladder	  would	  also	  facilitate	  better	  understanding	  of	  
how	   turpentine	   bladder	   inflammation	   alters	   behaviour,	   particularly	   looking	   at	   the	   extent	   of	  
mucosal	  denudation	  as	  this	  has	  been	  shown	  to	  correlate	  with	   increased	  sensitivity	   (Andersson	  et	  
al.,	  2008;	   Ikeda	  et	  al.,	  2009).	   Infiltration	  of	  mast	  cells	   could	  also	  be	  quantified,	  as	   this	   is	  another	  
factor	  known	  to	  contribute	  to	  the	  severity	  of	  inflammatory	  response	  (Sant	  et	  al.,	  2007).	  	  	  




Furthermore,	   immunohistochemical	   investigations	  examining	  co-­‐expression	  of	  neuromarkers	  such	  
as	  those	  involved	  in	  endogenous	  endocannabinoid	  activity,	  fatty	  acid	  amide	  hydrolase	  (FAAH)	  and	  
monoacylglycerol	   lipase	   (MAGL)	   (Connell	  et	   al.,	   2006),	   nociceptive	   activity	   (substance	  P	   receptor	  
neurokinin-­‐1	   (NK1)	   (Singewald	   et	   al.,	   2008),	   cytokine	   activity	   (calcitonin	   gene	   related	   peptide	  
(CGRP))	   (D’Hanis	  et	  al.,	  2007),	  stress	  modulation	  (corticotrophin-­‐releasing	   factor	   (CRF1))	   (Ji	  et	  al.,	  
2007),	  and	  opioidergic	  receptors	  (Marchant	  et	  al.,	  2007)	  with	  c-­‐Fos	  would	  enable	  a	  full	  picture	  of	  
the	   neurochemical	   response	   associated	   with	   amygdala	   activation	   under	   acute	   and	   repeated	  
bladder	  inflammatory	  conditions.	  This	  is	  particularly	  important	  in	  a	  heterogeneous	  brain	  area	  such	  
as	   the	   amygdala,	   as	   both	   inhibitory	   (GABA-­‐ergic),	   and	   excitatory	   (glutamatergic)	   innervation	   is	  
present	   (Cassell	  et	  al.,	  1999),	  such	  that	   the	  presence	  of	  c-­‐Fos	  alone	  can	  be	  taken	  as	  evidence	  for	  
both	   activation	   and	   inhibition.	  Quantification	  of	   the	   stress	   response	   (e.g.	   via	   CRF1),	  would	   allow	  
investigation	   into	   how	  much	   trait	   stress	   responses	   contribute	   to	   behavioural	   outcome,	  whereas	  
receptors	  such	  as	  FAAH	  and	  MAGL,	  NK1,	  and	  opioid	  receptors	  would	  give	  insight	  into	  activation	  of	  
pain	  circuits	  associated	  with	  endocannabinoids,	  substance	  P,	  and	  endogenous	  opioids	  respectively.	  
Furthermore	   using	   only	   c-­‐Fos	   and	   toluidine	   blue	   counterstaining	   made	   the	   task	   of	   precisely	  
delineating	   the	   Ce	   and	   its	   subdivisions	   difficult	   –	   this	   process	   could	   be	   optimised	   by	   using	  
fluorescence	   immunohistochemistry	   and	   combining	   c-­‐Fos	   detection	   with	   CGRP	   (CeL	   and	   CeC	  
specific)	  and	  Galanin	  (CeM	  specific)	  co-­‐localisation	  (Olucha-­‐bordonau	  et	  al.,	  2015).	  	  	  
It	   is	   clear	   that	   understanding	   of	   behavioural	   alterations	   associated	   with	   pain	   are	   best	   detected	  
when	   using	   a	   battery	   of	   ethological	   tests,	   allowing	   investigation	   of	   the	   different	   aspects	   of	  
behaviour	  such	  as	  conditioned	  responses,	  analgesia-­‐associated	  place	  preference,	  and	  at	  social	  and	  
cognitive	  impairments.	  This	  would	  yield	  a	  thorough	  picture	  of	  which	  behaviours	  are	  more	  strongly	  
impacted	  by	  pain	  of	  differing	  aetiologies.	  	  
The	   turpentine	   inflammation	   protocol	   could	   be	   refined	   by	   decreasing	   the	   interval	   between	  
inflammation	   sessions	   in	   the	   repeated	  model,	   as	   a	   second	   inflammatory	   stimulus	  within	   twenty-­‐
four	  hours	  of	  the	  first	  shows	  heightened	  hypersensitivity	  (McMahon	  &	  Abel,	  1987),	  although	  this	  
was	  conducted	   in	  decerebrate	  animals.	  When	  we	  were	  developing	  the	  repeated	  model,	  we	  were	  
looking	   to	   mimic	   the	   timeline	   seen	   in	   development	   of	   hypersensitivity	   in	   traumatic	   models	   of	  
neuropathy,	   hence	   dosing	   so	   close	   might	   risk	   unnecessary	   suffering	   for	   the	   animals.	   However,	  
investigation	   of	   the	   timeline	   effects	   following	   such	   dosing	   might	   enable	   modification	   of	   the	  
repeated	  model,	  enhancing	  the	  pain	  phenotype	  and	  more	  reliably	  mimicking	  the	  clinical	  situation	  
seen	  in	  chronic	  bladder	  pain	  conditions.	  	  




All	   experiments	   in	   this	   study	  were	   conducted	   during	   the	   light	   phase,	   with	   testing	   largely	   taking	  
place	   between	   9am	   and	   2pm.	   However,	   as	   rats	   are	   nocturnal	   animals,	   it	   is	   likely	   that	   different	  
results	  would	  be	  obtained	  were	  the	  behavioural	  studies	  performed	  between	  7pm	  and	  7am	  (i.e.	  the	  
dark	  phase).	  Studies	  have	  shown	  increased	  ambulation	  and	  wall-­‐supported	  rearing	  during	  the	  dark	  
phase	   in	   male	   rats,	   although	   there	   was	   no	   difference	   between	   free-­‐standing	   rearing	   activity	  
(Gentsch	  et	  al.,	  1982),	  and	  suggested	  stressful	  procedures	  of	  similar	  intensity	  have	  greatest	  effect	  
during	  daylight	  (Paredes	  et	  al.,	  2005).	  	  
10 Conclusion	  	  
In	  conclusion,	  the	  body	  of	  work	   included	   in	  this	  thesis	  has	  demonstrated	  bladder	   inflammation	   is	  
associated	  with	  up-­‐regulation	  of	  local	   inflammatory	  mediators	  in	  the	  urinary	  bladder,	  and	  acutely	  
with	  an	  increase	  in	  thigmotactic	  behaviour.	  It	  is	  also	  clear	  that	  a	  high	  level	  of	  variation	  is	  present,	  
suggesting	   larger	   group	   sizes	   and	   improved	   behaviour	   phenotyping	   prior	   to	   testing	   would	   be	  
beneficial	   in	   improving	   the	   ability	   of	   the	   open	   field	   paradigm	   to	   detect	   changes	   in	   behaviour.	  
Inclusion	  of	  detailed	  analysis	  rearing	  behaviour	  as	  demonstrated	  in	  the	  naïve	  repeated	  open	  field	  
exposure	  study	  has	  the	  potential	  to	  provide	  useful	   information	  on	  how	  experimental	  pain	  affects	  
arousal	  levels.	  The	  lack	  of	  observable	  effect	  of	  d4T	  on	  female	  rats	  was	  interesting,	  and	  suggestive	  
of	  differential	  metabolism	  compared	  to	  males.	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